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Abstract 
ABSTRACT 
PCOS is one of the leading causes of infertility worldwide affecting 1 in 10 women of 
a reproductive age. One of the fundamental abnormalities in women with PCOS can 
be seen within hormonal irregularities, which may include hyperandrogenemia 
hyperinsulinemia and hyper secretion of luteinising hormone (LH); and. it is 
hypothesised that a defect in steroid secreting ovarian theca cells is involved due to 
their contribution in non-PCOS hormonal synthesis. 
Hyperinsulinemia has been associated with hyper-androgenemia through in vitro 
studies of cultured PCOS theca, where it has been suggested that insulin increases 
progesterone and androstenedione secretion when compared to normal theca cells. 
Furthermore the augmented effects of LH and insulin have been seen to increase 
ovarian androgen synthesis in non-PCOS theca cultures whilst also increasing the 
expression of steroidogenic enzymes specific to the PI3-K pathway. 
Many theories exist toward the etiology of hyper androgenemia within PCOS. V cry 
few approaches however, consider dysfunction in multiple tissue types that may 
contribute to hormonal imbalances. It is well established that an association between 
obesity and PCOS exists and it is often the first therapeutic target for re-establishing 
reproductive function in obese PCOS patients. Furthermore PCOS patients tend to 
show distinct gynoid body fat distribution, which is reported to aggravate PCOS 
symptoms. It was therefore valid to examine the involvement in adipocyte function 
and its contribution to androgen levels within peos. This is further supported 
through the link between metabolic disorders such as insulin resistance and 
hyperinsulinemia, and their associations to obesity. 
Our study employed isolated preadipocyte and thecal cultures with close regulation of 
the influential factors LH and insulin. In doing so, we analysed androgen synthesis 
through activation and expression of steroidogenic enzymes CVPl7 within both 
normal and polycystic ovaries. This allowed us to examine whether proteinlhormonal 
concentrations vary across non-PCOS and peos cultures. This also allowed us to 
examine the possibility of a novel pathway leading to localised adipocyte synthesis as 
ix 
Abstract 
well as pinpointing whether dysfunction existed within the insulin-signalling pathway 
of thecal androgen steroidogenesis. 
The work in this thesis shows that adipocytes derived from non-PCaS and pcas 
women, maintained in vitro differ on the basis of their morphology, rates of 
differentiation and proliferation. Furthermore, they reacted differently under 
conditions designed to mimic pcas in vitro (increased insulin and LH), with reduced 
non-PCaS proliferation, and increased non-PCaS androgen secretion on insulin 
treatment. We also found increased steroidogenic CYP 17 expression in pcas 
cultures under insulin stimulation. However pcas adipocytes androstenedione 
secretion remained unaffected by insulin stimulation and secreted constant levels of 
androstenedione similar to that seen by insulin stimulated non-PCOS adipocytes. 
Our examination of non-PCaS and PCOS primary thecal cultures showed CYP 17 
expression is increased in pcas theca under basal conditions and that increases in 
insulin and LH leads to increases in in vitro theca proliferation. These conditions were 
also seen to lead to significant increases in androstenedione secretion over non-PCaS 
thecal cultures, and the results suggest it to be acting through the PI3-K pathway. 
These results therefore point to a specific area of dysfunction that should be further 
targeted for examination. Furthermore, they suggest that an adipocyte dysfunction 
exists within pcas patients that may significantly contribute to hyperandrogenemia 
through localized synthesis of androgens. 
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Chapter 1.' Introduction 
1.0 INTRODUCTION 
Polycystic ovarian syndrome (PCaS) affects approximately 10% of all women of a 
reproductive age and is one of the most commonly occurring endocrinopathy. pcas 
is recognised as a reproductive disorder and manifests through infertility, chronic 
anovulation, and hyperandrogenism (see 1.6). Pathogenesis is yet to be determined. 
1.1 Structure and function of the ovaries 
Understanding ovarian anatomy, morphology and typical biochemical function, is 
essential to understanding polycystic ovarian syndrome as an endocrinological 
disorder as well as its relationship to infertility. 
The ovaries are the female organs essential to fertility through their production of ova 
and synthesis of the hormones progesterone and oestrogen. These hormones are 
responsible for sexual development and regulation of the menstrual cycle through 
their ability in such actions as stimulation of endometrial and uterine growth [1]. 
Mesentery membranes from the broad ligament of the uterus suspend the ovaries 
(Figure 1). They also support and house the ovarian artery, ovarian vein, lymphatic 
vessel and nerve fibres. Each ovary rests within a depression on the ovarian fossa 
toward the lesser pelvis and are around 2cml4cm across decreasing in size with the 
age of the individual [2, 3]. 
Broad 
Ligament 
\ 
1 
Fallopian 
tube 
Figure I. Female Reproductive System showing the major organs including the cervix, uterus 
and ovaries. (Diagram adapted from http://3.bp.blogspot.com) 
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Chapter J: Introduction 
The outer structure of the ovary consist of columnar cuboidal cell forming the 
superficial epithelium, which alters at the hilum, the point of attachment for th 
mesentery. The internal ovarian structure combine the outer portion cortex and inner 
medulla (Figure 2). 
Arteries 
and veins 
Medullaty 
regiOn 
Figure 2. Anatomy of the ovary howing tage of fo ll icular de elopm ot. Picture adapt d from 
IIwww.mc.vanderbit.edu 
The outer portion consists of thin connective ti ue, tunica albuginea allowing a 
spongy protective membrane. The cortex is made up of tromal cell creating a fibre 
network, follicles and corpora lutea. The cortex upport germinal end crine and 
vascu lar elements such as the follicles or the corpus luteum. Typically within P 0 
thi surface area shows a cy t like appearance whereby follicles are halted during 
development (see Figure 14). 
1.1.2 The menstrual cycle and hormonal mechani m 
The orchestrated release of hormones during the men trual cycle allow the build up 
of the endometrium through oestrogen stimulated mitotic divi ion of the glandular 
epithileum in the stroma in preparation for oocyte relea e and po ible fertili ation 
during conception. Failing fertili ation the lining i hed (men e due to a reduction 
in oestrogen and progesterone whjch leads to con tnction of piral arterie and 
subsequent tissue necro i [4]. The menstrual pba e la t on average from 2. to 7 
days [5] . The key endocrine features oftbe men trual cycle are illu trated in Figur 3. 
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Figure 3. Concentrations of pituitary and ovarian hormones during the menstrual cycle. The 
chart shows the varying levels of key hormones required within the menstrual cycle and their 
relationship to the stages of follicular development. (Adapted from the http ;llwww.britannica.comi 
EBcheckedltopic/498625/human-reproductive-system). 
The menstrual phase is followed by the follicular phase, whereby the rise in follicular 
stimulating hormone (FSH) allows folliculogenesis (see 1.2). The follicular phase is 
also known as the proliferative phase and an increase in oestrogen secretion through 
folliculogenesis creates new formation of the endometrial lining generated from the 
stratum basale, or base epidermal layer. Once oestrogen levels reach their threshold, a 
midcycle gonadotrophin surge occurs which allows maturation of the ovum within the 
pre-ovulatory follicle and ovulation. Oestrogen is secreted increasingly via the 
developing follicles in response to FSH and circulating levels increase. At threshold 
negative feedback occurs inhibiting pituitary release of FSH. At this point the follicles 
begin atresia whilst the most developed follicle develops receptors for luteinising 
hormone (LH) and FSH allowing sufficient support for maturation. The mature 
follicle continues to increase estradiol secretion allowing positive feedback. This 
results in hypothalamic gonadotropin releasing hormone (GnRH) secretion and 
subsequent high-level pituitary secretion ofLH and FSH (midcycle surge). LH release 
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allows weakening of the follicle wall and initiation of ovulation. Ovulation typically 
occurs around the 13th day of menstruation. At this point formation of an opening 
within the pre-ovulatory follicle (stigma) allows excretion of the oocyte and 
" progression down the fallopian tube through fimbra tissue motion. Under the correct 
conditions the oocyte may now undergo fertilization and become implanted within the 
uterus [5, 6] 
The final luteal phase occurs following ovulation and the remammg follicle 
transforms into the corpus luteum following increased levels of LH during the 
midcycle gonadotrophin surge allowing trophic support. The formation of the corpus 
luteum allows steroidogenic production of high levels of progesterone and 
maintenance of the endometrium until eventual atrophy in the absence of fertilisation. 
The corpus luteum suppresses FSH and LH levels through its production of 
progesterone, this eventually leads to its atrophy due to the lack of luteotrophic action 
via LH. Degradation of the corpus luteum reduces progesterone secretion. 
The luteal phase, also known as the secretary phase, incorporates decreasing levels of 
progesterone and triggers menstruation along with the shedding of the endometrial 
lining. This is a result of insufficient levels of progesterone supporting maintenance. 
With the absence of progesterone, LH and FSH levels are able to increase and in 
doing so trigger degradation of the corpus luteum. This in turn leads to its 
transformation through breakdown, to the corpus albicans. This is seen as scar tissue 
and is eventually re-absorbed by the ovary. 
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1.1.3 Key hormones within the menstrual cycle 
Throughout menstruation steroid hormones alter significantly III response to their 
requirement within the reproductive cycle (Figure 3). The menstrual cycle utilises the 
interaction of the following hormones in order to initiate and proceed: 
Hormones related to the menstrual cycle Produced Menstrual function 
Gonadotropin releasing hormone Hypothalamus Stimulation of FSH and 
(GnRH) LH secretion 
Luteinizing hormone (LH) Anterior Maintaining luteal 
pituitary function and triggering 
ovulation 
Follicle stimulating hormone (FSH) Anterior Induces proliferation and 
pituitary development of 
folliculogenesis/gametog 
eneSlS 
Oestrogen Ovaries Reproduction and sexual 
development acting as a 
growth hormone for 
tissue (endometrium) and 
is vital within 
Estriol Placenta Reproduction and sexual 
development 
Progesterone Ovaries Steroid hormone 
involved in the menstrual 
cycle and pregnancy 
Androgen Ovaries and Sexual development, 
adrenals regulation of liver and 
kidneys 
Table l. Hormones relating to the menstrual cycle. 
Gonadotropin releasing hormone (GnRH). Synthesized and released in low 
frequency pulses from the hypothalamus and is responsible for the stimulation of FSH 
and LH secretion. It has been acknowledged that hyperinsulinemia found in peos 
encourages increased pulsatile secretion and results in increased LH levels (see Table 
1 and 1.1.2.). 
Luteinising hormone (LH). Produced in the anterior pituitary and responsible for 
maintaining luteal function and triggering ovulation. It also plays a key in the 
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hypothalamic pituitary ovarian axis (HPO axis) in its actions in ovulation and 
luteolysis (see Table 1 and 1.4) [7]. 
Follicle stimulating hormone (FSH) is stimulated by the anterior pituitary gland and 
is responsible for regulation of follicle growth and development. FSH also induces 
proliferation and development of folliculogenesislgametogenesis along with LHIFSH 
receptor expression within theca/granulosa during menstruation and the following 
follicular phase (see Table 1 and 1.4) [8] . 
Oestrogen. The primary female sex hormone exist in three forms estrone, estradiol 
and estriol. Estrone is secreted via the ovaries and stored in fatty tissue. Estrone is 
typically stored for later conversion to its more active form estradiol [9, 10]. Estradiol 
is the predominant sex hormone produced within the ovaries and responsible for many 
functions within the human body including; liver lipoprotein synthesis, brain 
antioxidant formation and bone maintenance. It is also vital within female 
reproduction and sexual development acting as a growth hormone for tissue 
(endometrium) and is vital within folliculogenesis for development (see 1.6) [9]. 
Estriol is only produced during pregnancy and can be used as either a weak or strong 
oestrogen. 
Progesterone. Derived from cholesterol through the conversion of pregnenolone. It is 
a steroid hOlmone involved in the menstrual cycle and pregnancy and is vital for 
initiation and maintenance of the endometrium along with initiation of luteal phase of 
menstruation (see Table 1 and 1.4). 
Androgens. These are vital to female metabolism produced predominately via the 
ovaries and adrenals and allow hormonal cascades such as puberty to be initiated in 
both males and females. They play key roles in regulation of organs including the 
liver and kidneys [11], and are important in muscle and bone development [12, 13]. 
Female androgens consist of dehydroepiandrosterone sulphate (DHEAS), 
dehydroepiandrosterone (DHEA), androstenedione, dihydrotestosterone (DHT) and 
testosterone. DHEAS, DHEA and androstenedione are considered pro androgens, 
precursors to testosterone with weak androgenic effect (Figure 4). 
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Figure 4. Female Androgen Synthesis within the Ovaries. (Adapted from Rosenfield, 1999a). 
Increased plasma testosterone and androstenedione has been seen during the mid 
cycle phase of the menstrual cycle. This suggests increased levels of androgen 
synthesis exist at this stage supporting its links to sexual health and maintenance (see 
1.4) [14-16]. The functions of androgens are physiologically diverse, and can have 
effects on regulation of metabolic activity including proliferation and biosynthesis. 
This has been seen within many tissue types including adrenal, muscle and adipose 
tissues [17-19]. Androgens are also regarded as a steroidogenic precursor necessary in 
the biosynthesis of testosterone and oestrogen [20]. 
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1.1.4 The hypothalamic-pituitary axis 
Regulation of the menstrual cycle occurs through the hypothalamic pituitary axis 
whereby hypothalamic pulse secretion of GnRH induces pituitary hormone secretion 
of LH and FSH and subsequent ovarian hormone activity (FIpre 3)[21]. A 
positive/negative feedback mechanism is utilized to sustain this monthly endocrine 
cycle as shown in Figure 5. Steroid hormone levels run in parallel to the phases of 
menstruation directly influencing the activities within each phase [22]. 
Step 1: Follicular phase 
folliculogenesis is initiated through FSH secretion stimulated via GnRH pulses from 
the hypothalamus. Initiation of follicular phase stimulates development of up to 20 
follicles per cycle allowing increased follicular secretion of oestrogen. Rising 
estradiol levels exert negative feedback on the hypothalamus decreasing GnRH 
secretion. Negative feedback is also present at the pituitary, decreasing its sensitivity 
to GnRH, resulting in reduced FSH secretion, which inhibits further follicle 
development (see 1.4). All but one follicle undergoes atresia due to the reduced levels 
of FSHlLH, however, the dominant follicle up-regulates FSWLH receptors 
facilitating further maturation [5,21,23]. 
Estradiol eventually reaches a threshold causing positive feedback on the 
hypothalamus, at which point an LH surge occurs (Fipre 3), which acts on the 
dominant follicle. The LH surge allows maturation of the egg and rupture of the 
follicle wall through luteinisation. This stimulates ovulation and the release of the 
oocyte into the fallopian tube. [24] 
Step 2: Luteal pbase 
The remaining ruptured follicle transfonns under the influence of FSHlLH, into the 
corpus luteum. Transfonnation allows increased progesterone and oestrogen secretion 
leading to suppression of FSH and LH (negative feedback). Failing fertilisation, 
progesterone will reach threshold. The decrease in concentration removes FSHlLH 
inhibition and these conditions will result in menstruation (Figure 3, Figure 5). 
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Step 3: Menstrual phase 
Atrophy of the corpus luteum through insufficient progesterone/estradiol levels; 
transform it into the corpus albicans after 14 days. Progesterone levels decrease 
further allowing removal of the feedback mechanism lifting inhibition of FSH 
secretion, which begins the cycle again. This whole process will occur over the 28-32 
day period of the menstrual cycle [25]. 
Removal ofNegallve 
Feedback I 
Ovulallon 
Decreased Progesterone 
and Estradiol Secrellon 
I Atresia of Corpus Luteum 
Increased FSH 
Secretion by Piturtary 
Gland 
Increased progesterone and 
Estradtol Secretion by the Corpus 
Luteum 
Menstruation 
Lutmeization of 
Follicle 
FSHInduced 
Increased Estradiol 
Secrellon by Follicles - Negative 
Feedback I Poslllve 
Feedback Decreased FSH 
and LH Secretion by 
LH Surge and Pituitary Gland 
FSH Ulcrease by 
PltU1tary Gland 
Figure 5. Positive and Negative feedback mechanisms of menstrual hormones. The flow chart 
shows positive and negative feedback mechanisms and their effect on hormonal secretions during the 
menstrual cycle. 
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1.2 Folliculogenesis 
The ovaries are responsible for dual functions of steroid hormone ynth i and 
gamete production (see 1.3.1)[26]. The follicle and corpora lutea are the main 
ovarian structures vital to reproduction (see 1.4). From birth the 0 arie contain a 
number of immature primordial follicles (around 7 million each containing an 
immature oocyte [24, 27, 28]. Folliculogene i the proce by which mall 
primordial follicle mature into pre-ovulatory follicle and enter the men trual cycle 
as shown in Figure 6 [6]. This proce act continuou Iy throughout the ti mal 
reproductive lifecycle whereby at any point multiple follicl will e i t 
simultaneously at tage of development from re ting primordial to d minant 
ovulatory [6, 29]. The primordial follicle consi ts of one cell layer of granul a 
ranging in size from 0.03-O.05mm [30]. Maturation involve oocyt grO\i th and F H 
receptor synthesis. A glycoprotein polymer al 0 form around the 0 yt allowing 
separation from the urrounding granulo a [2 31] . 
Pr.-:ltItnl 
(0.2 mm) 
Late T ertlary Stage 
I Early Tertlary Stage I 
/ 
o E:lrIy :on O"a' e 
20 mm 
\ 
I 
I 6 5 ~ ~ ~R R ~ I I~ n ; ; ; , ,~ : : - - . ; ;0 ~ ~ ® = 0 ~ _: . ._ . : : :__ =_.:: __ :: __ ~ ~_____________________________________ __ . ____________ _ 
> 1 2 0 d l ~ ~ I Second Stage I 
Figure 6. 375-da cycle offollkulogene i howing the follicle progre ion thr u b d I pment 
from re ting to dominant. (Diagram adapted from hup://www.ncbi .nlm.nih.go 
During the econd stage of folliculogene i , granulo a proliferation incre th 
follicle to 0.0 I mm in diameter. Continued development allow the emergence of a 
fibrocellular envelope of thecal cells urrounding multiple layer of granul a and 
doubling the follicles size to 0.2mm (Figure 6). At this point formation of the antrum 
occurs cushioning the oocyte in a fluid cavity [2 29]. Thi i known a the tertiary 
pha e, which is con idered in two part ; early (graafian) and late. The ecr ti n f 
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LH from the pituitary (see 1.1.3) begins allowing the stimulation of androgen 
fonnation and eventually leading to oestrogen production through aromatization 
within the granulosa cells (see 1.3.2). Late tertiary phase is only reached by the 
primary follicle which progresses to pre-ovulatory through the secretion of oestradiol 
and FSH signalling. At this stage the follicle can reach 20mm in size before entering 
ovulation. 
1.3 Steroidogenesis 
Steroidogenesis is the de novo fonnation of steroid honnones via the transfonnation 
of existing steroids or the biosynthesis of precursor carbohydrates [25]. Various 
pathways of human steroidogenesis exist leading to the production of three classes of 
steroid honnones: Mineralcorticoids such as aldosterone; Glucocorticoids, including 
cortisol; and sex steroids, oestrogen, testosterone and progesterone. These pathways 
including PI3-K, cAMP and MAPK, are present within specialized cells throughout 
various steroidogenic organs such as the adrenal gland (zona glomerulosa I fasciculate 
I reticularis cells) as shown in Figure 7 [32], and the ovaries (granulosa I thecal cells) 
as shown in Figure 10 [20, 33]. 
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Figure 7. (A) Compartmenta li ation of adrenal cell (8) drenal cell teroidogeneic path, a . 
The adrenal ce ll is made up of the Zona glomerul us. fa e ieulata and intermedia ( 
steroidogenesis occurs through compartmentalisat ion. (Diagram adapted 
www.endotex t.orgladrena l/adrenaI26/adrenaI26.) 
where 
from 
Ovarian function i dependent on the combined action of LH on thecal cell and F H 
on the granulosa cells activating bio ynthetic pathway (Figure 5) [I] . In re p n e the 
'Two cell model of ovarian stcroidogene i ' dictate tran portation of thecal 
steroidogenic products to the granulo a where, through the influence of F H on 
granulosa, activation of many gene, promoting proliferation and differentiation occur 
including MAP2D, inhibin-a and VEGF [34]. Furthermore FSH timulate up-
regulation of LH receptor and aromata e expre ion and therefore encourage, 
oe trogen formation (Figure 10) [9]. Eventually the required androgen ynthe i 
decreases due to ovulation and inhibition of FSH ecretion occur through increa ed 
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progesterone levels (see 1.4). This prevents maturation and initiates atresia of the 
undeveloped follicles [27, 35]. 
1.3.1 Regulation and transportation of steroidogenic precursors 
Cholesterol conversion occurs within the mitochondria as the fIrst rate limiting stage 
of steroidogenesis. Regulation is the result of cholesterol transportation via 
steroidogenic acute regulatory protein (StAR) to the internal mitochondrial membrane 
(Figure 8.)[36]. 
MoVDlTKlf'll into the inner 
mitochondrial rnGmbranG is 
1ha ratQ.jiniting stap 
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Figure 8. Cholesterol transportation to mitochondria within steroidogenesis. The importance of 
Star as a transport protein for movement of cholesterol across the mitochondrial membrane can be 
seen. (Diagram adapted from Arukwe, 2008). 
The two stage process begins with sterol transfer to the mitochondria through sterol 
carrier proteins (SCP-2)[37]. This stage is seen as non-essential, with compensatory 
methods of transportation existing in the absence of SCP-2. Typically within gonadal 
and adrenal steroidogencisis, transport occurs through StAR activity [38]. Increased 
StAR concentrations are found in the absence of SCP-2 supporting its importance as a 
primary transportation mechanism [39]. 
Stage two sees cholesterol translocation from the cholesterol rich exterior 
mitochondrial membrane, to the cholesterol poor interior. This process again utilises 
StAR which is required to translocate the largely hydrophobic cholesterol across the 
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aqueous phase between membranes [40]. The exact mechanism of cholesterol 
translocation is poorly understood. Structural alterations within the mitochondrial 
membrane are believed to allow cholesterol passage to its interior. However a loose 
association of StAR to its exterior exists during transportation [39, 40]. This may 
suggest StARs role in a larger molecular pathway through the inefficiency of this 
mechanism. 
Regulation of thecal steroidogenesis is primarily through LH action acting through 
cAMP dependent protein kinase A (PKA) [41]. With insulin and LH now believed to 
act both independently and synergistically in androgen synthesis when examined in 
both porcine and human theca cells in vitro, there maybe an association with the 
increased levels found in PCOS patients and the subsequent hyperandrogenmia. 
Furthermore these levels may therefore be linked to up-regulation of steroidogenic 
proteins such as CYP17 or StAR. It bas also been shown that co administration of 
insulin and cAMP analog 8-BR-cAMP increased progesterone precursor as well as 
StAR gene expression in porcine theca [42]. Examination of StAR expression within 
pcas theca has also shown increases over size matched control foUicles and may 
therefore offer a target for dysfunction in the regulation of androgen biosynthesis at 
this stage in the insulin signalling pathway [43]. When examined under insulin and 
LHlforskolin treatments no significant variations between PeOS and matched 
controls were seen [44]. Similar experiments ~ ~ Munir et 01., 2004 on ovarian theca 
of non-PCOS patients have shown increases in CYP17 expression and activity under 
insulin, LH and forskolin treatments [45] making its position in androgen biosynthetic 
pathway our focal point for a possible dysfunction in PCOS 
1.3.2 Steroidogenesis: substrate convenioDI 
The conversion of cholesterol to pregnenolone occurs in three chemical phases: 20 u-
hydroxylation, 22-hydroxylation and scission of the cholesterol side chain. P4SOscc is 
the single enzyme required for all three reactions [46, 47]. The first two chemical 
reactions hydroxylate the carbon atom at its structural points C-20 and C-22 before 
finally cleaving these bonds [48]. 
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Figure 9. Mitochondrial pregnenolone and progesterone synthesis. The process of cholesterol 
transformation to pregnenolone occurs within the mitochondria (Diagram adapted from Chapman et aI. , 
2005)[49). 
As with all P450 enzymes, P450scc is membrane associated, containing a single 
active site in contact with the hydrophobic bilayer. The sterol substrate remains bound 
to the site due to tight binding reactive intermediates. This results in cholesterols 
commitment to the reaction (see 1.10.2)[50]. The conversion of pregnenolone to 
progesterone subsequently occurs through 3 ~ - h y d r o x y s t e r o i d d dehydrogenase ( 3 ~ ~
HSD) action within the endoplasmic reticulum (Figure 9). 
Research into the expression of both P450scc and 3 ~ - H S D D 10 in vitro PCOS theca 
against matched controls ha shown no variation in mRNA levels under basal 
conditions [51]. However Nelson et aI., 200 I demonstrated that under forskolin 
stimulation 3 ~ - H S D D mRNA expression is increased in non-PCOS theca cells and still 
further in in vitro cultures of theca obtained from women with PCOS, suggesting a 
possible increase in PCOS sensitivity to LH [52]. Further evidence however by 
Comim et al., 2011 recently examining both 3 ~ - H S D D and CYP17 protein expression 
through quantitative immunohistochemistry concluded no significant variation in 3P-
HSD expression between non-peaS and peas theca cells [53] . Their results do 
however provide consistent evidence pointing to abnormal levels of CYP 17 
expression within peas theca cells, which suggests its more primary involvement in 
thecal dysfunction. 
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Figure 10. Steroid biosynthetic pathways, two-cell model of 0 arian teroidogene i . (Diagram 
adapted from Rosenfield, 1 999a). 
Steroid biosynthesis relies on the availability of precur or and enzymatic 
concentrations along with hormonal and cellular regulation [54] . Pregnenolone i the 
precursor for the synthesis of all ovarian teroid and bio ynthesi i dependent on it 
conversion by steroidogenic enzyme such a CYP 17 (17u- hydro yla e and 17,20-
lyase) and steroid oxido-reductase. Some of the e enzyme are Dot limited to ingle 
processes within a pathway a shown within Figure 10. YP 17 i active within both 
ovarian steroidogenesis and adrenal teroidogene is [9, 55, 56J and ha been 
associated to hyper ecretion within ovarian steroidogeneisi . Thi ha led to it 
current focus in PCOS research, and to date no variation III expre ion or acti ity 
have been reported for adrenal biosynthesis. 
All tissues require P450 enzymes, allowing the metabolism of mall hydrophobic 
molecules involved in metabolic and biosynthetic reaction [57]. teroidogenic P450 
resemble these with similarities such as membrane a ociation and active heme ite 
for substrate 0 2 and C02 binding. 0 2 and C02 compete for the e binding ite and can 
subsequently inhibit (C02) or activate (02) [47, 57]. Steroidogenic P450 do, howe er, 
differ in their mono oxygenation catalysation of specific part of molecule (teroid), 
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and within the series of these reactions which results in C-C bond cleavage and 
aromatization of steroid rings [57]. 
1.3.3 Ovarian steroidogenic enzymes and biochemical action 
The main enzymes involved in ovarian steroid biosynthesis are P450scc, P450c 17 3J3-
HSD, 17B-HSD and P450arom (Figure 10). P450scc acts through three mono 
oxygenations, hydroxylating the cholesterol bonds C-22 and C-20 followed by their 
cleavage. The hydroxylated intermediates then bind readily to P450scc, causing 
pregnenolone to dissociate from the enzyme as seen in Figure 9 [40]. P450scc is 
present in all steroidogenic tissues and its expression within the ovaries is typical to 
thecal cells. Its occurrence within the granulosa is dependent on the phase of follicle 
development and P450scc can increase a hundred fold within the corpus luteum [49]. 
Increased levels of both P450scc and 3B-HSD mRNA have also been seen during this 
phase suggesting enhanced transcription and their importance in progesterone 
synthesis. This increase is believed to relate to gonadotropin activation; with 
mitochondrial hydroxysteroid dehydrogenase (HSD) activity highest at the peak of 
LH secretion during ovulation [40, 49, 58]. With hypersecretion of LH typically 
associated with pcas the importance of both P450scc and 3B-HSD in the regulation 
of androgen synthesis can be seen, however as yet no variation between pcas and 
matched controls in either adrenal or ovarian androgen pathways has been determined 
(see 1.3.2). 
CYP17 (P45OC17 / 17a-hydroxylase/17,20 lyase/17,20 desmolase) is a cytochrome 
located within the cytosol and associated with enzymatic action on pregnenolone and 
progesterone, specifically within the PI3-K pathway (see 1.4.2)(Figure 10). It has 
been shown that LH stimulates CYP17Al mRNA expression in vitro porcine theca 
with similar results seen using forskolin in cultured human theca cells. These findings 
therefore suggest that LH may be associated with increased androgen synthesis and 
work by McAllister et al., 1989 has shown this to be true in non-PCaS human 
cultured theca [59, 60]. CYP17 is the steroidogenic enzyme responsible for two key 
reactions; 17a-hydroxylation of C-21, typically related to ovarian steroid biosynthesis, 
and cleavage of C17-C20 bond of C-21 steroids (Figure 10). The concentrations of 
CVP 17 correlate to the stage/size of pre-ovulatory follicles with increased CYP 17 
found with increased follicle size [45, 57]. CYP17 has substrate species specifity. For 
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example rat CYP17 has the ability to convert 17-0H-pregnenolone and 17-0H-
progesterone into OHEA and androstenedione allowing detenninations of androgen 
biosynthesis via pregnenolone or progesterone whereas human CVP 17 can only 
cleave the 17-0H-pregnenolone bond [46]. This limits the parameters of the human 
androgenic pathway but at the same time emphasises the possible versatility shown in 
other species. 
Ovarian 3P-HSD exists within the thecal cells acting to convert pregnenolone to 
progesterone before passage to the granulosa cells (see 1.JO)(Figure 10. Figure 4 [8]). 
3P-HSO has two major catalytic activities acting to convert 3p hydroxy-5-ene steroid 
into 3-keto-4-ene steroids. Two forms of 3P-HSDs exist (type I and II) both capable 
of using the substrates pregnenolone, 17-0H-pregnenolone and DHEA [61]. Although 
no variations in basal expression of 3J3-HSD has been seen within non-PeOS against 
peos thecal or adrenal samples the possibility of variations in its activity do exist 
(see 1.3.2) [53]. 
178 -HSO (17P-hydroxysteroid 117-keto-steroid reductase) is responsible for the final 
stages of androgen and oestrogen synthesis. It acts in the reversible conversion of 17-
keto and 17P-hydroxy groups into androstenedione, OHEA and 17B-estradiol either 
through oxidation or reduction. (Figure 10) [62]. In ovarian steroidogenesis 17P-HSD 
is found within theca cells and is believed to regulate androgen and oestrogen 
synthesis through substrate availability and catalysation [63]. Current knowledge 17P-
HSO suggests no variation exist in ovarian or adrenal activity of 17 P-HSO [52]. 
P450arom is expressed within the granulosa of the ovary, catalysing the conversion of 
androstenedione and testosterone to 17p-estradioVestrone. Specific P450arom action 
and location are species specific, with human expression found in the placenta, 
adipose and ovaries. P450arom expression is only maintained within luteinized 
granulosa [25, 46]. Increased FSH binding to granulosa membrane receptors in the 
luteal phase is linked to 17P -estradiol synthesis. It is believed that subsequent rises in 
intracellular cAMP as a result of this stimulates P450arom expression [9,46]. 
18 
Chapter 1: Introduction 
1.4 Insulin and steroidogenesis 
Insulin is secreted from pancreatic islets lof langerhans and is vital in maintaining 
energy homeostasis through cellular regulation of glucose. In the absence of insulin, 
body fat is used as an alternate source of energy through lack of glucose uptake. This 
is seen through the transfer of lipids from adipose to the liver for lipolytic processing 
[64]. 
Insulin's ability to stimulate steroidogenesis is unknown. Within the ovaries, it is 
possible it acts directly in stimulating ovarian androgen secretion and/or augmenting 
LH stimulated ovarian secretion. Evidence by Munir et a/., 2004 supports this and has 
shown progesterone conversion is activated by insulin action alone within the PI3-K 
pathway and through the involvement of the insulin receptor [33, 45]. It is also 
possible insulin may act indirectly in stimulating pulsatile LH release via GnRH with 
insulin shown to augment GnRH stimulation of LH gene expression. This would 
therefore suggest that insulin regulation of the reproductive axis maybe effective 
through its effects on pituitary activity [65]. High levels of circulating insulin and 
IGF -I have been shown to lead to decreases in serum hormone binding globulin 
(SHBG) and insulin like growth factor binding protein I (IGFBP-I). Research into 
examination of physiological levels has suggested that this leads to free IGF in turn 
stimulating androgen synthesis [66]. As IGF-l is similar in structure to insulin it 
stimulates androgen synthesis in a similar manner and is capable of activating the 
insulin-signalling pathway through PI3-K both through binding to its own receptor as 
well as IRS. IGF-l is a polypeptide hormone produced by the liver. Its effects 
however are twofold less effective in stimulation than insulin with regard to androgen 
synthesis [67]. 
SHBG is a glycoprotein produced by the liver that binds to sex hormones (oestrogen, 
testosterone) to allow their circulation. Free or unbound sex hormones are considered 
biologically active. Decreased SHBG levels leads to more unbound steroids and 
therefore more circulating biologically active sex hormones [20]. 
Insulin action typically precedes the onset of hyperandrogenemia possibly acting 
alone or with direct stimulation of androgen secretion and/or augmented LH 
stimulated LH secretion [68]. Alternately, it has been proposed that the indirect action 
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of insulin may enhance GnRH pulses as inc rea ed LH ecretion act to timulat 
increased pituitary LH secretion (see 1.4) [69]. 
1.4.1 Ovarian steroidogenesis and the Insulin signalling pathway 
lnsulin stimulates ovarian androgen through it own rec ptor [70] . The in ulin 
receptor is a heterotetramer consisting of two ligand-binding a ubunit and two 
tyrosine kinase p subunits (Figure 11) [71]. Its action occur through its e tracellular 
binding to the a-subunits of the insulin receptor (IR) (Figure 11). A conformational 
change within the ,B-chain (IR,B) activates its tyro ine kina e domain [72] and 
downstream activation of insulin receptor substrate IRS-l [73] compartm ntalizing 
the signal through multiple intracellular pathway , including pho phatidylino itol- -
kinase and MAPK. 
~ G I= ~ ~ ' '
up!.Jk. 
Figure II. Insulin receptor and activity \ ithin human theca cell. (Taken from Diamanti-
Kandarakis E ct aI. , 2007). 
These intracellular interactions are central in signal transduction allowing actions uch 
as translocation of GLUT4 vesicles to the plasma membrane [71 , 74-76]. 
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Phosphorylation of IR/J on serine residues results in inhibition of IR/J tyrosine 
phosphorylation and can result in interference of insulin action although insulin 
binding remains unaffected [77, 78]. 
Studies have shown increased serine phosphorylation of IRP and inhibition of IRS-l 
can be seen as a mechanism of insulin resistance [14]. Furthermore serine 
phosphorylation of CYP17 can increase androgen biosynthesis (Figure 12) [14]. 
Some women suffering from pcas have been shown to have increased serine 
phosphorylation of IRP and IRS although the mechanism leading to serine 
phosphorylation is uncertain [79]. The possibility exists as to extracellular 
serine/threonine kinase causing receptor activation. Alternatively, inhibition of 
serine/threonine phosphatases may be involved. An example of this is suggested by 
Guo and Damuni (1993) who have shown that inactivation of protein phosphatase 
2A2 (PP2A2) may contribute to increases in intracellular proteins in response to 
insulin and other mitogens [14]. 
Posltlv. Regulator(s) P450c17 , 
[ KINASE,S) I 
T 
.,...r0 Negatlv. Regulator(s) P45Oc17.s.0 
1 1 
1n .. lnR ...... nce Hype .. ndropnemla 
Figure 12 Serine Phosphorylation of IR- II and CYPI7. The serine hypothesis proposes serine 
phosphorylation through dominantly inherited kinase(s) that lead to insulin resistance and increased 
androgen biosynthesis. (Diagram adapted from Bremer 2008). 
It has also been suggested that a gain of function genetic mutation common to both 
pathways may exist and lead to hyperandrogenemia (Figure 12) [80, 81]. Both 
insulin and IGF-l, a polypeptide hormone similar to insulin and crucial in glucose 
metabolism, stimulate androgen synthesis via PI3-KlAkt [82]. It is possible that 
hyperandrogenism and insulin resistance within pcas is linked through a single 
serine phosphorylation mechanism (kinase) the result of a post-binding, gain of 
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function irregularity [14]. Although this theory potentially explain two of th major 
features of PCOS (insulin resistance and hyperandrogenernia re earch ha fo u d 
entirely on ovarian dysfunction. Furthermore examination of PCO patien has 
determined that only a mall proportion eern to ha e increa d nn 
phosphorylation ofIRP [14]. 
1.4.2 Phosphatidylinositol 3-kinases 
Phosphatidylinositol 3-kinases (PI3-kina es or PI3-Ks) are intracellular ignal 
transducer enzymes that phosphorylate the hydroxyl group of ph phatid lin it I 
inositol rings (Figure 13) [83]. 
Signalling events such as insulinlIGF-1 receptor binding allow pr duction of 
phosphorylated lipids at cellular membranes ub equently leading t the re ruitm nt 
and activation of various signall ing component . 
o 
OH 
:r 
Figure 13. Structure of Phosphatidylino ito!. (Taken from Karpova e l al. . 2006)[ 4]. 
These lipid products act as both membrane anchor and regulator allowing 
activation of downstream enzyme and sub equent protein ub trate [5]. In ulin 
signalling utilises lipid binding to PH domains of pho photidylino itide-depcndent 
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protein kinase (POK) and protein kinase B (PKB/Akt), regulating PKB 
phosphorylation. This mechanism is used in switch regulation of serine/threonine-
specific kinase cascades such as insulin [86]. 
Phosphorylation of phosphatidylinositol lipids occurs in response to cell stimulation 
by growth factors and hormones, allowing a coordinated cascade leading to cell 
growth, migration and/or survival. This process occurs through interactions with 
intracellular signalling proteins contained within the cytosol that accumulate at 
membranes during stimulation and prime protein kinase cascades. These include 
serine-threonine kinases and protein tyrosine kinases along with heterotrimeric 
guanosine triphosphate (GTP)-binding proteins (G proteins) and utilise specific 0-3 
phosphorylated phosphoinositide domains allowing tight chemical binding [83, 84, 
87]. 
Protein Kinase B (PKB) also referred to, as Akt exists in three isoforms termed PKBa, 
PKBL, and PKBQ. It is expressed in all human somatic cells. It can be activated 
through exposure to insulin allowing the critical link to insulin receptor activation of 
the PI3-K pathway [88]. Once the insulin receptor is activated PKB is recruited to the 
plasma membrane through a PI3-K dependent mechanism. This is accompanied by 
the phosphorylation of Thr'OA and SeT''' on the insulin receptor, activation of IRS-I and 
subsequent downstream activation ofPKBa [85, 88]. 
There are multiple forms of PI3-K falling into 3 classes. Typically class Ia are 
responsible for 0-3 phosphoinositide production through growth factor response and 
other stimuli, with class II and III varying through structural C2 domains located on 
the C-terminus [89]. Little is known about the functions of class II and III PI3-K and 
is yet to be fully examined as point of dysfunction within PCOS insulin signalling of 
steroidogenesis. 
Ovarian steroidogenesis utilises this pathway in the biosynthesis of androgen. 
Research suggests the involvement of class II PI3-K due to the high presence of PI3-
K-C2P found within ovarian theca [90]. 
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I.S Luteinising Hormone and associated androgen biosynthesis. 
Intrinsic control of androgen biosynthesis within bovine theca has been shown 
through LH secretion and contributory GnRH agonists [59]. Research using both 
human and animal models has also suggested increased androgen synthesis through 
the individual effects ofLH in both non-peOS and PCOS women [42, 59, 91]. 
As early as 1958 elevated LH levels were recorded in women with PCOS [92]. 
however experiments by Rebar et al., 1976 showed evidence of wide clinical 
presentation of peos involving normal LH concentrations [93]. The concept of 
peos presenting with LH hypersecretion was later seen as secondary to insulin 
resistance and not a diagnostic marker [94]. Studies began to focus more on ovarian 
steroidogenesis when hyperandrogenemia was seen to persist even on suppression of 
adrenal steroidogenesis through dexamethasome inhibition [95]. These studies 
support the concept of functional ovarian hyperandrogenism in PCOS [96]. 
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1.6 Polycystic ovarian syndrome 
Polycystic ovarian syndrome is the commonest ovarian endocrinopathy affecting up 
to 10% of women of reproductive age (9) and is associated with significant short and 
long-term consequences. At least 30% of all those afflicted with the syndrome show 
all the symptoms [97]. Worldwide prevalence statistics are however only loosely 
accepted due to variability within diagnostic criteria. 
The aetiology and pathogenesis of pcas is largely unknown. It can be defmed as a 
heterogeneous condition characterized by hyperandrogenic chronic anovulation that 
has associations with metabolic dysfunction such as peripheral insulin resistance with 
subsequent hyperinsulinemia [98, 99]. 
In 1935, Stein and Levinthal first described pcas as a condition characterised by 
amenorrhoea, hirsutism, obesity and infertility [100-103]. Their original diagnosis in 
1930 was mainly anatomical and was based on the presence of enlarged ovaries with 
thickened white capsules and multiple sub-capsular cysts. This diagnosis was 
achieved by surgical excision of 25-40% of the ovarian volume[104, 105]. 
The base criteria for pcas diagnosis has always been in dispute, possibly due to the 
absence of a widely accepted underlying mechanism. The National Institute of Health 
(NIH)lNational Institute of Child Health and Human Development (NICHD) 
conference in 1990 was the first to define diagnostic criteria for pcas. The diagnosis 
of peos was based on the presence of classic hyper androgenism (clinical and/or 
Biochemical), and oligo-anovulation after the exclusion of other androgen excess 
disorders [106]. 
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patients with peas. About 15% of peas women experience amenorrhoea and 10% 
may have regular cycles [117]. 
1.6.1 PCOS: Biochemical features: 
Hyperandrogenaemia is a common feature in peas women affecting about two-thirds 
of cases. It typically manifests as mild to moderate hirsutism and/or acne [118]. These 
features usually present in the peripubertal period or during adolescence [119, 120]. 
Recent studies suggest that hyperandrogenaemia improves with advancing age with 
subsequent improvement of menstrual pattern [26]. 
Hyperandrogenaemia in women with pcas is usually associated with high circulating 
oestrogen levels. This is possibly due to conversion of excessive peripheral androgens 
to oestrone especially in overweight women [121]. It has also been suggested that 
hyper secretion of LH, typical of pcas, may be associated with increased oestrogen 
levels [122]. This may lead to continual exposure of the endometrium to excessive 
unopposed oestrogen without periodic progesterone modulation. This explains the 
increased incidence and earlier presentation of endometrial hyperplasia and cancer 
[123]. This association was first noted by Speert in 1949 [124], with limited research 
into the area to date. Studies by Jackson and Doherty in 1951 are still cited, showing 
37% prevalence of endometrial cancer in peas patients [125, 126]. 
The small ovarian follicles found in peas have small numbers of granulosa cells 
with very little or no aromatase activity, which is the enzyme responsible for the 
conversion of androgens to oestrogen [127]. Those with aromatase activity tend to 
show high levels of oestrogen and FSH receptors. This suggests possible links to 
excess androgen formation [128]. 
Excess circulating androgens in pcas has been linked to alterations in peripheral 
steroidogenesis [33, 129]. Such hormonal dysregulation, which represent a key aspect 
of the pathogenesis of peas, have been the focus of research. Several key regulatory 
enzymes have been extensively investigated including CYP 11 a, CYP 17, 11 p-
hydroxysteroid dehydrogenase, and 5p-reductase [130-133]. Human and animal 
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studies have shown evidence of enhanced levels of both CYP 17 and 17,20-Iyase 
activity, in ovarian theca cells in pcas [134-136]. 
1.6.2 peos: Treatment 
Typically treatment of pcas focuses on insulin sensitizing agents including 
metformin and thiazolidinediones, which aid the reduction of insulin resistance and 
subsequent hyperinsulineamia. Furthermore metformin has been seen to reduce 
hyperandrogenemia and although it is unclear of the direct mechanisms behind this, it 
is understood that it is indirectly linked to both the reductions in circulatory insulin 
and the possible inhibition of steroidogenic enzymes. Research has shown that 
metformin stimulates adenosine monophosphate activated protein kinase (AMP-K) a 
major cellular regulator of lipid and glucose metabolism. In doing so glucose uptake 
is increased [137]. Additionally metformin has been seen to alleviate glucose toxicity 
aiding glyceamic control and lipid regulation [138]. In some cases metformin has 
been shown to inhibit the effects of CYPl7 and may therefore explain reductions in 
androgen levels [139, 140] however contradictory research in human studies has 
shown that no effect is seen suggesting any reductions in androgen is secondary to the 
effects metformin has on insulin levels [141]. 
Similarly to metformin, thiazolidinediones (TZDs) are used to assist insulin 
sensitivity acting through activation of nuclear peroxisome pro.liferator activated 
receptor g (PP ARg) which regulates glucose metabolism and fatty acid storage [142]. 
They also assist in the reduction of androgen levels however this mechanism is also 
unknown. TZDs such as troglitazone have been shown to directly inhibit the 
steroidogenic enzymes 3 ~ - H S D D / CYPI7 however it has been associated with 
hepatotoxicity [141, 143]. This has also been seen with pioglitazone and rosiglitazone 
but is only effective at supra-physiological concentrations [141]. The androgen 
lowering potential of those TZDs in current clinical use may therefore be effective 
through a more indirect mechanism. 
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1.7 Steroidogenesis in PCOS: androgen biosynthesis and hyperandrogenemia 
In pre menopausal women the ovaries are the main sites of testosterone biosynthesis 
(see 1.1.3) [14]. Additional testosterone steroidogenesis occurs within the adrenal 
gland and peripheral conversion of other steroids including androstenedione [134, 
144]. 
The developed ovanan follicle structure utilises the thecal and stromal areas 
surrounding the follicle as the primary site of androgen biosynthesis (Figure 15). 
Following CYP17 activity androstenedione is transported across the thecal membrane 
for aromatization within the granulosa (Figure 10). Failure of aromatization can lead 
to increases in circulating androgen and subsequent clinical consequences. 
Figure 15. Structure of the mature follicle showing the thecal layer surrounding granulosa. The 
granulosa encapsulate the oocyte adding to its protective cushion (Picture taken from 
http:// facu I t y. une. eduicom/abellih isto/secondfollw .j pg). 
Typically, excess androgen formation is believed to be associated with PCOS as a 
result of chronic LH stimulation and subsequent androgen hyper-secretion [144, 145]. 
However, research has shown abnormal steroid biosynthesis both before and after LH 
stimulation in human PCOS thecal culture (see 1.5) [91]. 
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Examinations into excess pcas steroid secretion suggests dysregulation maybe 
prominent at the thecal CYP 17 and 17, 20-lyase level [33, 45, 146]. However the 
effect of LH hypertrophy has not been ruled out. Furthermore, the synergistic effect of 
insulin excess and increased concentrations of IGF on pre-existing, LH-mediated 
theca hyper function cannot be excluded [135, 147]. Research has also seen insulin 
pathway activation through utilization of ovarian insulin receptors, IGF receptors and 
hybrid receptors, which function through combinations of a and p subunits from both 
receptors (see 1.4.1) [148]. 
1.8 PCOS and gonadatropin secretion 
The two cell two gonadotropin model theory states; both FSH and LH are necessary 
within normal follicular development and steroidogenesis (Figure 10). However 
research has shown that low dose LH is sufficient for normal development. 
Furthermore increased serum LH levels have been associated to low fertility rates and 
spontaneous abortion [149]. This can be seen in relation to peas where LH 
concentrations are typically elevated [69]. 
FSH levels have been shown to be disproportionately low and constant in peos 
patients when compared with those of non-PCaS women [150]. This may be 
associated with follicular arrest, although increased inhibin production may also be 
responsible due to its selective inhibition of pituitary FSH secretion and one primary 
cause is yet to be determined. 
A high steady state of circulatory gonadotropin as opposed to the cyclical fluctuating 
levels found within normal ovulatory women, has also been hypothesised to result in 
increased ovanan testosterone, androstenedione, DHEA, DHEAS, 17a-
hydroxyprogesterone and estrone [150, 151]. Increased levels of DHEAS have also 
been found in brothers and sisters of women with pcas suggesting underlying 
inheritance [152]. Alternatively the result of hypothalamic pituitary feedback from 
increased ovarian steroid concentrations may be linked (Figure 3, Figure 5). 
Exaggerated 17-hydroxyprogesterone (170HP) and androstenedione levels have been 
seen in response to gonadatrophin releasing hormone agonist (GnRHa) [135] and 
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human chorionic gonadotrophin (hCG) [153]. These results have suggested the 
syndrome may have a primary dysregulation of ovarian CYP 17 leading to enhanced 
activity of both 17«- hydroxylase and 17,20-lyase in ovarian. 
1.9 Insulln and peos 
The fundamental abnormality in women with pcas can be seen through ovarian 
steroidogenesis, specifically androgens. It is therefore hypothesised that a defect in 
the steroid secreting theca cell is involved [45, 154]. Thecal cells express LH 
receptors, IRs, lipoprotein receptors both HOLs and LDLs, StAR protein, P450scc, 
3B-HSD and CYPI7,all vital to ovarian steroidogenesis [99]. Examination into the 
variations in steroidogenic within PeOS theca cell has yet to pinpoint any dysfunction 
in expression or activity and insulin. 
Hyperinsulinemia has been associated with hyper-androgenemia through in vitro 
studies of cultured pcas theca, where it has been suggested that insulin increases 
progesterone and androstenedione secretion when compared to normal theca cells 
[ISS, 156]. It has been demonstrated that insulin acts via its own receptor within 
pcas cultures, increasing androgen concentrations [157-159]. Human PCOS and 
non-PCOS theca have been shown to increase testosterone secretion through the 
individual effects of insulin and studies have also shown increased androstenedione 
secretion in porcine theca under combined stimulation of insulin and LH [9, 157, 160]. 
Furthermore, recent data has shown a role for insulin and LH in the expression of 
genes encoding StAR and CVP17 in porcine cellular models [42]. Research has yet to 
fully support the individual effects of insulin stimulated androgen within human 
models and reports are contradictory with later studies using monolayer theca cultures 
showing lack of increasing insulin stimulated androstenedione secretion in non-PCaS 
samples [161, 162]. 
Many theories exist toward the etiology of hyper androgenemia within PCDS [14, 33, 
159]. Very few approaches however, focus on steroidogenic regulation utilising 
isolated thecal cells. Our study employs isolated thecal cultures with close regulation 
of the influential factors LH and insulin. In doing so, we have analysed androgen 
synthesis through activation and expression of steroidogenic enzymes CYP 17 within 
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both normal and polycystic ovaries. This allowed us to examine whether protein 
concentrations vary in relation to the existence of possible abnormalities in the 
insulin-signalling pathway theca [135, 153]. 
1.9.1 Insulin resistance in PCOS 
Abdominal obesity (BMIIWHR) is positively associated with increased risk of 
abnormal glucose tolerance with subjects showing marked increases in glucose levels 
[163, 164]. The strong correlation between increases in BMI and gradual increase in 
Glucose Tolerance Test (GTI) severity within peas patients suggests further 
deterioration of glucose metabolism when compared to normal patients [163]. 
Obese peas women tend to be more insulin resistant than obese non-peaS and 
obese non-peaS have been shown to be more resistant than lean Peas patients [165]. 
This suggests that the insulin resistance present in association with Peas is 
independent of obesity and that the co-existence of obesity is an additional albeit 
contributory factor. The Rotterdam consensus panel subsequently recommends 
glucose tolerance tests for obese peas patients recognizing this association [166]. 
Research has shown the pathogenic mechanisms of impaired insulin action are 
complex and multifactorial supporting the heterogeneity of peas. Insulin resistance 
leads to the prevalence of gestational (GDM) and type 2 diabetes (T2DM) and is 
common in peDS. This can subsequently lead to inadequate insulin secretion, p-cell 
exhaustion, insulinopenia and the development of T2D [167]. One theory is that the 
insulin resistance found in peas consequently amplifies the demand for insulin 
secretion via pancreatic beta-cells [168]. This in tum can lead to beta cell dysfunction 
and development of T2D or GDM [169]. It has also been shown that beta cell 
dysfunction is prevalent within peas patients and that a hereditary component may 
exist [170]. However with all this research it is still uncertain whether beta cell 
dysfunction precedes the development of insulin resistance. 
Pathophysiology and molecular defects within peas are typically associated with 
defects in insulin action/secretion leading to profound insulin resistance and 
pancreatic ~ - c e l l s s dysfunction [166, 167, 171]. Insulin resistance is the main 
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constituent of the metabolic syndrome with 70% of pcas patients suffering 
irrespective of 8MI [113]. Current concepts of insulin signalling defects point to an 
element of tissue specificity [33]. Insulin auto phosphorylation within adipocytes has 
been seen to be decreased by 30% in peas patients [172]. It has also been seen that 
serine phosphorylation in fibroblasts is increased by 50% and that insulin substrate 1 
association with PI3-K activity in muscle is lower in comparison to normal cells 
(IRSI associated P13-K)[33]. 
Metabolic abnormalities seem to be prevalent with the pcas diagnosis. These can 
include changes in cholesterol and triglycerides, fibrinolysis and plasminogen 
activation [173, 174]. The occurrence of diabetes mellitus and impaired glucose 
tolerance within PCOS sufferers with worldwide prevalence of around 30 - 40% 
[175]. Insulin resistance is defined as an impaired metabolic response to insulin and 
puts those suffering at an increased risk of glucose intolerance with 10% of PC as 
patients under 40 developing T2DM [176, 177]. The risk of diabetes mellitus within 
pcas patients is therefore believed to be linked to obesity; however studies show that 
the links to peos and the underlying insulin resistance may also contribute [112]. 
Although insulin resistance is believed to be independent of obesity, peos studies 
have shown that obesity may increase insulin resistance and subsequent 
hyperinsulinemia and increased insulin resistance has been shown in women with 
central fat distribution [17S]. Research has also shown that regardless of 8MI, pcas 
women present with central obesity and gynoid distribution [179]. Furthermore 
studies have reported that excess visceral fat and peripheral fat distribution is 
associated with metabolic disturbances, insulin resistance T2DM, dyslipidemia 
hypertension and CVD [17S, ISO, lSI]. It is therefore possible that the increase in 
obesity plays a crucial part in the occurrence of peas in susceptible individuals and 
reproductive disturbances are seen to be more frequent in obese women than normal-
weight women independent of PC as [IS2]. 
Although insulin resistance is seen in most women with peos [183], the effects of 
insulin action on such processes as mitogenesis and steroidogenesis, have been shown 
to be normal in peos patients with the effects on glucose and lipid metabolism 
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usually seen to be impaired [142]. This as a result affects whole body insulin 
sensitivity in peas [41, 159, 184]. 
The exact mechanism behind insulin resistance in peos is unknown. Typically 
insulin resistance is the result of inherited or acquired influences such as mutations in 
insulin receptor, glucose transportation or signalling protein [183]. Investigations into 
these areas in target tissues including ovarian and adipose within peos patients has 
yet to pinpoint any defect. Studies into adipocyte of peos patients have detennine 
decreases in maximal rates of glucose transportation suggesting post binding defects 
in signalling pathways [172]. A significant reduction has also been seen within 
glucose transporter 4 (GLUT4) and both these defects are seen to be independent of 
glucose intolerance, obesity and levels of circulatory sex honnones. This may 
therefore be reflective of an intrinsic peos related defect [185]. 
1.10 Obesity and peos 
The association of obesity and peos is well established with prevalence recorded as 
high as 75% dependent on country or ethnicity [174]. It is also accepted that PCOS 
patients tend to have a distinct gynoid body fat distribution independent of BMI with 
central fat accumulation known to be related to metabolic disturbance (see 1.14.). 
Infertility and menstrual irregularities are seen to be more frequent in obese patients 
both non-peOS and peos and there is no doubt in the ability of obesity to aggravate 
peos symptoms. Often weight reduction is seen as a therapeutic target that has been 
shown to alleviate reproductive dysfunction in peos patients reducing ovarian 
volume and follicle count [186, 187]. Reduction in weight in peos patients has also 
shown improved fertility rates and menstrual patterns [187, 188] Furthennore insulin 
resistance, which is seen as central to peos, is also aggravated by obesity and again 
studies have shown enhanced insulin sensitivity as a result of weight loss [188, 189]. 
Hyperandrogenemia is seen as diagnostic feature of pcas and with reduced plasma 
SHBG levels typically found in obese peos patients leading to increased free 
androgen levels further association may be seen. Androgen has also been shown to 
effect overall body fat distribution favouring centralized deposition and women with 
centralized obesity have been shown to produce more testosterone than those with 
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peripheral obesity [188, 190, 191]. All this evidence points to an underlying 
involvement of adipose I adipocytes in the occurrence of peas. 
1.11 Adipose, adipocytes and adipoldnes 
Up until the discovery of leptin in 1994 by Zhang et al., adipose was regarded as 
means of storage and mobilization of energy [192]. Since its communicative ability 
was determined via its effect on the hypothalamic neuropeptide-Y (NPY) and its 
subsequent energy balance regulation adipose tissue has been regarded as a more 
complex endocrine organ of which its full ability is yet to be understood [193]. 
Research has .shown it is capable of secreting many varied bioactive peptides and 
proteins known as adipokines (see 7.4). These have been shown to act locally with 
both autocrine and paracrine action, as well as throughout other areas of the body 
allowing cross talk with other physiological systems [194]. Its importance in acting on 
whole body homeostasis and influencing physiological processes has become more 
understood with its involvement in inflammation, blood pressure regulation, lipid 
metabolism, insulin sensitivity and coagulation [195]. It therefore seems that 
irregularities within adipokine secretion may lead to physiological dysfunction and it 
is believed that this may lead to influences in adrenal and ovarian function including 
steroidogenesis and fertility [196, 197]. This is supported by the importance leptin has 
in physiological process including energy homeostasis and its influence in gonadal 
and reproductive function. Whereby leptin has been seen to stimulate the 
hypothalamus and pituitary gland [198]. 
1.12 Adipokines in PCOS 
Adipokines have been shown to play important roles in female metabolism. Leptin 
has been seen to play a role within the female reproductive organs with target tissues 
including placenta mammary glands and endometrium subsequently influencing 
physiological processes including menstruation and pregnancy [198, 199]. Although 
leptin levels have not shown to be altered in weight and age matched peas patients 
[200] examination into the effects these levels may have on reproductive processes in 
peas patients is yet to be fully understood. Examination of additional adipokine 
secretion in peas and non-PeaS women, have shown disturbances may exist. 
35 

Chapter 1: Introduction 
The role of adipose as an endocrine organ includes the activation and deactivation of 
sex steroids (see Figure 16). Furthermore adipocytes have been seen to synthesize the 
steroid hormone oestrogen acting as the main physiological supply in post 
menopausal women [207]. It is understood that the main source of female androgens 
are from adrenal and ovarian synthesis, however research has shown that local 
adipocyte concentrations are significantly higher than levels found in systemic 
circulations [203]. This fact, coupled with the presence of steroidogenic enzymes key 
to androgen biosynthesis found in adipocytes tissue including aromatase, 313-
hydroxysteroid dehydrogenase (HSD) type I [191] 1113-hydroxysteroid 
dehydrogenase type 1 and 2 [208] 5a-reductase [209] and 1713-HSD types 2,3 and 5 
[210] suggest adipose may playa vital function in more than androgen activation and 
processing. Furthermore with androgens shown to significantly increase with respect 
to weight gain this may be seen as a possible mechanism in the symptomatic byper-
androgenemia found in peos. 
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2.0 HYPOTHESIS 
2.1 Primary hypothesis: 
The specific hypothesis to be tested is that adipocyte and theca cells in women with 
peas have an intrinsic defect within the insulin-signalling pathway resulting in 
increased sensitivity to insulin and increased androgen synthesis. 
2.2 Objectives 
• To detennine whether excess androgen production in women with polycystic 
ovarian syndrome (peaS) is due to a primary adipocyte/theca defect or 
secondary to hyperinsulinaemia and/or LH-hypersecretion. 
• To detennine the insulin-signalling pathway involved in the stimulatory 
effects of insulin on theca cells in peas. 
• To investigate the possibility of an alternate endocrine function within 
adipocytes and its association to symptomatic hyper-androgenaemia in peas. 
• To investigate the possibility of variations / dysfunction between nOD-PeaS 
and peas adipocytes. 
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3.0 MATERIALS AND METHODS 
3.1 Patient demographic and recruitment 
All samples were collected from the Department of Obstetrics and Gynaecology at the 
Royal Derby Hospital. The study and associated techniques for collection/processing, 
were approved by the Derbyshire Ethics Committee (Study reference: RO-5l 03-0 15-
08). 
The details of the study were discussed with each patient by the researcher or clinician. 
All patients were fully informed verbally and also given patient information sheets 
with the details of the research and procedure required for tissue collection (see 
appendix). All participating patients gave written consent in triplicate 
(patientIPIImedical records) and assigned study numbers in order to provide 
anonymity. 
3.1.1 Adipose tissue collection 
Adipose tissue biopsies (-5g) were taken from subcutaneous adipose tissue of the 
abdominal wall of participating women either during a planned surgical procedUre or 
under local anaesthesia in the outpatient clinic (for women not undergoing surgery). 
Two groups were selected; normal women (control group) and women with PCOS. 
Data was summarised in Table 2. 
The control group (non-PCOS) consisted of women with regular menstrual cycles 
(28-32 day cycle), normal serum levels of androgen (0.2-2.9nmol/l), luteinizing 
hormone (luteal phase 1-11 nmol/l) and fasting insulin (17.8-173pmol/l) with data 
summarized in Table 2. All women were of childbearing age, ranging from 20-45 
years with a 8MI s 35 kglm2 • 
39 
Chapter 3: Materials and Methods 
The women within the PCDS group were diagnosed according to the 2003 Rotterdam 
ESHREI ASRM consensus with two of the required criteria from: 
• Chronic oligo- or anovulation 
• Clinical and/or biochemical evidence of hyperandrogenism (biochemical: 
testosterone ~ ~ 2.5nmolll or free androgen index ~ ~ 5) 
• ultrasound appearance of polycystic ovaries. 
Diagnostic criteria based on Rotterdam revised consensus and not clinical 
management debate which argues to include subcategories of patients by the previous 
NIH criteria which does not include signs of polycystic ovaries [108, 211, 212]. 
Exclusion criteria included for both adipose and ovarian sample collection; 
• 
• 
• 
• 
• 
• 
• 
Metabolic or endocrine disease, such as diabetes mellitus and thyroid disease. 
Bilateral ovarian disease (excluding simple/functional ovarian cysts). In 
women with a unilateral disease, the biopsy was to be taken from the non-
diseased ovary. 
Concurrent treatment with: hormonal therapy such as hormonal contraception, 
progestogen therapy, thyroxin hormone or corticosteroids. 
Metformin. 
Cholesterol lowering agents. 
Patients unable to give signed informed consent e.g. those with mental 
incapacity . 
Patients unable to understand verbal or written information in English. 
Women with a diagnosis of pcas were screened for the above inclusion/exclusion 
criteria for the study group by taking a medical history, performing a clinical 
examination, arranging an ultrasound scan and a blood test. All these screening 
measures were part of the routine management of women with pcas. Patients who 
were suitable for the study were given a Patient Information Sheet (PIS) and filled out 
the relevant consent form. 
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Parameter Normal (n= 17) PC OS (n=10) 
Age (yrs) 33.8 (24-44) 30.5 (25-38) 
Body Mass Index ( k g l m ~ ) ) 26.4 (17.6-33.1) 32.3 (19.8-37.65) 
Insulin (pmolll) 26.0 ± 5.8 118.6 ± 31.8 
Testosterone (nmolll) 1.4 ± 0.2 2.4 ± 0.4 
Luteinising Hormone (nmolll) 6.7 ± 1.4 29.9 ± 11.2 
Table 2. Patient demographic of cultured samples. Data summarised as mean (range) I SEM (±). 
The age range of our samples allowed them to be closely matched between groups 
with all subject. All samples used were chosen from subjects that were not midcycle 
and therefore either in the luteal or follicular phase of their menstrual cycle allowing 
normalization, with only 4 of the peas women having oligo-ovulation. Those 
subjects midcycle have increased LH levels typically found in pcas women 
(>96nmoVI). Biochemical variations between the groups existed with significant 
increases in testosterone (>2.9runoVI), insulin (> 170pmoVI) and LH levels 
symptomatic of pcas women. Recent studies have shown that DHEAS is less 
reliable than testosterone with only 5% of hirsute patients examined showing elevated 
levels [213]. For this reason we measured free testosterone levels. 
3.1.2 Ovarian tissue collection 
Following patient consent a 1-2cm biopsy was taken from each ovary either during 
surgery (hysterectomy) or on removal of the ovary (oophorectomy) through careful 
scalpel incision. Both control and pcas samples were collected using the same 
exclusion criteria as mentioned in 2.1.1 . Samples were then immediately transported 
to the laboratory in collection media consisting of Hanks Balanced Salt Solution 
(HBSS) containing, 1% penicillin (IOOU/ml), IOOU/ml streptomycin (IOOOOU/ml), 
HEPES (15mM). Samples not used for primary culture were snap frozen and stored at 
-80°C for later use in western blotting. 
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3.2 Mammalian cell cultures 
3.2.1 3T3-Ll pre-adipocytes 
Initial adipocyte experiments utilized an established animal cell line (3T3-LI) whilst 
awaiting ethical approval for use of human biopsies. These were kindly supplied by 
Dr Saoirse O'Sullivan (Division of Vascular Medicine, School of Graduate Entry 
Medicine & Health, University of Nottingham). This cell line was stored frozen in 
DMSO/serum and taken from nitrogen storage at passage 20, quickly thawed by 
immersion in a water bath at 37°C then seeded in T25 flasks in DMEM media with 
high glucose 4500mgll (v/v) and 10% fetal bovine serum (FBS). The composition of 
all the various buffers used throughout this project including suppliers and their 
addresses, have been listed in the appendices (see appendix). 
Following 24 hrs incubation at 37°C, culture media was refreshed to remove DMSO. 
Culture medium was changed every 48hrs thereafter until confluence was reached at 
around day 7 and the cells were passaged further in a T75 flask to increase cell 
number. 
3.2.1.1 3T3-Ll pre-adipocyte differentiation 
Preadipocytes were seeded in 96 well plates in DMEM high glucose (4500gll) + 10% 
FBS media. These were grown to 80-90% confluence (see Figure 17) and the media 
(termed initiation media) consisting of high glucose DMEM (high glucose), 10% FBS, 
2mM L-glutamine, I % penicillin/streptomycin, 0.5mM isobutylene-I-methylxanthine, 
111M insulin, 111M dexamethasone. Following 3 days incubation at 37°C, initiation 
media was removed and differentiation media added consisting of high glucose 
DMEM (high glucose), 2mM L-glutamine, 1% penicillin/streptomycin 50nM insulin, 
111M dexamethasone. Media was replenished for fresh differentiation media every 2 
days until lipid droplet formation was observed, typically at around 28 days (see 
Figure 18). Differentiation was then validated using Oil Red 0 staining (see 3.2.2. J). 
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Figure 17. 3T3-LI Preadipocytes 7 days Figure 18. 3T3-LI Adipocytes. Preadipocytes 
following dispersal maintained at around 90% following 4 weeks of routine media changes 
confluence. Preadipocyte appear as phase-dark, occurring every 3 days with media consisting of 
polygonal cells. (A) Inset show preadipocytes insulin, IBMX and dexamethasone. 
beginning to diITerentiate. 
3.2.2 Preparation of subcutaneous human adipose primary cultures 
Approximately 5g of subcutaneous adipocyte tissue (Figure 19) collected from 
theatre or under local anaesthesia in the outpatient clinic was immediately transported 
to the laboratory in a collection media consisting of HBSS, 1 % penicillin (1 OOU/ml), 
streptomycin (1 OOU/ml), HEPES (15mM). 
Figure 19. Subcutaneous adipose biopsy. Subcutaneous adipose tissue biopsy (-Sg) taken from 
consenting patient within the outpatient clinic under local anaesthesia. 
Adipose biopsies in HBSS were minced with a scalpel blade and tissue enzymatically 
digested with collagenase (lmglml), prepared in HBSS, for I h at 37°C. Thereafter, 
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the digested material was filtered through a double-layered mesh (200u nylon cell 
micro sieves). Following separation through the mesh the isolated cells were then 
centrifuged at 250x g for 10 mins (x2) at room temperature in HBBS and the 
supernatant was discarded. Finally the pellet was re suspended in DMEM (high 
glucose), 2mM L-glutamine, 1 % penicillin/streptomycin 10% FBS and incubated at 
37°C 5% 0 2/95% C02 until sufficient yield typically used at passage 2 for the 
differentiation procedure. 
All passages followed the same protocol whereby culture media was removed and 
cells carefully washed using HBSS (without MgC02 or CaCh). TrypsinlEDT A was 
then added and incubated for 2 mins at 37°C 5% 0 2/95% C02 until rounding of the 
cells was seen under a microscope. Media containing 10% FBS was then added to 
deactivate the trypsinlEDT A and plates were then gently tapped to remove any 
remaining adherence. Cells were then spun at 250 x g for 5 mins in relevant media 
dependent on the cells, and supernatant removed before plating in the relevant media. 
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Figure 22. 4 weeks differentiation of non-PCOS adipocytes stained with Oil Red O. Lipid droplets 
are clearly apparent as a pink to deep red colour. 
Differentiation of adipocytes (also used with theca cultures) was measured using a 
method adapted from the Oil Red 0 staining (adapted from the protocol by L. 
lenkarova (2005)). PCOS and non-PCOS cell cultures were grown to confluence and 
differentiated (see 3.2.3). Adipocytes were then stained at time courses (1, 3, 6 and 9 
weeks). The Oil Red 0 was eluted by adding 100% isopropanol and incubated for 10 
mins. The solution; including isopropanol and Oil Red 0, was transferred to a 96 well 
plate to be read via spectrophotometry (OD 500nm). All results were examined 
against preadipocytes grown under non-differentiation conditions and blanks. 
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3.2.3 Ovarian theca culture. 
All women scheduled for any abdominal or laparoscopic gynaecological urgery, uch 
as laparoscopic ovarian diathermy (for women with peOS), laparo copic terili ation 
or hysterectomies were considered fo r the study under the inclu ionlexclu ion c ' t ria 
(see 3.1.1). During surgery, one small cortical biopsy wa taken from the anti-
mesenteric surface of the ovary by one of the investigators (Mr Amer or Profe or 
Shaw). Ovarian tissue was then collected into HEPES-buffered Minimum E ential 
Medium for immediate transfer to the laboratory. Sample were anonymi ed and 
coded immediately 
Ovarian specimens were placed in a 6mm petri dish and wa hed with HB 
immediately to remove blood. Individual follicle were identified under a di ecting 
microscope then dissected from the ovarian troma u ing fine forcep , taking e treme 
care not to rupture the follicle. For cell dispersal, viable un-ruptured follicle were 
chosen based on their size (>4mm) so as to allow di ection without the aid of a 
microscope. Typical biopsies contained 1-2 follicle no larger than 4mm which 
required careful processing in order to obtain viable cells. 
A 
Figure 23. Ovarian follicles. (A) Follicles removed from ova ri an troma through carefu l di ' ec tlOn. 
(B) Once fo lli cular fluid is removed the fo ll ic les a re opened up to show thc theca l sheet . 
Follicles were dissected carefully minimising contamination from non-follicular ti u 
(see Figure 23). The granulosa were removed through a piration by careful in ertion 
of a 25Gx I mm needle (25ml syringe). Aspirated follicular fluid wa centrifuged 250 
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3.3 Hormone assays 
Cells (adipocyte/theca) (passage 3) were maintained in serum-free conditions for up 
to three days to eliminate any contribution from hormones in serum and used in 
honnone assays. 
• The effects of insulin were tested by incubating cells with insulin (10-
lOOng/mI). 
• The effects of LH were tested by incubating cells with LH (lOng/mI). 
• The effects of insulin and LH were tested by incubating cells with insulin (10-
100ng/ml) + 1 Onglml LH. 
• All treatments were also tested under PI3-K inhibition using L Y294002 
treatment (see Figure lS / hypothesis 2.1.). 
Following passage of primary cultures cells (adipocyte/theca) the viability of the 
theca cells was assessed using trypan blue exclusion. A solution of 10",1 of media and 
10",1 trypan blue was added to a I ml solution of media/cell suspension. A 
haemocytometer was used to examine 10",1 of the cell suspension solution under a 
microscope and the % viability was calculated using haemocytometer (% viable cells 
= no. of unstained/total cell count). 2x 1 05 cells were then plated in the appropriate 
serum free thecaladipocyte media (see method 3.2.113.2.3) + treatments (see Figure 
15) and harvested dependent on the required time course (24, 48 or 96hrs). 
At the relevant time point (see Figure lS) cells were harvested and conditioned media 
removed which was stored at -80°C for later examination of hormone levels. 
In order to investigate cell viability we monitored proliferation and took regular cell 
counts using trypan blue (see 3.4). Cells were carefully washed with HBSS and 100",1 
of trypsin/EDT A added for 2 minutes before cell suspension removed from the well. 
Cells were counted using a haemocytometer and further washed in HBSS. Cells were 
then centrifuged at 250 x g for 10mins and supernatant discarded. The cells were then 
lysed for use in western blotting (see 3.6). 
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Figure 25. ThecaJAdipocyte cell treatments. Cells were plated 2xl05 in varied insuliniLlI treatments 
and harvested at varied time courses (24, 48 and 96 hours). 
3.4 Proliferation Assays 
Proliferation assays of theca cells and adipocytes were undertaken in addition to the 
honnone assays. This was measured using the MTS assay (3-( 4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-su1fophenyl)-2H-tetrazolium) and colorimetric 
assessment through spectrophotometry (490nm OD). This allowed examination of 
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both adipocyte and theca primary culture viability and also the effects of varied 
honnonal treatments. 
Known cell numbers (1 x 1 03 - 40x 1 03) were plated into 96 well plates following trypan 
blue exclusion and cell counting (see 3.2.2.1). MTS works through bio-reduction to 
fonnazen. Mitochondrial activity within living/viable cells allows the metabolism of a 
water-soluble tetrazolium salt within the MTS into a formazan product, which is 
visible as a yellow to purple colour change through the addition of a dye. The results 
can be measured using a spectrophotometer at a wavelength of 490nm and 
proliferation is based on the ability and presence of viable cells to cause this 
transfonnation. The measured absorbance of known values were used to create a 
standard curve for comparison of results to known values (Figure 26). 
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Figure 26 Non-Peos preadipocyte proliferation standard curve. Non-PCOS preadipocytes 
were used in the MTS assays and absorbance measured at 490nm as a measure of cell viability. This 
process was used for known cell numbers to form a standard for cell number against absorbance 
(@490nm). 
For assessment of proliferation, non-PCaS/PCOS preadipocyte and theca 
proliferation assays were established to examine variations across basal levels. Cells 
taken from primary cultures between passages 3-4 were plated at a density of 5x 1 03 
(n=5). At consistent time intervals (24, 48, 96, 120 and 144hrs) 20J.l.l of MTS was 
added to each well and incubated at 37°C for 1 hour before measuring absorbance at 
490nm. A standard curve was created using known cell numbers and their 
corresponding absorbance. All results were examined using the standard curve Figure 
26. 
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Adipocyte proliferation levels were also measured to examine the influence of insulin 
and LH independently and in combination on proliferation of adipocytes. Insulin and 
LH were added in a dose dependent manner (0, 10, 100ng/ml) to media 
(DMEMladipocytes) in the absence of FBS following 24hr serum starvation of 
primary cultures. Controls included wells containing media only. All results were 
expressed relative to the standard curve in relation to cell number as seen in Figure 
26. 
3.5 Immunofluorescence. 
Immunofluorescence (IF) uses primary antibodies to identify proteins of interest 
whilst secondary antibodies conjugated to a fluorochrome act by showing 
fluorescence. Excitation of fluorophores bound to the secondary antibody results in 
fluorescence at specific wavelengths and can be viewed using a fluorescent 
microscope. This technique therefore allows the localisation of target proteins within 
the cell. Fixation of the desired cells is required. This allows preservation of a sample 
in its native state. It is necessary to prevent diffusion or osmotic damage through 
expansion or shrinkage of cells. Permeabilisation of the cell facilitates access of the 
chosen antibody. Various methods of fixation exist including acetone or methanol, or 
a combination acetone:methanol (I: 1). These two methods fall into the organic 
solvents category, which removes lipids and dehydrates the cell whilst precipitating 
the proteins [218]. Alternately cross-linking methods including paraformaldehyde 
preserve the cell structure by forming hydroxyl-methylene bridges between reactive 
end groups of adjacent proteins [218]. This method however can remove antigenicity. 
Determining the correct fixative immobilizes antigens and maintains the cell structure 
to as close to its native state as possible with minimal denaturation of the protein of 
interest. 
It is necessary to inhibit non-specific antibody binding through a blocking procedure. 
The second phase of the protocol is primary antibody incubation of the cells, 
Following this, a complementary secondary antibody is added (anti-goat corresponds 
antibodies raised in goat etc.) and an external energy source such as a light of specific 
wavelength, excites the electrons and causes fluorescence which can be observed 
through a fluorescence microscope see Figure 27. 
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Light Source 
Fluorescent 
Secondary 
Antibody 
n 
FITC 
T rget Protein 
Figure 27. ImmunoOuore cence mechanic . Target protein are located by the corrc ponding primary 
antibodies. The cell is then incubated with a econdary FITe conjugated antibody. Thc addlli n of 
light source excites fluorophores and fluore cence occurs through energy rele e. ",hlch can be lew d 
via a fluorescent micro cope revealing the location of the protein . 
3.5.1 Immunofluorescence protocol: Fixation 
All primary cells were probed u ing immunofluore cence in order to c nfinn th ir 
identity. Specific antibody marker were cho en and appropriate control u d 
verify the protocol u ed (see Table 3). Leucocyte culture were purified from bl d 
and used as a negati ve control against all our primary cell (Figure 28). Leuc cyt 
cultures were also probed u ing ~ - a c t i n n antibody to en ure a ucce fui lF pr t I. 
Figure 28. Human blood Leucoc te culture grown to act a a neg ti e con trol ~ ~ r an tib od • 
markers round in adipocyte and theca cell. Fluore cence -how l3-actm antlbod for po 111\ 
control of I F protocol Blank micrograph on the extreme right, hO\ no fluore cen e \\ hen cell 
were incubated in non-immuno erum in place of primary antibody _ II image 10 magnlficatl n . 
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Cell Type Primary Antibody Control Antibody Control Cells 
Human Preadipocyte anti-OB ~ - a c t i n n Leucocyte 
CYP17 
LHR 
Human mature 
Human Mature adipocyte cell 
adipocyte anti-OB ~ - a c t i n n line 
CYP17 Leucocyte 
Human Theca CYP17 LHR CHO 
LHR ~ - a c t i n n Leucocyte 
Table 3. Table showing the primary antibodies used in this study to characterise the specific cell 
type and the supporting control antibodies and cells. 
Due to the differences in fragility between theca and mature adipocytes both 
acetone:methanol and paraformaldehyde protocols were used to fixed cell cultures. 
However we found that the acetone:methanol protocol proved more successful as it 
led to less damage and maintained cell integrity. 
Preadipocyte and theca cultures were grown to around 50% confluence at a passage 
between 2-3. In doing so enough space existed between the cells to allow 
identification of the cell morphology (see 4.4.2.2). It was however necessary to grow 
the mature adipocytes to confluence due to the protocol required in differentiation 
(see 3.2.2). 
Cells were seeded at 5xl03 in 24 well plates and grown to required confluence (1 -2 
days) before careful removal of media and washing in ice cold PBS (x2). 3001-l1 
chilled acetone:mcthanol (1:1) (v/v) was added to each well and left for 10 mins 
before careful removal and further washes in ice cold PBS (x2). 
3.5.1.1 Blocking of non-specific antibody binding sites 
Fixed cells were blocked using 20% goat serum in PBS and left for 30 mins at RI. 
Following incubation, blocking solution was removed and the antibody of interest 
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diluted in PBS as required and added to the wells (see Table 3) (see appendix II for 
details). Cells were incubated overnight at 4°C with gentle rocking. All procedures 
were done alongside negative and positive control cells utilizing the same protocol. 
Further negative controls were prepared using fixed cells omitting the primary 
antibody and stored in PBS overnight at 4°C. Primary antibodies were carefully 
removed and all cells washed for 5 mins in ice cold PBS (x4). 
3.5.1.2 FITC antibody and examination 
A single isomer fluorescin isothiocyanate (FITC) tag was used bound to the chosen 
secondary antibody. This derivative of fluorescein emits green fluorescence on 
excitation at a wavelength of 494nm. Following PBS washes, secondary antibody at 
dilutions as per appendix II, was added to all cells and incubated at room temperature 
for I hour 30mins, wrapped in foil to prevent direct light bleaching or fluorophore 
excitation. The foil wrap was then carefully removed and all cells washed carefully in 
ice cold PBS for 5 mins (x7). Cells in PBS were then viewed in a dark room using 
Carl Zeiss Axiovert 25 Scope with Celll\F imaging software (Build I I31). Images 
were viewed and edited in Ziess LSM image browser V 4.2.0.121. 
3.6 Western blotting 
Western blotting (immunoblot) is a widely used semi quantitative method for the 
detection of specific proteins from a given sample. It utilizes gel electrophoresis 
separating denatured proteins by weight/size. Proteins are then transferred to a 
nitrocellulose membrane and probed with antibodies specific to the target protein (see 
3.6 for detail). This study-utilised protein from Iysates prepared from both tissue and 
cultured cells, allowing a comparison representative of physiological conditions. As a 
control, CHO cell cultures were grown and Iysates created for use alongside all 
experiments. Original stocks of all controls were utilized through frozen stores at _ 
80°C. 
It is necessary to prepare Iysates using various protocols (see 3.5. J) before western 
blotting. 
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3.6.1 Tissue homogenization 
Tissue was collected from the Department of Obstetrics and Gynaecology at the 
Royal Derby Hospital (see 3. J) and immediately processed within the clinical 
sciences lab to limit protein degradation. Human follicles were finely chopped in 
homogenization buffer consisting of sucrose 300mM, tris base pH 7.4 2SmM 
(Invitrogen Life Technologies), monothyioglycerol 10mM, EDTA ImM, protease 
inhibitor cocktail 0.5% (v/v), 2.S% (v/v) igepal (see appendix). The tissue (0.5-1g) 
was then added to 3ml of homogenization buffer on ice and minced using a 
homogenizer (Hiedolph Diax 900) within a fume cabinet. The homogenate was then 
centrifuged for 30min at 2S0 x g at 4°C. The supernatant was removed, and placed in . 
2 eppendorf tubes. The remaining pellet contained homogenised tissue and was re-
suspended in 2 0 0 ~ 1 1 of solubilisation buffer consisting of Tris base pH 7.S 20mM, 
EDT A 10mM, sodium chloride 120mM, potassium chloride SOnM, dithiothreitol 
2mM, protease inhibitor cocktail O.S% (v/v) phosphatase inhibitor cocktail II 2.S% 
(v/v) igepal. This was then centrifuged for IOmin at 2S0 x g 4°C allowing the 
detergent within the solubilisation buffer to solubilise cell membranes, releasing 
proteins and leaving sedimentation of the insoluble components. The supernatant was 
then stored at _80°. The 2-eppendorf tubes containing supernatants from the original 
step were then centrifuged for I hour at 2S0 x g at 4 0c. The freshly solubilised 
supernatant from the 2 eppendorf tubes was then removed and stored at -80 ° or 
immediately used in protein estimation (see 3.6.3). The same protocol was used 
for adipocyte tissue however homogenization! solubilisation buffer varied (see 
appendix). 
3.6.2 CeU lysis 
Cell cultures used in western blotting were grown to as low a passage as possible 
allowing for sufficient yield (2-4). Following treatment cell were lysed. Cells were 
carefully washed in HBSS (x2) and lysis buffer consisting of Tris base pH 7.S 2SmM, 
sucrose 300nM, monothyioglycerol 10mM, EDTA ImM, 1% (v/v) igepal, protease 
inhibitor cocktail l00JlI in lOOmis, phosphatse inhibitor II (I 0 0 ~ 1 1 in lOOmis). 
Following S mins incubation at room temperature cells were aspirated from the well 
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using a syringe and placed in eppendorfs and centrifuged to remo e d bri . The 
were either used for immediate protein estimation or tored at - 0°. 
3.6.3 Bicinchronic acid assay (BCA) method for e timation of protein 
concentration 
The BCA method of protein estimation u es the reduction of Cu2+ to Cu + in th 
presence of protein, which produces a measurable colour change in the reagent. Thi 
is quantified by measuring absorbance at 562nm through pectrophotometry. By 
preparing protein standards, comparisons can be made and protein e timation taken 
for specific tissue. Standards were prepared by erial dilution of a 10mg/ml t k 
solution of bovine serum albumin (BSA) ((0.9%) aCI + 1 O ~ 1 1 of B 10mg/ml) t 
generate BSA concentrations at 0, 0.05, 0.1, 0.2, 0.4 0.6 O. and 1 mg/mt. Th 
standards were loaded in duplicate in a 96 well plate along with the unknown ampl 
with 200"",1 of BeA working reagent (4% copper ulphate (Cu 0 4) in B reagent. 
This was then added to each well and incubated for 10min at 32 ° with g ntl 
agitation. The absorbance of the standard and unknown ample were r ad at 5 2nm 
on a plate reader (Thermo Electron Corporation Multi can pectrum . Thi 
information was taken and a tandard curve generated ( ee Figure 2 ). ing thi 
protocol with processed tis ue/cell ly ate, results were collated and e amm d again t 
linear regression to determine protein concentration e timation. 
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Figure 29. Graph howing the absorbance of known protein concentration. Kn wn protein 
concentrations were used to produce a standard curve. Thi could then be u ed to e tlmate unkn wn 
protein concen tra ti ons . 
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3.6.4 Preparation of gels (SPS-P AGE) and western blotting 
Gels for western blotting were cast using glass gel plates. These were first cleaned 
using 70010 ethanol and two plates secured using petroleum jelly within cast clamps. 
The acrylamide percentage was chosen in accordance with the molecular weight of 
the proteins being separated [26] (7,10,12%). High acrylamide percentage gels were 
used to separate low molecular weight proteins (10 - 15kDa). Low acrylamide 
percentages were used to separate high molecular weight proteins [26]. The resolving 
gel was prepared using 7-12% acrylamide stock (30%), resolving gel buffer consisting 
of dH20, Tris 1.5M pH 8.8,0.1% (v/v) SDS, 0.001% (w/v) ammonium persulphate 
and 0.1 % (v/v) Temed (see appendix). This was carefully syringed between the plates 
and left to set with a fine layer of butanol to prevent oxygen exposure (drying out and 
inhibition of polymerization) and promote polymerisation. The gel was left to set for 
-3Omin. The stacking gel was prepared using 4% acrylamide stock (30%), stacking 
gel buffer consisted of ddH20, Tris 1M pH 6.8, 0.1% (v/v) SDS, 0.001 % (w/v) 
ammonium persulphate and 0.1 % (v/v) Temed. The butanol was removed with careful 
dHzO washing and the stacking gel was added immediately followed by insertion of a 
lane comb and left to set for -3Omin. Throughout this method The Bio-Rad mini-
protein II electrophoresis unit was used (see appendix). The percentage gel chosen 
was based on the molecular weight of the proteins of interest with higher percentage 
gels allowing heavier proteins to be separated more easily. As these weights remained 
similar throughout a 10% gel was sufficient. 
Protein concentration was adjusted to IOmglml using Laemmli buffer. The samples of 
interest were then denatured by exposing them to a hot plate set to 95°C for 5mins, 
before transferring to ice ready for electrophoresis. Each lane was loaded with 1 O O ~ g g
of protein (see Figure 31). In addition, the first lane was loaded with 1 O ~ 1 1 of 
kaleidoscope pre-stained molecular weight markers to facilitate protein size 
determination (see Figure 31). The gels were then carefully placed into a bath of 
running buffer consisting of Tris (25mM), Glycine (192mM) and ddHzO. This was 
run for I hour at 40mA (constant). The proteins were then electro-blotted onto 
nitrocellulose membranes in ice cold transfer buffer (tris base (24mM), glycine 
(80mM), 20% (v/v) methanol) within a BioRad miniprotean blotting system where a 
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sandwich of gel to nitrocellulose see Figure 30 was added and a charge of 100 
(constant) run for - 2 hours at 4·C. 
-<:> 
lid 
Sample burttfcUdt M O ~ 9 ~ ~ - - ~ ~ ~ ~
bU'Ior 
-'" 
Figure 30. Bio-Rad mini-protein II electrophoresi un it. Each sample wa carefully loaded into epa rate lanes. 
The blue dye front line shows the migration of the samples and the run wa topped when the dye front reached the 
bottom of the gel. Image obtained from http://www.currentprotocol .comlprotocolln 0519 
Completed transfers were dismantled and the protein tained in a bath of ponceau r d 
(Sigma) for 10 min. These were then carefully rinsed within dH20 and canncd to 
determine proteins had transferred efficiently (Figure 31). The membrane wer then 
washed with di tilled water to remove the ponceau. 
Figure 31. Ponceau Staining. Ponceau tain wa used on the nitroccl lulo e following ele tro-blo tting. 
The red staining show the protein separation and transfer. 
The nitrocellulose was then immer ed in a bath of 5% Marvel milk and TB (Tri 
(12. 11 g), NaCI (146.1 g), dHzO (5 I) for 1 hour, allowing blocking of the binding ite 
regions on the nitrocellulose. This prevented any further interaction b twecn the 
membrane and additional protein i.e. the antibody. The rcle ant antibody wa th n 
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added at the correct dilution, in a 3% marvel solution (see appendix II) and incubated 
overnight with gentle agitation at 4·C. A washing procedure was then used with TBST 
(x6) for 10 minutes followed by TBS washes (x3) for a further 10 min each. The blots 
were then incubated with alkaline phosphatase (AP) conjugated secondary antibodies 
(for dilutions see appendix II)in 3% marvel for 2 hours at room temperature with 
agitation. The membrane was washed again as described above and incubated for 
IOmin using enhancer and substrate solution (non-isotopic chemiluminescent 
detection system Immun-Star-Alkaline phosphotase kit (AP:Biorad». This method 
utilises the enhancer and substrate that produces luminescence. The alkaline 
phosphatase (AP) method uses a hydrolase enzyme that removes phosphate groups to 
initiate a chemiluminescent reaction that can be viewed directly using a camera. 
Visualisation was enabled, by using 5 0 ~ 1 1 of enhancer added to 2.5ml substrate evenly 
coating the nitrocellulose blot. The Chemi Doc (vers 4.2.1) imaging system was then 
used to visualise the immune-reactive bands on the membrane. 
3.6.5 Positive controls 
Western blotting is a long and complex procedure, which can take up to 48 hours to 
produce results. Multiple stages in the procedure therefore leave room for error. These 
may include inconsistent transfer, protein degradation and unequal protein lysate 
loading. We took necessary precautions where possible, including ponceau staining 
and positive/negative controls. CHO cell lysates were prepared, stored and used 
throughout all western blot procedures. When signs of degradation occurred these 
were replaced with lysates from the same passage of culture previously stored at -
SO°C. Negative lysates in the form of leucocyte taken from human blood (see 3.5.1) 
were also used. 
Following each experiment for the protein of interest the same nitrocellulose was 
probed for (3-actin, which was use as our loading control antibody due to its 
ubiquitous nature [219]. Reblot was used and the nitrocellulose incubated for 10 mins 
(ReB lot Plus, Chemicon International). This allowed previously bound antibody to be 
stripped away through an alkaline based solution. Blots were then washed in TBS-T 
(x3) for 10 mins and blocked using 5% marvel milk solution for 90 mins. The blots 
were then washed twice with TBS-T for Imin each before application of the ~ - a c t i n n
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(I :8000 antibody dilution) in 3% w/v marvel milkfTBS overnight on a gentle shaker 
at 4°C. 
3.6.6 Data analysis 
All control blots were analysed alongside the results and exposure was kept constant 
to each protein of interest dependent on optimisation and resultant levels of over 
exposure. Once all areas of the blot had been normalized using a rolling disc option 
that allowed areas of background overexposure (dirty blot) to be considered. Both the 
average and total band intensities were measured. Variation against the IJ-actin was 
examined. The software also allowed calculation of the molecular weight of the 
proteins identified using the pre-stained molecular weight markers as a guide (see 
Figure 31). All western blotting experiments were repeated at least three times for 
each patient sample and both the mean ± SEM along with median ± interquartile 
range (lQR) were recorded (see results). Nonnality was tested using Shapiro-
WilklKruskal Wallis normality test within the prism software (vers. 5.0b). Multiple 
means for unpaired samples were compared using either one way analysis of variance 
(ANOVA) (parametric) with Bonfe"oni post-hoc test while paired observations were 
analysed using two tailed students' t-test (parametric). P-values <0.05 allowed for 
rejection of the null hypothesis. 
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3.7 Hormone measurements by ELISA 
ELISA or enzyme linked immunosorbent assays allow the measurement of a specific 
protein within a solution. They rely on specific interaction between an epitope, and a 
matching antibody. Therefore the basis of all enzyme immunoassays (EIA) is the 
separation of specific or non-specific interactions through serial binding to a solid 
surface and quantification of the results via colour change examination. The coloured 
end product correlates to the amount of analyte present in the original sample. The 
process is rapid and allows examination of multiple samples in parallel. They were 
first developed independently and simultaneously by the research group of Peter 
Perlmann and Eva Engvall at Stockholm University in Sweden and by the research 
group of Anton Schuurs and Bauke van Weemen in The Netherlands as an alternate to 
radio-immunoassays in 1970 [220]. In some cases can allow for multiple analytes per 
well, highly sensitive readouts, and direct cell-based output. 
Typically, 96 well plates are used and coated with either an antigen or antibody 
through adsorption or the passive attachment of a liquid to a solid surface to form a 
film. Once coated, blocking and detection steps are used to determine concentrations 
within the chosen sample (see Figure 32). 
Coating . " t-
.. P O l y s t y r e n ~ ~ plate Is treated . .:t . ' 
With a solution of either ."" c'-
antigen or anllbody . 
Detoctlon , •. 
• Enzyme-conjugated antibody or . 
: antlgenbindsspeclficaJlytothe . 
target antigen or antibody 
,.move 
liquid .nd 
w •• hplalo 
Read Results . , .! t l 
.. Substrate IS added and the signal · '0' : ' .. 
produced by the enzyme· ' (". t·; 
substrate reaction is measured I 4' '. ','" 
Figure 32. ELISA Technique. Protocol for basic ELISA showing the necessary stages including 
coating, blocking, detection and examination of results. Diagram taken from 
http://www.abdserotec.com/resources/elisa-technical-resources-and-Iroubleshooting.html . 
Assays rely on surface binding for separation. Several washes are required between 
each step to remove unbound materials allowing for specificity. It is therefore 
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important that excess liquid is removed preventing dilution of the olution add d in 
later stages. 
Four ELISA techniques exist allowing for a ba is of a ay fonnation . Direct indirect 
sandwich and competition. Our protocol relied on competition ELI A for all our 
honnones of interest. The ELISAs were bought a ready-made kit that had b n 
optimized to the specific hormones we were inve tigating allowing for reliable 
results. Competition ELISAs measures antigen lantibodie by examining interfer n 
within a know output i.e. using ready-made standard ample . An ample of a 
competition ELISA can be seen in Figure 33. 
Coat well with known antigen and block as u U3I 
Add sample containing unknown anti en 
Add labeled detection anti ody 
No signal results because no labeled detection antibodyh 
bound. This indicates a hi h level of ntl en in the sample. 
Figure 33. Competition ELlS . Bound and free antigen 'compete . for a labelled detection 
antibody. Image adapted from hHp ://www.abderotec.com/rc ource leli a·technical·re ource ·and. 
troubleshooting. 
An ELISA plate is prepared with a bound known antigen. The unknown ample i 
added and if the antigen within the ample i the arne a the bound antigen then one 
the labelled detection antibody i added it will compete between free and bound 
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antigen. High sample concentration will cause detection antibody binding, which will 
then be removed during the washing process leading to reduced signal changes. A 
lack of similar antigen within the sample will lead to detection antibody binding to the 
bound antigen resulting in increased signal change. Therefore a reduction in signal 
intensity shows the existence of the antigen of interest within the sample. Signal 
changes were detected through colour changes measured via spectrophotometry at a 
wavelength of 450 ±lO nm. 
3.7.1 ELISA standards 
Three ELISA kits were chosen measuring progesterone, androstenedione and 
testosterone (results not shown). The progesterone ELISA (Ridgeway) allowed for 
measurement of samples to a sensitivity of 0.025ng/ml-0.39pmoVl 000 cells using a 
standards range of known progesterone samples as supplied. Absorbance was 
measured (57Onm) to create a standard curve (see Figure 34). The standard curves 
produced failed to form a linear result across the entire ranges of known samples 
however all results fell within an acceptable range for reliability. If higher values had 
been found within our unknown samples dilutions could be used to create a more 
reliable standards range. All results for the specific ELISA were obtained using this 
standard curve showing values falling within the ELISA range of sensitivity. Values 
were converted throughout to pmoVlOOO cells; this allowed direct comparisons to 
published findings ([221, 222]). This would also allow for comparison of levels of 
metabolism in relation to the specific cell type. 
O.O+--......,--.,......--r----, 
o 100 200 300 400 
PIogestarone pmoU1000 
Figure 34. Standard curve showing ELISA progesterone levels through measured absorbance. 
Known levels of progesterone were measured using ELISA technique and levels of absorbance @490 
taken to determine a standard curve for which all results could be measured by. 
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The androstenedione ELISA (GenWay Science) allowed for a sensitivity of 
O.OI9nglml-O.03pmolllOOO cells) and standards of known androstenedione (as 
supplied) allowed to produce a standard curve to which all results were compared and 
produced (see Figure 35) 
2. 
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Androstenedione pmortOOO 
Figure 35. Standard curve showing ELISA androstenedione levels through measured 
absorbance. Known levels of androstenedione were measured using ELISA technique and levels of 
absorbance @490 taken to detennine a standard curve. 
3.7.2 Controls 
Controls were used throughout all ELISAs and included supernatant from theca 
incubated with IOOnglml insulin following three days treatment (see 
3.3)(Intraipositive marker for both progesterone and androstenedione presence); 
osteoclast culture media following three days culture in standard media (DMEM) was 
used as a negative control for both progesterone and androstenedione levels (negative 
control). Media samples alone were also used as intra assay throughout, DMEM alone 
for adipocyte culture examination and DMEMIF 12 alone for theca cell examination. 
3.7.3 ELISA procedure 
The procedure remained the same for all three ELISAs used. All ELISA plates were 
brought to room temperature and I O ~ l l of standards/samples and controls added to 
duplicate wells. These included a blank well for comparison and removal of any 
background interference. 2 0 0 ~ 1 1 of either progesterone/androstenedione/testosterone_ 
enzyme label was added and left for 2.5 hours at room temperature covered and 
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gently shaken. The enzyme label was then removed and each well washed (x3) in 
200 .... 1 of wash buffer for 2 mins at a time. Wash buffer was then removed and the 
wells tapped dry onto an absorbent tissue and air-dried. 200 .... 1 of alkaline phosphatase 
substrate was added to each well and incubated at room temperature for 30 mins. 
Colour development was immediately measured using a spectrophotometer 
(progesterone 57Onm, androstenedione/testosterone 450nm 00) and results analysed 
by comparison to standards (see Figure 34, Figure 35). 
3.7.4 Data analysis 
All control samples were analysed alongside the results and on examination was kept 
constant to the ELISA used (progesterone 57Onm, androstenedione/testosterone 
450nm OD). All samples were analysed as duplicates. Furthermore an intra assay 
sample of insulin treated and untreated 3 day media was used from frozen stock 
throughout all experiments and media blanks included dependent on the cells used 
(DMEMlhigh glucose and OMEMlF12). Once known, sample standards were 
analysed (taken from each ELISA kit) standard curves were created by collating 
spectrophotometry data within Microsoft Excel 2010. This data was organized and 
transported to the prism software (vers. 5.0b) where once interference was removed 
from each result, was interpolated against the standard curves to give hormone 
secretion data (nglml). This was then converted to pmoVIOOOcells for standardization 
and normalized using Shapiro-WilklKruskal Wallis normality test. Multiple means for 
unpaired samples were compared using either one way Analysis of variance 
(ANOVA) or un-paired I-test (non-parametric) with Bonferroni post-hoc test while 
paired observations were analysed using two tailed students' t-test (parametric). P-
values <0.05 allowed for rejection of the null hypothesis. 
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4.0 CULTURE AND CHARACTERISTICS OF 3T3-Ll CELLS 
AND PRIMARY ADIPOCYTES FROM NON-PC OS AND PCOS 
WOMEN 
4.1 Introduction 
Mature adipocytes show little proliferative ability and controversy exists as to 
whether they have this capability [223]. In vitro differentiation is therefore a suitable 
alternative. This allows establishment of high cell yields through preadipocyte 
cultures and maturation to adipocytes through differentiation treatments. 
It is only within the last 20 years that adipose tissue has been considered to act as an 
endocrine organ [207, 224] following the identification and characterization of leptin 
discovered by Zhang et al.. 1994 [225]. Research has since detennined various 
bioactive peptides (adipokines) that allow systemic signalling to adipocytes (Table 4). 
It has also been shown that adipocytes express various receptors that mediate 
adipocyte responses to many traditional hormones including insulin, androgens and 
eostrogens [226-228]. With the importance of obesity and the association this has 
with metabolic abnormalities such as insulin resistance (diabetes) and 
hyperinsulinemia, and conditions including cardiovascular disease, and metabolic 
syndrome, examination of adipocyte function and subsequent malfunction is of great 
clinical importance. 
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Adipocyte-derived proteins Endocrine function 
Leptin, Hormone energy regulator. 
TNF-a, IL-6 Cytokines and cytokine- related proteins. 
Immune system intercellular mediators. 
Plasminogen activator inhibitor-l (PAIl), Proteins involved in the fibrinolytic system 
Tissue factor 
Adipsin (complement factor D), Complement and complement-related proteins 
Complement factor B, ASP, Adiponectin that allow antibody binding and immune 
reaction. 
Lipoprotein lipase (LPL), Cholesterol ester Lipids and proteins for lipid metabolism or 
transfer protein (CETP), Apolipoprotein E transport and use in steroidogenesis 
NEFAs 
Cytochrome P450-dependent aromatase, Enzymes involved in steroid metabolism 
1 7 ~ - H S D , , IIHSDI 
Table 4. Examples of adipocyte derived proteins and their endocrine function. Many bioactive 
peptides known as adipokines have been detennined since the discovery of endocrine function of 
adipose tissue. 
Although peas has always been considered to be a reproductive disorder, its 
metabolic implications are often highlighted, with insulin playing a significant role in 
its pathogenesis [159]. Approximately 50-70% of women with peas have insulin 
resistance and subsequent hyperinsulinemia [229]. This has major implications for 
metabolic abnormalities and hyperinsulinemia has been associated with increased 
ovarian androgen synthesis with Nestler (1989) showing that hyperinsulinemia in 
obese peas women may directly increase serum testosterone [230, 231]. Although 
this is believed to be a major contributory factor toward hyperandrogenic peas, it is 
not seen as solely responsible. Research into insulin actions on metabolic function 
within target tissue in comparison to the ovary is therefore of clinical relevance with 
regard to peas. 
With 50% of peas women suffering from obesity, associations to peas and 
adipocyte dysfunction have been made [115, 232, 233]. One overriding factor seems 
to be abdominal fat distribution regardless of BM! [234]. In whole adipose tissue 
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samples taken from central abdominal deposits, data suggest that subcutaneous (SC) 
adipose tissue has higher rates of both androgen synthesis from precursors and 
androgen inactivation than omental fat (OM) [191]. However comparisons in levels of 
androgen secretion between PCOS and non-PCOS have yet to be carried out. 
Research into abnormalities within PCOS adipose tissue is a fairly new area of study 
possibly due to the relatively recent acceptance of adipose as an endocrine organ and 
the association this may have with PCOS as an endocrinological disorder. 
Comparative studies into SC adipocytes from women with PCOS have revealed 
morphological variations with a 25% increase in adipocyte cell size seen in PeOS 
samples [235]. Other studies have shown a decrease in hormone-sensitive lipase 
expression and adiponectin levels in PCOS women which maybe suggestive of further 
biochemical abnormalities [232]. Further to this, Dickerson el al., (2010) have shown 
that testosterone treatment of SC PCOS adipocytes was linked to reductions in 
adipokines and may point to pcas adipocyte impairment being secondary to 
hyperinsulinemia [236]. This study therefore suggests possible variations between 
non-PCOS and PCOS adipocytes may exist in the pathogenesis of PCOS warranting 
further investigation. 
In the present study, we sought to compare adipocytes from PCOS and non-PCOS 
women in order to determine any dysfunction (with particular focus on androgens), 
that may exist and obtain a more detailed insight into adipocyte function. Specifically, 
the focus of this Chapter includes an examination of adipocyte proliferation and 
differentiation as well as expression of adipokine receptors and hormonal influences 
on metabolism. 
We also sought to determine the effects of LH and insulin on SC hormonal secretion 
to determine any variation within or between non-PCOS and PCOS SC adipose 
samples. LH and insulin were selected based on their well-characterised association 
to pcas. 
In order to investigate hormonal influences on adipocyte metabolism in women with 
PCOS, it was necessary to establish a workable human primary adipocyte cell culture 
model. Initial protocol optimization of culturing and differentiating adipocytes was 
achieved using the 3T3-L 1 mouse cell line [237]. To date, this fibroblast cellline has 
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been widely used as a reliable model in the examination of the influence of insulin in 
adipocyte signalling pathways and pre and mature adipocyte intracrinology. This has 
led to discoveries such as insulin regulation of leptin secretion and TC 10 modulation 
of insulin-stimulated GLUT4 translocation [238-241]. Collison et 01., (2000) were the 
fIrst to examine the direct effect of sex steroids on peripheral insulin-sensitive tissue 
utilizing the 3T3-Ll cell model, supporting the role of oestrogen's influence in 
reduced insulin stimulated glucose uptake [242, 243]. 
The 3T3-LI cell line has also been used as a model in which the proliferative effects 
of LH releasing hormone agonist (LHRH) and its involvement in prostatic cancer 
treatment were shown to reduce tumour growth [244]. It was concluded that the 
mechanism involved may be the suppression of the pituitary-testicular axis and 
subsequent reduction in testosterone secretion [242, 244]. 
The availability and supporting background studies have made the 3T3-LI cell line a 
suitable animal cell line for our investigations but only with regard to determining 
suitable culture and differentiation protocol. No studies have utilised this model in 
respect to PCOS dysfunction and biochemical alterations from immortalisation gave 
limitations to adipocyte metabolism results. Therefore all comparisons were limited 
to our primary human model. Whilst the 3T3-L 1 preadipocyte cultures required 
straightforward maintenance, establishing maturation of these cultures was more 
complex [237]. Although protocols exist for culturing primary mature adipocytes 
through ceiling methods, cell lysis has been shown to occur within 72 hours due 
principally to a lack of access to available nutrients within the media as a result of the 
lipid buoyancy of the cells [245]. In addition, primary mature adipocyte cultures have 
yet to be validated in their ability to retain all of their in vivo function [246], although 
it is unlikely that culture models mimic exactly in vivo functions. 
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4.2 Objectives 
1. To successfully culture a viable 3T3-LI cell line and differentiate to 
mature adipocytes for later use in expression studies with a view to 
transfer protocols to a human model. 
n. Successfully establish primary human preadipocyte cultures from 
abdominal SC adipose biopsies and achieve differentiation of confluent 
preadipocyte cultures. 
Ill. To compare proliferation and differentiation in adipocytes cultured from 
adipose tissue of normal women and those with PCOS. 
4.3 Method 
Cultures of the 3T3-L I cell line at a passage of 20 were taken from liquid nitrogen 
storage and grown to confluence (see 3.2./). Once confluent, normally within 7 days, 
preadipocytes were transferred to T75 flasks to increase yield. On achieving 80% 
confluence, preadipocytes were then plated in 24 well plates at a density of 2x I OS per 
well and grown to 70-80% confluence for differentiation within an incubator at 5% 
CO2/airat37°C. 
Primary preadipocyte culture: In order to establish primary human preadipocyte 
cultures, SC abdominal biopsies were processed using enzymatic digestion (see 3.2) 
and the remainder filtered through 200",m nylon cell microsieves (BioDesign Inc., 
N200c)(see 3.2.2) This method was a variation of a technique used previously in our 
lab (Wood et al.: 2005) and originally established by Quinkler el al., (2004) It was 
necessary to carefully separate all adipose tissue from the sample prior to digestion 
removing all vascular and collagen components, minimising contamination from other 
cell types [247, 248]. 
Primary cultures were prepared from SC biopsies and grown to around 80% 
confluence before differentiation over the course of 3-5 weeks as described in Chapter 
3. Maturation of adipocytes was determined using oil red 0 staining of the lipid 
droplets (see 3.2.2.1) [237]. 
Human adipocyte proliferation was assessed using the MTS (3-( 4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay allowing 
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colorimetric assessment of cell proliferation and viability. Adipocytes were cultured 
over 5 days and proliferation assessed daily using the chemical reduction of MTS to 
fonnazen (see 3.4). Absorbance measurements were made by spectrophotometry at a 
wavelength of 49Onm. 
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4.4 Results 
4.4.1 Culture and differentiation of 3T3-Ll preadipocytes: 
Figure 36 shows 3T3-Ll preadipocytes grown to 90% confluence over 7 days. The 
cells were arranged in clusters and became tightly packed producing a cobblestone 
appearance allowing for stabilisation and support of the cells. For this reason the 
initial differentiation media (see 3.2) was added to cultures at around 70-90% 
confluence. In doing so, all preadipocytes underwent growth arrest. This also occurred 
with increases in cell number so may be a result of cell to cell contact, which is 
believed to initiate adipocyte conversion as well as leading to secretion and exposure 
to initiation signals (CCAAT/enhancer binding protein a (CIEBP-a) and PPAR-y,) of 
neighbouring cells [249]. This, along with the solution required to initiate 
differentiation, allowed for simultaneous maturation of the preadipocytes to mature 
adipocytes and prevented only partial maturation of cell patches within fully confluent 
cultures. Although preadipocytes adhered tightly to the plastic substrate, at this stage 
we found it necessary to grow the cells to confluence thus creating a sturdier matrix 
before differentiation. Figure 37 shows 3T3-L 1 cells following 4 weeks 
differentiation treatment. Following initiation of differentiation (see 3.2.2.1), the cells 
begin to elongate weakening the support matrix of their neighbouring cells and could 
be seen as cells breaking away from the cultures to form patchy grouping, gaps 
between or individual cells. Occasionally this action would lead to cells detaching 
from the base of the plate and floating within the media. Small lipid droplets formed 
in approximately 70% of the cells. Using light microscopy, these droplets were seen 
as light circular spots within the cells and can appear blurred due to the need to focus 
on a higher plane within the z-axis than would be needed for flat, adherent cells. The 
buoyancy of the lipids within the cells caused the cells to detach and required careful 
handling during media changes. Lipid droplet size increased from 10 ± 7 ~ m m (n = 10) 
to up to 100 ± 15 ~ m m (n =10) with maturation as seen in Figure 38 and Figure 39. As 
the cells continued to alter in morphology, becoming rounder, the distance between 
neighbouring cells continued to increase. This coupled with increased lipid buoyancy 
led to sheets of cells tearing away from the base of the well and loss of cultures. Daily 
monitoring was required towards the end of differentiation in order to minimise such 
losses. 
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Figure 36. 3T3-Ll Preadipocytes 7 days 
following culture. Preadipocytes maintained at 
around 90% confluence. Preadipocytes are seen 
as flat and beginning to form a tight mosaic 
formation. (A) hows preadipocytes beginning 
to differentiate. 
Figure 37. 3T3-LI Adipocytes. Preadipocytes 
following 4 weeks of routine media changes 
occurring every 3 days with media consisting of 
insulin, IBMX and dexamethasone. Approximately 
70% of the preadipocytes have undergone 
differentiation showing developing lipid droplets. 
Validation of adipocyte differentiation was confirmed using, Oil Red 0 staining. Oil 
Red 0 is fat-soluble and stains neutral triglycerides red [250]. Figure 39 shows both 
large lipid vacuoles and smaller lipid accumulation with red staining by Oil Red O. 
Figure 38. 3T3-Ll Adipocytes. Preadipocytes after Figure 39. 3T3-LI Adipocytes. Preadipocytes 
6 weeks in vitro. Preadipocytes have undergone following 6 weeks differentiation stained with Oil 
differentiation into mature adipocytes as seen by the red O. Red staining shows lipid droplets and 
extensive accumulation oflipid droplets. subsequent maturation of adipocyte. 
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4.4.2 Human adipocyte cultures from non-PCOS and PCOS women 
Patient demographics 
Adipose tissue biopsies (-Sg) were taken from SC adipo e ti ue of the abdominal 
wall of participating women either during a planned surgical procedure or under local 
anaesthesia in the outpatient cJinic (for women not undergoing urgery. Two group 
were selected, normal women (control group) and women with PO . (See 3.1 for 
selection criteria). Data are summarised in Table 2 
Bod 
• 
6.7 ± IA 29.86 ± 11.2 •• 
T able 2. Patient demographic of cultured samples. Data summari ed as mean (range) / EM (±) • 
P<0.05 ** P <0.0 I *** P<O.OO I. 
The age range of our samples allowed cultures to be cia ely matched for compari on 
of peos and non-peOS women. Table 2 shows tbat the 8MI between our age 
matched groups was significantly increased in women with PO. Biochemical 
variations between the groups existed with ignificant increa e ill te to teron 
(>2.9nmol/l), insulin (> 170 pmol/I) and LH level ymptomatic of P 0 women. 
Recent studies have shown that DHEAS i less reliable than te to terone with only 
5% of hirsute patients examined showing elevated levels [213]. For thi rca on we 
measured free testosterone levels (see 3. /). 
Significant increases were seen in 8MI, insulin, te to terone and LH within the P 0 
samples, however in some women (n= 6), free testosterone did not exceed 2.9 nmo 
typically related to the condition . Studies within the hyperandrogenic hur uiti m 
phenotype have shown that 72% of patients examined had normal free te to terone 
levels with 55% of these also showing normal F AI. The e result al 0 howed 
increased androstenedione levels [213]. peos diagnosis was al 0 up ported by 
ultrasound presence of polycystic ovaries within our ample group. A ignificant 
variation across groups with LH secretion of which 90% of peo ample (n== 9) had 
LH levels exceeding normal levels (follicular phase > 13 nmol! I). LH hyper ecretion i 
76 
Chapter 4: Results: Comparison of non-PCaS and pcas Adipocytes 
often associated with PCOS and LWFSH ratios are often used as a diagnostic marker, 
although not independently. A strong correlation between LH levels and PCOS was 
seen within our samples (see Table 2). 
Although the peos group showed significant increases in insulin secretion against 
the non-PCOS, the insulin levels typically seen within PCOS in accordance with 
hyperinsulinemia was only found within around 50% of our peos sample group. 
This allowed us to split this sample group between non-hyperinsulinemic-PCOS / 
hyperinsulinemic -peos for further examination (see Table 5). 
Parameter Non hyperinsulinemic Hyperinsulinemic P 
PCOS (n=4) PCOS (n=6) 
A2e (yrs) 29.33 (25-35) 32.25 (29-38) NS 
Body Mass Index 28.33 (19.8-35.4) 30.28 (22.6-37.6) NS 
(k2/ml) 
Insulin (pmolll) 48.44 ± 12.49 190 ± 32.32 0.002** 
Testosterone 1.50 ± 0.10 3.05 ± 0.62 0.032 * 
(nmoVl) 
Luteinising 11.25 ± 3.3 26.75 ± 8.4 NS 
Hormone (nmolll) 
Table 5. Patient demographic of peos cultured samples. peos samples with hyperinsulinemia 
against non-hyperinsulinemia. Data summarised as mean (range) / SEM (±) * P<O.05 ** P<O.OI *** 
P<O.OOI. 
Examination of BMI between hyperinsulinaemic PCOS and non-hyperinsulinaemic 
PCOS showed no significance, suggesting no correlation exists between increased 
insulin and 8MI, although our dataset is small. When examining our biochemical 
results, significant increases in testosterone levels found in our hyperinsulinemic 
PCOS women was seen. 
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sporadic differentiation. Examination of both 3T3-LI and human primary 
preadipocyte cultures (n=6) showed that following 80-90% confluence, failure to add 
differentiation media caused sporadic differentiation of cell patches. If these cells then 
underwent the differentiation procedure via media treatment these patches would 
eventually de-differentiate with observations showing a noticeable decrease in lipid 
droplets throughout the cultures. Observations showed that these patches would then 
detach from the well plate leaving cellular debris typical of cell death. With the 
cellular matrix broken the remainder of cell would eventually detach halting 
maturation and cellular debris suggested signs of cell death. 
Careful maintenance, suitable confluence and the addition of differentiation media 
immediately as the cells reached 80-90% confluence therefore allowed colony wide 
maturation of preadipocytes obtained through our protocol as recommended by 
Bujalska et al., (1999)[251]. 
4.4.2.2 Characterisation of preadipocytes 
SC biopsies required separation and processing to establish primary fibroblast cultures 
in order to minimise cellular contamination occurring during this process. 
Immunofluorescence and western blotting techniques were used to identify 
preadipocyte markers (anti-human 08 R&D Systems (AF398». All samples were run 
against positive (Ji-actin and commercially available human adipocyte cell lines) with 
leucocytes serving as a negative control against adipocyte markers (see 3.5.1). 
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Figure 4 t. Immunofluore cence of mature Figure 42. Bright field micrograph of mature 
human adipocytes. Mature adipocyte cell human adipoc te 6 weeks ill vitro. Mature 
sta ined with anti-O B 
conjugated econdary 
immunofluorescence IS 
membranes. 
antibody and FITC 
antibody. Anti-OB 
loca li sed to the ce ll 
human adipocyte differentiated to around 0%. 
Bright field allow detenninatlOn of cell 
morphology and lipid droplet can be ccn in the 
mature adipoeyte . 
Figure 42 and Figure 41 how mature human adipocyte In bright fi eld and 
fluore cent staining allowing cellular morphology to be een clearly. Figure 41 how 
leptin was predominantly expressed within the cytopla m urrounding the lipid 
droplets where it is known to localise to the ER [252). egative control (leu 0 yt 
culture and incubating in econdary antibody alone) did not di play taining for leptin 
but taining for p-actin was een. Adipocytes from a commercial primary adip yte 
cell line (PromoCell C-I2730) and p-actin po iti e control al 0 upportcd finding 
with leptin seen staining human adi pocyte culture a well a p-actin po iti ity. 
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4.4.3.1.2 Western blotting 
Expression of leptin protein was seen III both the human adipocyte cell line and 
primary adipocyte cultures through western blotting. 
Pre-Ad Mat-Ad 
Pre-Ad Mat-Ad 
(cell line) (cell line) 
~ ~ ~ ~ ~
1 2 3 4 
so 
37 
20 I ~ - - - - - - - - - - - - - - - - - - - - - - - - ~ I I ~ : : : :
Figure 43. Western blot of leptin expression in preadipocyte (Pre-Ad/lane 1 and 3) and mature 
adipocyte (Mat-Adllane 2 and 4) Iysates (n=2 vs. 2). Preadipocyte (lanes 1-3) and mature adipocyte 
Iysates (lane 2-4) were probed using the polyclonal antiOB antibody. Exposure at 640sec shows band 
at predicted 16kDa, which were observed to be more abundant in preadipocyte samples. The blot was 
then stripped using reblo! and re probed using ~ - A c t i n n to control for protein loading I. ~ A c t i n n shows 
exposure density reading . Human mature adipocyte Iysates were used as positive controls (lane 3-4). 
Western blotting of primary human adipocyte lysates and human adipocyte cell line, 
from both preadipocyte and mature adipocyte cultures were used to examine and 
further support characterization of our primary culture. Anti-Ieptin (OB) antibody 
probe (anti-human OB R&D Systems (AF398)) was used as a positive marker in both 
the preadipocyte and mature adipocyte lysates of primary and cell line harvests (see 
3.6). Figure 43 shows positive band exposure at 640sec representative of leptin 
expression in all lysates (lane 1-4). Lane 2 primary mature adipocyte lysates shows 
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weaker exposure suggesting reduced leptin when compared to mature adipocyte 
lysates within the cell line (lane 4). 
4.4.3 Comparison of differentiation In non-PC OS and PCOS adlpocytes 
The differentiation protocol adopted for this study was based around our experience 
with our animal cell line and the protocol used by Quinlder el al. (2004) and Chen et 
al., (1997)[247, 253]. Once established and with suitable yield (typically passage 3), 
human preadipocyte cultures were grown to confluence within either 6 well plates for 
expression experiments, or 24 well plates for examination of rates of differentiation. 
Once 70-80% confluence was reached media used for initiation of differentiation was 
added (see 3.2.2) Figure 44. We found that increasing the insulin within both 
initiation and maintenance media gave more reliable differentiation as some of our 
original cultures had reduced differentiation sometimes as low as 20%. This was 
therefore increased within our primary human cultures. Within 3-4 weeks cells were 
seen to change morphologically by rounding and small lipid droplets would begin to 
form within the cytoplasm as seen in Figure 45. 
We found that enlarged lipid accumulation did not exceed 70% of the differentiated 
culture, which took 6-9 weeks dependent on the culture (Figure 47). At this point 
cells would begin to differentiate and this would eventually lead to cell death. 
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Similar to the 3T3-Ll mouse cell line, Oil Red 0 was u ed to validate maturation of 
the adipocytes. Figure 48 shows both large lipid acuole and mailer Lipid 
accumulation with red staining by Oil Red O. 
o Staining. 70% of the culture have ma tured wi th large lipid 
droplet fo rmation hown through O il Red 0 taining. 10 
magnification 
By staining both non-peaS and peos culture with Oil Red O. compari on In 
morphology could be made. Age and BMI matched culture at 2nd/3rd pa age w r 
used to examine lipid droplet formation. Comparison of non-PCO and P 0 lipid 
droplet formation in week 4 of differentiation were made. Although lipid 
accumulation was not quantitatively assessed, ob ervation con i tently ugge t d 
(Figure 49, Figure 51) samples from peos women had a greater number of matur 
cells based on the prevalence of larger lipid droplet formation . Mea urement of th 
larger droplets within peos and non-peOS mature adipocytc culture following 10 
week differentiation showed peos lipid droplet izes at 0 ±29.3I1m (n= I 0). 
Typically non-peOS adipocytes, lipid droplet matured to 30 ± 12. 711m (n= I 0) in iz 
over a 10 week period. 
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Figure 49. 4 weeks differentiation of non- Figure 50. 9 weeks differentiation of non-
peos adipocytes with Oil Red 0 Staining. peos with Oil Red 0 Staining. 80% of the 
50% of the cultures have filled with small lipid cultures have filled with lipid droplet. Larger 
droplet. Larger droplets are beginning to fom1 droplets show fully matured cells through Oil Red 
shown through Oil Red 0 staining. lOx 0 staining. lOx magnification. 
magnification. 
Figure 51. 4 weeks differentiation of peos 
adipocytes with Oil Red 0 Staining. 70% of the 
cultures have filled with small lipid droplet. 
Larger droplets arc beginning to form. The Oil 
Red 0 staining hows that more adipocytes are 
maturing with increased lipid droplet size and 
number when compared to non-PCOS cells at the 
same time course. lOx magnification. 
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Figure 52, 9 weeks differentiation of peos 
adipocytes with Oil Red 0 Staining. 80% of the 
cultures have filled with large lipid droplet. When 
compared with non-PCOS adipocytes at the same 
time course the droplets size is larger and 
numbers increased. lOx magnification. 
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Figure 53. Non-PCOS and PCO differentiation (9 'eek n=6 v . 6). on-P and P 
preadipocytes were di ffe renti ated over 9 weeks. Media wa remo ed e ery 3 eek and ell lained 
with Oil Red O. Oil Red 0 were removed and ab orbance mea ured 490nnm. on-P 
preadipocytes were cultured along ide and different iation not initiated for control. 
By using Oil Red 0 staining of cell cultures at 3 week time cour e we wer abl to 
measure differentiation. The oil Red 0 would tain lipid droplet formati on and a t a 
measure of maturation. This could then be mea ured through remo al of th 
remaining Oil Red 0 and absorbance mea ured again ee 3.2.2. 1) imilar to th 
morphological findings, a comparison of 9 week differ ntiation of non-P and 
peos adipocytes showed significant variation acro cultures. Figure 53 ho that 
by week 3 a significant difference in differentiation occur (Mean ± .E.M. 0.109 ± 
0.03933 *P<O.O 1 06). Although a decrea e in absorbance i eeo by week 6 ignificant 
variations between the culturcs is maintained until week 9 where the highe tiel of 
maturation is reached . This is een statistically to be a imilar I vel over both non-
peos and peos groups with no significance bctween the ab orbance found. 
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4.5 Proliferation in non-PCOS and PCOS adipocytes. 
In order to examine the effects hormonal treatments may have on adipocyte 
proliferation within both non-peos and peos preadipocytes, it was necessary to 
establish a growth curve under stable conditions. In order to do this, MTS assays (3-
(4,5 -dimethylthiazo 1-2-yl)-5-(3-carboxymethoxypheny 1)-2-( 4-sulfophenyl)-2H-
tetrazolium) were used to colormetrically assess proliferation and cell viability in cells 
derived from non-peOS cells and peos patients. 
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~ ~
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c 
C'O 
Jl 
~ ~
0 0.2 II) 
Jl 
< 
0.0 
0 24 48 72 96 120 
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Figure S4 Non-PeOS preadipocyte S day proliferation (n=5). MTS assay was used on Non-PeOS 
preadipocytes to delennine proliferation. 5x I 03 cells were plated and MTS added every 24 hours with 
absorbance measured at 490nm. After initial decrease in proliferation following 48 hours cell numbers 
increased to reach its maximum level at around 96 hours before levelling off at 120 hours. 
Non-PeOS cells were plated (n=5 / 5xl03 cells) and MTS absorbance measured every 
24hrs from day 1. Results were measured against a standard. Once plated absorbance 
showed an initial decrease. Rapid growth then occurred to its peak cell density of 
around 0.733 ± 0.013 represented by absorbance at 96 hours. At this stage cell 
numbers decreased to 0.652 OD ± 0.20 (see Figure 54.) 
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Figure 55. peos preadipocyte 5 day proliferation (n=5). MT a ay wa u ed on P 0 
preadipocytes to determine proliferation. 5x I oj cells were plated and MTS added every 24 hours v ilh 
absorbance measured at 490nm. After initial decrease in proliferation to 0.3 2 ±O.O 13 fo llowing 4 
hours cell numbers increased to reach its maximum level 0.822 ±O.O II at around 96 hours before 
levelling off at 0.802 ±0.027 at 120 hours. 
The MTS assay was repeated using PCOS cultures (0=5). Similar to the non-PCO 
growth curve we saw slight drops in absorbance repre entative of cell number at 4 
hours followed by a sharp rise in proliferation at 72 and 96 hours to a maximum O. 22 
±O.O 11 00 (see Figure 55). By 120 hours the cultures had ettled at 100% confluence 
at around 0.822 ±0.011O.027 00. Cross-examination of non-PCO again t P a 
growth curves showed no significant difference in plating den ity or final cell yield. 
However 72 hours showed a significant ri e in proliferation within the P a cell 
(P=O.1 035, 3332 ± 368)(Figure 56). 
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Non-PCaS adipocytes 
• pcas Adipocytes 
Figure 56. PCOS against non-PCOS preadipocyte 5-day proliferation (n=5). Column analysis of 
non-PCOS against PCOS cell proliferation over 5 days showed no variation in cell numbers at seeding 
or final yield suggesting no variations in preadipocyte morphology. Results are mean ± SEM, Day 3 
showed significantly increased growth (***P<O.OO I) following examination with unpaired f-test. This 
suggest increased rate in proliferation within peos preadipocytes. 
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4.6 Discussion 
4.6.1 Culture and differentiation of 3T3-Ll preadipocytes 
The aim of this chapter was to determine the suitability of the murine 3T3-Llcellline 
as a model for examination into adipocyte steroidogenesis. This would then be used as 
a basis for protocol optimization with a view to transfer methodology to a future 
human primary culture once ethical approval was received. In order to do this it was 
necessary to maintain and differentiate preadipocyte cultures to be used 10 
immunofluorescence and immunoblotting procedures. The first objective was to 
establish and differentiate 3T3-L I preadipocyte c u l t u r ~ s . . This has been a long 
established protocol and although the cell line proved to be proliferative and achieved 
confluence within T75 flasks over 8-9 days, initial difficulty was found in using the 
protocol as described in Chawla et al., (1994)[254]. Following cyclic changes 
between maintenance media and stimulatory media, cultures showed partial 
differentiation but were unable to survive. Successful differentiation occurred 
utilizing the protocol as described by Chen et al., (1997) using a single stimulatory 
step with increased insulin, dexamethasone and the addition of IBMX [253]. The 
combination of dexamethasone and IBMX, a phosphodiesterase inhibitor, acted as an 
inducing agent, which has been suggested to either trigger or accelerate differentiation 
[249]. Differentiation did occur spontaneously prior to dilution of initiation media in 
some cases as seen in Figure 36 suggesting this media may therefore act as an 
accelerant of differentiation. Partial differentiation was achieved after 4 weeks with 
no adipocytes retaining preadipocyte cobblestone or elongated morphology. Mature 
adipocyte formation was measured on enlarged lipid droplet formation, which did not 
occur until week 6 and did not develop beyond 80% of the cell culture. By continuing 
the differentiation procedure beyond 6 weeks, eventual de-differentiation occurred 
followed quickly by cell death. This maybe as a result of cytokine release as described 
by Prins et al., 1997 [255, 256] whereby increased adipocity signals increased tumour 
necrosis factor-alpha (TNF-a) this subsequently leads to de-differentiation as a means 
of regulation and results in apoptosis [255]. This dynamic process therefore requires 
careful monitoring in order to maintain adipocyte cultured at the desired stage of 
differentiation. 
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4.6.2 Differentiation in non-PCOS and PCOS adipocytes 
Past research into peos adipose tissue has shown variations within morphology and 
function [232]. These include increased waist to hip ratios indicative of 
abdominaVvisceral fat accumulation, enlarged adipocytes, reduced serum adiponectin 
[257] and lower LPL activity [232, 258]. Although there is limited research into the 
examination of adipocyte differentiation across normal and peos adipocytes 
Danforth has proposed that an inability for preadipocytes to differentiation as a result 
of excess energy intake within obese patients may account for observed metabolic 
dysfunction [259]. If this were the case it would lead to redistribution of fat depots 
where ectopic distribution has been shown to encourage insulin resistance. This 
hypothesis has been supported by Yang who on examination of adipocytes from obese 
and non-obese subjects showed those with insulin resistance had reduced expression 
of genes associated with differentiation such as aP2 and adiponectin [260]. In addition 
to this, Gupta et al.. have demonstrated reduction in differentiation as well as lipid 
accumulation in normal human adipocytes when exposed to dihydrotestosterone 
typically found to be increased within peos women [261]. 
Our results suggest that samples taken from peos women have reduced rates of 
differentiation across a range of BMIs from lean to obese. As all samples were 
matched across non-peOS and peos groups the significant variation seen is 
supportive of these hypothesis. Findings also showed that although a decrease in 
differentiation occurred at week 6, the variation between groups remained 
significantly different supporting a difference within rates between groups. This is 
further confounded by the point at which both groups of adipocytes reach an equal 
level of maturity. The dip in lipid droplet formation at week 6 may be explained by an 
inadequacy of the protocol chosen. Typically oil red 0 staining is used as a marker of 
the characteristics of adipocytes rather than a comparative measure of differentiation. 
Although 6 samples per group were used in duplicate, cells were seeded in 4 different 
plates to allow examination of a specific plate at a specific time course i.e. week 3, 6, 
and 9. As adipocyte cells are particularly delicate during maturation especially due to 
lipid buoyancy, the required washing and treatments involved within the protocol may 
have affected the results. The suitability of this method for this experiment would 
therefore require comparison to an alternate measure of maturation and with further 
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work biochemical examination may support this possibly by examining glycerol 3-
phosphate dehydrogenase (GPOH) levels [262]. Studies of in vitro cultures of both 
animal and human have however shown that differentiating adipocytes can undergo a 
stage of dedifferentiation and still fully develop into mature adipocytes with no effect 
on the characteristic seen within normal adipocyte maturation [263, 264]. 
4.6.3 Proliferation in non-PCOS and PCOS adipocytes. 
Previous research has shown hypertrophy within pcas abdominal SC mature 
adipocytes independent of BMI [185, 232]. Examination of preadipocytes 
morphology showed no differences between sample groups at this stage of 
differentiation. This may suggest variation occurs during adipocyte development. 
This was further supported through equal levels of confluence reached within our 
proliferation assays (Figure 54, Figure 55). Both culture groups stabilized at around 
absorbance 0.7 00 (approx. 11,000 cells). Assuming both cell types behaved 
similarly avoiding stacking / clumping during proliferation, then cell morphology 
would dictate the space available and the subsequent yield. 
Studies into non-obese pcas women have shown marked decreases within 
catecholamine-induced lipolysis in SC abdominal adipocytes suggestive of resistance 
[235, 265]. If this were the case it would prevent mobilization of triglycerides 
increasing lipid droplet storage, which accounts for 95% of mature adipocytes and 
dictates the subsequent size of the cell. This would also explain why variations in 
peas morphology only occur following differentiation. 
Separate examination of both sample groups allowed us to see similar growth curves 
with slight decreases in proliferation following seeding typically found in plating 
density due to acclimatization. Increased growth was seen by day 3 reaching the 
optimum level of confluence for the experiment by day 4 and showing a slight 
decrease in number to stabilize by day 5,6 and 7. This is typically due to depletion of 
growth factors, space available and nutrients; all contributing to an inability to sustain 
increased cellular yield. Rapid growth can also often lead to initial clumping and 
stacking of cells. Depending on the cell type some cells cannot survive in this state 
and numbers decline to a more stable level. Unpaired t-test analysis of each day 
between non-peaS and peas showed no variation within sample groups with the 
92 
Chapter 4: Results: Comparison of non-PeOS and peos Adipocytes 
exception of day 3. At this point significant variation was seen suggesting 
hyperplastic behaviour within PCOS preadipocytes as theorised within pcas ovarian 
theca cells [266, 267]. This result may be considered a biological observation, 
however it may be attributed to the sample numbers examined and therefore statistical 
limitations. Mature adipocytes proliferate at a very slow rate and controversy exists as 
to whether this ability exists at all [223, 268]. Increased adipose tissue is therefore 
typically attributed to hypertrophic expansion of existing adipocytes. Although we are 
aware that PCOS mature adipocytes show increases in hypertrophy, this has been 
linked to increased pro-inflammatory markers with chemokine levels (MCP-I and 
MIP-I) having been shown to correlate with BMI within PCDS women [269-271]. 
Although this hypothesis may explain the association with obesity and PCDS, it 
would require further examination into why this increase in pro-inflammatory 
mediators would not initiate cell death typically found in non-PCDS adipocytes and in 
tum would reduce cell numbers. Hyperplastic PCDS preadipocytes may therefore go 
some way to explaining the pathogenesis of associated obesity within the condition. A 
combination of preadipocyte hyperplasia and possible decreased triglyceride 
mobilization within PCDS may therefore offer a link between obesity and pcas. 
In summary, this chapter suggests that variations exist in the metabolic activity of in-
vitro SC adipocytes from PCDS patients. 
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5.0 CHARACTERISATION OF THE STEROIDOGENIC PA TRW A Y 
IN 3T3-Ll CELLS AND ADIPOCYTES OF WOMEN WITH AND 
WITHOUT PCOS 
5.1 Introduction 
Studies as early as 1987 have shown adipose to be a major site of sex steroid 
metabolism with interest arising from positive correlation to increased oestrogen and 
androgen levels found with increases in weight gain [207,272]. The identification and 
characterisation of leptin in 1994 [225] further refuted the myth that adipose was a 
passive reservoir for energy storage. It also created the possibility of a loop system 
theory, whereby brain and peripheral communication were involved in fuel and body 
weight homeostasis. Leptin was secreted and seen to effect the hypothalamic 
neuropeptide Y (NPY) allowing energy regulation [193]. Since then, adipose function 
has been widely examined with adipocytes shown to express and secrete a variety of 
bioactive peptides that include C-reactive protein (CRP), angiotensinogen, leptin and 
resistin, that act in both an autocrine and paracrine manner [224. 249, 252]. 
Additionally, it has been shown that adipocytes express various factors and receptors 
that mediate their autocrine responses. Receptors have also been determined with 
regard to many traditional hormonal signals leading to subsequent activation of 
intracellular pathways and supporting the communicative abilities of adipocytes (see 
Table 6) [226-228]. Leptin is synthesised by adipocytes and is believed to act in both 
an autocrine and paracrine manner. The signal pathways regulated by leptin are now 
known to be diverse including both cytokine and growth factor receptor Signalling 
[273]. It has also been seen to act through its own receptor in lipolytic regulation 
within adipocytes, as well as its action following secretion, in other organs including 
the hypothalamus through which it regulates satiety [226]. 
Research has begun to establish the major involvement adipose tissue has in the 
regulation of levels and bioactivity of sex steroids. This can be seen within adipocyte 
conversion of peripheral androstenedione to more potent androgens, and in the 
synthesis of oestrogen, with adipocyte biosynthesis seen as the main contributor to 
physiological oestrogen levels in postmenopausal women [224, 274. 275]. 
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Examination into the steroidogenic pathway involved m oestrogen 
conversion/synthesis has shown the involvement of cytochrome P450-dependent 
aromatase in precursor androstenedione transformation to oestrone, and it is believed 
that changes in localised levels of these hormones may be involved in sex related fat 
deposition [208]. 
Adipogenesis and subsequent fat deposition, is dependent on preadipocyte precursor 
development and induction via transcriptional activation from key factors including 
adipsine, aP2, LPL as well as a variety of hormones including insulin, IGF-l and 
glucocorticoids. (5, 6, 7). Although the role of sex steroids in this process is yet to be 
fully understood, studies by Dieudonne et aI., 2002, have shown that oestrogen has a 
preadipogenic effect whereas androgens show a more antiadipogenic effect on the 
production of SC fat in 3T3-LI cells [276]. 
Factors secreted by adipocytes for autocrine Reference 
Leptin Zhang et al., 1994 
Agouti Bultman et aI., 1992 
Sex Steroids (progesterone, oestrogen, Bouloumie et aI., 1994 
Cytokines, tumour necrosis factor (TNFa) Hotamisligil et aI. , 1993 
Interleukin-6 (lL-6) Fried et al., 1998 
Free fatty acids e.g. Coppack et al. , 1994 
Lipoprotein lipase Fried and DiGirolamo et aI., 
Apoprotcin E (Apo E) Zechner et al. , 1991 
Insulin-like growth factor-l (IGF-l) Doglio et al., 1987 
Table 6. Receptor expression in adipocytes. Studies have shown a wide array of receptors expressed 
within sub-cutaneous adipocytes that would allow signalling to occur through homlonal influence 
[226-228). 
It is well recognised that androgens are produced in both the ovaries and the adrenal 
glands [8, 277, 278]. However, few studies have examined the capabilities of 
peripheral tissues such as the skin, liver and adipose tissue to convert weak circulatory 
androgens into stronger androgens or oestrogen. Investigation into adipose steroid 
conversion has shown 15 steroidogenic enzymes exist within adipose tissue including 
aromatase, 3 P-hydroxysteroid dehydrogenase (HSD) type 1 (31), 11 ~ - h y d r o x y s t e r o i d d
dehydrogenase type 1 and 2 (35), 5a-reductase (36) and 1 7 ~ - H S D D types 2,3 and 5 
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[210]. Many of these are also present in the ovary. Based on these fmdings, the 
capacity for peripheral tissue to synthesize and inactivate androgens is feasible. 
Our findings shown in Chapter 4, suggested that variations in metabolic behaviour 
may exist between non-PCOS and PCOS SC adipocytes. We therefore further 
examined comparisons between the two sample groups with focus on PeOS 
associated dysfunctions. In the present study we therefore aimed to show the viability 
of localized androgen synthesis through the presence of the steroid-converting 
enzyme 17a-hydroxylase (CYPI7) and the progesterone precursor. Our rationale was 
based on the androgen synthetic pathway found within ovarian steroidogeneisis and 
how the presence of the precursors and key enzymes necessary for thecal steroid 
metabolism, if determined present within adipocytes, would allow androgen synthesis. 
This theory was examined within preadipocytes and following differentiation under 
controlled conditions. Subcutaneous adipose biopsies of both non and peas adipose 
samples were used in primary culture as previously determined to be more 
steroidogenically active than visceral samples [209]. SC biopsies were also used due 
to the occurrence of abdominal obesity typically associated with peas and suggested 
metabolic dysfunction, which has been hypothesised (see 1./0). Examination of a 
localized source of androgen production is therefore of clinical relevance due to the 
association of obesity and increased androgen secretion, asymptomatic of PCOS. 
5.2 Objectives 
1. Determine the presence of 17a-hydroxylase within preadipocytes and 
mature 3T3-L 1 cultures. 
11. Determine the presence of the steroidogenic enzyme 17a-hydroxylase 
within adipocytes obtained from non-PC OS and peos patients. 
Ill. To examine hormonal secretion of androstenedione and progesterone in 
non-peOS and peos adipocytes in vitro. 
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5.3 Method 
Readily established 3T3-Ll and primary human adipocyte cultures (non-PCaS and 
PCaS) were used as either preadipocytes or mature adipocytes (see 3.2.113.2.2). 
The expression of CYP17 in 3T3-Ll cells was investigated by immunofluorescence 
(JF)(see 3.5). 3T3-Ll cultures where used prior to receiving ethical approval of the 
human model. This allowed validation of the chosen protocol whilst identifying its 
suitability if required for any further work. From this, optimization of protocols for 
use within our human primary cultures was achieved. 
Sparsely cultured (5xl04) 3T3-Ll preadipocytes were fixed with acetone methanol, 
incubated with anti-CYP17 antibody (1 :50 Abgent AP7879c) and secondary FITC, 
and washed. These were then examined under a fluorescent microscope (see method 
3.2.1). 
Chinese hamster ovary (CHO) cells at passage 12 were used as a positive control for 
CYP17 immunofluorescence [192,279]. p-Actin antibody (Abeam Ab8227) was also 
used as a positive control for the protocol. Negative controls included leucocytes 
prepared using the same protocol [280]. Preadipocytes, CHO and leukocytes were 
also incubated in the absence of primary antibody. 
In order to support the expression of CVP 17 within our adipocyte cultures we used 
semi-quantitation of proteins by western blotting (see 3.6). The BCA technique along 
with Ponceau S staining and P-Actin probe was used on preadipocyte lysate harvests 
and subsequent immunoblot to confirm equal protein loading (see 3.6.3). 
Nitrocellulose blots were probed using the polyclonal CYP17al antibody (1 :50 
SantaCruz Sc46085) Following optimisation of protocol; exposure at 640sec was 
examined for band exposure at 57 kDa band which is the predicted molecular weight 
ofCYP17 
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5.4 Results 
5.4.1 Expression of the steroidogenic enzyme CYP17 within 3T3-Ll cell u iog 
immunofluorescence 
Preadipocytes were cultured to approximately 50% confluence to allow individual cell 
morphology to be seen under fluorescence (Figure 57) and pha e contra t (Figure 58) 
microscopy. Negative controls (leucocyte culture and econdary antibody alone) 
showed no fluorescence indicative of no CYP 17 expres ion. CHO culture howed 
fluorescence positive for CYP 17 (Figure 59). ~ - A c t i n n probing howed fluore cence 
substantiating the protocol used (Figure 57) based on the wide pread expre ion of 
this housekeeping protein. 
Figu re 57. Imm u nofluorescence of 3T3-L I 
adipocytes. 3T3-L I preadipocytes sta ined with P-
Actin and FITC conjugated secondary antibody. 
p-Actin wa used as a positive control due its 
occurrence as a ce llular component of the 
cytoskeleton. 
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Figure 58. Pha e contra t 3T3-LI dipoc 'te . 
3T3-L1 pre adipocyte ' hown in phasc contra l. 
Used to see ce ll morphology a a compari on for 
succes Cu i fluore cence via P- clln . 
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Figure 59. Immunofluorescence of Chinese 
hamster ovary cells (CHO). CHO cells passage 
Figure 60. Phase contrast CHO. CHO cells 
shown in phase contrast. Showing cell 
12 stained with CYP 17 and FITC conjugated morphology and comparison 
secondary antibody. CHO cells were used a a immunofluorescence images. 
positive control showing the expression of CYPI7 
within the cytosol. 
for 
Figure 61. Immunofluorescence of 3T3-L I Figure 62. Phase contrast image 3T3-Ll 
preadipocytes. 3T3-Ll preadipocytes 16th preadipocytes. 3T3-LI preadipocytes grown to 
passage stained with CYPJ7 and FITC conjugated 40-50% confluence to allow imaging of cell 
anti-rabbit secondary antibody. Fluorescence is morphology. 
localised in the perinuclear region and in the 
cytosol. A) Concentrated perinuclear CY P 17 
staining can be seen. 
Figure 63 shows that CYP 17 was predominantly expressed within the cytoplasm with 
abundant perinuclear localisation. Mature adipocyte cell morphology was clearly seen 
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with rounding of the preadipocytes following development of lipid droplets, which 
encompassed the majority of the cytosol. These results showed CYP 17 localisation 
within the 3T3-L I preadipocytes cytoplasm prior to differentiation. 
Figure 63. Immunofluorescence of 3T3-LI Figure 64. Phase contra t 3T3-L1 mature 
mature adipocytes . 3T3-L1 mature adipocytes adipocytes. 3T3-L1 mature adipocytes hown in 
fo llowing 6 weeks differentiation stained with phase contrast following 6 weeks differentiation. 
CYP 17 and FITC conjugated secondary antibody. Lipid fomlation following differentiation can be 
(A) Fluorescence ean be seen surrounding lipid seen within cells and raised acro s the z-axi due 
droplet formation and wi th in the cytosol. Some to buoyancy. 
staining occurs across cellular debris. 
The perinuclear staining seen in Figure 63 also suggests CYP 17 i present at tbi 
stage of development. Following differentiation the same protocol was used for 3T3-
LI mature adipocytes. Although the technique was not as robust due to the fragility of 
adipocytes, Figure 63 shows that CYP 17 antibody did produce fluorescence. The 
variation in z-axis caused by the large size of these cells made focu ing difficult, 
however fluorescence can be seen surrounding the lipid droplets and in the cytoplasm 
(Figure 63 (A» when compared to phase contrast (Figure 64). Fluore cence was al 0 
observed within some lipid droplets. This may be uggestive of rupturing during 
acetone-methanol fixation , or presence of CYP 17. This may also be a result of 
di sparity within the z-axis or general culture debris. These re ults show the expression 
of CYP 17 at both pre and mature stages of differentiation. 
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5.4.2 Western blot analysis of CYP17 expression in 3T3-Ll adipocytes 
Western blot analysis of CYP17 expression in 3T3-Ll adipocytcs both preadipocylcs 
and mature, showed a predicted band at 57kDa suggesting the presence of CYP 17 in 
both pre and mature 3T3-Ll adipocytes. All blots were exposed for 640sec Figure 65 
using equipment and conditions as described in 3.6.4. 
250 
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Figure 65. Shows Western blot CYPI7 expression of3T3-Ll preadipocyte (lane 1-3) and mature 
adipocyte (lane 4-6) Iysates. Preadipocyte (lanes 1-3) and mature adipocyte Iy ales (lane 4-6) probed 
using CYP17al antibody against po itive control cell line Chinese hamster ovaries (CHO lane 7). 
show bands at 57kDa, which were more prominent in preadipocyte samples. The blot was then 
stripped and re-probed using p-Actin to control for protein loading. 
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CVP17 57kDa 
*** 
Pre 3T3 M3T3 
Figure 66. Densitometry graph of 3T3-L1 Preadipocyte and mature adipoc te YP 17 ex pre ion 
taken from WB (n=3). Usi ng p-Actin normalisation to compare Ie el of band inten it in \ e tcrn 
blot CYPI7 expression howed significant difference in preadipocyte YPI7 e pre ion again t 
mature adipocyte Iysates Data summarised as median ± IQR (*** P<O.OO I). 
Although a detectable band can be seen within the mature adipocyte ample band 
intensity varies between preadipocytes and mature adipocyte ample Figure 66. Th 
variation in band intensity suggest a greater presence of CYP 17 protein within 3T3-
L I preadipocytes. 
CYP17 n MEDIAN ±IQR P. 
Pre Adipocyte 3 107.8( 103.7-115.5) 0.007 
>-
Mature Adipocytes 3 59.46(52.25-66.02) ••• Ig 
Table 7. ummarising the densitometr y r epresen tati ve of average exp re ion of YPI7 in pr 
and mature 3T3-L1 sa mples. A ignificant difference wa scen in expre ion of YP 17 (Mwt 7 
kDA) between the ample with preadipocytes showing the greater protein yield. Data ummari ed a 
median ± IQR (*U P<O.OO I) 
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Examination of our results shows J3-Actin did not vary between samples and from this 
we can assume equal protein loading across all lanes. ~ - A c t i n n was therefore used for 
nonnalisation and semi-quantitative expression. The box graph seen in Figure 66 (B) 
shows the percentage intensity against the ~ - a c t i n n control and variation between 
samples can be seen. There is a significant difference in CYP 17 expression across the 
two samples with preadipocyte 3T3-Ll showing the greatest expression and 
suggesting a large decrease in CVP17 expression occurs during maturation. 
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5.4.3 Expression of the steroidogenic enzyme CYP17 within primary human 
adipocytes 
Figure 67. Immunofluorescence of human Figure 68. Pha e contra t human 
pread ipocyte . Human preadipocytes tained prcadipoc te. Human preadipocytc grown to 
with Cyp 17 and FITC conj ugated anti-rabbi t 40-50% confluence to allow imaging f cell 
secondary antibody. CYP 17 expres ion is located morphology. 
wi thin the cytopla m. (A) Concentrated 
perinuclear CYP 17 taining can be een. 
Figure 69. Immunofluore cence of human Figure 70. Pha e contra t human mature 
mature adi pocytes . Mature human adipoeytes adipoc te . Iluman mature adipocyte hown in 
sta ined with CYPI7 and FITC conjugated pha e contra t. Lipid formation fOllowing 
secondary antibody. (A) Fluorescence can be seen differentiation can be een within cell nd rai ed 
surrounding lipid droplet fomlation and within the acros the z-axis due to buoyancy. 
cytosol. 
Examination of the pre ence of CYP17 within pre and mature adipocyte of our 
human cultures showed almo t identical results a een in the mou e 3T3- I cell . 
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Preadipocytes showed good fluorescence when probed with CYP L 7 antibody with 
areas of fluorescence localized to the cytosol. Once again we found peri-nuclear 
staining Figure 67. All results were supported through comparative CHO cultures, 
negative control leucocyte cultures (see 3.5.1) and in the absence of primary antibody 
(not shown). Using the 3T3-Ll cell line allowed us to optimize the protocol and we 
found that using the acetone-methanol method of fixation rather than the published 
paraformaldehyde [252], allowed better results to be seen within our mature 
adipocyte cultures and showed better representation of the formation of enlarged lipid 
droplets Figure 69 (A). 
5.4.4 Western blotting analysis of CYP17 expression within human adipocytes 
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Figure 71. Shows Western blot CYPI7 expression of human preadipocyte (lane 1-3) and mature 
adipocyte (lane 4-6) Iysates. Preadipocytc (n=3 lanes 1-3) and mature adipocyte Iysates (n=3 lane 4-
6) probed using CYP 17a I antibody. Exposure at 640sec shows bands at 57kDa, which were more 
predominant in preadipocyte samples. The blot was then stripped and reprobed using p-Actin to allow 
for loading contro\. (B) Shows the box plot for CYPl7 in both pre and mature lysates normalised to 
match p-actin expression. 
A western blot analysis was run using lysates harvested from primary human pre and 
mature adipocyte cultures (Figure 71 n=3 vs.3). After using various P450Cl7/CYP17 
antibodies we found the best results were achieved using CYP17al (ab7879c) 
antibody, allowing for a relatively clean specific blot at reasonably low exposure. This 
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antibody was kept constant throughout all our human sample work. Figure 71 showed 
predicted bands at around the 57kDa mark in both preadipocyte and mature adipocyte 
samples. Mature adipocytes (lanes 1-3) showed consistently less band intensity than 
that of the preadipocytes as were seen within our animal cells. Control lysates from 
CHO cultures were used to validate (Figure 71, lane 7). All lanes were also 
normalized using ~ - a c t i n n antibody. 
CVP1757kDa 
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Figure 72. Summarising the densitometry representative or average espressio. or CYP17 I. pre a.d mature 
human samples. Using /J-Actin nonnalisation to compare levels of band intensity in western blot CYPI7 
expression Figure 71, densitometry graphs were created. A Significant difference was seen in expression of 
CYPI7 between mature adipocyte lysate (n=3) and preadipocytes (n=3). The samples with preadipocytes showed 
the greater protein yield. Nonnally distributed data summarised as mean (range) / SEM (±) (*P<O.OS) and analysed 
using unpaired I-Iesl. Results are mean ± SEM 
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5.4.5 Western blotting analysis of CYP17 expression in non-PCOS and PC OS 
human adipocytes 
Non-PCaS and pcas lysates from mature adipocytes were examined using the 
western blot technique for expression of CYP17 (non-PCaS n=4 vs. pcas n=3) 
Figure 73 shows expression at 57kDa was seen in both mature adipocyte lysates 
taken from non-PCaS and those taken from pcas lysates, suggestive of the presence 
of CYP 17. All lanes were normalized against J3-Actin. 
150 
100 
75 
57 
50 
37 
Non-PCaS pcas cHa 
1 2 3 
CYP17 
Figure 73. Shows Western blot analysis of CYPI7 expression of mature human adipocytes from 
non-PCOS (n=4) and PCOS lysates (11=3) (lane 1-2). Expression at 57kDa was seen in all lanes 
including the CHD positive control (lane 3) suggestive of CYP 17 presence. No variation in band 
intensity was seen between non and PCDS samples. p-Actin was used as a loading/positive control. 
Figure 73 showed no variation III band intensity between non-PCaS and pcas 
mature adipocyte lysates. Figure 74 shows no significant variation when examining 
the densitometry results in western blot exposures between non-PCaS and pcas 
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mature adipocyte Iysates (n=4 vs. n=3). This would suggest no difference in CYP17 
expression occurs across the two groups . 
• 
• 
5 ~ - - - - - - ~ - - - - - - - - - - - - - r - - - - - - -Non-PCDS pcas 
Figure 74. Summarising tbe densitometry representative of average elpression of CYPI7 in nOD-
PCOS (n=3) and PCOS (n=4) human mature adipocyte samples. Using Jl-Actin nonnalisation to 
compare levels of band intensity in western blot CYPI7 expression Figure 73 densitometry graphs 
were created. No Significant difference was seen in expression of CYP17 between non-PeOS and 
peos mature adipocyte Iysates through unpaired I-Iesl examination. Nonnally distributed data 
summarised as mean (range) / SEM (±). 
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5.4.6 Hormone secretion in mature adipocytes 
Following careful control of media and environmental conditions from biopsy, culture 
development and maturation (see 3.2); mature adipocytes were assayed and secretion 
of various hormones including progesterone, androstenedione and testosterone were 
measured using ELISA. 
5.4.6.1 Adipocyte progesterone secretion. 
Non-PeOS mature adipocytes were cultured (passage 2-3 n=5) from biopsy and 
matched with PCOS sample for age and BMI. Following maturation, media was 
changed and fresh media added for 3 days before removal and examination for 
progesterone using ELISA (see 3.6). 
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Figure 75. Progesterone secretion by non-peaS and peas mature adipocytes (n=5) over 3 days. 
peos and non-PeOS progesterone secretion was measured and examined against negative/positive 
control using one-way ANOYA. Osteoclast progesterone secretion was used as a negative marker and 
theca progesterone secretion used as a positive marker. In both non-peOS and peos samples 
significance was seen ·P<O.OS . No significance was seen between non-peOS and peos progesterone 
secretion. Results are mean ± SEM. 
Figure 75. shows progesterone was measured within adipocyte media following 3 
days maintenance (Mean 5.5 ± 1.29pmolllOOO cells). A significant difference was 
seen between non-PCOS and osteoclast samples with an increase in progesterone 
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levels in the non-peOS samples (P = 0.018). Theca cells were also used as a positive 
marker of progesterone secretion as well as an intra control throughout all the ELISA 
techniques performed. Again 3 day untreated media was removed from theca cultures 
and results normalised to pmol/IOOO cells. Results seen in Figure 75 showed 
progesterone secretion to be 3 times that found within the adipocyte media (mean 
16.37 ± 0.44pmol/1000). 
5.4.6.2 Comparison of non-PCOS and PCOS adipocyte progesterone secretion. 
Progesterone secretion was also measured within media harvested from peos 
samples (Figure 75) examination of media taken from peos cultures maintained for 
3 days was done using the same protocol. 
Progesterone levels were measured alongside the same osteoclast negative control 
cultures used in previous experiments (see 5.4.6.1). Figure 75 shows significant 
progesterone levels were found alongside osteoclast media measurement following 
removal of media blanks (P=O.027 n=5). With all adipocyte cultures grown from 
biopsies and matured from 2-3 passage preadipocytes, we were able to control and 
maintain all growth conditions. Although the progesterone levels measured from both 
adipocyte cultures are significantly lower than those examined within the positive 
theca (intra) control (Figure 75) the osteoclast readings support these results as more 
than background levels. This is further supported through the media blanks and the 
sensitivity of the chosen ELISA (see 3.7). With no progesterone exposure in vitro 
these findings are particularly interesting. 
5.4.6.3 Adipocyte androstenedione secretion 
Based on the presence of the precursor involved in the gonadal steroidogenic pathway 
involved in androstenedione synthesis (see 1.3); and determination of the key enzyme 
necessary to locally synthesis androstenedione (see 5.4.6). We next examined 
androstenedione levels. The extracellular levels were measured in media taken from 
non-peOS cultures (n=12) following 3-day maintenance in controlled conditions 
using a specific androstenedione ELISA (Genway 40-056-205044). 
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Figure 76. Non-PCOS mature adipocytes androstenedione secretion. 3 day media was harvested 
from non-peOS adipocyte cultures and measured for androstenedione levels against negative control 
osteoclast media harvests and positive control theca media harvest. Results are mean ± SEM. 
Significant readings were seen against the negative control using one-way ANOV A and bonfferoni 
post hoc test statistical examination (***P<O.OOI 0=12) . 
• 
The presence and levels of androgen within media harvests taken from our non-peOS 
mature adipocytes were measured using the ELISA technique. Figure 76 shows 
androstendione was present within the media examined. These readings were 
supported through cultured theca cells media harvests, which have been proven to 
secrete high levels of androstendione in vitro [91]. Although androstendione levels 
were determined, measurements taken from theca secretion did show significantly 
higher levels within the media harvests (***P<O.OOl). Unsupported these readings 
could be suggestive of background levels however the ELISA kit used was chosen for 
its specifity and sensitivity with readings capable of examination as low as 0.019 
nglml with adipocytc readings showing mean 0.125 ± 0.002 nglml. In order to further 
support these levels negative controls were used through osteoclast harvests and 
media blanks. Figure 76 shows significant decreases were found in adipocyte against 
negative controls (***P<O.OOI). 
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Figure 77. Scatter showing correlation between Figure 78. Scatter sbowing correlation 
BM) and androstenedione levels non-PCOS between Age and androstenedione leveh in 
adipocytes (n=II). No correlation was found. non-PCOS adipocytes (0=11). No correlation 
was found. 
The non-PCDS samples chosen for examination allowed ranges across premenopausal 
age (24-40) and BMI (20-33). Although sample numbers were limited this allowed a 
limited study of correlations that may exist between the androstenedione levels found 
within media harvests and these patient factors. Examination of non-PCaS samples 
showed no correlation existed between either age or BMI in the levels of 
androstenedione determined (Figure 77, Figure 78). 
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5.4.6.4 Comparison of non-PCOS and PC OS androstenedione secretion 
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Figure 79. pcas mature adipocytes androstenedione secretion against non-PCaS and controls. 3 
day media was harvested and measured for androstenedione levels against non-peOS secretion and 
negative control osteoclast media harvests and positive control theca media harvest. Results are mean ± 
SEM. Significant readings were seen against the negative control following one-way ANOV A and 
bonfJeroni post hoc tests (* P<0.05 n= I 0) . 
peos adipocytes were also cultured to maturity and assayed for 3 days before media 
harvests were examined for androstenedione using the same protocol as non-peos 
harvest (see 3.6). Theca and osteoclast controls were used to support findings and the 
same ELISA kit was used. Results showed similar levels of androstenedione within 
peos mature adipocyte media. No significant differences were seen between non-
peos and peos groups Figure 79, and when results were examined across patient 
samples for correlations in androstenedione against BM! and age no correlation was 
found. 
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Figure 80. Scatter showing correlation Figure 81. ndro lenedione level from media 
between testosterone and andro tenedione harve ted from h perandrogenic (n=3) nd non-
levels in peas adipocytes (n=8). egative hyperandrogenic (n=5) p a ample. 
correlation was seen with androstenedione ignificance was een between andro tenedione 
decreasing with increased level of testosterone level from hyper and non-hyper androgenic P 
( n = I I / R ~ ~ O . 5 1 1 . . ample following unpaired I - Ie I (*P<O.O I). 
Result are mean ± EM 
Examination across hyperinsulinemic and hyper secretion of LH group al 0 howed 
no correlation existed. However examination of te tosterone Ie cl 10 
hyperandrogenic and non-hyperandrogenic peos ample medium correlation wa 
found. Figure 80 shows that in sample taken from peo patient with increa ed 
testosterone levels adipocyte androstenedione levels within the media harve t would 
decrease. Further examination found that andro tenedione level betw n 
hyperandrogenic ample were significantly reduced than those mea ured in non-
hyperandrogenic samples (P = 0.047) (Figure 81 ). 
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5.5 Discussion 
5.5.1 Expression of the steroidogenic enzyme CYP17 within pre and mature 
adipocytes 
Immunofluorescence and comparative phase contrast, showed clear cell morphology 
and fluorescence representative of CYP17 expression in the 3T3-Ll preadipocyte 
cytoplasm as well as the human pre and mature SC adipocyte cultures. Blouin et af., 
(2009) compared human omental and subcutaneous samples for steroidogenic activity 
at both preadipocyte and mature adipocyte stages [281]. They found increased activity 
in SC cultures with a greater expression of the steroidogenic enzymes AKRIC3, 
RDH5, AKRIC2, P-450 aromatase, steroid sulfatase, ERa and 17P-HSD-3, following 
maturation. We however, found perinuculear staining for CYP17 within our 
preadipocyte cultures, which pointed to active protein synthesis at this stage of 
adipocyte development. This coupled with increased expression against our mature 
adipocyte cultures shown by our western blot analysis suggests an increase of this 
particular steroidogenic enzyme during the preadipocyte phase. Interestingly, Blouin 
also reports CYPl9 increases following differentiation contradictory to reports by 
Mcternan et al., (2002) and Dieudonne et af., (2006) who both report CYP19 mRNA 
reduction in mature / differentiated SC cultures [276, 282]. Decreased CYPI9 
expression following differentiation may support our findings. If an androgen 
synthesising pathway exists within adipocytes, increased oestrogen synthesis may 
require greater CYP 17 expression to satisfy the necessary precursor. Although 
Blouin's fmdings show the opposite results, he accounts for variation in findings as a 
result of discrepancies in RNA isolation in the presence of large amounts of lipids 
[276]. By using our protocols to examine aromatase expression we would be able to 
examine these reports further and look into the possible existence of this pathway. 
Although our mature adipocytes showed fluorescence surrounding the lipid droplets, 
the technique proved inadequate in pinpointing the exact localization of CYP 17. This 
may be as a result of the discrepancy in z-plane phase. This may also be linked to 
cellular debris that tends to accumulate during differentiation. We also found 
fluorescence occurring in some larger lipid droplets. This again may be as a result in 
phase variation or debris and could be further explored utilizing the 3 dimensional 
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images acquired through confocal microscopy. It may be that CYP17 is expressed 
within lipid droplets. This may also be as a result inadequate fixation leading to 
rupture of some lipid droplets and subsequent protein seepage into this area of the cell. 
Although acetone-methanol fixation is recommended for cytoplasmic based proteins 
it is particularly harsh and can damage the fragility of lipid droplets. This rupture 
would therefore explain the discrepancy seen where cells have retained cytoplasmic 
fluorescence surrounding the lipid droplets. For this reason parafonnaldehyde fixation 
may be more suitable when examining the human primary cultures as recommended 
by Mallide, 2008. 
By showing the existence of the steroidogenic enzyme CYP 17 and its cellular 
localization within both preadipocytes and mature adipocytes we have supported the 
validity of using these protocols and primary cultures as well as our animal cultures to 
examine steroidogenesis within adipocytes. This in turn has also given evidence 
towards the possible capability of adipocytes to locally synthesize androgens. 
Currently adipocytes are known to take part in steroidogenic activity with their role in 
oestrogen and androgen synthesis [127, 283, 284] however to date this is believed to 
utilize circulatory precursors. Examination into this area would therefore assist the 
current understanding of adipocyte metabolism. 
Both the immunofluorescence and western blot results also show that CYP17 is 
present prior to and following differentiation. Studies into the effects of oestrogen on 
preadipocytes have shown a positive influence on proliferation [285] and with the 
importance of androgen as a precursor for oestrogen synthesis the presence of CYP 17 
and subsequent androgen synthesis, may be linked to proliferation. No variation in 
expression across either our non-peOS or PCOS samples was seen. 
Examination of our non-PCOS against PCOS human adipocyte cultures looking at 
CYPI7 expression, did show slight discrepancy within our control results. CHO were 
used as a positive comparison for CYPl7 and the band exposure was as strong as 
those in both non-PCOS and PCOS samples. Based on the other results and knowing 
that the CHO was used as an intra control we would expect the intensity to be stronger. 
This may be explained through repeated use of control lysate. which were used within 
as many experiments as possible to allow for continuity. However over time these 
Iysates would degrade from freeze thawing or on some occasions run out. When this 
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occurred new CHO cultures would be grown to replace. Where possible the 
replacement lysates would be run on a known samples repeating a past blot. The 
results seen here may be a CHO lysate beginning to degrade. They may also be the 
result of variation in a new CHO cell line due to a further passage and subsequent 
generation change. Time constraints meant we could not repeat the experiment. For 
the purpose of showing CYPI7 presence between groups this result was sufficient but 
maybe considered in future work. 
The existence of androgen receptors (AR) in both pre and mature adipocytes further 
supports the presence of an androgen pathway. It has also been shown that ARs are 
more abundant within preadipocytes more so in human/animal model comparison 
[228], which support a greater involvement of androgen at the preadipocyte stage of 
development. This is suggested by our finding of significantly greater levels of 
CYPI7 expression within our 3T3-LI and human preadipocytes. 
The importance of androgens on the inhibition of adipocyte proliferation has been 
shown in animal models along with its ability to inhibit differentiation [285-287]. By 
showing the existence of CYP 17 both pre/post differentiation, we find suggestion that 
androgen may also play an important regulatory role and therefore require localized 
synthesis. We therefore continued examination of these findings using human cells as 
to develop the study further. 
5.5.2 Hormone secretion in non-PCOS and PCOS adipocytes 
Both our findings and the reported existence of other steroidogenic enzymes in human 
adipocytes points to the validity of localised hormone secretion (see 1.13). With 
androstenediones relationship to PCOS and the association PCOS has to BMI we 
wanted to examine this theory further in adipocytes. 
Progesterone plays a vital role as a precursor within ovanan androstenedione 
synthesis. By determining its presence we could further support the requisites 
necessary for a steroidogenic pathway. Careful control of the culture environment 
ensured limited exposure to supplements that may have confounded results and the 
inclusion of a negative and positive control along with sufficiently sensitive 
techniques, meant that the progesterone presencellevels found could be supported. 
Progesterone was seen in both non-PCOS and PCOS media harvests and shown to be 
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significant against the negative controls. Although no significant variation was seen 
between the two groups. a trend did seem to suggest increased progesterone levels 
within the peas samples that may require further analysis through increasing the 
sample size. It is understood that progesterone is synthesised by the ovary, testis 
adrenal glands and the placenta during pregnancy. Although it is yet to be established. 
it is also believed that neurons also have the ability to locally produce progesterone. If 
this were true it maybe produced via P450scc/desmolase action on the cholesterol 
precursor and converted to pregnenolone for further conversion by dehydrogenase 
(see 1.3.2)[46. 47]. With adipocytes shown to have the necessary proteins and related 
precursors necessary to also locally biosynthesise progesterone the possibility remains 
feasible and supports our findings of progesterone presence in isolated adipocyte 
cultures. However. progesterone can also be stored at any stage of preadipocyte 
development, as can any of the precursors required for synthesis. It may be possible to 
prove this theory through increasing the passage of the cells examined. The stores 
may then be utilised through increased passage of the preadipocyte cultures and the 
lack of supplements required to replenish the stocks. This would however reduce 
physiological comparison 
With the discovery of the progesterone receptor by O'Brien (1978) more evidence 
pointed to progesterone's involvement in adipocyte metabolism. Secretion from 
localised production may allow self-regulation and research has shown that 
progesterone may be involved in the regulation of lipogenesis through stimulation of 
transcription factors such as ADDIISREBPlc [288]. Progesterone is also known to be 
stored within adipocytes and used for progressive release [289]. Although this would 
explain its presence within our harvests, our samples were 3nl generation primary 
cultures differentiated from preadipocytes and therefore we would expect any 
cholesterol stores to be exhausted through passage. 
Other steroid hormones have been shown to influence adipocyte proliferation 
including androgens and oestrogens [283]. Based on these reports progesterone's 
involvement in adipocyte metabolism is not entirely understood. 
Repeating the ELISA on the same media harvest also showed the presence of 
androstenedione in both non-peaS and peas samples. Similar to the progesterone 
results, no significant variation across groups was seen. 
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; 
With reported evidence supporting the involvement of androstendione in adipocyte 
metabolism a localised production and subsequent secretion seems founded and has 
been previously theorised [281]. However its involvement in adipocyte metabolism is 
not fully understood and validation of this biosynthesis is required as well as mapping 
of the pathway involved. In doing so we would get some idea of not only the effect 
but also the influences this may have on the physiological condition. Furthermore we 
could examine any associations this may have in endocrinolgical disorders. aur study 
attempted to go someway to introduce this with focus on peas. Although limited by 
our samples size we began a pilot correlation of androstendione secretion across BMI, 
age and symptomatic hyperandrogenimic and hyperinsulineamic patients in non-
peas and peas samples. Our non-PeaS samples showed no correlation in BMI or 
age with regard to androstenedione secretion. Similarly in the peas group no 
correlation was found in BMI, age hyperinsulineamic or hypersecretion of LH. 
However our peas group interestingly did show a negative correlation between 
testosterone levels and androstenedione secretion. This may suggest that a reduction 
in androstenedione is as a result of increased demand/conversion to testosterone. This 
result therefore justifies further examination. 
Limited availability of peas biopsies meant that we could not control for all factors 
that may affect the levels of androstenedione secretion. aur results were based in 
accordance to BMI, hyperandrogeneamia / hyperinsulinemia groups. We have 
suggested that a negative correlation may exist between hyperandrogenic samples and 
androstenedione secretion showing a decrease in androstenedione with increased 
testosterone. If this were true it would explain a possible associated to the lack of 
significance in androstenedione seen between our non-peaS and peas groups 
knowing that testosterone is typically elevated in peDS samples. 
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6.0 HORMONAL INFLUENCES ON ADIPOCYTE FUNCTION IN 
NON-PC OS AND PCOS WOMEN 
6.1 Introduction 
Approximately SO% of women with peas are overweight or obese [173]. abesity is 
believed to pose possible involvement in the development of peas with abdominal 
obesity showing links to insulin resistance and the associated hyperinsulinemia 
asymptomatic of peas [173, 278]. Further research has shown that obesity related 
hyperandrogenemia found in peas may play a key role in the pathogenesis of 
hyperinsulinemia [290]. The increased metabolic dysfunction shown in both non-
peas and peas obese patients also offers mechanisms for associated conditions; 
increased oestrogen production rate [173], increased activity of the opioid system and 
of the hypothalamic-pituitary-adrenal axis [291, 292], decreased sex hormone binding 
globulin synthesis [293] and, possibly, high dietary lipid intake [173, 294]. Whether 
these links are valid or not, enough evidence is available to suggest increased severity 
of hyperandrogenism and related clinical features seen in obese peas women [liS, 
278]. Patients with pcas are often encouraged to reduce their weight, which has 
been shown to be beneficial to improving clinical and endocrinological features [118, 
29S]. The addition of insulin sensitizing agents and anti-androgens to weight loss 
programs, have also been seen to give positive results, reducing hisuitism, 
endocrinoligical abnormalities and amenorrhea [296, 297]. This further supports the 
possibility that insulin related dysfunction associated to peas may correlate to a 
possible androgen adipocyte relation, and studies have shown that androgen 
significantly decreases levels of differentiation in both omental and subcutaneous 
adipocyte cultures this may in tum lead to a direct effect through increased 
proliferation in preadipocytes [209, 298] or an increase in the availability of substrate 
necessary to increase oestrogen synthesis which has been shown to encourage 
adipogenesis in mature adipocytes [276]. 
Luteinising hormone is a key endocrine factor in pcas both in its positive effect on 
steroidogenic responses seen in ovarian androgen secretion [299] and its symptomatic 
hyper secretion [14S]. Little is known about luteinising hormone's action on 
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adipocytes with only recent studies into the effects of human chorionic gonadotropin 
(HCG) on adipose development, suggesting the existence of a luteinising honnone 
receptor (LHR) [300]. With the increased association of LH secretion with PCOS 
[145,301], further investigation is of clinical relevance and it is currently unknown if 
PCOS abnormalities in LH hyper secretion are primarily due to sensitivity to GnRH, 
or secondary to the influence of sex steroids [145, 302]. Furthennore, both in-vitro 
and in-vivo evidence exists as to the possible synergistic effects of insulin and LH on 
ovarian metabolism with Cara and Rosenfiled (1988) showing controlled increases in 
LH and IGF-llinsulin correlating to increased androgen secretion within rat theca 
cells [302-304]. It is understood that adipokines, secretory products of adipocytes, act 
to communicate with the brain, however it has only been in the last 6 years that the 
discovery of pituitary hormone and hypothalamic peptide receptors including ACTH, 
TSH, GH, prolactin, and vasopressin within adipocytes has led to the suggestion that 
the brain may any influence metabolic function [305]. Mapping of adipocyte structure 
and function has allowed adipocytes to no longer be regarded as an inert tissue with 
its importance as an endocrine organ under the possible influence of hypothalamic-
pituitary-adipose axis requiring investigation due to its possible clinical impact. With 
these realisations and with the relationship adipose plays with many physiological 
conditions, further examination into the role adipose may playas a possible 
therapeutic target is of great importance. Biochemical dysfunction is central to PCOS 
and the possible involvement adipocytes may therefore play, was a focal point in my 
study. 
6.2 Objectives 
Our first objective was to ensure that an LH receptor existed within adipocytes and in 
doing so we would allow evidence of an LWadipocyte relationship. Once this was 
achieved we would examine whether receptor expression remained sufficient under 
biochemical levels found in PCOS (LH and insulin). This would justify further 
examination into the effects these biochemical levels would have on various aspects 
of adipocyte metabolism. 
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1. Detennine the presence of the LH receptor within pre/mature human 
adipocytes and therefore detennine a possible relationship between LH and 
adipocyte metabolism. 
11. Detennine whether altering insulin and LH concentrations in-vitro influence 
LH receptor expression and therefore detennine whether the biochemical 
conditions found in PCOS allow adipocytelLH relationship. 
On detennination of adipocyte LHR expression under PCOS biochemical conditions, 
we examined three areas associated to increased androgen contribution under the 
same condtions. This focus was taken from our comparative ovarian theca study and 
theories associated to PCOS ovarian hyperandrogenemia (Munir el al .. 2004) 
iii. Detennine whether altering insulin and LH treatments influences non-PeOS 
and PCOS adipocyte proliferation. 
iv. Detennine whether altering insulin and LH treatments influences 
steroidogenic enzyme expression in non-PCOS and PCOS adipocytes. 
v. Detennine whether altering insulin and LH treatments influences progesterone 
and androstenedione secretion by non-PCOS and PCOS adipocytes 
6.3 Results 
6.3.1 Expression of LH receptor in non-PCOS and PCOS adipocytes 
Non-PCDS and PCOS adipocytes were cultured from human biopsies (n=6) and 
examined for LH receptor using the immunofluorescence technique (see 3.5.1). 
Primary preadipocyte cultures were cultured until 40% confluent to allow 
examination of individual cell morphology as was seen in phase contrast images 
(Figure 83, Figure 85). Positive and negative controls were used to support all 
findings and included preadipocytes markers, leptin immunoreactivity (anti-human 
OB R&D Systems (AF398» commercially available cell line preadipocyte / mature 
adipocyte comparisons (PromoCell C-12730), and j3-actin. Negative controls included 
human leukocyte cells for marker comparisons and secondary antibodies alone. 
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Figure 82. Human preadipocyte expression of Figure 83. Matched phase contrast 
LHR. Human non-peOS preadipocytes stained micrograph of human preadipocytes. Human 
with LHR and FITe conjugated anti-rabbit non-peOS preadipocytes grown to 40% 
secondary antibody. (A) Fluorescence is localised confluence al\owing detennination of cel\ 
to the cell membrane while nuclei are un-stained. morphology to be seen in both phase contrast 
This suggests LHR is located within the cel\s image and on comparison to incubation with 
membrane. fluorescent antibody probe (Figure 82) 
Figure 84. Human mature adipocytes expression Figure 85. Matched phase contrast 
of LHR. Mature adipocytes stained with LHR and micrograph of human mature adipocytes. 
FITe conjugated anti-rabbit secondary antibody. Adipocytes grown to 90% confluence al\owing 
Fluorescence i weak and varied due to ccl\ debris maturation. (A) shows ful\y matured adipocyte 
and lipid formation however fluorescence suggests identified through lipid droplet fom1ation. 
LHR exists within the cells membrane of the 
adipocyte. 
Figure 82 shows localised fluorescence around the preadipocyte membrane. 
Fluorescence can also been seen within differentiated adipocytes as seen in Figure 84 
however this was observed to be lower levels of fluorescence within the mature 
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adipocyte cultures, sugge tive of reduced expression. Thi finding wa con i t nt 
throughout experiments (n=6). To further examine tbi , both preadipocyte and mature 
adipocyte Iysates were harvested from human primary culture (n-) and LHR 
protein expression was assayed using western blotting. Figure 86 how a we tern 
blot for LHR expression using the polyclonal LHR antibody ( anta Cruz 25 2 ). 
An immunoreactive band at the predicted ize of 5kDa wa detected. Lane 1 gi e 
expression of LHR within non-PCDS preadipocyte Iy ate. p-actin wa u ed to control 
for protein loading and following this, compari on to mature adip cyte LHR 
expression shown in lane 2, showed significant reduction ugge ti e of reduced LHR 
expression. Shown expression of LHR at either tage of adipocyte de elopm nt i 
however indicative of a possible LH-adipocyte relation hip and further encourage 
investigation of potential autocrine metabolic function within adipocyte . 
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Figure 86. Western blot LHR expression in non-PCO pre and mature adipoc te (la ne I a nd 2) 
against PC as pre and mature adipocytes (lane 3 and 4). Pre and mature adipo yte Iy ate from 
non-PCOS and PCOS cultures (n-4) were probed u ing LHR (H-50) antibody. xpo ure at 
shows bands at 85kDa, which were predominant in preadipocyte ample of both non-P 0 and P 
Iysa tes . The blot was then tripped and re-probed u ing p- ctin to control for protein lading. 
Abundant LHR expression i evident in CHO Iy ate, which wa u ed as a po iti e control. 
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These experiments were continued using human peas preadipocyte and mature 
adipocyte cultures to examine possible variations in expression of LHR (lane 3 and 4) 
however based on the results obtained from the western blotting (Figure 86) no 
significant difference (P>0.05) based on band intensity was found, although 
observation of the western blot (Figure 86) showed a predominant double banding 
effect within the non-peaS lysates. These results did however further support the 
variation seen in the non-peaS group with reduced band expression in mature peas 
samples indicative of reduced expression of LHR in differentiated cultures. 
II) • Non-PeOS ~ ~ ~ ~ -!- peos s::: 9 • :) ~ ~
C'O • 
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Figure 87. Summarising the densitometry representative of average expression of LHR in 
prcadipocytc and mature human samples from both non-peOS and peos. Using p-Actin 
normalisation to compare levels of band intensity in western blot LHR expression Densitometly 
examination of western blot results using unpaired I-tests (Figure 86) showed no significant difference 
was seen in expression of LHR between preadipocytes of non-peOS and peos groups (n=3 vs. n=3). 
This was also true for comparison of non-peOS and peos mature adipocyte lysate (n=3 vs. n=3). 
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6.3.1.1 The effects of insulin and LH treatment on LH receptor in non-P 0 and 
PCOS adipocytes 
The results showing the expression of the LH receptor in primary culture from both 
non-peOS and peos biopsies allowed us to further examine hormonal influence on 
adipocytes typically associated with the peos condition. The e incIud 
hyperinsulineamia and hypersecretion of LH. The effect of aried hormonal 
treatments on the expression of LHR were initially inve tigated. It wa nec ary to 
study the effects of these conditions on LHR expres ion before further e amination of 
subsequent adipocyte metabolism, as these results may lead to an as ociation b tv n 
conditions and expression, and/or po sible factor that would pre ent furtb r 
examination such as inhibition of LHR expres ion a hown in Fi ure 8. 
MWM peDS/ on-PeDS PeDS/Non-peDS PeDS/ Non·PeDS peDS/ on-PeDS 
1 2 3 4 5 6 7 8 
Olnlulln Ing/ml tOng/ml lOOngjml 
Insulin Insulin Insulin 
1 0 0 ~ ~ - - - - - - - ~ ~
85 LHR 
75 
50 
~ ~ -Actin 
Figure 88. WeSlern blot LHR expression in P 0 (lan e 1,3,5 and 7) again t non- P 0 mature 
adipocyte (lane 2,4,6 and 8) under va ried in ulin (0=3 VS. n=3). Mature adipocyte were trea ted with 
vary ing doses of insulin in-vitro ( insulin 0 (lane 1-2) Inglml (lane 3-4) 10nglmi (la ne 5-6) 100nglmi 
(lane 7-8) . Ce ll s were then harvested and prepared fo r WB. Lanes were probed u ing LHR (H- 0) 
antibody. Ex posure at 580 ec shows immunoreacti ve band at 85kDa wi th increa ed LHR prote in 
correlating with increased in ulin trea tment. Littl e variation wa een between non-P and P 
amples. The blot was then tri pped and re probed using p-Actin to contro l fo r protein loadi ng. 
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Our initial experiments focused on insulin treatment alone in non-PeDS and peDS 
samples. Western blotting was used to analyse LHR expression in peos (lanes 1,3,5 
and 7) and non-peOS Iysates (lane 2,4,6 and 8) following varied insulin treatments 
(0-100 ng/ml). The experiments were focused on mature adipocyte cultures (n=3) due 
to their reported increased steroidogenic enzyme expression and activity [228,282]. 
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Figure 89. Summarising the densitometry representative of average expression of LHR in non-
PCOS mature adipocytes (n=3) under varying insulin treatments. Using j3-Actin nonnalisation to 
compare levels of band intensity in western blot LHR expression Figure 88 densitometry graphs were 
created (as shown here). Significant differences were seen in expression of LHR with increases in 
insulin treatment of 0-1 0 and 10-100 ng/ml and examined using one-way ANOV A. Data shows mean / 
* SEM. Significance was seen from Ong/ml-IOngiml (··P<O.OI) and 0-100 ng/ml (·"P<O.OOI). 
Significance was also seen from 1-lOngim ("P<O.OI) and 1-IOOngiml (···P<O.OOI). Finally 
significant increases in LHR expression were seen between treatments of 10-100ngiml ("P<O.OI). 
Analysis of LHR expression showed increased LHR protein in response to increased 
insulin treatment with a sudden increase seen from l-IOng/ml in progressive 
treatments (lane 3-4 (l ng/ml) to lane 5-6 (10 ng/ml». Levels of band intensity were 
quantified and compared against f3-Actin to give statistical analysis of LHR 
expression. No significant variation was seen between within treatment groups across 
non-peOS and peos tysates. Figure 89 and Figure 90 show significant increases 
between insulin treatments following Ing/ml 1-10 ng/ml (**P<O.Ol), 1-100ng/ml 
(*··P<O.OOI) and 1O-10Ong/mt (**P<O.OI) in both non-peOS and peos groups. A 
127 
Chapter 6: Results: Hormonal Influence on Adipocyte Function 
large increase in LHR band intensity (Figure 88) and expression (Figure 89) was 
seen between O-IOng/ml, suggesting 10 ng/ml was optimal level required to cause 
increase LHR protein above basal. peos samples showed similar levels of LHR 
protein. In conclusion these results suggest no significant variation in LHR expression 
is seen between non-PCaS and PC as mature adipocyte within insulin treatment 
groups. 
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Figure 90. Summarising the densitometry representative of average expression of LHR in 
peos mature adipocytes (0=3) under varying insulin treatments. Using j}-Actin nonnalisation to 
compare levels of band intensity in western blot LHR expression (Figure 88) Densitometry 
examination of western blot results (as shown here). Significant difference were seen in expression of 
LHR with increases in insulin treatment of 0-10 and 10-100 nglrnl using one-way ANOV A. Data 
showed examination of mean /::1:: SEM. Significance was seen from Onglml-lOnglml ("P<O.OI) and 0-
100 nglml (***P<O.OOI). Significance was also seen from 1-IOng/m ("P<O.OI) and 1-IOOnglrnl 
(***P<O.OO I). Finally significant increases in LHR expression were seen between treatments of I Q_ 
100ng/ml (**P<Q.OOI). 
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Figure 91. Western blot LHR expression in non-peOS mature adipocyte (lane 1-8) under varied 
insulin and LH treatments combined (n=4). Mature adipocyte were treated with varied doses of 
insulin alone or in combination with LI-I in-vitro (insulin 0 (lane 1-2) Ing/ml (lane 3-4) IOng/ml (lane 
5-6) IOOng/ml (lane 7-8) / with LI-I IOOng/ml (lane 2,4,6 and 8). lanes were probed using LI-IR (H-50) 
antibody. Exposure at 580 ec shows increasing band exposure at 85kDa in lanes 1,3,5,7 and 8. The blot 
was then tripped and re-probed using p-Actin to control for protein loading. 
We expanded our study to examine LH treatment alone and in combination with the 
insulin range used previously (as discussed in 6.1). Western blot experiments were 
earried out on non-PCOS lysates (n=4) to examine both insulin and LH treatments 
combined. Exposure time was reduced to 580sees due to overexposed band seen in 
lane 8 Figure 91 under treatment levels of 100 ng/ml insulin and LH. All results were 
examined alongside CHO cell line positive controls shown to express LHR [306]. LH 
treatments of 100 ng/ml, based on the ranges chosen in previous studies for optimal 
responses [91, 144] were used to examine the effects on LHR protein levels in both 
non-PCOS pre and mature adipocytes. Insulin treatments were also examined with 
ranges including 0, 1,10 and 100ng/mt. Decreased LHR protein levels were seen after 
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LH treatments alone when compared alongside insulin treatments (Figure 82). 
Comparison of 0 and 10Ong/ml LH treatment (lane I and 2, Figure 91) showed 
reduced levels of LHR when LH was zero pointing to possible inhibition of LHR 
expression. 
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Figure 92. Summarising the densitometry representative of average expression of LHR in nOD-
PCOS mature adipocytes (n=4) under varying insulin treatments. Using jl-Actin normalisation to 
compare levels of band intensity in western blot LHR expression (Figure 91) Densitometry 
examination of western blot results (as shown here) showed significant difference were seen in 
expression of LHR with increases in insulin treatment of 0-10 and 10-1 ()() nglml Data showed 
examination of mean I :i:: SEM using one-way ANOV A. Significance was seen from Ong/ml-I Onglmt 
(···P<O.OOI) and 0-100 nglml (···P<O.OOI). Significance was also seen from 1-lOngim (··P<O.OI) 
and 1-100nglml (···P<O.OOI). Finally significant increases in LHR expression were seen between 
treatments of 10-1 OOnglml (···P<O.OO I). 
Increased insulin treatments showed a positive relationship with LHR protein levels 
under the treatment range O-lOnglml insulin (lanes 3, 5 and 7, Figure 91). Similar 
levels of LHR protein were seen at both 10 and 100 nglml insulin treatments (lanes 5 
and 7) as was seen in Figure 86. However, reduced LHR expression was seen with 
LH treatment and shown within insulin/LH augmentation (4 and 6) with LHR protein 
at 1-IOnglml insulin decreased with the addition of 100nglmi LH (Figure 91). 
Interestingly, the combination of 100 ng/ml insulin and 100 nglml LH showed the 
highest levels ofLHR protein when compared to 100 nglml insulin alone (Figure 91). 
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This was seen throughout all experiments (n=4). Quantification of western blot band 
intensities confinned these results showing significant increases in LHR expression 
(***P<O.OO I) throughout all increases in insulin treatments alone, as shown in Figure 
92. 
6.3.2 The effects of LH on non-PCOS and PCOS adipocyte proliferation. 
With confinnation of the presence of the LH receptor in adipocytes seen and results 
showing the honnonal effects on expression, we could begin to examine possible 
influences of LH on adipocyte cell responses. HCG has been shown to have varied 
regulatory actions dependent on target tissues both inhibitory as shown by Czerwiec 
et al., (1989) in their work in human Leydig tumour cells; or stimulatory as seen by 
Rao et al., (2004) within corpus lutea with research also describing LH involvement 
in cell proliferation and possible activation of cell death (307]. Based on these reports 
and under the knowledge that LH hyper secretion is typical for patients suffering from 
PCOS [145], the effects of LH on adipocyte proliferation is of interest. This is 
particularly important with the association adipocytes and obesity has within pcas, 
as a dysfunction in adipocyte metabolism may be linked to the condition. Knowledge 
of the general effects of LH on adipocyte proliferation/metabolism would allow for 
comparison and possible detennination of the existence of any dysfunction. We 
therefore began by examining the effect that LH treatment may have on preadipocyte 
proliferation. This would allow optimisation of treatment levels, ensure stability of 
our cultures under these treatments and detennine possible levels of toxicity. 
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Figure 93. Non-PCOS preadipocyte proliferation under varied LH treatments. on-peOS preadipocyte 
cu ltures (n=5) were grown with and without varied LH treatments ( 10/100 ng/ml). Proliferation was 
measured (A bs @490) over 5 days us ing MTS assays. A significant decrease was seen in proliferation when 
examined using unpaired t-test between I Ong/ml treated non-peOS on day 4 and un-treated (· P<0.046) 
Significant decreasc was a lso seen on day 4 under 100 ng/ml (* P<0.032). Resu lts are mean ± SEM . 
LH treatments of 0110 and 100ng/ml were chosen to mimic LH hyper secretion and 
examined in both non-PCOS and PCOS primary cultures (n=5) using the MTS assay 
(see 3.4). Non-treatment groups were used as controls and media alone also examined. 
All groups were found to remain stable over the five-day proliferation course with no 
signs of cell death seen through cellular debris or cell counts. 
E 
c: 
0 
en 
~ ~
@ 
ell 
(J 
c: 
ftI 0.4 
.0 
... 
0 
~ ~ 0.2 
< 
0.0 
0 24 48 72 
Hours 
96 120 
- (Ong/ml LH ) 
~ ~ (10 ng/ml LH ) 
-- (100 ng/ml LH) 
Figure 94. PC OS preadipocyte proliferation under varied LH treatments (n=5). Non-PeOS 
prcadipocyte cultures (n=5) were grown with and without va ried LH treatments ( 10/1 00 ng/ml) and 
proliferation measured over 5 days us ing MTS assays. No vari at ion in proliferation was seen with 
increased LH treatment throughout cu ltures. Results are mean ± SEM . 
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Examination of non-peOS untreated cells showed a growth curve reaching a 
proliferative peak by day 4 and reducing to a lower cell number at day 5 capable of 
being sustained by the cultures environment (Figure 93). Both 10 and 100ng/ml LH 
treatments on non-peOS adipocytes showed consistent inhibitory effects with no 
significant increase in proliferation over the course of 5 days. There was a significant 
difference between treated and controls by day 4 (lOng/ml P=0.046, 100ng/ml 
P=O.032). These results suggested that the LH treatment range chosen was capable of 
maintaining the preadipocyte cultures with no sign of cell death however proliferation 
was inhibited and seen at treatments from 10 to 10Ong/ml. 
The proliferation assay was repeated using peos primary adipocytes (n=5) and the 
same treatment ranges. Results varied from non-peOS with all treatments having no 
significant variation on proliferation when compared to non-treatment culture 
proliferation Figure 94. This suggested that the PCOS adipocyte differed from non-
peos through lack of LH inhibition on proliferation. Closer inspection also showed 
that the growth 'pattern seen in non-peOS proliferation was different to that seen in 
peos and although both showed similar peak proliferation in untreated groups, 
peos cells maintained these levels over 5 days whereas non-peOS cells showed a 
decrease on day 5. These results gave interesting findings and points to a possible 
variation between non-peOS and peos adipocytes they also allowed for necessary 
information for maintain our primary cultures and enabling us to proceed with 
examining hormonal effects further. 
6.3.3 The effects of Insulin on non-PCOS and PCOS adipocyte proliferation 
Due to its association with peos we also examined the effects of insulin treatments 
both individually and in combination with LH treatments. It would therefore be 
necessary to examine the effects on proliferation within our primary cultures through 
MTS proliferation assay. 
Both animal and human studies have revealed the proliferative effects of insulin 
action in subcutaneous adipocytes and more so in omental adipocyte cells in-vitro 
[308, 309]. It has also been shown that increased levels of insulin treatments can be 
cytotoxic (400nM) to cultured human adipocytes [310]. For this reason examination 
of treatment range was necessary to optimize both culture maintenance and further 
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work. This would also allow us to determine whether variation between non-peaS 
and peas preadipocyte proliferation under these conditions existed and if any 
metabolic variation may be associated. 
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Figure 95. No n-Pe a S preadipocyte proliferation under varied in ulin treatments. on-PCO 
preadipocyte cultures (n=4) were grown with and w ithout varied insu lin treatments (10/1 00 nglml) and 
proli fe rati on measured over 5 days using MTS assay . 0 significant variation in proliferation wa 
seen under varying doses of insulin . Results are mean ± SEM . 
Figure 95 shows no significant changes in proliferation occurred in non-peaS 
preadipocytes. This did not vary across our treatment range (OIIOII OOng/ml Insulin) 
[310]. These results also showed no cytotoxic effect on the primary cultures over the 
5 day assay period. MTS proliferation assays were run on peas culture along ide 
non-peaS experiments (n=5). 
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Figure 96. PC OS preadipocyte proliferation under varied Insulin treatments. peos preadipocyte 
cultures (n=5) were grown with and without varied insulin treatments (10/100 ng/ml) and proliferation 
measured over 5 days using MTS assays. Significant increases in proliferation on day 3 in both 10 and 
lOOnglml insulin treatments against untreated was seen (**P<O.O 1 lOng/ml and **P<O.OI 100ng/ml) 
with significance also seen on day 5 under 100ng/ml treatments (*P<0.05). Statistical analysis was 
done using unpaired t-tests. Results are mean ± SEM . 
Insulin was seen to increase peas preadipocyte proliferation. This was more 
predominant in peas cultures with significant increases seen by day 3 in both 10 and 
IOOng/ml insulin treatments (P=O.009 IOng/ml and P=O.008 100ng/ml). In IOOng/ml 
insulin treatment when examined significant increase was also secn in proliferation on 
day 5 against un-treated (*P<O.05). 
Insulin and LH has been seen to enhance steroidogenic function in gonadal tissue 
througb increased steroid biosynthesis [145, 299]. This may be as a result of increased 
proliferation under these conditions. As our later experiments would be examining 
steroid biosynthesis within adipocytes it was therefore necessary to explore this 
combined effect of insulin and LH across both groups. This may allow possible 
association in any later metabolic response results. Figure 97 showed that the 
increased proliferation shown in non-peaS adipocytes after treatment with 10ng/ml 
insulin was inhibited by the addition of IOOng/ml LH. These results furthcr support 
the inhibitory response seen in our results from non-peaS adipocyte LH treatments 
alone (Figure 93). However we continued to see no significant inhibition of peas 
adipocytes again supporting the lack of effect LH has on inhibiting peas adipocyte 
proliferation. However, the proliferative effects of insulin are slightly decreased with 
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the addition of LH as seen when comparing insulin against insulin + LH (see Figure 
95, Figure 96, Figure 97). This may suggest that LH inhibition may be reduced 
rather than not exist in peos adipocytes. 
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Figure 97. (A) Non-PCOS preadipocyte proliferation under varied LH and Insulin treatments. on-peOS 
preadipocyte cultures (n=5) were grown wi th and without a combination of LH and insulin treatments (I Onglml 
insulin and either 10 or 100nglmi LH ) Proliferation was measured over 5 days using MTS as ay. Significant 
decreases were seen on day 4 with both (IOins/ IOLH) and ( IOins/ IOOLH) (* P<0.05) when compared to un-treated 
non-peOS cells. (8) PCOS preadipocyte proliferation under varied LH and Insulin treatment. on-peOS 
preadipocyte cultures (n=5) were grown with and without a combination of LH and insulin treatments (I Onglml in 
and either 10 or IOOng/ml LH) Proliferation was measured over 5 days using MTS assays. 0 significant variation 
was seen in proliferation between treated and un-treated cultures. Statistical analysis was done using unpaired t-
tests. Results are mean ± SEM. 
6.3.4 The influence of insulin and LH on CYP17 expression in non-PCOS and 
PCOS adipocytes 
Insulin and LH have been shown to influence both proliferation and steroidogenic 
function in gonadal tissues, specifically ovarian granulosa and theca cells [145, 299]. 
In peos this has been hypothesized to be associated to hyperandrogenemia [145]. 
rt has already been established that androgen synthesis comes from circulatory 
precursors within adipocytes with increased secretion from subcutaneous adipocytes 
whcn compared with omental adipocytes [191]. aUf results have supported published 
findings that steroidogenic enzymes exist within adipocytes with the capacity to 
produce locali zed androgen synthesis. We have also examined levels of expression of 
the key enzyme CYP 17 in both non-PCaS and peas sc adipocytes. Further to this 
we exam ined whether the hormonal treatments with pcas would affect these levels 
and whether variation between non-peaS and pcas would occur. This would 
therefore add possible mechanisms of peas associated hyperandrogenemia. 
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Figure 98. Western blot of CYP 17 expression in non-PCOS and PCOS mature adipocyte (lane 1-
8) after LH treatment. Mature adipocyte (n=3) were treated with 100 nglml LH in-vih·o (Non-PCOS 
lane 1-3) (PCOS lane 4-6). Lanes were probed using CYP17al antibody. Exposure at 1240sec shows 
immunoreactive bands at 57kDa with no variation in band intensity. The blot was then stripped and re 
probed using p-Actin to control for protein loading. All blots were probed against CHO controls (not 
shown). 
Firstly we examined the effects of LH on CYP 17 expression in both non-PCOS and 
PCOS mature adipocytes (see Figure 98). Following normalization using (}-Actin, no 
significant variation was seen between sample groups. With no effect seen in LH 
treatments we moved on to our second hormone of interest, insulin. Insulin treatments 
were examined individually. Figure 99 showed paired samples; non-PCOS, PCOS 
adipocytes lysates following 0-1-1O-100ng/ml insulin treatments (lane 2, 4). In 11011-
PCOS samples CYP17 was seen to increase at around 10ng/ml treatments with no 
variation in expression with further increases to 100ng/mt. Similar expression was 
seen across non-PCOS and PCOS samples in the treatment range 10-100 with no 
significant variation in expression found. However PCOS samples showed increased 
CYPl7 expression at lower insulin treatments when compared to non-PCOS (lng/ml) 
and showed significant variation (***P<O.OOI) when quantification of WB band 
intensities against the ~ - a c t i n n was examined (see Figure 100). 
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Figure 99. W estern blot CYPI7 expression in non-PC OS against PCO mature adipocyte (lane 1-
8) after va ri ed insulin . Mature adi pocyte were treated with varied doses of in ulin in- vitro (i nsulin 0 
(l ane 1-2) Ing/ml (lane 3-4 ) IOnglml (lane 5-6) IOOnglml (lane 7-8) . Lanes were probed u ing 
eyp 17a I antibody. Exposure at 640sec hows bands intensity at 59k Da wi th inerea es in in uli n. Li ttl e 
varia tion was seen between non-pe OS ( lanes I, 3, 5, 7) and peos samples (lane 2, 4, 6, 8). However 
increased e yp 17 expression ean be seen in pe o s (lane 4) at I nglml insu lin trea tment. The blot wa 
then stripped and re probed usi ng /3-Actin to control for protein loading. All blots were probed aga in t 
leucocyte negati ve controls (not shown). 
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Figure 100. Summarising the densitometry representative of average expression of CYPI7 in 
non-PCDS and PCDS mature adipocytes (n=3) under varying insulin treatments. Using p-Actin 
normalisation to compare levels of band intensity in western blot CYP 17 expression (Figure 99) 
Densitometry examination of western blot results (Figure 99), showed significant di fference were seen 
in expression of CYP 17 with increases in insulin treatment of I ng/ml (***P<O.OO I). Statistical analysis 
was done using one way ANOVA data expressed as means / ± SEM. No variation in CYP 17 
expression was seen between any other non-PCOS and PCOS insulin treatment groups. 
6.3.5 Hormonal influences on non-PCOS and PC OS steroid secretion. 
With suggested differences seen within proliferation and CYP 17 expression between 
non-peaS and peas adipocytes and with peas showing increased sensitivity to 
insulin treatments, we decided to examine whether the treatment levels used within 
our previous experiments would influence our determination of androstenedione 
secretion (see Chapter 5). Androstenedione secretion under controlled conditions, and 
following varied hormonal treatments of insulin and LH treatments were examined to 
determine levels across non-PCaS and pcas mature adipocytes and whether any 
variations may exist. 
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6.4.5.1 Effects of insulin on non-PCOS and PCOS adipocyte androstenedione 
secretion 
Our initial experiments focused on androstenedione secretion with 0, I, 10 and 
lOOng/ml insulin using the androstenedione ELISA as described in 3. 7. The standard 
curve, seen in Figure 35 showed that the levels determined secreted by the adipocytes 
fell within the standard curve for levels of detection (0.00 19n9/ml I O.03pmoll1000 
cells). 
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Figure 101. Standard curve showing ELISA androstenedione levels through mea ured 
absorbance. Known leve ls of androstenedione were meas ured using ELISA techn ique and level of 
abso rbance @490 taken to determine a standard curve. 
We then compared androstenedione secretion from our two primary culture group's 
non-peaS and peas adipocytes using the standard curve produced. Figure 102 
shows non-peaS adipocytes (n= 12) secreting significant androstenedione levels 
when compared to the non-secreting osteoclast negative control. The effect eemed to 
be dose dependant with increased androstenedione secretion at 10 and 100ng/ml when 
compared to no treatment (10 ng/ml *P<0.05 I 100 ng/ml **P<O.O I). 
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Figure 102. Androstenedione secretion (pmoUIOOO cells) by non-PCOS adipocytes after varied 
insulin treatment. Non-PCOS mature adipocyte cultures (n= 12) were grown after varied insulin 
treatments (I, 10, and 100nglml) for 3 days. Androstenedione levels were measured in conditioned 
media using ELISA. All measurements were compared to negative osteoclast controls llsing one-way 
ANOV A and bonfferoni post hoc test analysis and androstenedione levels found to bc significant 
(**"'P<O.OO I) in all untreated and treated adipocyte cultures. Results arc mean ± SEM. 
Examination of peos adipocyte androstenedione secretion (n=9) after the same 
insulin treatments again showed significance against the negative control but had no 
variation across insulin treatments range. No variation was seen across any insulin 
treatment Figure 103. 
141 
Chapter 6: Results: Hormonal Influence on Adipocyte Function 
-
'" Q) 
(J 
o 
o 
o 
.... 
::::::. 
o 
E 
c.. 
-Q) 
c: 
o 
=s 
Q) 
c: 
.! 
'" o~ ~
'C 
c: 
~ ~
* 
Insulin (nglml) 
Figure 103. Androstenedione secretion (pmoUIOOO cells) by PC OS adipocytes after varied insuli n 
treatment. peas mature adi pocyte cultures (n=9) were grown after varied in ulin treatment (I, 10, 
and 100ng/ml ) for 3 days and media examined for androstenedione levels using ELISA technique. 1\ 
measurements were compared to negati ve osteoclas t control cu ltures and androstenedione level found 
to be signi ficantly higher (* P<0.05)when examined us ing one-way A OVA and bOI1JJerol1i po t hoc 
tests. 0 signifi cance was seen aga inst the untreated cultures through any treatment . 
Non-Pe aS androstenedione secretion was compared against pe as secretion under 
varied insulin treatments as seen in Figure 104. Stati stical analysi showed no 
significant variation between groups however a trend does seem to exist between non-
pe as and pe as androstenedione secretion that may suggest pe a s eeretion i 
increa ed. 
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Figure 104. Comparison of non-PCOS and PCOS adipocyte androstenedione secretion after 
varied insulin treatment. Comparison of non-PCOS (n= 12) and PCOS adipocyte (n=9) 
androstenedione secretion. No significance was seen within groups of insulin treatment using oneway 
ANOYA. Results are mean ± SEM . 
With the possible influence insulin may therefore play in androgen synthesis we 
examine a possible signalling pathway through inhibition of PI3-K which has been 
shown to be involved in ovarian steroidogenesis [45]. Figure 105 shows that no 
variation in either non-peOS or peos groups was seen whether through insulin 
stimulation of androgen secretion or through inhibition of PI3-K pathway. Results 
however again show that an increase in androgen secretion was seen throughout all 
treatments in the peos group when compared to the non-peOS. 
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Figure 105. (A) Comparison of non-PCOS androstenedione secretion with and without inhibition 
of the insulin-signalling pathway. on-PCOS adipocytes (n= 12) were treated wi th insu lin with and 
without the PI3-K inhibitor L Y292004 and androstenedi one secretion measured. 0 signi fica nt 
va ria tion was fo und between trea ted and untreated culture . (8) Com pari on of pca 
androstenedione secretion with and without inhibition of the insulin-signalling pathway. 
A ndrostenedione secretion by PCOS mature adipocyte cu ltures (n= I 0) were a lso examined and no 
s igni fica nt variati on between levels of secretion were seen. Resu lts are mean ± EM 
6.4.5.2 Effects of LH on non-PCOS and PCOS adipocyte androstenedione 
secretion 
With augmentation ofLH and insulin shown to increase androgen secretion in ovarian 
theca cells [91] we treated the non-peOS cultures with a combination of treatments 
and measured the effects on androstenedione levels found in media following 3 days 
maintenance. A trend was seen throughout all treatments with the addition of LH to 
insulin treatments showing reduced androstenedione levels suggestive of inhibition. 
Furthermore significant increases were seen on days 4 (***P<O.OO I) and day 5 
(*P<O.05). 
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Figure 106. Comparison of non-PCOS mature adipocyte androstenedione secretion with and 
without varied insulin and LH treatments. Androstenedione secretion was measured from non-
peos mature adipocyte (n= 12) after varied insulin secretion (0, I, 10 and IOOng/mt) and with or 
without lOng/mt LH treatments. Results are mean ± SEM .Significant increases were seen between 
androstenedione levels from IOnglml insulin treatments against IOng/ml with IOng/ml LH treatmcnts 
(* ...... p<O.OO I). Significant increases in androstenedione secretion were also seen within IOOng/ml 
insulin treatment against IOOng/ml with IOng/ml LH treatments (*P<O.05) when examined using one-
way ANOV A and bonfJeroni post hoc tests. 
In peas cultures we saw minimal effects at low insulin and LH treatments and 
minimal reductions in androstenedione secretion at the higher insulin and LH 
treatments in comparison to non-peaS. It should be noted that although no 
significant differences were seen within any treatments in the peas groups the trend 
was the same as seen in the non-peaS groups (Figure 103). This may suggest 
reduced sensitivity if examined further. 
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Figure 107. Comparisons of PC os mature adipocyte androstenedione secretion with and witho ut 
varied insulin and LH treatments. Androstenedione secretion wa mea ured from PCO mature 
adipocyte (n=9) after varied insulin secretion (0, I, 10 and 100nglml) and with or without 10nglmi LH 
treatments. Results are mean ± SEM. 0 significant variations were een between treated or untreated 
groups. 
6.4.5.3 Effects of Insulin and LH on non-PCOS and PCO adipocyte 
progesterone secretion. 
Using a progesterone ELISA (see 3.7) we examined progesterone ecretion in both 
non-PCaS and pcas adipocytes. Known levels of progesterone were examined using 
the same ELISA and absorbance measured to create a standard curve. All re ults were 
obtained using this standard curve showing value falling within the ELISA range of 
capability. 
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Figure 108. Standard curve showing ELISA progesterone levels through measured absorbance. 
Known levels of progesterone were measured using ELISA technique and levels of absorbance @490 
taken to detennine a standard curve for which all results could be measured by. 
Examination of ELISA results taken from non-peOS adipocytes treated with varying 
doses of insulin with and without additional LH treatment (lOOng/ml) Figure 109 
showed progesterone secretion occurred against negative osteoclast controls. 
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Figure 109. (A) Non-PCOS mature adipocyte progesterone secretion with varied Insulin 
treatment. Insulin treated and un-treated non-PCOS mature adipocytes (n=5) media was examined for 
progesterone using ELISA technique. Results arc mean ± SEM. All levels were significant against the 
control (*P<O.05). No significant variation between treated and un-treated was seen. (8) PCOS 
mature adipocyte (n=5) progesterone secretion with varied Insulin treatment. PCOS mature 
adipocyte media showed no significant variation in progesterone secretion between treated and un-
treated . All samples were examined against osteoclast media negative control and one-way ANOV A 
and bonfferoni post hoc tests. 
No significant variations occurred across treatments in both non-peos and peos 
groups. However examination of peos progesterone secretion showed increased 
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levels. Although no significant increase was seen throughout treatments an increa ed 
trend was seen within insulin and LH treatment combined against insulin alone. 
Although the results suggest LH alone increased progesterone secretion in peas 
samples, no significant variation was seen between untreated and LH treated secretion. 
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Figure 110 (A) Non-PCOS mature adipocyte progesterone secretion with varied Insulin and LH 
treatment. Insulin and LH treated and un-treated non-PCa S mature adipocyte (n=5) media was 
examined for progesterone using ELISA techniq ue. Resu lts are mean ± SEM. No ignificant variation 
between treated and un-treated was seen. (8) PCOS mature adipocyte (n=5) proge terone ecretion 
with varied Insulin and LH treatment. pc a s mature ad ipocyte med ia showed no significant 
variation in progesterone secreti on. All samples were examined again t osteocla t med ia negative 
control. 
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6.4.6 Effects of progesterone on non-PCOS and PC OS adipocyte proliferation. 
With results suggesting the presence of progesterone secreted by adipocytes into the 
media we decided to examine whether localized secretion would have an effect on 
adipocyte proliferation at the levels measured. The progesterone treatments chosen 
were therefore kept within the range 0, 0.25 and 0.1 ng/ml (5-15 pmolllOOO cells) and 
MIS assay used to examine 5 day proliferation. Results showed that within 24hr of 
incubation significant decreases in proliferation were seen in comparison to untreated 
groups in both non-PCOS and PCOS cultures Figure 111. Cell morphology showed 
rounding and large numbers of cellular debris suggestive of cell death. 
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Figure III. (A) Non-PCOS 5 day proliferation after varied progesterone treatments. Non-PeOS 
adipocytes (n=3) were examined after varied progesterone treatments (0.25 and 0.1 ng/ml) for 
proliferation over 5 days using MTS assay. Results are mean.J: SEM. Significant variation was seen by 
day 2 under 0.25 nglml (day 2/3 "P<O.O 1 day 4/5 ***P<O.OO I). Significant variation was seen by day 
3 under 0.1 ng/mt (day 3 **P<O.OI day 4/5 ***P<O.OOI). (8) PCOS 5 day proliferation after varied 
progesterone treatments. peas adipocytes (n=3) were examined after varied progesterone 
treatments (0 .25 and Ot ng/mt) for proliferation over 5 days lIsing MTS assay. Significant variation was 
seen by day 2 under 0.25 nglml (day 2 *P<0.05 day 3/4/5 ***P<O.OO I) . Significant variation was seen 
by day 2 under 0.1 ng/ml (day 2 *P<0.05 day 3/4/5 ***P<O.OO I) using one-way ANOV A statistical 
examiation. 
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6.5 Discussion 
6.5.1 Expression ofLH receptor in non-PCOS and PCOS adipoq'tes 
The aim of this chapter was to investigate the expression the LH receptor within 
pre/mature adipocytes as first examined by Dos Santos et al., (2007) and to also 
determine what effect PCOS may have on LHR function in adipocytes [300]. To 
achieve this we studied the possibility of variation between non-PCOS and PeOS 
LHR expression as well as variations that may occur across stages of adipocyte 
development. 
The LH receptor is recognized as a trans-membrane receptor and is found in ovarian 
thecal cells [311] and uterine serosa [312]. Since the early 1990s the presence of the 
HCGlluteinising receptor has been reported in various non-gonadal tissues including 
neuronal, thyroid and adrenocortical cells [313, 314]. Research has also suggested the 
importance HCGILH receptor and gonadotropin secretion may play in steroid 
hormone metabolism within these tissues through investigations of human and pig 
mammary glands. These studies indicate a possible inhibitory role for HCGILH 
within mammary carcinogenesis and the growth of breast tumours [315, 316]. This 
research therefore points to the existence of an LH mechanism in non-gonadal tissue; 
and a subsequent relationship in steroid hormone metabolism which to date has been 
well documented in gonadal tissues [317-319]. Our findings support the localisation 
of the LHR within non-PCOS adipocytes with immunofluorescence and western 
blotting techniques showing positive results at both preadipocyte and differentiated 
adipocyte development. Our western blot results also showed a double banding effect, 
which may be a due to glycosalation/phosphorylation. Lysates studies into ovarian 
LHR have shown that prolonged receptor occupancy can result in conformational 
changes and phosphorylation which may also explain our findings[320]. Our findings 
are supported by Dos Santos et 01., (2007) who suggested there maybe variation in 
LHR expression between pre- and mature adipocytes which we examined further and 
confirmed (300). Interestingly the reverse is seen in published studies into other 
hormonal agonists including insulin where IRS-I and 2 is up regulated following 
differentiation of adipocytes [321]. 
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These results may therefore suggest a central role of LH in post differential activity. 
The results obtained through immunofluorescence were useful in determining the 
presence and location within the cell membrane of the LH receptor stressing the 
possible involvement of external regulation. These results should however be seen as 
more indicative than conclusive. They allowed us to justify further extension into the 
presence and regulatory mechanisms of LHR expression and function through similar 
findings within our western blots results. Furthermore, due to the difficulty of 
working with the fragile mature adipocytes it was necessary to optimize the fixation 
aspect of the immunofluorescence protocol to reduce cell damage as seen in Chapter 4. 
This improVed the clarity of the images. It was observed that due to the level of 
confluence necessary to allow maturation of the adipocytes there was an increase in 
'noise' within the field of view, which was also prone to photo-bleaching and viewing 
was limited to within an hour of the washing procedure. From this we determined that 
reduction in dilution of the primary antibody and a reduction in cell number would 
increase the clarity of images and reduced the bleaching effect. Ideally we required a 
protocol that allowed maturation in smaller cell numbers. Although we failed to 
achieve this optimisation, further work would have included smaller growth 
environment with reduced cell numbers and using fibronectin to support cell adhesion 
[322]. We should also consider quantification of this technique with a constant 
exposure time this can be achieved using a suitable software package and a micro 
spectrofluorimeter as described by Casperson et al (1965) . The semi quantification of 
western blot was however a more suitable protocol and allowed the findings to be 
supported. Due to time constraints we were unable to examine this further utilizing 
RT-PCR as we had intended and the results shown were sufficient in supporting 
expression in order to justify the further work into hormonal activity. 
Further to this work we were able to examine results within pcas primary cultures, 
to determine whether any variation exists across development. In conclusion we found 
no differences between non-PCDS and PCOS LHR expression at any stage. 
The determination of other hormone receptors in adipocytes and their subsequent 
ability to communicate resulting in an adipocyte response is becoming more apparent. 
Research by Hansen et al .• (1998) showed growth hormone (GH) exerting an 
influential adipogenic effect on preadipocytes through its own receptor and animal 
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studies have shown that an inhibitory effect on preadipocyte differentiation exists 
under increased GH conditions [323]. Our evidence to support the existence of the 
LHR receptor in both non-PDCS and pcas, adipocytes enhances these findings 
through its suggestion of alternate honnonal influences on adipocyte metabolism and 
regulation. Combined with further examination, these results may go someway to 
suggest an area associated with endocrine dysfunctions seen in conditions such as 
metabolic disease and PCDS where hyper secretion of steroid messengers leads to 
exaggerated adipocyte responses. 
6.S.1.2 The effects of Insulin and LH on LH receptor in non-PC OS and PCOS 
adipocytes 
With results suggesting the presence of LH receptor in PCDS adipocytes, many areas 
of research become open to examination, such as responses to physiological and 
hyper-physiological honnonal levels. With honnonal dysfunction being one of the 
key characteristics associated with PCOS, specifically hyperinsulinemia and hyper 
secretion of LH, we examined the receptor response from varied insulin and LH 
treatments in the context of the condition. All experiments were carried out on mature 
adipocytes and the treatment ranges chosen were those used in gonadal steroidogenic 
studies specifically Gilling-Smith et al., (1994) and Munir e/ al., (2004) [45, 91]. 
These treatments ranges had been previously shown to exhibit optimal insulin and LH 
responses. Experiments on non-PCOS and PCDS cultures showed reduced LHR 
expression following LH treatments. Our western blot results showed LHR expression 
in untreated cells but should ideally have been run on separate blots to avoid 
saturation during exposure. By removing the insulin treatment we could have 
increased the exposure time without saturation occurring and therefore further support 
the influence found. This may have allowed us to see the range of LH treatments used 
has a more sensitive inhibitory effect or whether IO-IOOnglml of LH has the same 
inhibitory effect shown from our results. Further to this a more quantitated analysis 
could be achieved through RT-PCR allowing the exact levels of variations through 
mRNA analysis. This would give us an idea of variation at another level of regulation 
they may refute or support our current analysis. 
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The inhibitory effect of LH shown on LHR is similar to that seen by Yamamura et al., 
(2000) who examined granulosa cells in chickens. Yamamura showed that both LHR 
and FSHR mRNA was down regulated by LH, progesterone and estradiol during the 
ovulatory cycle and concluded that steroid mediation of both receptors was possible 
both directly and indirectly through their interaction with LH stimulation [324]. It is 
therefore feasible that adipocytes show similar traits in LH mediated expression of its 
own receptor limiting a downstream cellular response yet to be determined. 
Results presented here in, also showed an increased response in LHR expression with 
increasing insulin treatments in both non-PeOS and peos samples. The first increase 
was seen with the addition of a IOng/ml treatment and remained similar at 100ng/ml 
suggesting IOnglml was the optimum treatment required for the greatest response in 
LHR expression within this range. This did not vary across PCOS samples and we can 
conclude from these results that the increase in LHR expression due to increases in 
insulin treatments was the same for non-peOS and peos adipocytes Research has 
established the positive effects of insulin and insulin like growth factor (IOF) on 
increasing LHR expression in gonadal tissues such as theca and granulosa ovarian 
cells [325]. Examination into non-gonadal tissue has also been examined, studies into 
leydig tumour cells by Zhang et al., (1998) showed similar results with the addition of 
IGF-! [326]. Under the treatment range O.I-IOOng/ml, they found that levels around 
the 20-30ng/ml were sufficient to cause an increase in LHR mRNA. Furthermore they 
found that an increase in IGF -1 levels up to 100nglml did not lead to further increases 
in LHR [326]. From our results we can determine a possible agonistic response in 
LHR expression exists within both pre and mature human adipocytes in response to 
insulin, suggesting an involvement in adipocyte metabolism and sensitive in-vitro to I 
ng/ml insulin with no variation up to 100 ng/mI. 
6.5.1 The effects of LH and Insulin on non-PCOS and PCOS adipocyte 
proliferation. 
Although the hormonal effects of both LH and insulin on proliferation in both gonadal 
and non-gonadal tissues have been examined, research into adipose is yet to be 
examined. Furthermore research into PCOS adipocytes proliferation under these 
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conditions is yet to be observed and with recent discovery of the adipocyte LH 
receptor [300] it is of particular interest with regard to the condition. 
It is widely accepted that ovarian cell proliferation is increased during LH secretion in 
the follicular phase of the menstrual cycle. This allows greater androgen synthesis 
through stimulation of increased theca cell production as well as encouraging 
androgen secretion and differentiation [299,327]. The importance ofLH in regulation 
of cell proliferation has also been seen in other tissues including Leydig cells where, 
conversely, Srinnan et al., (2000) by monitoring the levels of proliferating cell 
nuclear antigen (PCNA) with the addition of LH, showed a significant decrease in 
proliferation [328]. From this we can see that LH plays a key role in regulating 
proliferation in certain tissues and also the importance this regulation plays in 
honnone metabolism within gonadal tissues. 
Although adipocyte metabolic response to LH has yet to be examined thoroughly, our 
results suggest a proliferative response exists and that the addition of LH to non-
peas preadipocytes leads to a significant decrease in proliferation. More specifically 
results from our assay indicated complete inhibition of proliferation over the five day 
assay. 
Our comparative peas model however showed different results and lacked inhibition 
of proliferation within the same insulin treatment range. From this we can suggest that 
a possible lack of LH sensitivity exists within peas adipocytes, that affects the LH 
regulatory mechanism of a proliferative response. Similarly this effect is seen in 
peas gonadal cells under the influence of insulin and it is understood that an 
association with insulin resistance exists in PCOS that has been linked to 
hyperinsuilnemia and hyperandrogenemia. This may therefore also exist with LH. 
Interestingly the responses in adipocytes seen with the addition of insulin were not as 
potent with regard to proliferation as would be expected. Studies have shown that 
insulin increases the proliferative response of adipocytes within the doses we tested 
[310, 321]. No significance was seen between our non-peaS samples and insulin 
treatments which suggested less potent response than previously published [310]. It 
should, however, be noted that the limited sample numbers used in this study may 
account for this variation as shown through the level of error in findings. A reduction 
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in the error found may therefore show significance between the control and both 
insulin treatments which showed similar results and pointed to a possible increase 
over the 0 treatment. Although MTS assays focuses on mitochondrial activity, 
allowing a good measure of viable proliferation, the observation would be better 
supported using additional techniques such as evaluation of cell death through lactate 
dehydrogenase (LDH) release. This is routinely used as a measure of tissue 
breakdown through its involvement in pyruvate to lactate conversion [329]. Time 
restraints meant this was not an option. 
It should also be noted that MTS assay is a measure of metabolic activity through its 
cellular conversion to formazen. Treatments used may have an effect on this activity 
and therefore affect proliferation results. Huang et al., (2004) reported that the 
albumin content in serum may reduce absorbance by as much has 50% [330]. 
Although these conclusions are still under examination and vary on repeats, results 
taken from MTSIMTT assays can be supported through cell counting. 
This study did allow us to see differences between non-peaS and peos adipocytes. 
Firstly, growth patterns varied between the two groups with peos reaching the same 
level of proliferation as non-PeaS. However, non-peas cell numbers where seen to 
decrease over the longer term when compared to peos. This may be attributed to 
PCOS cells clumping or stacking which fails to occur in non-peaS cells. By 
increasing the MTS assay period from 5 days we would be able to establish whether 
peos can exist in this state for longer as when this begins to occur in non-peOS cells, 
numbers begin to reduce as seen by day 5 in our results. Our results are not conclusive 
enough to report peas cells can exist in a different growth state than non-PeOS 
although evidence may suggest this. Secondly, the peas adipocyte response to 
insulin showed a greater sensitivity with increased proliferation seen. This may be a 
peos adipocyte dysfunction that should be examined further. Our findings also 
showed further increases in proliferation occurred on day 5 within our largest insulin 
treatment group suggesting that hyperinsulineamic conditions may playa greater role 
on the effect on adipocyte metabolism. 
Finally the results seen using insulin treatment further supported the capacity of LH to 
inhibit proliferation and all effects seen in non-peOS with the addition of insulin 
were reduced with the addition of LH. Although such a strong inhibitory effect was 
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once again not seen in the PCOS samples we did find that the large increase in 
proliferation found with the addition of insulin treatments alone was reduced with the 
addition of LH. This may also suggest that the defect that may exist in PCOS 
preadipocytes is linked to sensitivity rather than a complete abolition of the effect of 
LH. With future work I may examine this further and an increased treatment range 
would be considered both increasing and decreasing the dosages of LH used to 
determine actual sensitivity. 
6.5.4 The influence of insulin and LH on CYP17 expression in non-PCOS and 
PCOS adipocytes 
With the possibility that proliferation in adipocytes is influenced by hormonal 
stimulus we began to look into areas of associated metabolic response particularly 
those associated to peas. 
Studies have shown IGF-I has positive effects on steroidogenic enzyme expression 
and increased IGF-l influence on both adrenal cortical cells and leydig cells have 
been shown to up-regulate 17 alpha-hydroxylase/C 17-20 lyase, cholesterol side-chain 
cleavage, and type I 5 alpha-reductase (5 alpha R-l) all known to play vital roles in 
androgen synthesis. This has also been seen in ovarian cells, with studies by Munir et 
al.. (2004) showing an increase in steroidogenic enzyme expression in theca cells. 
Our examination into the steroidogenic enzyme CYP 17 further supports these 
findings and our results (as seen in Chapter 5) showing .the presence of CYP17 in 
adipocytes allowed us to examine its expression under the influence of insulin and LH 
treatments [45]. Initial experiments comparing CYP17 expression across non-PCOS 
and PCOS samples showed no significant variation, however when compared 
following insulin treatment PC OS cells showed signs of increased sensitivity to 
insulin at lower treatments than those seen in non-treated, suggesting a defect may 
exist. With the prevalence of insulin resistance within PCOS this finding seemed 
paradoxical. Similar hypotheses exist within ovarian theca studies with suggested 
molecular defects of CYP 17 expression under increased insulin levels leading to 
increased androstenedione synthesis within PCOS [45]. These results should only be 
considered as a pilot study. Lysate examination was limited (n=3 vs. 3) and we 
attempted to keep results consistent to high BMI, hyperinsulinemia groups leaving 
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room for error. In order to further validate /support these findings it would be 
necessary to increase the sample size. In further work I would also use direct 
homogenization of biopsies to eliminate any cellular metabolic variations associated 
to in-vitro treatment. The availability of samples meant that culturing was however 
required for all experiments to be undertaken. T h e ~ e e results may however require 
further repetition with increased samples and would be more valid utilising 
examination ofCYP17 mRNA under.RT-PCR experiments. 
6.5.5 Effects of Insunn and LH on non-PCOS and PCOS adlpocyte hormone 
secretion. 
Following examination and determination of androstenedione present within our 
media harvest and shown within both our non-PCOS and pcas primary adipocyte 
culture groups (see 5.4.7) we ran the same protocol under varied hormonal treatments 
to determine if any influence on levels of secretion existed. The same ELISA was 
used alongside intra / positive theca culture control and negative osteoclast culture 
media harvests (see 3.6.1). Both groups were found to have increased levels of 
androstenedione significant against the negative osteoclast under all treatments. The 
addition of our insulin treatment range within non-PCOS cultures showed an increase 
in androstenedione secretion at 10-1 OOng/mt with no variation between these 
treatments. From this we can therefore suggest insulin influences androstenedione 
metabolism in non-PCaS mature adipocytes at this treatment level causing an 
increase in secretion over 3 days. We took these results further and examined a 
possible pathway in which insulin could be affecting androstenedione synthesis 
similar to that seen in ovarian androgen synthesis. The protocol used was similar to 
that used by Munir et al., (2004) and used a PI3-K inhibitor (L Y294002) in 
combination with insulin treatment levels previously shown to increase 
androstenedione levels. This allowed us to examine the effects insulin had on levels of 
secretion (see 3.7). The results in both non-PCaS and PCOS samples showed no 
variation occurred between inhibited and un-treated samples. This would suggest that 
if insulin was stimulating androstenedione secretion it is not working through the PI3-
K pathway. Results taken for the PCOS samples did however show slight discrepancy 
in samples treated with the inhibitor alone. We found androstenedione levels in these 
samples were similar to all insulin treated and untreated samples. Although this result 
157 
Chapter 6: Results: Hormonal Influence on Adipocyte Function 
supports lack of influence on androstenedione levels found in all the peos samples. 
we did expect this to be reduced in the inhibited group due to the reported toxic effect 
of LY294002 [331]. We may be able to associate this to the sample size and the 
resultant room for error this incurred. Future work would include increase in these 
numbers to support these fmdings. Although future work may benefit the study 
through use of radio immune assay (RIA) examination. the main benefit would be the 
level of sensitivity. The ELISA used was chosen for its ability to recognise very low 
levels of androstenedione and therefore RIA would be more supportive than used as 
an alternative. 
Our further examination into the progesterone precursor required for localised 
androstenedione synthesis. also showed supportive evidence of a hormonal influence 
and the pathway involved in androgen synthesis. Although no significant difference in 
progesterone level were found under hormonal treatments the results showed a 
possible trend toward decreased progesterone synthesis at 10 nglml insulin. This is the 
same level required to cause androstenedione levels to increase. If a pathway utilising 
progesterone existed in the conversion to androgen then a possible reduction may be 
seen at this point. The lack of significance may be accounted for again through lack of 
sample size. We should also consider that due to restrictions, we were limited in 
examination of our insulin range for progesterone and only examined 10 nglml as this 
was the lowest level shown to cause androstenedione increase. With more time we 
could have examined a greater range to see if this effect increased. Examination of the 
peos sample may also support this hypothesis as the lack of effect of insulin on 
androstenedione secretion seen in our peos samples may lead to a stable or increased 
level of progesterone in this situation, which was found on examination. This may 
also suggest either increased progesterone though lack of synthesis or presence of a 
defect in peos adipocytes leading to increased progesterone secretion or synthesis. If 
we compare this to the results we found with our androgen secretion then an increase 
trend or at least a similar level of androgen secretion would point to no less use of 
progesterone within the hypothesised pathway. We could therefore speculate that if an 
increased level of androgen is being synthesised then the increased level of 
progesterone is linked. Further examination is required and as mentioned examination 
of progesterone levels within increased sample numbers through RIA would test the 
hypothesis. 
158 
Chapter 6: Results: Hormonal Influence on Adipocyte Function 
Although brief examination of the results comparing non-peaS and peas 
progesterone suggested an increase in progesterone existed in peos adipocytes, no 
significant variation was found. The error bars shown and sample size used suggest 
further examination is required again with a larger sample groups. This is also seen 
when comparing the influence of LH and insulin combined where a defmite trend is 
seen not only increasing with the addition of insulin in both non-peOS and peas 
more predominantly in Peas, but also increasing even further with the addition of 
LH. This does show significant increases within our peos samples with insulin and 
LH combined giving greater secretion of progesterone over insulin alone. These 
results point to a definite augmented effect of LH and insulin combined in peos 
samples and with further examination this may be the case within our non-peOS 
samples although to a lesser degree. If this were the case it would suggest that the 
combination of insulin and LH not only had a greater effect on progesterone synthesis 
but that peos adipocyte were more sensitive to the action. If we were to determine 
that progesterone was active in adipocyte androgen synthesis pathway and that peDS 
cells are also producing increased levels of androgen then the increased levels 
associated to a combination of LH and insulin would support the increased androgen 
secretion. This could easily be associated with conditions found in peDS with 
symptomatic hyperinsulineamia and hyper secretion of LH acting to increase 
androgen synthesis within adipocytes due to a possible defect within peos 
adipocytes. Furthermore our results in examining androstenedione secretion showed 
significant increases in non-PeDS samples through augmented LH and insulin 
treatments and although no significance was seen within our peas samples a trend 
was noted. 
6.4.6 Effects of progesterone on non-PCOS and PCOS adipocyte proliferation. 
Various studies have shown that progesterone may increase adipocyte accretion [288, 
332, 333] and it has been theorized this is through increased lipoprotein lipase (LPL) 
the enzyme responsible for lipolysis [334]. Although controversy exists, recent studies 
by Zhang et al., 2008 have argued this not be the case, showing too many 
inconsistencies within results [335]. Further research into the influence of 
progesterone within proliferation of 3T3-Ll preadipocytes by Monjo et al., 2004 has 
shown a significant positive effect at similar treatment levels to those in our study 
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[239]. However this was examined within omental adipocyte samples and they also 
report that the same examination into brown adipocytes showed the opposite effect 
occurs possibly through down regulation within the androgen receptor to which the 
study found association [239]. Furthennore progesterone bas been shown to reduce 
the estradiol-induced proliferation of breast epithelial cells as well as endometrial 
proliferation in-vivo, and inhibition of proliferation of vascular smooth muscle bas 
been reported [336]. Examination of our non-PCOS and PCOS primary cultures 
showed that a defmite decrease in proliferation occurred at progesterone levels similar 
to those seen within our media harvests. Although limited by sample size our pilot 
study allows interesting infonnation in this broad area of examination and may 
suggest that localized progesterone secretion may also be inked to a mechanism of 
regulation associated with proliferation. 
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7.0 HORMONAL INFLUENCES ON THECA CELL FUNCTION IN 
NON-PCOS AND PCOS WOMEN 
7.1 IatrodactioD. 
Polycysti<: ovarian syndrome is a disorder of diverse clinical and biochemical 
symptoms ranging from anovulation to hyperinsulinemia [337-339]. Typically peos 
is associated with high circulatory LH and testosterone levels [144, 302]. Although 
evidence exists as to elevated adrenal androgen secretion contributing to 
hyperandrogenemia in PCOS patients [340, 341], whether this is through thecal 
hypertrophy or dysfunction leading to hyper secretion remains to be fully supported. 
Steroidogenic activity within the ovaries is dependent on the collaboration of two cell 
types; granulosa and theca. Androgen biosynthesis occurs predominantly within the 
ovarian theca cells and contributes to around 50% of overall physiological 
androstenedione secretion [342]. The excess androgen synthesis found within peos 
is thought to relate to excess ovarian biosynthesis; although the exact underlying 
aetiology of the syndrome remains largely unexplained a significant body of evidence 
suggests that an excess of ovarian androgen production remains central in the 
pathogenesis of PCOS [119, 339]. Three possible mechanisms for this androgen 
hyper-secretion have been postulated including an intrinsic functional thecal defect, 
namely thecal hypertrophy; hyperinsulinemia resulting from insulin resistance, which 
is common in women with peos, or pituitary LH hyper secretion resulting in 
excessive thecal stimulation. Although, several publications exist on thecal function, 
in normal and polycystic ovaries including in vitro and in vivo studies [343-345], 
identification of a primary defect in PCOS is yet to be determined. In particular, the 
exact cellular mechanism of action of insulin in the theca cell remains to be fully 
understood. 
Despite the prevalence of insulin resistance in women with pcos [185], several 
studies have shown insulin receptors to be normal in structure [346], quantity and 
insulin binding affinity in these women [172]. It is therefore, now recognized that 
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insulin resistance in pcas is due to post-receptor defects in the insulin-signalling 
pathway. 
It has been clearly shown that insulin acts on theca cells through its own receptor [45, 
157]. Despite insulin resistance in women with pcas, ovarian theca cells show 
hypersensitivity to insulin resulting in excess androgen production. This paradox 
could be explained by selective defects of insulin sensitivity, which affects metabolic, 
but not mitogenic insulin signalling pathways [347, 348]. Another explanation for this 
paradox is that defects in insulin sensitivity are tissue-specific with resistance in 
peripheral (skeletal and adipose) tissues and hypersensitivity in ovarian theca cells 
[99]. In support of this hypothesis, a recent study has shown cell-specific alterations 
in insulin receptor substrate (IRS) protein concentrations in theca cells from 
polycystic ovaries that are consistent with an exaggerated amplification of the insulin 
signal [70]. 
Data on the mechanisms regulating androgen production distal to IRS are limited and 
conflicting. Research involving theca cells from normal ovaries has suggested 
phosphatidylinositol-3-kinase (PI3-kinase) (but not mitogen-activated protein kinase 
[MAPK]) as a possible insulin signalling mediator for the stimulatory effects of 
insulin on 17a-hydroxylase (CYPI7), the enzyme involved in androgen biosynthesis, 
[45]. Alternately Poretsky et 01., 2001 found that insulin-mediated increase in 
steroidogenesis in granulosa lutein cells of normal ovaries is independent of PI3-K 
pathway [68]. No studies have been conducted on PI3-K in polycystic ovaries. The 
role of PI3-K pathway therefore remains uncertain in normal and polycystic ovaries. 
Another area of uncertainty is whether insulin stimulates ovarian steroidogenesis 
independently or through augmentation of LH stimulated androgen synthesis by 
interacting with LH-induced cAMP. Nestler et al., (1998) demonstrated that insulin 
alone stimulated and increased testosterone production by cultured theca cells from 
normal (4 fold increase) and polycystic ovaries (13 fold increase) [349]. In contrast to 
this Munir et al., (2004) found that insulin alone was not able to stimulate 17« _ 
hydroxylase activities in cultured theca cells from normal ovaries, but required 
activation of cAMP by adding forskolin [45]. Given this we sought to examine 
whether this same finding occurred within PC as theca cells or whether a dysfunction 
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existed that might lead to an understanding of increased androgen synthesis seen 
within PCOS ovarian theca cells . 
. 
Clinical studies by Barnes et al., (1989) and Erickson et al., (1985) suggested that the 
key to dysregulation is related to the steroidogenic enzyme CYP 17, and with results 
from Munir et al., (2004) showing that expression of CYPl7 is increased following 
augmentation of insulin and LH in non-PCOS thecal cultures [42, 45, 134, 340], 
further examination using cultures prepared from the theca of PCOS women is 
warranted. 
In addition to these studies Gilling-Smith et al., (1994) examined androstenedione 
secretion under varied LH treatments within non-PCOS and pcas theca cells and 
found significant increases did exist between basal and LH-treated pcas cells [91]. A 
combined effect is yet to be examined in PCOS cells with regard to effects on 
androstenedione secretion but all these results point to variations existing within the 
PCOS thecal cell steroidogenic pathway. More specifically research by Munir et al., 
(2004) found that inhibition of the PI3-K pathway but not MAPK, showed insulin-
forskolin driven CYP17 expression was decreased in non-PCaS theca cultures [45]. 
This suggests a focal point for examination within the insulin-signalling pathway 
where dysfunction may lie in PCOS theca cells. 
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7.2 Objectives 
I. To culture primary human theca cells capable of survival through passage 
for later use in expression studies. 
ii. To examine the expression of steroidogenic enzymes including CYP17 in 
non-PCOS and peos theca cells 
iii. To examine the influence of hormonal treatments including LH and insulin, 
on CYPI7 expression within non-PCOS and PCOS theca cell cultures. 
iv. To examine the influence of LH and insulin on androstenedione secretion 
by non-PCOS and PCOS theca cells. 
7.3 Methods 
Ovarian specimens were collected based on specific patient criteria and following 
informed, written consent (see 3.1). Only small antral follicles <5mm in diameter 
were used for the study. Such individual follicles were hemisected. The theca intema, 
observed were micro-dissected with sharp forceps and enzymatically dispersed used 
to prepare for cell culture based on published methods Munir et 01., (2004) Mcallister 
et al., (1994) Gilling Smith et 01., (1997) and described within section 3.2.3. The 
isolated theca cells were then grown to confluence and passaged as required. Theca 
cell cultures were then incubated for 3-days in the absence of any additions or in the 
presence of insulin, LH, insulin + LH, insulin + PI3-kinase inhibitor (L Y294002) or 
insulin + LH + PI3-kinase inhibitor for the aims slated above (see 3.3). Hormone and 
drug concentrations for the aforementioned were determined based on findings by 
Gilling-Smith et al., 1994, Munir et al., 2004, and Zhang 2000 who showed optimal 
ranges for activation and stimulation [45, 70, 192, 221]. All conditions used were 
shown to be supportive of the primary cultures and checked using proliferation assay, 
which also allowed examination of hormonal influence on proliferation. Protein 
expressions of CYPI7, phospho-PKB and levels of androstenedione (see Chapter 8) 
were then compared between treated and untreated cells using western blotting, 
immunofluorescence and ELISA allowing us to examine the role of the insulin 
signalling pathway and its involvement in androgen synthesis within theca. Data were 
analysed as described in section 3.0. 
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7.4 Results 
704.1 Cbaracte ..... tloD of DOD-PCOS aDd PCOS human theca ceDs in primary 
culture 
It is well documented that primary human thecal cultures are difficult to establish and 
maintain in a differentiated functional state capable of steroidogenic activity [350-
352]. This is thought to be due specific environmentallhormonal requirements 
difficult to pinpoint and reproduce in vitro and often requiring high serum 
supplementation that can affect treatment experiments. Even more difficulties are 
apparent in isolation of the specific theca cell types due to their location embedded 
deep within ovarian tissue and existing in close association with granulosa cells, 
typically functioning as a two-cell model. 
Methods for theca cell isolation have been developed utilising intricate dissection 
protocols, which unfortunately yield limited cell numbers with reduced proliferative 
and metabolic ability [350]. During this project, in initial experiments and with a 
limited number of ovarian biopsies, it proved extremely difficult to perfect a suitable 
dissection technique and subsequent culturing protocol capable of sustaining a viable 
thecal primary culture. Using bovine ovaries kindly supplied by Dr Sinclair (School 
of Veterinary Medicine and Science, Sutton Bonnington, The University of 
Nottingham), we were able to hone the technique necessary to dissect individual 
follicles, and also experiment with the necessary media required to sustain the 
cultures (see 3.2.3). Although the bovine tissue varied significantly, particularly in the 
size of the follicles, we were able to transfer the technique to human cells and 
successfully maintain primary cultures to a passage of 7 -8. With such difficulties with 
the protocol and reported frequency of granulosa contamination [350] it was 
necessary to .carefully characterize the theca cultures. This was achieved by firstly 
examining theca cultures using immunofluorescence. 
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Figure 112. (A) Human theca cells po itive control howin HR e pre i n. I lated theca cell 
were probed with anti-LHR and FITC conjugated econdary antibody through Immunonu re 
Fluorescence repre entative of LHR locali ed to the membrane. ( 8 ) Immunofluores en e ill 
control for human theca cells howing p-Actin expres ion. 
Figure 113. (A) Human theca cell at Da 5 pa age 2, e n und r bright Ii Id, ho\\ d elong t d 
theca cell morphology. (8 ) Human theca cell howing PI 7 ex pr ion . I latcd the a ell wer 
probed with anti-CYP 17 and FITC conjugated econdary antibody. Fluore cence \\ al 0 cen ithin 
the cytoplasm howing CYP 17 with trong peri-nuclear locali ation . 
Theca cell culture were grown to around 30-40% confluence to allow indi idual cell 
morphology to be seen (Figure 113). (A) Examination of the bright pha e Image 
show the elongated shape a previou ly reported for theca cell in vitro [ 5 ]. 
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Figure 114. Chine e Ham ter Ovarian cell howing CYP 17 expression. Immunofluorescence of 
Chine e ham ter ovary (CHO) cell howing CYPI7 expression shows strong peri-nuclear 
fluorescence . CHO cell were u ed a a po itive control for CYP17. egative control also shown with 
no fluore 'cence cen. 
From Figure 113 we can ee fluorescence representative of CYP 17 expressIon 
localized to the cytopla m. Peri-nuclear staining was also observed, suggestive of 
CYP 17 synthe is. Although examination for CYP 17 expression is a suitable marker 
for determination of theca cells [45] we decided to include further controls to fully 
support the primary cultures. 
Luteini ing hormone receptor antibody (LHR), which is shown to exist in theca cells 
(see Figure 112) but not present in granulosa [354], allowed fluorescence to be seen 
with in the cultures examined. Localisation was also seen within the cell membrane as 
reported with the presence of LHR [311]. Additional positive controls tested the 
protocol and CYP 17 antibody. Figure 114 shows Chinese hamster ovary cells eCHO), 
which have been shown to express CYPI7. The e were used as an alternate cell line 
and grown alongside the theca cells a a positive control [192, 279]. ~ - a c t i n n antibody 
was also used on all cultures examined to support the protocol. 
egative controls were used on all cultures and kept to the same exposure. Results 
showed lack of fluorescence (see 3.5 and Figure 114). Leukocyte cultures as used by 
Wang et al., (2005) ( ee 3.5) with no recorded presence of CYPl7 expression or 
steroidogenic activity were cultured and probed with CYP17 antibodies [280]. Using 
secondary antibody alone and omitting the primary was also used to rule out non-
specific binding. Finally cultured cells were grown and examined for CYP 17 
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expressIOn. No fluorescence was seen under examination showing no CYP 17 
presence. 
In order to further support characterisation of theca cells and compare morphology of 
non-PCOS and pcas cultures, both non-POCS (n=6) and PCOS (n=3) primary 
human theca cultures were stained with oil red 0 ( ee 3.2.2.1) for lipid droplet 
accumulation. When compared the non-PCaS cells, pcas cells were ob erved to 
have greater numbers of lipids within the cytoplasm and large accumulation were 
found to clump in areas Figure 115 (B). 
Figure lIS. Human theca culture showing lipid droplet taining. () on-PCO theca cu lt ure 
(n=6) were grown for 2 1 days and stained with oil red 0 to examine lipid droplet content ( I ). (8 ) 
PCOS human theca stained with oil red O. PC OS theca cell cu lture ( n ~ 3 ) ) were grown along ide non-
PCOS cells and stained with oil red 0 content to compare lip id droplet fo rmation. (2) how large lipid 
droplet accumulati on and ba ed on observa tions, a grea ter number of lipid drop let seemed pre ent in 
PCO theca ce ll s over thi s period. 
Following the determination of the theca cell pre ence and i olation (Figure 113 
Figure 115) the steroidogenic pathway was examined. We focused on CYP 17 due to 
it involvement in androgen synthesis through in ulin signalling. Primary human non-
PCOS (n=3) and PCOS (n=2) culture were examined u ing immunofluore cence to 
determine whether any uggestion of variations exi ted in CYP 17 expre ion between 
groups and therefore warrant further examination. Exposure time was reduced to 0.3 
in both cell types due to the increased fluorescence een in the PCO cell . P a 
cells were observed to have increased fluore cence when compared to non-P a 
cells. This was suggestive of increased CYP 17 expre sion and although thi re ult 
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was not sufficient as a stand-alone quantitation, it allowed information supportive of 
further study using a more conclusive method of examination. 
Figure 116. (A) Non-PCDS human theca immunofluorescence showing CYPI7. Non-PCOS 
cultures (n=6) were probed for CYP 17 expression using immunofluorescence and compared to PCOS 
thecal culture (8) (n=3). Exposure was kept to 0.3 seconds with fluorescence seen to be greater in 
PCOS cultures. 
Western blotting was undertaken to confirm findings of CYP 17 expression in lysates 
prepared from theca cultures of non-PCOS and PCOS. These were examined for 
CYP 17 expression (n=4 vs. n=4) and protein bands ~ 5 7 7 kDa in size were observed in 
both groups. This was suggestive of CYP 17 presence based on the predicted size of 
CYP17. Results seen in Figure 117 and Figure 118 show increased band intensity 
within the PCOS lysates when probed with CYP 17 antibody but not within the non-
PCOS group suggestive of increased expression. Quantification against ~ - A c t i n n
controls allowed for statistical analysis. Results showed a significant increase in 
PCOS band exposure against non-PCOS (seeFigure 118). Western blotting was also 
used to examine non-PCOS and PCOS tissue homogenates. Unfortunately 
examination was limited to one sample due to availability (not shown). Optimisation 
required use of the majority of the PCOS theca lysate and we were unable to repeat 
this experiment to achieve a result suitable for quantification. 
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Figure 117. (A) Western blot anal i of YP 17 e pre ion in human th ca c lis fr m non- P a 
and PCO Iyate (lane 3-4). on-P as (n=4) and P a culture n- ) were e amined for YPI7 
expression. An immuno-reactive band was een at 57kDa, in all lane including the H po iti 
control (lane 4) indicating CY P 17 expre sion in the e cell. ariation in band inten Ity wa cen with 
peas showing result ugge tive of greater expre ion in YP17. p- ctin w u ed a 
loading/positive control. 
CYP1756kDa 
Non-PCOS 
• PCOS 
Non-PCOS vs PCOS Theca 
Figure J 18. ummari ing the d en itometry repre entati e of a er age expre ion of YPI7 in 
non-PCO liS. PC O theca lysate. sing p-Aclin nonnali alion to compare level of band inlen ity 
in western blot, CY P 17 expre ion a shown in Figure 11 7 den itomelry graph were created. Re ults 
howed ignificanl difference were een in expre ion of YPI7 in P 0 theca Iy te ("P<O.OI 
howing means / ± SEM) using unpaired I - Iesl talistical examination. 
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7.4.2 Proliferation in non-PCOS and PCOS theca 
With difficulties surrounding establishing and maintaining primary human theca cell 
cultures it was necessary to ensure our conditions were suitable for proliferation. A 
growth curve of cells was first established in both non-peaS and peas cultures. 
This allowed us to support the stability of our primary cultures. MTS assays were 
used to colourmetrically assess proliferation and cell viability (see 3.4). Although 
examination of theca cell proliferation from non-peaS and peas subjects showed an 
increased trend in peas theca cell proliferation, sample numbers were not sufficient 
for statistical significant. 
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Figure 119. Non-PeOS and peos theca cell proliferation. Non-PeOS and peos cell cultures 
(N=3 vs. 2) were grown for 5 days and proliferation examined using MTS assay. Results are mean ± 
SEM. Proliferation was seen with no significance between non-peOS and peos cells. However a 
trend toward increased peos theca proliferation would support further examination through increased 
sample size. 
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7.4.3 The influence of insulin and LH on CYP17 expre ion in non-P 0 and 
peos theca ceUs 
Thecal cell cultures were processed into primary culture from biop ie taken from 
non-PCOS and PCOS patients and cultured to pas age 3 to increa e cellular yi Id 
(n=3) (see 3.2.3). Cultures were then treated with arying in ulin treatm nt 0-100 
ng/ml) for 3 days. The cells were then lysed and protein e tracted for u e in we tern 
blot analy i . CYP 17 antibody (I :50 Abgent AP7 79c) wa u ed to probe blot and 
comparisons of non-PCOS and PCO CYP 17 expre ion made. 
MWM 
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75 
57 
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Non-PeDS IPeDS 
1 2 
o InlUlln 
on-PeDS IpeDS on-PeDS I PeDS 
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Insulin Insulin 
figure 120. Western blot anal si of YPI7 expre ion in non-P 
on· PeDS IPeDS 
7 8 
lOOng/ ml 
Ins ul in 
and P hum n theca 
cells under varied insulin treatment. Human theca cu lture (n=3) were lreated to an cd in ulin 
do es (O- IOOng/ml) and harve tcd fo r we tern blot analy I . Y P 17 anti body pr bmg howed n 
variation occu rred under varied treatment in non-PCO or P group . 
Figure 120 hows an increase in YP 17 expre ion wa een between n n-P and 
PCOS groups throughout all treatment. Figure 120 al 0 howed that although in ulin 
treatment wa een to show slight increa e in expre ion between untreated and 
treated, no variation wa hown with increa e in in ulin treatmen in either group. 
Stati tical analy is supported this ob ervation and ignificant increa e were een in 
expre ion of CYP 17 between P 0 and non-P 0 theca Iy ate throughout all 
insulin treatments (*P<0.051**P<0.0 I). However no ignificant difference wer n 
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across the insulin treatments range in CYP17 expression within non-PCaS and pcas 
groups see Figure 121. 
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Figure 121. Summarising the densitometry representative of average expression of CYP17 in 
non-PCOS vs. PC OS theca Iysates under varying insulin treatments. Using IJ-Actin normalisation 
to compare levels of band intensity in western blot CYPI7 expression as shown in Figure 120 
densitometry graphs were created. Results showed significant increases were seen in expression of 
CYP 17 in PC OS theca Iysates throughout all insulin treatments (*P<O.OS/**P<O.OI showing means / ± 
SEM) examined using oneway ANOV A. No significant differences were seen across the insulin 
treatments range in CYP 17 expression within non-PCOS and PCOS groups. 
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~ ~ -Act in 
Figure 122_ We tern blot analy i of YPI7 e pre i n in non-P human th a 
cells under aried in ulin and LH treatment _ Human theca culture (n=3) were trea ted to \ an ed 
in ulin do es (0- 100 nglml ) with and without LH (l Onglml) and harv ted for we tern blot anal i _ 
Cyp 17 antibody probing howed va riation occurred wi th increa ed YP 17 e pre I n een \\ IIh th 
increase in in ulin and the addition of LH treatment . 
Following examination of the effect of in ulin treatment alone had on non-P a and 
PCOS groups, I examined tbe effect u ing the arne in ulin range with the addition of 
LH ( IOng/m t) as recommended by Gil1ing- mith el al. . 1994) to al10w for the 
optimum re pon e when examined a an individual treatment in thecal cultur [221]. 
Western blot wa u ed to determine CYP17 expre ion . imilarly to in ulin 
treatments alone, increased CYP 17 expre ion was een between n n-P and 
PCOS group throughout all treatment and upported tati tically when e amin d 
against p-Actin normalization (* P<O.05). Furthermore, YP 17 e pre i n wa al 
een to increa e in both non-PCO and PCO with the addition of LH tr atm nt, \! ith 
the large t expre ion een following IOOnglml in ulin + IOnglml LH in b th group 
Figure 122. See 3.0 for further details. 
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Figure 123. Western blot analysis of CYPI7 expression in non-PCOS and PCOS human theca 
cells under varied insulin and LH treatments. Using p-Actin normalisation to compare levels of 
band intensity in western blot, CYP 17 expression as shown in Figure 122 densitometry graphs were 
created. Results showed significant increases were seen in expression of CYP 17 in PCOS theca Iysates 
throughout all insulin treatments and LH treatments (Sig not shown *P<0.05). Significance was also 
seen within non-PCaS and pcas groups with increases in insulin treatment (Sig not shown *P<0.05) 
with the largest increa e seen from 10-\ 00 nglml insulin + 10ng/mi LH (***P<O.OO I means I ± SEM) 
as shown here following oneway ANOY A analysis. 
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Figu r e 124. Western blot ana lysi ofCYP I7 expre ion in P hum nth c cell und r in ulio 
and PI3-K in hibition. Human PCO theca culture (n=2) were timulated u ing IOng/ml in ulin (Ian 
I) with and without the addition of the PI3-K inhibitor L Y294002 and e amined for YP 17 e pre 1 n 
u ing we tern blot technique . Re ult howed that inhibition of PI3-K howed noticeable d cre e in 
CYP 17 expression when compared to insulin alone. 
Using the we tern blot technique we began to examine the in olvement of th PI3-K 
pathway through activation using insulin treatment a hown by Munir e/ al.. (20 
and the level of CYP 17 expre sion [45]. Inhibition of the PI3-K pathway \i a 
achieved through incubation of the theca culture with L Y24002 ( ee 3.3). Thi wa 
followed by the addition of in ulin treatment known to timulate the PI3-K pathway 
[45]. Ly ales were created from the culture (n=2) and e ami ned for YP 17 
expre sion. Figure 124 how no variation in CYP 17 expre ion to the applicati n of 
either 0 or on using L Y294002 inhibitor alone. A combination of in ulin and PI -K 
inhibitor however sugge ted reduction in YP 17 expre ion . Further re uIt ar 
required to substantiate thi . 
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7.4.4 Effects of insulin on non-PC OS and PCOS Theca androstenedione 
secretion 
Studies into human ovarian steroidogenesis have typically been limited to ovarian 
slices however Hillier et al., (1991) were one of the first groups to establish 
monolayer theca cultures in serum free media [355]. From this they were able to 
examine the effects of activin A on androgen inhibition. This method was also used 
by Gilling-Smith el al., (1994) in the examination of hyper secretion of 
androstenedione by PeOS theca cells [91]. They were able to examine the effects of 
LH treatment and showed increases over basal androstenedione secretion [91]. With 
the hypothesis that augmented insulin and LH leads to even greater increase in 
androstenedione secretion both physiologically and in vitro, and the understanding 
that hyper secretion of these hormones occurs within PCOS patients we examined the 
effects of LH and insulin treatments. This was done within a serum free monolayer 
theca culture processed from biopsies taken from non-PCOS and peos patients (see 
3.3.2). 
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Figure 12!. Standard eurve showing ELISA androstenedione levels through measured 
absorbanet. Known levels of androstenedione were measured using ELISA technique and levels of 
absorbance @490 taken to delennine a standard curve. 
Using the androstenedione ELISA we measured known levels of androstenedione to 
create a standard curve. Unknown values were then interpolated to determine 
androstenedione levels in our samples, (see 3.7) see Figure 125. This also ensured 
that androstenedione levels measured in our cultures fell into the range capable of 
being read by our chosen ELISA (0.00 I 9nglml / 0.03pmol/IOOO cells). 
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Figure 126. (A) Androstenedione sec r etion from non-peO human theca under varied in ulin 
treatments. Human theca cells were cu ltured (n=9) and treated with varyi ng do e of in ulin (0-
IOOng/ml) for 3 days. Re ults are mean ± SEM. Media wa harve ted and mea ured for 
andros tenedione using ELISA technique. Results howed a mall but ignificant increa e in 
androstenedione secretion was observed following IOng/ml in ulin treatment (*P<0.05) wi th no further 
difference seen across treatment ranges. Data analysed u ing oneway OV (8) The addi tion of LH 
( IOng/ml ) to eac h insu lin treatment was seen to inc rea e andro tenedione presence . A ignificant 
increase in andros tenedione secretion was observed following LH treatment. In ulin treatment howed 
signifi cant increases in androstened ione ecreti on in a do e dependent manner when treated with a 
si ngle dose of LH (IOng/m l) (.u P<O.OOI) and IOOng/ml in ulin + LH (u·P<O.OOI). Data analy ed 
using oneway A OVA. 
Once established human theca cells from non-peOS and PCOS biop ies wer 
cultured to passage 3 to increase cell yield, lOx I 04 cells were then plated in erum 
free media and treated with varying doses of insulin (O- IOOng/ml with and without 
LH (IOng/ml) for 3 days. Within 24 hours the cells had adhered and formed colonie 
and by 48 hours they showed cell morphology in accordance to publi hed rc ult with 
elongated spindle haped appearance [350]. Thi wa een throughout all treatment. 
After 72 hours media was harvested and examined for andro tenedione u ing ELI A 
technique (see 3.3). Examination of non-PCOS harvests (n=9) howed that a mall but 
significant increase in androstenedione secretion was ob erved following 10ng/ml 
insulin treatment (* P<O.05). However, IOOnglml in ulin treatment how no 
difference in androstenedione ecretion from ba al (Figure 126). However th 
addition of 10ng/ml LH to each insulin treatment showed ignificant increa e with a 
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1.8 fold increase over the basal level with LH alone (median basal 1.3pmolll 000 cells, 
o insulin +LH=2.4pmolllOOO cells), a 3-fold increase seen with the addition of 
10ng/ml insulin +LH over the basal, and 4.3-fold increase over the basal with 
100ng/mt insulin +LH (Table 8.). 
10ng/m Insulin 100ng/ml 
o Insulin o Insulin + LH +LH Insulin +LH Intra 
Minimum 0.48 1.08 1.67 2.16 5.48 
25% 
Percentile 0.71 1.37 3.10 5.01 5.48 
Median 1.31 2.40 4.00 5.71 6.50 
75% 
Percentile 1.70 2.79 5.55 6.33 6.71 
Maximum 1.78 3.70 6.08 7.50 6.71 
Mean 1.22 2.28 4.14 5.49 6.23 
Std. 
Deviation 0.48 0.87 1.46 1.55 0.65 
Std. Error 0.17 0.30 0.51 0.55 0.37 
Table 8. Table of variation in androstenedione across insulin and LH treatments in non-PeDS 
theca cells. Androstenedione secretion was examined under insulin +/- LH treatments. Statistics 
showed 1.8 fold increase over the basal level with LH alone; a 3 fold increase seen with the addition of 
10ng/ml insulin +LH over the basal; and 4.3 fold increase over the basal 100ng/ml insulin +LH. 
Further comparison of insulin treatments against insulin and LH, within non-peOS 
Figure 127 showed significant increases in androstenedione under insulin and LH 
treatments, across all groups with the largest increases seen in 100ng/ml and LH and 
showing a positive correlation with increased insulin. These results suggest that 
insulin and LH act to augment and increase androstenedione secretion in human theca 
cells and that this effect is not present with insulin alone. It also shows that LH alone 
also has a positive effect on androstenedione secretion. 
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Insulin Treatments (nglml) 
• With LH 
Without LH 
Figure 127. Com pari on of andro tenedione secretion in non-PCO human theca follo\ ing 3 da 
treatments with varying insulin +/-LH. Human theca media harve t (n=9) were taken followi ng 
day treatments wi th varying insulin (O-IOOnglml) +/- LH (I Onglml). Results are mean ± EM. 
Compa ri son of insu lin treatments wi th and w ithout LH howed s ignificant increa es in andro tenedione 
in all insulin treatments w ith the addi ti on of LH. A dose dependent increa e was een with increa ed 
in ulin treatments in all LH groups (0 in ulin +LH " P<O.O I) (10-100 nglm l in ulin +LH "·P<O.OOI). 
Data ana ly cd usi ng oneway A OVA following bonferrolli post-hoc test. 
Figure 128 showed no variation in androstenedione under varied insulin treatment 
within PCOS theea media harvests. However compari on of non-PCO with P 0 
(Figure 130 (A» showed significant variation in ba al levels (***P<O.OO 1) 
suggesting increased androstenedione over non-peOS ecretion by P 0 theca 
without any hormonal influence. 
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Figure ]28. (A) Androstenedione secretion from peos human theca under varied insulin 
treatments. Human theca cells were cultured (n=4) and treated with varying doses of insulin (0-
100nglml) for 3 days. Media was harvested and measured for androstenedione using ELISA technique. 
Results are mean ± SEM. Results showed androstenedione was present with no significant variation 
occurring across treatment ranges. (8) The addition of LH (lOng/ml) to each insulin treatment was seen 
to increase androstenedione levels. A significant increase in androstenedione secretion was observed 
following LI I treatment. Insulin treatment showed significant increases in androstenedione secretion in 
a dose dependent manner when treated with a single dose of LH (lOng/ml) (***P<O.OO I) and 100ng/ml 
insulin +LH (***P<O.OO I). Data analysed using one way ANOV A following bonferroni post-hoc test. 
10ng/m Insulin 100ng/ml 
o Insulin o Insulin + lH +lH Insulin +lH Intra 
Minimum 5.07 63.00 80.40 104.00 6.25 
25% 
Percentile 5.37 64.00 80.75 105.00 6.25 
Median 6.51 69.85 82.65 109.00 6.39 
75% 
Percentile 6.82 77.95 93.63 110.00 6.53 
Maximum 6.85 79.7 97.00 110.00 6.53 
Mean 6.23 70.6 85.68 108.00 6.39 
Std. 
Deviation 0.81 7.256 7.65 2.82 0.19 
Std. Error 0.40 3.628 3.82 1.41 0.14 
Table 9. Table of variation in androstenedione across insulin and LH treatments in peos theca 
cells. Androstenedione secretion was examined under insulin +/- LH treatments . Statistics showed 10 
fold increase over the basal level with LH alone; a 12.6 fold increase seen with the addition of 10ng/ml 
insulin + LH over the basal ; and 16. 1 fold increase over the basal 100ng/ml insulin +LH. 
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Significant rises were also seen between insulin treatment groups without LH and 
insulin with LH (Figure 129) with further rise seen with increase in in ulin+LH in 
all pcas cultures. 
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Figure 129. Comparison of and rostenedione secretion in PCO human theca following 3 da 
treatments with varying insulin +/-LH. Human theca media harvest (n- ) were taken following 3 
day treatments with varying insulin (O-IOOnglml) +/- LH (IOnglm l) . Re ults are mean ± EM. 
Com pari on of insulin treatments with and wit hou t LH showed significant increa es in androstenedione 
in all insulin treatments with the addition of LH. Positive correlation wa een in increa ed insulin 
treatments in all LH groups (0 in ulin +LH ***P<O.OOI) (10-100 nglml in ulin + LH ***P<O.OOI). 
Data ana lysed using oneway A OVA following bonferroni post-hoc test. 
Furthermore the addition of LH to increasing insulin treatments had large effect on 
the androstenedione levels measured with levels increasing - tenfold from 
6.5pmo1l1000 cells ba al to 69.8pmolll000cells with the addition of LH (IOng/ml). 
Increasing the insulin treatment with the addition ofLH showed further increase with 
a l2 .6-fold increase een with 10nglmi insulin and a 16.I-fold increa e een in 
IOOng/ml insulin (Table 9). Compari on of non-peaS with pcas androstenedione 
levels under insulin treatment with the addition of LH showed ignificant increa e 10 
androstenedione within groups shown in Figure 130 B (***P<O.OO I). 
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B 
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Figure 130. (A) Androstenedione secretion under varying insulin treatments from non-peOS and 
peos human theca cultures. Following 3 day varied insulin treatments of non-peOS (n=9) and 
peos (n=4) theca cultures androstenedione levels were measured in media. Results are mean J: SEM. 
Significant variation in androstenedione secretion was seen with insulin treatments between non-peOS 
and peos levels (***P<O.OOI). (8) Androstenedione levels were also measured from cultures treated 
with varying insulin with the addition of LH (IOng/mt). A significant increase in androstenedione 
secretion was seen in a dose dependent manner when treated with a single dose of LH (I Ong/ml) within 
all treatment groups between non-peOS and peos (***P<O.OO I). Data analysed using oneway 
ANOV A following bonferroni post-hoc test. 
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7.5 Discussion 
7.5.1 Culture and charaderisation of theca cells from non-PCOS and PCOS 
women 
Thecal steroidogenesis works in conjunction with granulosa cells within ovarian 
tissue as a two-cell model whereby theca steroid synthesis creates precursors which 
are transported, trans-membranously for further processing within granulosa cells (see 
1.4.1) [356]. The morphology of the follicle tissue is such that separation and isolation 
of theca cells is notoriously difficult [350] due to size of the follicle, the availability, 
the tight association to surrounding tissue and the fragility of the tissue itself. In order 
to establish primary theca cultures and characterise them fully, it was necessary to 
thoroughly control for granulosa contamination. Any co-culturing would later affect 
levels of hormone secretion and subsequent enzyme activity and expression. CVPl7 
is involved in the androstenedione pathway not present in granulosa cells [9, 20]. This 
is also true of the LH receptor, which is present in theca cell regulation and 
metabolism [357]. Immunofluorescence results showed positive findings of both these 
markers supporting theca cell phenotype. This was also seen in the western blot 
results with CYPl7 presence seen in both non-PCOS and PC OS lysates. Separate 
culturing of granulosa cells allowed validation of the protocol and controls and 
showed no CYP17 or LHR presence (data not shown). 
Other characteristic markers of theca cells further supported the establishment of a 
predominantly theca culture. The elongated cellular morphology and presence of 
lipids in both cultures further supported the existence of isolated theca cells [350, 358]. 
Theca cells contain structural features including plentiful mitochondria comprising 
vesicular cristae, as well as cytoplasmic granular endoplasmic reticulum, and lipid 
vesicles as shown by Magoffin (2005) [359]. The presence of lipid vesicles allowed 
us to examine lipid droplet accumulation through oil red 0 staining as well as 
examining variations that may exist between non-PCOS and PCOS cultures. With the 
hypothesis that PCOS thecal cells may contain a dysfunction associated with 
increased steroid synthesis [360], analysis of lipid droplet accumulation was of 
interest as they may give evidence for increased hormonal synthesis in PCOS theca 
and it has been reported that the lipid droplets are used as cellular storage containing 
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the precursors required for steroidogenesis [358]. Althougb not quantified the 
observations showing increased numbers of lipid droplets in our pcas results when 
compared with non-PCOS cultures, may therefore be explained through the increased 
demand for steroid synthesis in pcas cells. This is supported by research by Convery 
and Brewer (2005) who examined thecal rat cells and found increased large and 
clumped lipid cells in experimentally induced PCO rats [154]. Although this 
observation is made in human cells, the similar occurrence gives further evidence to a 
possible variation in PeOS and rat models are becoming more frequently used to 
examine the condition as they exhibit both the metabolic and morphological 
characteristics of human pcas [361]. Although this is an excellent model for 
experimentation, physiological variations in human and rat samples emphasise the 
importance of results taken from working with human samples. It should also be 
noted that although reduced, granulosa have been reported to exhibit lipid like 
granular components and this characterization alone would not be enough to support 
identification of theca cells but was intended more as a comparative examination 
across groups. This method was also not quantifiable and purely observational. We 
could a d a ~ t t this method through removal of the oil red 0 stain and measurement of 
absorbance. Comparison against controls could show variations in stain indicating 
variation in lipid content. Alternatively, measurement with quantitative reverse 
transcription-PCR analysis of lipid metabolism-related genes. such as carnitine 
palmitoyltransferase (CPT) I, fatty acid binding protein, pyruvate dehydrogenase 
kinase-4, and NADP-dependent cytosolic malic enzyme, would allow a more in depth 
analysis as described by Kondo et 01.. (2005) [362]. 
PCOS has been associated with thecal hyperplasia and ovarian enlargement both of 
which have been hypothesised to be linked with increased androgen synthesis [266, 
363]. Our results, although showing a trend to increased proliferation within PCOS 
theca, showed no significance between groups. This may be attributed to limited 
sample groups. However Givens (1984) examined PCOS patients with associated 
ovarian follicular cysts that showed no signs of theca hyperplasia [364]. Further 
examinations into the area suggested classification was necessary with type IV PCOS 
showing reduced follicular cysts but with noticeable hyperplasia and 'hyperthecoesis' 
[364, 365]. This would later support the Rotterdam classification of PCOS (Rotterdam, 
2(04) where endocrinological features were noted in the absence of morphological 
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features of PCOS. Limitations in sample collection may explain variations seen within 
our results. This may go someway to explain why our findings go against existing 
data that suggests thecal hyperplasia in PCOS [102, 366]. The results do however 
show that the growth environment was suitable for proliferation. 
7.S.2 Tbe influence of insulin and LH on CYP17 expression in non-PCOS and 
PCOS tbeca ceOs 
Research has shown that insulin acting through ovarian receptors and in combination 
with LH, allows stimulation of androgen synthesis [42, 161]. This supports the 
hypothesis that symptomatic hyperinsulinemia and hyper LH secretion in PCOS plays 
an important role in the aetiology of ovarian linked hyperandrogenism. Further 
experiments have examined the use of metformin and troglitazone, which are used as 
insulin sensitizing agents. La Marea et al .. (2000) showed that metformin treatment 
reduced stimulated ovarian CYP 17 activity in hyperinsulinemic PCOS women [367]. 
suggesting that insulin resistance found in PCOS patients may play a key role in 
hyperandrogenism. If this were to be considered true, further study into the exact 
defect within the insulin signalling pathway would require careful examination. 
Studies have also shown that no variations exist in the function or expression of IRS-
112 associated PI3-K in PCOS fibroblasts or adipocytes when compared to non-PCOS. 
it is therefore believed that alterations in signal regulation exist downstream of these 
proteins [368, 369]. Our examination concentrated on the insulin stimulated PI3-K 
pathway and our results support the treatment ranges as published by Munir et al., 
(2004) with IOng/ml insulin stimulating the pathway through its activation of IRS-l 
and that the resultant effects of the specific inhibitor L Y294002 [45], were seen to be 
effective in reducing the response. This result also supports the involvement of the 
PI3-K pathway. It was intended to further investigate this pathway by examining PKB 
phosphorylation associated with PI3-K activation. Although we carried out initial 
western blot probing for PKB and phosphorylated-PKB in all the Iysates examined for 
CYP 17 we were unable to support the finding with sufficient repetition. Our results 
from examining the inhibition of the PI3-K pathway in theca cells did however 
suggest a subsequent reduction in CYPI7 expression. Further work would be required 
in order to found these results that included more repeats and PKB examination. 
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Our results show that insulin treatment alone did not increase CYP 17 expression. This 
finding supports previous studies into thecal steroidogenic activity that show the same 
result [45). Furthermore, our examination into PCOS cultures shows this to be true in 
PCOS theca cells in vitro and western blot results, showed increased band intensity 
within the PCOS group suggestive of increased CYP17 expression within these cells. 
In conclusion our results suggest that although there is no dysfunction within the 
effect of insulin on non-PCOS and PCOS theca cells on CYP 17 expression, increased 
CYPl7 expression exist within PCOS theca independently. 
The co-stimulatory effect of LH and insulin on CYPI7 expression shown in our 
results gives evidence to support that co-activation of the androgen synthesis pathway 
is required through both insulin and LH. Furthermore our results show CYP 17 is 
reduced in comparison, within individual insulin or LH treatments. Munir postulated 
that this stimulation is different to that seen in glucose uptake, as it requires insulin 
alone. Insulin thecal androgen regulation through alternate intracellular mechanisms 
to that of glucose, seems feasible. This is therefore supported by the requirement of 
co-activation of the PI3-K and cAMP pathway [45]. If this is the case and with our 
results showing LH+Insulin increases in CYPl7 expression in non-PCOS and PCOS 
theca cells, then a possible pathway divergence may exists downstream to PI3-K that 
would regulates androgen synthesis through insulin activation independently of 
glucose metabolism. 
7.5.3 The inftuence of insulin and LH on androstenedione secretion in non-PCOS 
and PCOS theca ceDs 
The objective was to determine the effects of insulin and LH both individually and 
combined, on androstenedione secretion in cultured theca cells. This was to be 
examined in both non-PCOS and PCOS cultures to allow comparison and to 
determine if any variation existed that may be associated to symptomatic 
hyperandrogenemia. Due to the effects serum may have on steroidogenesis through 
insulin supplementation a similar serum free monolayer culture was established as 
used by Gilling-Smith et 01., (1991) [91). Examination of non-PCOS cells showed 
that insulin alone had no effect on androstenedione levels throughout the chosen 
treatment range (10-1 OOng/ml). Similar results were shown by Stewart et 01., (1995) 
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in examination of bovine theca cultures using identical treatment range and showing 
no variation in androstenedione secretion within cultures through radioimmunoassay 
techniques [161]. This has also been shown in rat interstitial theca cells when 
subjected to 100ng/ml insulin treatments leaving basal levels unaffected [162]. 
Magoffin and Weitsman (1994) have also shown this to be true for IGF-l with an 
inability to stimulate steroidogenesis through its lack of cAMP or protein kinase A 
production [370]. Some contradictory studies do exist such as Barbieri et al., (1984) 
who showed that examination of ovarian stroma of women with hyperandrogenemia 
showed androstenedione secretion when stimulated equally by an insulin treatment 
range 50-500ng/ml [156]. However these early studies can be criticised through use of 
direct tissue incubations that may lead to discrepancies from alternate cell 
contamination. These studies also used serum-supplemented media. Stewart et al., 
(1994) also noted that these studies failed to account for cell numbers following 
incubatory periods, which would also affect measured basal secretory levels [161]. 
Based on this we can support findings that show the stimulatory effect of insulin on 
androstenedione secretion in in vitro theca cells is unaltered through increased insulin 
treatment within the range 10-1 OOng/ml. 
Examination of insulin treatments across non-peOS and peos cultures does however 
show a marked increase in androstenedione levels suggestive of increased basal levels 
secretion in peos cells (***P<O.OOI). This has been shown previously by Gilling-
Smith et al., (1994) who reported non-peOS basal levels around 1.7pmolllOOO cells 
against basal peas androstenedione 32pmolllOOO cells [221]. Although this supports 
our findings the peos basal androstenedione levels reported in this study are higher 
than those found in our results [91, 128]. 
Interestingly our results show no variation between basal and insulin treated peas 
androstenedione secretion. Similar results were shown by Stewart et al., (1995) when 
examining bovine theca, it should be noted that an outlying value does exist within 
our data that prevents significance [161]. Although there are few studies specifically 
focused on peas thecal androgen synthesis under insulin treatment, research by 
Zhang et al., (2000) has shown that a treatment of 100ng/ml insulin showed a small 
increase over basal androstenedione secretion [371]. Furthermore Nestler et al., 
(1996) also reported insulin stimulation of testosterone synthesis in peas theca 
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cultures [157]. Furthennore it has been shown that CYP17 is reduced in pcas 
women following reduced insulin secretion [372]. Our result may however, be 
suggestive of active steroidogenesis in PCOS theca that leads to increased androgen 
secretion regardless of insulin stimulation. Examination into the influence of insulin 
action has shown variation in responses within different target tissues in samples 
taken from PCOS patients. These included fibroblasts, skeletal muscle and adipocytes. 
Although these studies focused on the mechanism of insulin regulation, including 
binding sites and receptor response and showed a 30% reduction in adipocyte auto-
phosphorylation (Ciraldi, 1992). This may suggest that although stimulation is seen in 
non-PCaS theca cells, variation in pcas theca response exists similar to other target 
tissue variation. The paradox has always existed as to how insulin resistant women 
found in pcas have hyper responsive ovarian androgen synthesis as a result of 
compensatory increased hyperinsulinemia. With this in mind the answer maybe, this 
is not the case. Although the evidence fails to support this, it should not be completely 
ruled out and with the variations found and limited research into in vitro examination 
of pcas theca cells, further examination into the influence of insulin action alone on 
androgen synthesis would be of interest. It may also be that insulin requires co-
stimulation of androgen synthesis. This seems likely with the evidence of LH 
augmentation in both non-paCS and PCOS theca cells. 
Examination of LH stimulation of both non-PCOS and PCOS theca cells showed 
increased levels of androstenedione over both insulin stimulated and basal levels as 
found in similar studies in in vitro bovine and rat theca. This was found to be true in 
both non-PCaS and pcos groups. Further to this a significant increase was seen in 
the effect ofLH treatment on androstenedione in comparison of non-PC as and PCOS 
groups. This result was seen in research by Gilling-Smith et ai., (1995) and although 
they detennined an even greater response to LH by PCOS in androstenedione 
secretion, this may be accounted for through their examination of follicle size where 
they found that theca cells derived from follicles <10mm produced significantly less 
androstenedione than those taken from follicles> 10mm [221]. 
Our research went a stage further from published data in an attempt to examine 
augmented LH and insulin response in PCOS thecal cultures. Examination into this 
effect has been shown by Nahum et al., (1995) in non-PCaS theca in vitro using a 
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similar serum free monolayer system to establish the cultures [222]. They found that 
with the addition of IOnglml LH to similar insulin treatments, androstenedione was 
increased 2-3 fold by cultured theca. Similarly to our findings in non-PeOS cultures 
the augmented effect of LH and insulin was significantly increased over basal and LH 
stimulated androstenedione secretion. Non-PCOS secretion was seen to be increased 
4-fold with the addition of insulin and LH (10 and 10 ng/ml) and correlated with 
increases in insulin with lOOnglml insulin leading to a 8-fold increase in 
androstenedione secretion. These values were seen to be substantially increased in 
PCOS cultures, rising from basal levels of 6pmoV I 000 cells to 80-1 OOpmoV I 000 cells 
(IO/IOOnglml insulin). These effects not only support the augmentation of insulin 
+LH but also the increased sensitivity shown within PeOS theca. These levels also 
show a dramatic contribution to physiological androgen and emphasise the 
involvement in peos ovarian androgen synthesis in the condition. It should be noted 
however that variations may be present in vitro to those seen in vivo. 
In summary, our results show that foHowing examination of non-PCOS and pcas 
theca primary cultures, variations do exist. Whether this is within the direct 
physiology, specifically protein expression; or in the metabolic response of the cell to 
hormonal influences, the differences found have direct implications to peas. 
Furthermore the effects on the associated symptoms can be seen in the exaggeration 
of androgen secretion. 
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8.0 DISCUSSION 
Four main theories of pathophysiology have been proposed to explain the 
mechanisms that cause pcas. These are the ovarian, adrenal, metabolic and 
neuroendocrine hypotheses. Both the ovarian and adrenal hypotheses focus on 
dysfunction within these two organs resulting in increased androgen secretion [147, 
373-375]. The neuroendocrine hypothesis involves hyper secretion of basal LH, 
classically indicative of pcas, and acting as an associated agonist for increased 
androgen synthesis [376]. Finally, the human metabolic hypothesis indicates an 
association between insulin resistance and hyperandrogenism in women, mainly 
related to obesity and subsequent decreases in insulin sensitivity [185, 234, 377]. 
Most of the research into these areas has identified aspects of dysfunction that 
contribute to our understanding of pcas but no true primary cause for this syndrome 
has been found. 
The research presented in this thesis has attempted to incorporate aspects of these four 
theories with a view to bridge the hypotheses and direct future work. Whilst doing so 
it has remained focused on the importance of androgen excess as a key endocrine 
abnormality. 
Androgen excess is considered the key biochemical abnormality associated with 
pcas, usually manifesting during puberty [120, 353]. Research by Corbould et al., 
(2008) suggests hyperandrogenemia encourages the development of pcas as well as 
metabolic disturbances associated with PCDS. Corbould also hypothesizes that 
reduction of androgen levels may improve insulin sensitivity and showed that 
decreasing androgen levels or blockade of androgen action improved insulin 
sensitivity when examined through euglycemic hyperinsulinemic clamps [378]. 
Furthermore, administration of testosterone into female rats induced skeletal muscle 
insulin resistance supporting the associated influence androgen may have on 
decreasing insulin sensitivity [378]. This supports the belief that insulin resistance is a 
secondary presentation associated with pcas and although common, it is not found 
in all patients, with a study into a large pcas population by DeUgarte et al., (2005) 
estimating around 64% prevalence [379]. Similarly those showing insulin resistance 
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tend to acquire compensatory hyperinsulinemia. With this understanding it is believed 
that insulin resistance is not essential in the development of PCOS and that androgen 
dysregulation is intrinsically fundamental to the pathogenesis of PC OS [380-382]. 
The importance of androgen synthesis is seen throughout research into PCOS and 
ovarian biosynthesis and has been shown to account for around 50% of production in 
non-PCOS women, with these levels found to be significantly increased in PCOS 
women. Although the mechanism for this is not established, a variety of enzymes and 
signaling pathways have been examined. 17a-hydroxylase/17,20 lyase has been 
theorized to be involved as it plays a key role in androgen synthesis. This enzyme has 
been shown to respond positively to a co-stimulatory effect of insulin and LH 
(typically elevated in PCOS) within ovarian androgen biosynthesis [45, 91). 
Although adrenal and ovarian sources account for the majority of secreted androgen 
(specifically androstenedione), it has been shown that peripheral tissues such as 
epithelia and adipose [208, 284, 383-385] also contribute to steroid conversion. With 
obesity considered a condition associated with sex hormone imbalances [386] and 
with its occurrence in between 38-88% of pcas patients [387, 388], its association as 
a major contributory factor particularly to androgen excess and therefore warranting 
further investigation in our study. Although it is understood that androgen plays an 
important role in body fat distribution and also that androgen excess is linked to 
central obesity [19], it is uncertain whether obesity is implicated in the pathogenesis 
of PCOS. However, it is understood that obesity does aggravate androgen excess in 
pcas. Evidence also exists showing that levels of SHBG are found to be lower in 
women suffering from pcas. With an inverse relationship seen between plasma 
SHBG and abdominal obesity this maybe further indication of a relationship between 
obesity and PCOS [190, 389]. Furthermore research has shown that exogenous 
treatment with androgens in female to male transsexuals has shown evidence that 
androgens can lead to increased abdominal fat accumulation [390]. 
Thus evidence is consistent with obesity being a risk factor in the development of 
pcas pointing to a key role of adipose in PCOS. With the relatively recent discovery 
of adiposes ability to act as an endocrine organ through the discovery of leplin in 
1994 [225], examination into mechanisms of regulation and metabolic function are of 
clinical importance in metabolic disorders of endocrine dysfunction. This thesis 
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therefore has examined both metabolic function and regulation and suggests the 
importance adipocytes may have in both peas and non-peaS. This has allowed for 
both mapping of non-PeaS adipose function; and understanding of the mechanisms 
that may be involved in peas. We further supported these examinations through a 
comparative study of ovarian thecal steroidogenesis and their involvement in peas 
dysfunction under the same hormonal conditions typically found in peas patients. 
This was all achieved through in vitro examination of the two tissue types 
(ovarian/adipose) using primary cultures. 
The work described in this thesis attempted to examine: 
• Variations / dysfunction between non-PeaS and peDS adipocytes 
• An association between peDS adipocytes and hyperandrogenemia 
The central findings of this work are: 
• Adipocytes derived from non-PeDS and peDS women and maintained in 
vitro differ on the basis of their morphology, rates of differentiation and 
proliferative abilities (Chapter 4, 5). PCDS adipocytes were shown to have 
increased size, increased rates of proliferation and decreased rates of 
differentiation compared with those from non-PeDS women. 
• Demonstration of altered metabolic responses in adipocytes under conditions 
designed to mimic peDs in vitro. These responses included proliferation, 
protein expression and honnone secretion. Both non-peaS and peas 
adipocytes were seen to have reduced rates of LHR expression on LH 
treatment. Non-PeaS adipocytes showed reduced rates of proliferation not 
seen in peDS adipocytes under LH treatment. Non-Peas and peas 
adipocytes were seen to have increased LHR expression following incubation 
with insulin. Proliferation of peDS adipocytes was increased with insulin 
treatment compared with adipocytes from non-PeDS women. Interestingly, 
expression of CVPl7 in PCDS samples was increased following incubation at 
lower levels of insulin than that seen in non-PeDS adipocytes. 
• Secretion of progesterone and androstenedione from non-peDS and peDS 
adipocytes in vitro and their endocrine modulation. Non-PeDS adipocytes 
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were seen to have increased androstenedione secretion on insulin treatment. 
Whereas peos adipocytes remained unaffected by insulin stimulation and 
secreted constant levels of androstenedione similar to that seen by insulin 
stimulated non-peOS adipocytes. 
• The involvement of the cAMP pathway in mediating adipocyte hormone 
secretion in response to insulin and LH levels associated with peos, which 
requires further exploration (see 8.2) 
8.1 Comparing non-PCOS and PCOS adipocytes 
Investigation of adipocytes in vitro faces immediate limitations. As with vinually all 
culture-based studies, in vivo conditions can never be truly replicated. Following any 
length of culture, further adaptions by the cell type to its in vitro environment can 
occur making any results less representative of physiological conditions or response 
[391-393] 
With the limited ability of adipocytes to proliferate following maturation [223]. and 
due to the difficulty of culturing mature adipocytes directly from biopsy. it was 
necessary to culture preadipocytes then to differentiate them into viable cultures. The 
method of differentiation using a cocktail of dexamethasone. IBMX and insulin (see 
3.2.2) and as reported by others ([247, 253]), was found to produce lipid drople1 
formation in the adipocytes indicative of a mature phenotype. This enabled 
characterization of peos and non-peOS mature adipocytes and examination of 
morphology and behavior. The morphological changes of the cultures shOwed 
qualitatively, increased size due to lipid droplet formation within peos adipocytes. 
Furthermore examination of differentiation showed that PCOS preadipocytes matured 
at a slower rate than non-PeOS over a period of 4-6 weeks. Our investigation focused 
on subcutaneous abdominal biopsies as previous studies have shown a relationship 
exists between peDS and increased abdominal fat accumulation [380]. Secondary to 
this, reduced serum adiponectin and lower LPL activity has been seen in PeOS 
abdominal adipocyte biopsies and this may be indicative of metabolic disturbances 
specific to peDS [130, 232, 257]. These studies support the possibility of dysfunction 
in peas abdominal preadipocytes as was seen in our results through slower 
differentiation. Our results have shown slower differentiation and suggested increased 
194 
Chapter 8: Discussion 
lipid droplet size and although the size variation is qualitative data it is not the first 
documented occurrence of this fmding [232, 257]. I propose one possibility for these 
findings as a reduction in the ability of peas adipocytes to undergo lipolytic 
expansion as a result of accommodating excess energy intake by the individual and 
leading to alteration in the adipocytes metabolic processes. This could eventually 
result in serious health issues including type II diabetes, over production of hepatic 
glucose and reduced insulin secretion [259,264]. This defect would also be expected 
to result in increased insulin resistance. As all these symptoms are seen within peas 
patients and with the knowledge that peas patients tend to have an increased energy 
intake due to insulin resistance. this observation in peos adipocytes may therefore be 
substantiated and seen to aggravate the condition dramatically. With this in mind we 
can begin to understand how studies showing weight loss can reduce pcas symptoms 
removing the pressure of lipid accumulation within muscle and pancreatic stores and 
allowing resumption of insulin action. In our model the defect would be seen in our 
primary pcos cultures due to the low passage of the cultures examined and seen in 
the reduced speed of differentiation. This theory could be further examined by further 
passage of the cultures in low serum conditions representative of reduced energy 
intake and may lead to resumption of normal metabolic function when examining 
differentiation. 
Morphological variation seen following differentiation. were particularly interesting. 
The increased adipocyte size seen in in vitro peas cultures shown by Manneras-
Holm is indicative of increased storage through availability and although seemingly 
contradictory to the slow development from preadipocytes this may support the theory 
of excess availability forcing preadipocyte development to slow down to 
accommodate for existing hypertophic mature adipocytes as described by Faulds et al .. 
(2003). It should be noted that we saw similar results within non-obese peas patients. 
which has also been suggested by both Faulds et al .• and Moro et al., through 
examination of catecholamine-induced lipolysis in subcutaneous samples. Faulds 
results showed reductions in triglyceride mobilization and may therefore offer an 
explanation as to the increased size of lipid retention following maturation [235, 265]., 
This may also go someway in explaining later development of obesity within peas 
patients. Faulds examinations hypothesized decreased ~ 2 , - a d r e n e r g i c c receptor as 
playing an important role in this dysfunction. This catalytic component of protein 
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kinase A (PKA) would therefore decrease lipolytic activity through inactivation of the 
protein. Our results also showed variation in proliferative responses between non-
peas and peos cultures with hyperplastic behavior shown by peos cells. A 
combination of these traits in in vivo abdominal peos adipocytes could contribute to 
the increased abdominal obesity typically seen within PCOS patients. 
With the predominance of increased LH levels within peas we examined the 
possibility of an association with adipocyte metabolism including proliferation and 
the insulin pathway. Examination of all samples taken from non-peaS and peas 
adipose biopsies aHowed us to confirm the expression of the LH receptor at all stages 
of differentiation with no variation in expression in peos cells. As a relatively novel 
area of investigation, the relationship between LH and adipocyte metabolism is yet to 
be fully understood but implicates LH in influencing adipocyte behavior. Furthermore 
our results have suggested that LH significantly inhibits proliferation of Don-PCaS 
adipocytes determined using mitochondrial activity in vitro as a marker of cell 
viability. We also found pcas adipocytes failed to elicit the same response, with LH 
having no effect on proliferation. This suggests that a dysfunction may exist in peas 
adipocytes that removes possible LH regulation over proliferation. A plausible 
mechanism could be the activation of cAMP via PKA with cAMP-dependent 
activation having been shown to inhibit proliferation in cells including adrenocortical 
and smooth muscle, through possible increased sensitivity to TNFa-induced apoptosis 
[394-396]. It should be noted that the proliferation experiments focused on pre 
adipocytes and therefore did not include media supplementation with IBMX which, 
based on our theory, may have affected the actions of LH through increases in 
intracellular cAMP. 
The fl2-adrenergic receptor dysfunction hypothesized to exist within pcas 
adipocytes may therefore be associated with both differentiation and proliferative 
responses seen in the peas phenotype and is a target area for further examination. 
8.2 Androgen-adipocyte relationship in both DOD-PCOS and PCOS ceO, 
peas is characterized predominantly by hyperandrogenism, however 50% of pcas 
women show phenotypic abdominal obesity with many features of the metabolic 
syndrome such as insulin resistance, hyperinsulinemia, diabetes and cardiac disorders 
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occurring inconsistently [397]. With the aetiology of PCOS still unknown, it has been 
suggested that obesity may play an important role in its development [157, 398]. With 
obesity believed to be responsible for insulin resistance and hyperinsulinemia in 
PeOS through increased amounts of non-esterified fatty acids, glycerols, hormones 
and pro-inflammatory cytokines [399], there maybe a subsequent link to its key 
involvement m symptomatic hyperandrogenemia. Additionally studies in 
adipose/androgen associations have suggested that increased activity within the opioid 
system and hypothalamic pituitary adrenal axis [400] as well as decreased SHBG 
synthesis and high dietary lipid intake [40 I], may encourage increased androgen 
srnthesis. 
Our fmdings have shown evidence of secretory androgen levels in vitro not only 
through its presence within the culture media but also the presence of the precursor 
progesterone and CVPI7; the key enzyme involved in androgen synthesis. This may 
suggest not only the existence of androgen processing but also a biosynthetic pathway 
within adipocytes for androgen. If this were the case it would give avenues for 
examination into additional influx of androgens possibly associated with PCOS and 
may also point to an area that may be involved in hyper secretion. Although the levels 
determined were comparatively lower than those seen in gonadal and adrenal 
androgen secretion by in vitro cultures as shown within our results in Chapter 7 as 
well as findings by Gilling-Smith et al .• (1994) and Hughes (1988), they were seen to 
be significant against negative controls. When considered in a physiological model, 
levels of secretion would correlate to increases in adipose tissue resulting in a 
cumulative response typically associated to PCOS weight gain [221, 267]. 
Furthermore the levels found from all these cell types correlate to physiological levels 
via their physiological contributions whereby ovarian and adrenal levels have been 
shown to supply the greatest inputs of physiological androgen [342]. Whether these 
secretory levels are seen to be for auto/intracrine function is yet to be established, 
however the results suggest a localized androgen synthesis and further the 
understanding of the endocrine function of adipose. Our comparison of secretory 
androstenedione levels from non-PCOS and PCOS adipocytes showed that no 
variation within levels reached exists under our in vitro conditions. This may suggest 
that no dysfunction exists within PCDS adipocytes androgen synthesis however 
further investigation into not only determining the pathways involved but also 
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conditions representative of the in vivo environment would be necessary to support 
this. 
The physiological levels of insulin and LH found in PCOS patients are typically 
elevated. Cells often respond to insulin through increases in metabolic response such 
as proliferation or increased rates of biosynthetic pathway activity; which has been 
seen within androgen biosynthesis in both thecal and adrenal cells [398, 402]. This 
has been further examined under hyper physiological insulin treatment ranges in vitro 
representative of PCOS [403]. Munir et al., (2004) showed significant increases in 
thecal steroidogenic enzymes key to androgen synthesis [45, 351]. With our findings 
suggesting an additional source of physiological androgens via adipocyte cell 
synthesis and, secretion, the examination of insulin on adipocyte metabolism allowed 
for a greater understanding of adipose function. It also enabled us to see how any 
dysfunction that may exist in PCOS adipocytes may be affected by these biochemical 
variations. Insulin treatments resulted in an increase in androstenedione secretion in 
non-PCOS adipocytes at 10ng/ml, which remained the same regardless of further 
increases in insulin. This result was similar to that seen in insulin's action on gonadal 
and adrenal tissue androgen synthesis suggesting a similar mechanism of regulation 
may exist in adipocytes. From this similar hypothesis to those found in ovarian and 
adrenal steroidogeneisis, may therefore be drawn to the involvement of 
hyperinsulinemia and its associations to increased androgen secretion that results in 
hyperandrogenism. With this in mind the link between insulin resistance and obesity 
would therefore give a possible foundation to increased androgen secretion. Although 
our examination of PCOS adipocyte androgen secretion showed no variation within 
the levels of androstenedione secretion against the non-PCOS culture we found that 
they did not react to insulin stimulation. Our results therefore suggested that the 
PCOS adipocytes were in a constant state of stimulation and dysfunction may exist in 
androstenedione regulation as a result of PCOS hyper stimulation. 
To further support the possibility of an androgen synthetic pathway in our adipocyte 
cultures, our results showed that levels of progesterone decreased ( I pmoV I 000 cells) 
at the same insulin treatment level that caused an increase in androgen secretion. This 
finding may indicate progesterone's involvement in the androgen biosynthetic 
pathway. The increase in androgen synthesis as a result of insulin stimulation would 
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therefore require a greater supply of precursors. In addition to this we found the 
presence of the enzyme CYP17, necessary for the conversion of progesterone to 
androstenedione. This enzyme did not vary in expression between non-PCaS and 
pcas samples suggesting that it is unlikely that a dysfunction exists at this stage of a 
steroidogenic pathway. Furthermore this reinforces our evidence that no variation in 
adipocyte androstenedione production exists between non-PCaS and pcas in the 
absence of treatment. However lack of variation may suggest CYP 17 is expressed at 
similar levels to those found in non-peaS but activity is reduced. 
Examination of n o n - P e ~ S S and PCOS adipocyte samples showed no differences in 
increased insulin stimulation of androstenedione secretion. Overall variation in insulin 
treatment did not cause any variation in levels of pcas and non-PC as 
androstenedione secretion and a constant level was maintained within our treatment 
range (2.8pmoVlOOO cells). This was supported by stable progesterone levels, as seen 
in non-PeOS samples. If representative of in vivo activity this would indicate a 
constant state of androstenedione secretion regardless of increased stimulation, which 
would enhance serum androgen levels. Furthennore it would also support the insulin 
resistant dysfunction already associated with obesity and PCOS, particularly in 
adipocytes. aur ELISA results did show possible room for error and to fully support 
this theory further repetition of these results would be required as our sample size was 
limited. We did however attempt to support this through our protein expression 
findings. 
Documented evidence has shown that LH increases ovarian and adrenal androgen 
synthesis [32, 91]. With hyper-secretion of LH often found in pcas patients its 
involvement in the mechanisms surrounding symptomatic hyperandrogenism has been 
of particular interest. This factor, coupled with adipocyte androgen secretion, may 
further increase physiological androgen levels in pcas patients and it has been 
determined that LH increases non-PCaS ovarian androgen secretion significantly. In 
addition to this, LH and insulin treatment has been shown to increase non-PCaS 
ovarian androgen secretion 8-fold [91]. Examination of this influence on adipocyte 
androgen secretion showed that androstenedione increased with insulin treatment, 
although no variation was seen with LH treatment alone. However our findings 
showed this response was reduced in the pcas samples. This may suggest that the 
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dysfunction seen in proliferation and differentiation also exists in androstenedione 
secretion, however our examinations gives no evidence of an association and would 
require further work to confmn this. With the influence of insulin seen to increase 
androstenedione in non-PCOS adipocytes it may suggest that the loss of effect 
dysfunction arises as a result of the onset of PCOS. This may be true as abnormal fat 
deposits suggestive of changes in adipocyte activity are associated with PCOS as are 
the effects of increased androgen exposure that lead to changes in adipocyte 
metabolism through reduced proliferation and differentiation [298]. 
With such a variation often seen in the presentation of symptoms found in PCOS our 
determination of a more active and key role of adipocytes within PCOS dysfunction 
may begin to address a more central pathogenesis of the condition. From this. we may 
therefore gain a better understanding of the correlation often seen in weight 
fluctuations of peos patients and the severity of the conditions or symptom. 
8.3 Ovarian theca ceUs in non-peOS and PCOS padents 
Hyperinsulinemia and PCOS are often associated [302, 398]. Increased insulin action 
is believed to lead to increased synthesis of ovarian androgen, with both increased 
insulin and increased androgen considered diagnostic features of the syndrome. 
Research has shown an increase in the number of steroidogenic theca cells of PeOS 
patients when compared with controls [129], moreover it has been shown that peos 
theca interstitial cells are in a state of hyper stimulation in those samples taken from 
patients with biochemical abnormalities including hyperinsulinemia and hyper 
secretion of LH [221]. Additionally, examination into the steroidogenic pathways 
involved in androgen biosynthesis has shown increased expression of key enzymes 
including StAR, CYPIIA and 3P-HSD in theca cells within PCOS [404] All these 
factors are suggestive of a key involvement of peos ovarian theca in the 
hyperandrogenic component central to the condition. Androgen is also increased at 
basal/untreated levels of secretion in peos cultures compared to controls, further 
emphasizing a dysfunction that would lead to a greater influx of circulatory androgen. 
With ovarian androgen synthesis responsible for 30-50% of overall androgen 
secretion, further increases in peos theca and/or activity can be seen as a major 
physiological addition that would upset androgen homeostasis. The second 
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component of this thesis therefore looked to examine variations in pcas ovarian 
theca in vitro and the physiological factors that may affect androgen steroidogenesis 
including insulin and LH. It also looked briefly into the pathways that may be 
involved in androgen hyper secretion in order to determine whether dysfunction exists 
and at what point of synthesis. 
The key findings of this thesis derived from work described in Chapter 7 on theca and 
therefore include: 
• CYP 17 expression is increased in pcas theca under basal conditions and that 
augmentation of insulin and LH leads to increases in in vitro theca 
proliferation and expression ofCYP17 in both non-PCaS and pcas samples. 
• Demonstration of lack of variation between basal and insulin stimulated in 
vitro thecal androstenedione secretion. 
• Demonstration of increased in vitro thecal androstenedione secretion under 
LH treatment in both non-peas and pcas theca cells which was further 
increased through augmentation of insulin+LH. 
• Increased androstenedione secretion by in vitro pcas theca cells under 
augmented insulin+LH treatment over non-PCaS theca cells under the same 
conditions. 
• Findings suggestive that insulin is acting through the PI3-K pathway in thecal 
androstenedione synthesis. This however requires further evidence and 
examination. 
With the importance of ovarian steroidogenesis as a source of androgen production in 
premenopausal women, research has focused on thecal cell dysfunction in pcas as a 
possible root for androgen synthesis. In the past, much of this research has been 
carried out on direct tissue incubations [398] or freshly pooled theca cells capable of 
steroidogenic activity. These sources have limited the area of examination through 
their inability to be sustained or limited cell yields [43, 221]. However, the production 
of a sustainable in vitro monolayer culture system by McAllister et al.. (1989) 
allowed better insight into the steroidogenic function of theca cells as well as 
variations that may occur within pcas samples [60]. Using the protocol we were able 
to adapt and reproduce the techniques described and maintain cultures in vitro (see 
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3.2. J). Difficulties did arise in establishing peas theca cultures outside of the 
technique in maintaining cell numbers in the initial passage. This was remedied by 
increasing insulin and the addition of a high serum supplement and was used 
throughout all our cultures. This high-energy requirement may reflect the initial in 
vivo environment. As discussed in 8. J peos patients typically have high 
physiological insulin levels (hyper insulinemia) as a result of insulin resistance and 
also increased energy intake. This theory seems concurrent with reported findings and 
I was unable to find any protocols that used serum free to establish a primary peas 
theca culture, and those that did used high insulin, glucose supplements within the 
media. Although many methods existed for non-peos primary theca cultures that 
were serum free as stated in the original protocol created by Magoffin and Erickson 
(1982). Following establishment of the primary cultures, we used 
immunofluorescence (see 3.5.1) as a marker for contamination by other cell types and 
oil red 0 staining of lipids. Through this. we were able to examine morphological 
variations including size and lipid fonnation (size and number) in theca as well as 
adipocytes (described 8. J) that may exist across non-PCOS and Peas sample groups. 
Published results examining rat thecal cultures induced with estradiol valerate (EV) to 
mimic peos [154]. reported larger cell morphology and number within the PeOS 
group. Our results also showed increased cell size within our peos cultures and 
therefore suggested this hypothesis may be valid within our human cells. Variations in 
theca size maybe as a result of larger lipid droplet fonnation and number. These 
characteristics may be associated with the increase in steroidogenic activity 
documented by Manna et a/.. (2003) with lipid droplets used as cellular storage for 
precursors such as carbohydrates. progesterone and cholesteryl esters (358). Increased 
size may therefore dictate increased demand or possibly decreased demand without 
decreases in production. Alternately this may point to similar dysfunction as 
suggested within our adipocyte work whereby studies into non-obese peas women 
showed decreases within catecholamine-induced lipolysis in subcutaneous abdominal 
adipocytes suggestive of resistance [235, 265]. This would therefore prevent 
mobilization of triglycerides increasing lipid droplet storage, dictating the subsequent 
size of the cell. Studies into therapeutic agents such as metfonnin have shown that 
through increased insulin sensitivity, symptoms associated to the hyperandrogenic 
conditions of peos are reduced and that metfonnin can directly inhibit androgen 
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production in human theca [405]. Nestler et 01., (1998) also showed that 
administration of metformin allowed spontaneous ovulation [406]. Furthermore La 
Marca et 01., (2000) noted that following metformin treatment stimulated CYP17 
activity was reduced [367]. This gives a great deal of information toward thecal 
androgen steroidogenesis and points to the importance of CYP17 activity through 
insulin pathway activation. Our study however found that although variations in 
CVP 17 exist between non-PeaS and pcas groups, variations in insulin treatment 
did not lead to any changes in CVP17 expression. With this in mind the effects of 
therapeutic insulin sensitizers such as troglitazone and metformin would therefore not 
be effective through their effects on insulin behavior alone. The agonistic effect of LH 
on ovarian androgen synthesis has been documented in both non-PCaS and peas 
patients. It has also been seen that the effect is more sensitive in pcas theca cells 
[91]. More importantly the augmented effect of insulin and LH in both non-PCaS and 
pcas samples is considerably greater than basal levels [221]. Our results can confirm 
this effect within pcas theca and showed significant effects through augmentation of 
LH and insulin when compared to individual treatments and on comparison to non-
pcas cultures. From this we can hypothesis that the reduction in hyperandrogenic 
symptoms often seen from the use of insulin sensitizing agents maybe linked to a 
process that helps to reduce this augmentation. Furthermore treatment of PCOS with 
metformin has shown to re-establish feedback control of testosterone through LH 
secretory rates and therefore improving neuroendocrine abnormalities such as LH 
hyper secretion often associated to PeOS [407]. 
It has been proposed that in PCOS patients presenting with hyperinsulinemia and 
hyperandrogenemia the augmentation of LH and insulin is central to excess androgen 
stimulation [45, 221]. However we have shown that the effects of LH work 
independently in stimulating increases in androstenedione secretion above basal levels 
(see 7.4.tf). Furthermore, our examination of both normal and supra-physiological 
treatments shows that normal circulatory insulin levels can cause significant increases 
in androgen stimulation. This may go someway to explain why pcos ~ a n n present 
without hyperinsulinemia and that thecal dysfunction central to the pathogenesis can 
lead to symptomatic increases in insulin. This coupled with our work with adipocyte 
cultures may suggest that gradual increase in physiological androgen can cause 
central obesity and adipocyte dysfunction that results in aggravated increases in 
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insulin further encouraging both adipocyte and thecal androgen ecretion through LH 
insulin augmentation. 
With the importance this dysfunction therefore po e with tbe condition, pinpointing 
the exact mechani m is therefore neces ary. Munir ef aI. , 2004 ha confirm d thecal 
insulin action on steroidogenic androgen synthe is through the in ulin rec ptor and 
studies have shown that no abnormality exi t in either function or expre ion in 
PCOS theca. Munir al 0 examined the involvement of two key pathway in normal 
theca cultures and determined that PI3-K rather than MAPK wa primarily in 01 ed 
in CYP 17 activity [45]. 
INSULI 
LH 
IRS-I 
ATP o RAS 1 
--A-n-dr-og-e-n b- iO· s-yn-th-e-slS- 1IIIII ~ ~ ~
Figure 131. ugge ted pathwa hO\ ing c MP and in ulin co- tivation of PI3-K I ding to 
ubsequent androgen bio ynthe i . 
The stimulatory effects of insulin on CYP 17 acti ity wa al 0 en to be dependent on 
the co-activation of the cAMP ignaling pathway [45] which again upp rt th 
importance of the involvement of LH in incrca ing teroidogcnic acti ity. Figur 131 
how the pathway that link LH and ub equent cAMP acti ation to PI -K and may 
therefore be a ociated with the involvement of in ulin and con equcnt co-acti ati n 
of teroidogensis. Lutcininsing hormone / chorionic gonadotropin acti ate multipl 
signal tran duction y tern [311 , 40 ]. Mo t of the equcntial tep in olved aft r 
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honnone binding, until G protein activation on the inner face of the plasma membrane 
remains poorly understood. However in many experimental systems, LH or hCG 
binding to LHR results in activation of both protein kinase A and protein kinase C 
[311], and at relatively low concentrations of LH and hCG protein Gs' appear to be 
the preferred signaling pathway that results in a rapid increase in the intracellular 
concentration of cAMP. 
If the pathway in Figure 131 did operate, the inhibition of PI3-K would lead to a 
reduction in both LH and insulin stimulated CYP 17 and resultant reduction in 
androstenedione synthesis. Our results show this to be true for insulin stimulation 
alone in both n o n - P e ~ S S and PCOS through reduced CYP17 expression. This study 
therefore requires further examination into the effects PI3-K inhibition may have on 
LH stimulation and combined LH and insulin on CYP17. Moreover this would 
require support through measurements of androstenedione secretion under these 
conditions. From this we could detennine the importance CYP 17 may be as a target 
for dysfunction within this pathway and subsequent disturbances within 
androstenedione synthesis and also include the involvement of LH within this 
pathway. 
This thesis has identified the potential importance of adipose tissue as a source of 
androgens as well as furthering the current understanding of ovarian androgen 
synthesis within peos. Although there are few reports, this thesis describes for the 
first time the presence and modulation of androgen synthesis in both tissue types 
under the influence of insulin and LH within pcos. In doing so we have highlighted 
a potentially new pathway in adipocyte metabolism and therefore increased the 
understanding of peos with a hope of assisting in its management. 
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9.0 FUTURE WORK 
9.1 LH and the MAPK pathway 
Through the examination of the findings in this study and based on previous work I 
have begun to examine the possible pathway in thecal steroidogenesis that may link 
LH activation of androstenedione and harbor an area of dysfunction that requires 
focus for future work. Ras proteins are located on the inner surface of the thecal 
plasma membrane and are GTPases involved in receptor-mediated signal transduction 
pathways (Figure 132) transmitting extracellular signals that promote growth. 
proliferation, and differentiation. The signaling cascade starts from the plasma 
membrane where the agonist binds to its enzyme-linked receptor. Receptor-linked 
tyrosine kinases such as the epidermal growth factor receptor (EGFR) are activated by 
extracellular ligands and binding of EGF's. This leads to phosphorylation of the 
intracellular domain of the receptors, activating guanine exchange factors 
(GEFs)[409], such as son of sevenless (SOS) [410]. GEFs allow the ex.change ofGDP 
to GTP activating Ras. The major downstream target of Ras-GTP is mitogen-activated 
protein kinase (MAPK), but it also activates phosphatidylinositol 3-kinase (PI3-
kinase)(Chapter 8 Figure I), and Ras-related guanine nucleotide dissociation 
stimulator (RaIGDS). Activation of MAPK occurs through specific phosphorylation 
of Raf, which is activated on the plasma membrane by Ras-GTP. Raf phosphorylates 
mitogen-activated kinase 112 (MEK 112 kinase), in tum activating the extracellular 
regulated kinase 1/2 (ERK1/2 kinase or p44/42 MAPK) by phosphorylation. 
The second class of enzymes in the ERK cascade, the MEKs, phosphorylate threonine 
and tyrosine residues. MEK I and MEK2 are involved in ERK signaling and activated 
via their only substrate, Raf kinase. Inactivation of the ERKs is through de-
phosphorylation via serine threonine or tyrosine phosphatases [411. 412]. ERK 112 
kinase phosphorylates a variety of downstream targets, which results in changes in 
gene ex.pression and the catalytic activities of enzymes [413]. 
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Ras 
Raf-l 
ERKlj2 
Figure 132. RA tRAFt IEKIERK signalling cascade. ERK acti va tion through MAPK initiated by 
many extracellular cues such as extracellular gro\\-th signals (shown he re via EG F receptor) and 
tyrosine klOases. The s ignal is transduced from RAF to ERK through GTP bound RAS ac ti va tion. 
A recent study showed that both MAPK kinase (MEK1I2) phosphorylation and 
extracellular signal related kinase (ERK1I2) phosphorylation were reduced by 50% in 
pcas cells compared with that in normal cells [414]. A reduction in phosphorylation 
within this pathway may therefore lead to an activation or reliance on an alternate 
pathway and with the involvement of LH and insulin acting through the convergence 
of two pathways this maybe the case. This is further supported with the reduction in 
MEK1I2 and ERKI /2 phosphorylation showing association with increased thecal 
CYP 17 gene expression and androgen biosynthesis [45]. Treatment of theca cells with 
the MEK inhibitor PD98059 has been also shown to augment thecal CYPl7 gene 
expression and androgen biosynthesis [414]. This may suggest that if this pathway is 
involved in androgen synthesis it may act to regulate as well as stimulate 
steroidogeneisis. The extent to which the other components of the MAPK pathway 
contribute to overall androgen biosynthesis requires further examination. 
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Although LH has been reported to activate the cAMPIPKA pathway and the 
ERKlMAPK pathway in theca cells, whether and how LH stimulates the PI3-K/ Akt 
cascade in theca cells remains unclear. Recent studies have shown LH stimulates Akt 
phosphorylation in cultured bovine theca cells, and that activation of PI3-K/ Akt is 
involved in CYPI7AI mRNA expression and androgen production in theca cells thus 
supporting LH activation of PI3-K [415]. H89, a potent and selective inhibitor of 
PKA, did not affect LH-mediated changes in phospho-Akt, indicating that a pathway 
distinct from that of the PKA is involved in LH-induced Akt phosphorylation in theca 
cells. 
In contrast to the PKA inhibitor, the MEK inhibitor (UOI26) blocked LH-mediated 
Akt phosphorylation and androgen production in theca cells [59]. We are therefore 
aware that LH stimulates CYP17AI mRNA expression and androgen production in 
theca cells via activation of the PI3-KI Akt pathway and with the involvement of the 
MAPK pathway. Further supporting a combined pathway that may not only stimulate 
but regulate and may work independently and through individual stimulating factors 
as seen with LH. 
While the precise mechanism for the activation of PI3-K pathway by LH in theca cells 
is not known, it is possible that the LH-induced phospho-Akt up-regulation may 
involve MAPK-mediated down-regulation of phosphatase and tensin homologue 
(PTEN; a tumor suppressor which negatively regulates Akt phosphorylation). In this 
context, it has been shown that PI3-K is required for estradiol-stimulated hepatic cell 
growth and that the MAPK pathway reduces the level of PTEN, allowing estradiol-
induced phosphorylation of Akt [416]. However my focus would be on GTP bound 
RAS due to its interactions within the pathway through its activation of class Ia 
kinases as shown by Downward, 1998 [417, 418]. 
Clarification of the LH-mediated intracellular signaling events is essential, along with 
consideration for cross talk and compensatory mechanisms between pathways. This 
will allow for better understanding of not only ovarian physiology, but also of the 
pathophysiology of PCOS. 
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Figure 133. Suggested pathway for LH activation of theca androgen biosynthesis acting through 
cAMP aclivation of MAPK. 
Studies in granulosa have shown elevated cAMP maybe associated with ERK 
activation [419]. PKA forms inactive RAP 1 inhibiting RAFI and preventing MEK 
phosphorylation of ERK and subsequent androgen synthesis [420]. I propose 
increased cAMP may allow phosphorylation of cAMP-responsive guanine nucleotide 
exchange factors (Epacl and Epac2). Upon binding of cAMP, Epac \ /2 rapidly 
activate Rap I, which subsequently promotes activation of B-raf and the rest of the 
ERK cascade (see Figure 133)[421]. 
cAMP has been shown to directly activate RAP 1 [421] this would subsequently lead 
to BRAF activation and MEK phosphorylation (LH mediated androgen synthesis). 
Inhibition of PKA would prevent RAP I formation. This would therefore lead to the 
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eventual return to RAF I inhibition of the pathway due to a reduction in RAPl 
formation. Studies have shown that LH mediated ERK. phosphorylation only occurs 
within 24hrs of LH exposure during PKA inhibition, and this factor may be seen in 
effect within our theory. Furthermore Tajima et al., 1998, has shown that inhibition of 
cAMP activated ERK. has shown to decreases androstenedione secretion and 
expression of Star and CYPI7 expression [420]. 
In summary this study provides experimental evidence to support the importance of 
LH in its involvement in PCDS. We have shown that this peptide hormone is linked to 
both adipose and ovarian regulation, indicating the significant role of both these tissue 
types in contributing to hyperandrogenemia, one of the key factors central to PeOS. 
More importantly, the influence of LH in stimulation of ovarian androgen synthesis 
seems to be predominant in both this research and many other studies [42,45, 414]. 
However little is known about the pathways involved in this mechanism. It is for 
these reasons that I believe this thesis directs future work toward this area of 
examination. 
210 
Chapter 10: Bibliography 
10.0 BIBLIOGRAPHY 
1. Armstrong, D.T. and J.H. Dorrington, Estrogen biosynthesis in the ovaries 
and testes. Adv Sex Horm Res, 1977.3: p. 217-58. 
2. McMinn, R., Lasts Anatomy, Regional and Applied. 2003(9): p. 391. 
3. Cunningham, D., Cunninghams Text book of Anatomy. 1818. 5. 
4. Jones, I.H., Menstruation: the curse of Eve. Nurs Times, 1980. 76(10): p. 
404-6. 
5. Rosenblatt, P., Menstrual Cycle. MERCK Medical Journal, Womens Health 
Issue, 2007. 
6. Erickson, G.F. and S. Shimasaki, The physiology of folliculogenesis: the role 
of novel growth factors. Fertility and Sterility, 2001. 76(5): p. 943-949. 
7. Carla, R., et ai., Novel Signal Transduction Pathway for Luteinizing 
Hormone and Its Interaction with Insulin: Activation of Janus Kinase/Signal 
Transducer and Activator of Transcription and Phosphoinositol 3-
Kinase/Akt Pathways. Endicrinology, 2003.144(2): p. 638-647. 
8. Rosenfield, 1.., Ovarian and adrenal function in polycystic ovary syndrome. 
Endocrinol Metab Clin North Am, 1999. 28. 
9. Evans, G., et al., Estrogen, Androgen, and Progesterone Biosynthesis by 
Theca and Granulosa of Preovulatory Follicles in the Pig. Biology of 
Reproduction, 1981.25: p. 673-682. 
10. Crews. D .• et al.. The Relative Effectiveness of Estrone, Estradiol-17fJ, and 
Estriol in Sex Reversal in the Red-Eared Slider (Trachemys scripta), a Turtle 
with Temperature-Dependent Sex Determination General and Comparative 
Endocrinology, 1996.102(3): p. 317-326. 
11. Cheng, x., et al., Endocrine regulation of gender-divergent mouse organic 
anion-transporting polypeptide (Oatp) expression. Mol Pharmacol. 2006. 
70(4): p. 1291-7. 
12. Dochi, M., et al., Relationship between shift work and hypercholesterolemia 
in Japan. Scand J Work Environ Health, 2008. 34(1): p. 33-9. 
13. Sauerwein, H. and H.H. Meyer, Androgen and estrogen receptors in bovine 
skeletal muscle: relation to steroid-induced allometric muscle growth. J 
Anim Sci, 1989.67(1): p. 206-12. 
14. Bremer, A. and W. Miller, The serine phosphorylation hypothesis of 
polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia 
and insulin resistance. Fertility and Sterility, 2008. 89(5): p. 1039-1048. 
15. Check, I.H., et ai., The effect of follicle-maturing drugs on mid-cycle 
androgen levels in women with normal baseline levels. Gynecol Endocrinol, 
1992.6(2): p. 107-11. 
16. Michael, R.P., et al., Artificial menstrual cycles, behaviour and the role of 
androgens in female rhesus monkeys. Nature, 1978. 275(5679): p. 439-40. 
17. Buyalos, R.P., et ai., Androgen response to hypothalamic-pituitary-adrenal 
stimulation with naloxone in women with myotonic muscular dystrophy. J 
Clin Endocrinol Metab, 1998. 83(9): p. 3219-24. 
211 
Chapter 10: Bibliography 
18. Sinha-Hikim, I., et al., Androgen receptor in human skeletal muscle and 
cultured muscle satellite cells: up-regulation by androgen treatment J Clin 
Endocrinol Metab, 2004. 89(10): p. 5245-55. 
19. Blouin, K., A. Boivin, and A. Tchernof, Androgens and body fat distribution. 
J Steroid Biochem Mol BioI, 2008. 108(3-5): p. 272-80. 
20. Burger, H., Androgen production in women Fertil Steril, 2002. 77(4): p. 3-
5. 
21. Heffner, L., Human Reproduction ata Glance. 2001. 
22. Davis, S., The clinical use of androgens in female sexual disorders Journal of 
Sex & Marital Therapy, 1998.24(3): p. 158-168. 
23. Pitkin, J., et at, Obstetrics and gynaecology. 2003. 
24. Blandau, R., E. Warrick, and R.E. Rumery, In vitro cultivation of fetal mouse 
ovaries. Fertil Steril, 1965. 16(6): p. 705-15. 
25. Sanderson, J., The Steroid Hormone Biosynthesis Pathway as a Target for 
Endocrine-Disrupting Chemicals. Toxicol. Sci., 2006.94(1): p. 3·21. 
26. Elting, M., et at, Women with polycystic ovary syndrome gain regular 
menstrual cycles when ageing. Hum Reprod 15, 2000. 1: p. 24-28. 
27. Hillier, S. and M. Tetsuka, Role of androgens in follicle maturation and 
atresia . . Baill Clin Obstet Gynaecol, 1997. 11(2): p. 249-260. 
28. Fortune, J., et at, The primordial to primary follicle transition Molecular 
and Cellular Endocrinology, 2000. 163(1-2): p. 53-60. 
29. Kolibianakis, E., et al., Estrogen and folliculogenesis: is one necessary for the 
other? Curr Opin Obstet Gynecol. , 2005. 17(3): p. 249-253. 
30. Baggish, M. and M. Karram, The Atlas of Pelvic Anatomy and Gynaecologic 
Surgery. 2006. 2. 
31. Wandji, S.A., G. Pelletier, and M.A. Sirard, Ontogeny and cellular 
localization of 1251-labeled basic fibroblast growth factor and 1251-labeled 
epidermal growth factor binding sites in ovaries from bovine fetuses and 
neonatal calves. Bioi Reprod, 1992.47(5): p. 807-13. 
32. Azziz, R., et al., Adrenal androgen excess in the polycystic ovary syndrome: 
sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J 
Clin Endocrinol Metab, 1998.83(7): p. 2317-23. 
33. Diamanti-Kandarakis, E., et al., Defects in insulin signaling pathways in 
ovarian steroidogenesis and other tissues in polycystic ovary syndrome 
(peos). The Journal of Steroid Biochemistry and Molecular Biology, 2008. 
109(3-5): p. 242·246. 
34. Hunzicker-Dunn, M. and E.T. Maizels, FSH Signaling pathways in immature 
granulosa cells that regulate target gene expression: branching out from 
protein kinase A. Cell Signal, 2006.18(9): p. 1351-9. 
35. Polan, M., et al., Ovulation induction with human menopausal gonadotropin 
compared to human urinary follicle-stimulating hormone results in a 
significant shift in follicular fluid androgen levels without discernible 
differences in granulosa-luteal cell function . . 63, 1986. 6: p. 1284-1291. 
36. Miller, W.L., StAR search--what we know about how the steroidogenic acute 
regulatory protein mediates mitochondrial cholesterol import Mol 
Endocrinol, 2007. 21(3): p. 589-601. 
37. Schroeder, F., et at, Intracellular Cholesterol Trafficking. 1998: p. 213-234. 
212 
Chapter 10: Bibliography 
38. Petrescu, A., et aI., Steroidogenic acute regulatory protein binds cholesterol 
and modulates mitochondrial membrane sterol domain dynamics. J BioI 
Chern, 2001. 276(40): p. 36970-82. 
39. Miller, W., Mechanism of StAR's regulation of mitochondrial cholesterol 
import Molecular and Cellular Endocrinology, 2007. 265-266,: p. 46-50 
40. Arukwe, A., Steroidogenic acute regulatory (StAR) protein and cholesterol 
side-chain cleavage (P4S0 scc )-regulated steroidogenesis as an organ-
specific molecular and cellular target for endocrine disrupting chemicals in 
fish. Cell Biology and Toxicology, 2008. 24(6): p. 527-540. 
41. Diamanti-Kandarakis, E. and A. Papavassiliou, Molecular mechanisms of 
insulin resistance in polycystic ovary syndrome. Trends in Molecular 
Medicine, 2006. 12(7): p. 324-332. 
42. Gongqiao, Z., et aI., Interactive Stimulation by Luteinizing Hormone and 
Insulin of the Steroidogenic Acute Regulatory (StAR) Protein and 17-
Hydroxylasell7, 20-Lyase (CYP17) Genes in Porcine Theca Cells 
endicrinology, 2000.141(8): p. 2735. 
43. Jakubowicz, D.J. and J.E. Nestler, 17 alpha-Hydroxyprogesterone responses 
to leuprolide and serum androgens in obese women with and without 
polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol 
Metab, 1997. 82(2): p. 556-60. 
44. Nelson, V., et aI., Augmented Androgen Production Is a Stable Steroidogenic 
Phenotype of Propagated Theca Cells from Polycystic Ovaries. Molecular 
Endocrinology, 1999. 13(6): p. 946-57. 
45. Munir, I., et aI., Insulin Augmentation of 17{alpha}-Hydroxylase Activity Is 
Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-
Regulated Kinase-112 in Human Ovarian Theca Cells. Endocrinology, 2004. 
145(1): p. 175-183. 
46. Hanukoglu, J., Steroidogenic enzymes: structure, [unction, and role in 
regulation of steroid hormone biosynthesis. Steroid Biochem. Mol. Bioi., 
1992. 43: p. 779-804. 
47. Pikuleva, I., Cytochrome P4S0s and cholesterol homeostasis. Pharmacology 
& Therapeutics, 2006.112(3): p. 761-773. 
48. Shikita, M. and P. Hall, The Stoichiometry of the Conversion of Cholesterol 
and Hydroxycholesterols to Pregnenolone (3p-Hydroxypregn-S-en-20-one) 
Cata/ysed by Adrenal Cytochrome P-450. Proc Natl Acad Sci USA, 1974. 
4(71): p.1441-1445 .. 
49. Chapman, J., et al., Mitochondrial 3 beta-hydroxysteroid dehydrogenase 
(HSD) is essential for the synthesis of progesterone by corpora lutea: An 
hypothesiS. Reproductive Biology and Endocrinology, 2005. 1: p. 1477-
7827. 
50. Felig, P. and L. Frohman, Endocrinology & Metabolism. 2001. 
51. Sander, VA., et aI., Alterations offolliculogenesis in women with polycystiC 
ovary syndrome. J Steroid Biochem Mol Bioi, 2011. 124(1-2): p. 58-64. 
52. Nelson, V.L., et aI., The biochemical basis for increased testosterone 
production in theca cells propagated from patients with polycystic ovary 
syndrome. J Clin Endocrinol Metab, 2001. 86(12): p. 5925-33. 
213 
Chapter 10: Bibliography 
53. Comim, F.H., K. Franks, S., Increased intensit;y of P4S0c17 protein 
expression in theca cells from polycystic ovaries. Society of Endicrinology, 
2011(11): p. 25. 
54. Somma, M., T. Sandor, and A. Lanthier, Site of origin of androgenic and 
estrogenic steroids in the normal human ovary. J Clin Endocrinol Metab, 
1969.29(4): p. 457-66. 
55. Miller, W., Molecular biology of steroid hormone synthesis. Endocr. Rev., 
1 9 8 8 . 9 : ~ 2 9 5 - 3 1 a a
56. Stevens, V., T. Xu, and J. Lambeth, Cholesterol pools in rat adrenal 
mitochondria: use of cholesterol oxidase to infer a complex pool structure. 
Endocrinology, 1992.130: p. 1557-1563. 
57. Bowen, R., Steroidogenesis. 2001. 
58. Ruckpaul, K. and H. Rein, Molecular Mechanisms of Adrenal Steroidogenesis 
and Aspects of Regulation and Application. Frontiers in Biotransformation, 
1990.3. 
59. Fukuda, S., et aI., Luteinizing Hormone Stimulates CYP17Al mRNA 
Expression and Androgen Production in Bovine Theca Cells via Activation of 
the PI3K/Akt Pathway. BIOLOGY OF REPRODUCTION, 2009. 81(525). 
60. McAllister, J., et ai., Regulation of cholesterol side-chain cleavage and 17 
alpha-hydroxylase/lyase activities in proliferating human theca interna 
cells in long term monolayer culture .. endicrinology, 1989. 125(4): p. 1959. 
61. Labrie, F., et al., Structure, function and tissue-specific gene expression Of 
3P-hydroxysteroid dehydrogenase/S-ene-4-ene isomerase enzymes. J. 
Steroid Biochem. Molec Bioi, 1992.43: p. 805-826. 
62. Jnano, H., et aI., Purification and properties of enzymes related to steroid 
hormone synthesis .. Annals N.Y. Acad. Sci., 1990. 595: p. 17-25. 
63. Martel, C., et aI., Distribution of 17p-hydroxysteroid dehydrogenase gene 
expression and activit;y in rat and human tissues. J. Steroid Biochem. Molec. 
Bioi, 1992.41: p. 597-603. 
64. Steiner, D.F. and P.E. Oyer, The Biosynthesis of Insulin and a Probable 
Precursor of Insulin by a Human Islet Cell Adenoma. Proc Natl Acad Sci U S 
A, 1967. 57(2): p. 473-480. 
65. Buggs, C., et al., Insulin augments GnRH-stimulated LHbeta gene expression 
by Egr-1. Mol Cell Endocrinol, 2006. 249(1-2): p. 99-106. 
66. LeRoith, D., et al., Insulin-like growth factors. Bioi Signals, 1992. 1: p. 173-
81. 
67. Marsters, P., N. Kendall, and B. Campbell, Temporal relationships between 
FSH receptor, type 1 ins.ulin-like growth factor receptor, and aromatase 
expression during FSH-induced differentiation of bovine granulosa cells 
maintained in serum-free culture Molecular and Cellular Endocrinology, 
2003.203(117-127). 
68. Po retsky, L., et aI., Phosphatidyl-Inositol-3 Kinase-Independent Insulin 
Action Pathway(s) in the Human Ovary. J Clin Endocrinol Metab, 2001. 
86(7): p. 3115-3119. 
69. Clarke, I. and J.T. Cummins, GnRH pulse frequency determines LH pulse 
amplitude by altering the amount of releasable LH in the pituitary glands of 
ewes. 73, 1985: p. 425-431 
214 
Chapter 10: Bibliography 
70. Yen, H.W., et aI., Selective alterations in insulin receptor substrates-l, -2 and 
-4 in theca but not granulosa cells from polycystic ovaries. Mol Hum Reprod, 
2004.10(7): p. 473-9. 
71. Virkamaki, A, U. Kohjiro, and C. Ronald Kahn, Protein-protein interaction 
in insulin signaling and the molecular mechanisms of insulin resistance. J. 
Clin.lnvest, 1999. 103(7): p. 931-943. 
72. Tee, M., D. Quing, and W. Miller, Pathways Leading to Phosphorylation of 
P4S0c17 and to the Posttranslational Regulation of Androgen Biosynthesis. 
Endocrinology, 2008.149(5): p. 2667-2677. 
73. Hirshfield, AN., Development of follicles in the mammalian ovary. Int Rev 
Cytol, 1991.1.24: p. 43-101. 
74. Virkamaki, A, K. Ueki. and C. Kahn, Protein-protein interaction in insulin 
signaling and the molecular mechanisms of insulin resistance. I Clin Invest, 
1999(103):p.931-943. 
75. White, M., The insulin signalling system and the IRS proteins . . Diabetologia, 
1997.40. 
76. White, M. and L. Yenush, The IRS-signaling system: a network of docking 
proteins that mediate insulin and cytokine action. Curr Topics Microbial 
Immunol. 1998. 1228: p. 179-208. 
77. Stadtmauer, L. and O. Rosen, Increasing the cAMP content of IM-9 cells 
alters the phosphorylation state and protein kinase activity of the insulin 
receptor . . I Bioi Chem, 1986. 261: p. 3402-3407. 
78. Takayama, S., et ai., Phorbol ester-induced serine phosphorylation of the 
insulin receptor decreases its tyrosine kinase activity . . I Bioi Chem, 1988. 
263: p. 3440-3447. 
79. Sigalit, B.-H. and Z. Yehiel, Phosphorylation of IRS proteins, insulin action, 
and insulin resistance. Am J Physiol Endocrinol Metab 2008. 296. 
80. Gen, I., et al., Adrenarche results from development of a 3{J-hydroxysteroid 
dehydrogenase-deficient adrenal reticularis. J Clin Endocrinol Metab 1998. 
83. 
81. Meng, K. T .• D. Qing, and M. Walter L, Pathways Leading to Phosphorylation 
of P4S0c17 and to the Posttranslational Regulation of Androgen 
Biosynthesis. endicrinology. 2008. 14S(9): p. 2667-2677. 
82. Craig, C., et al., Insulin Rapidly Inhibits Insulin-Like Growth Factor-Binding 
Protein-l Gene Expression in H4-11-E Rat Hepatoma Cells Mol. Endocrinol., 
1991.5: p. 1180-1187. 
83. Cantley, L., The Phosphoinositide 3-Kinase Pathway Science 2002. 
296(S573): p. 1655 -1657. 
84. Karpova, A, P. Sanna. and T. Behnisch, Involvement of multiple 
phosphatidylinositol 3-kinase-dependent pathways in the persistence of 
late-phase long term potentiation expression. Neuroscience, 2006. 137(3): 
. p. 844-841. 
85. Shepherd, P., D. Witherspoon. and K. Siddle. Phosphoinositide 3-kinase: the 
key switch mechanism in insulin signalling. Biochem, 1998. 333: p. 471-
490. 
86. Stephens. L.R., T.R. Jackson. and P.T. Hawkins. Agonist-stimulated synthesis 
of phosphatidylinositol(3,4,S)-trisphosphate: a new intracellular signalling 
system? Biochim. Biophys. Acta. 1993. 1179(27): p. 75. 
215 
Chapter J 0: Bibliography 
87. Fruman, D., R Meyers, and L. Cantley, Phosphoinositide kinases. Biochem., 
1998. 
88. Alessi, D. and C. Downes, The role of PI 3-kinase in insulin action. Biochim 
Biophys Acta, 1998.1436: p.151-164. 
89. Brown, R., et aI., Insulin Activates the ls%rm 0/ Class 1/ Phosphoinositide 
3-Kinase" J Bioi Chern, 1999. 274(21): p. 14529-14532. 
90. Leevers, S.J., B. Vanhaesebroeck, and M.D. Waterfield, Signalling through 
phosphoinositide 3-kinases: the lipids take centre stage. Current Opinion in 
Cell Biology, 1999. 11(2): p. 219-225. 
91. Gilling-Smith, C., et aI., Hypersecretion 0/ androstenedione by isolated 
thecal cells from polycystic ovaries. J Clin Endocrinol Metab, 1994. 79(4): p. 
1158-1165. 
92. McArthur, J., F. Ingersoll, and J. Worcester, The urinary excretion 0/ 
interstitial-cell and follicle stiimulating hormone activity by women with 
diseases of the reproductive system. J. Clin, Endicrinol, Metab, , 1958. 18: p. 
1202-1215. 
93. Rebar, R., et al., Characterization of the inappropriate gonadotropin 
secretion in polycystic ovary syndrome. J Clin Invest, 1976. 57(5): p. 1320-
9. 
94. Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 
41-7. 
95. Lachelin, G., et ai., Long term effects of nightly dexamethasone 
administration in patientswith polycystic ovarian disease. J Clin Endocrinol 
Metab, 1982. 55: p. 768-773. 
96. Rittmaster, R. and D. Thompson, Effect of leuprolide and dexamethasone on 
hair growth and hormone levels in hirsute women: the relative importance 
of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin 
Endocrinol Metab, 1990. 70: p. 1096-1102. 
97. National Womens Health Center, N. Prevalence and incidence statistics for 
polycystic ovary syndrome. Womens Health (Web Page] 2009; Available 
from: http://www.womenshealth.gov/. 
98. Khan, C., J. Flier, and R. Bar, The syndromes of insulin resistance and 
acanthsis niagricans: insulin receptor disorders in man. New England 
Journal of Medicine, 1976.294: p. 739-745. 
99. Baillargeon, J. and J. Nestler, Polycystic Ovary Syndrome: A Syndrome Of 
Ovarian Hypersensitivity to Insulin? J Clin Endocrinol Metab, 2006. 91(1): 
p.22-24. 
100. Belosi, C., et ai., Is the PCOS diagnosis solved by ESHREjASRM 2003 
consensus or could it include ultrasound examination of the ovarian 
stroma? Hum Reprod, 2006. 21(12): p. 3108-15. 
101. Stein, I. and M. Leventhal, Amenorrhea associated with bilateral polycystic 
ovaries. Am J Obstet Gynecol, 1935. 1(29): p. 181. 
102. Dewailly, D., et ai., Ovarian stromal hypertrophy in hyperandrogenic 
women. Clin Endocrinol (Oxt), 1994.41(5): p.557-62. 
103. Andrews, M.C., Bilateral polycystic ovaries associated with sterility, 
amenorrhea and hirsutism. Va Med Mon (1918), 1952.79(10): p. 544-8. 
216 
Chapter 10: Bibliography 
104. Stein, I. and M. Cohen, Surgical treatment of bilateral polycystic ovaries -
Amenorrhea and sterility. American Journal of Obstetrics and Gynaecology, 
1939. 38: p. 465-478 
105. Tulandi, T. and S. Took, Surgical management of polycystic ovarian 
syndrome. Baillieres Clin. Obstet Gynaecol, 1998. 12: p. 541-553. 
106. Carmina, E. and R. Azziz, Diagnosis, phenotype, and prevalence of polycystic 
ovary syndrome Fertility and Sterility, 2006. 86: p. 7-8. 
107. Franks, S., et al., Ovulatory disorders in women with polycystic ovary 
syndrome. CUn Obstet Gynaecol, 1985. 12(3): p. 605-32. 
108. Franks, S., Controversy in clinical endocrinology: diagnosis of polycystic 
ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol 
Metab, 2006. 91(3): p. 786-9. 
109. Azziz, R., Controversy in clinical endocrinology: diagnosis of polycystic 
ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol 
Metab, 2006. 91(3): p. 781-5. 
110. Geisthovel, F. and T. Rabe, The ESHRE/ASRM consensus on polycystic ovary 
syndrome (PCOS)--an extended critical analysis. Reprod Biomed Online, 
2007.14(4): p. 522-35. 
111. Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome. Fertil Steril, 2004. 81(1): p. 19-25. 
112. Diamanti-Kandarakis, E., Role of obesity and adiposity in polycystic ovary 
syndrome. International Journal of Obesity, 2007(31): p. 8-13. 
113. Corbould, A., Effects of androgens on insulin action in women: is androgen 
excess a component of female metabolic syndrome? Diabetes/Metabolism 
Research and Reviews, 2008. 24(7): p. 520-532. 
114. Poretsky, L., et ai., The Insulin-Related Ovarian Regulatory System in Health 
and Disease. Endocr Rev, 1999.20(4): p. 535-582. 
115. Barber, T.M., et al., Obesity and polycystic ovary syndrome. Clin Endocrinol 
(Oxf), 2006. 65(2): p. 137-45. 
116. Schmid, f., et ai., Infertility caused by PCOS--health-related quality of life 
among Austrian and Moslem immigrant women in Austria. Hum Reprod, 
2004.19(10): p. 2251-7. 
117. Goldzieher, J.W. and J.A. Green, The polycystic ovary. I. Clinical and 
histologic features. J Clin Endocrinol Metab, 1962. 22: p. 325-38. 
118. Pasquali, R., et al., Clinical and hormonal characteristics of obese 
amenorrheic hyperandrogenic women before and after weight loss. J Clin 
Endocrinol Metab, 1989. 68(1): p. 173-9. 
119. Abbott, D.H., D.A. Dumesic, and S. Franks, Developmental origin of 
polycystic ovary syndrome - a hypothesis. J Endocrinol, 2002. 174(1): p. 1-5. 
120. Franks, S., Adult polycystic ovary syndrome begins in childhood. Best Pract 
Res Clin Endocrinol Metab, 2002.16(2): p. 263-72. 
121. Norman, R.J., R. Wu, and M.T. Stankiewicz, 4: Polycystic ovary syndrome. 
Med J Aust, 2004.180(3): p.132-7. 
122. Watson, H., et al., Hypersecretion of luteinizing hormone and ovarian 
steroids in women with recurrent early miscarriage. Hum Reprod, 1993. 
8(6): p. 829-33. 
123. Solomon, C., The epidemiology of polycystic ovary syndrome. Prevalence 
and associated disease risks. Endocrinol. Metab. Clin., 1999. 28: p. 247-263. 
217 
Chapter J 0: Bibliography 
124. Speert, H., Carcinoma o/the endometrium inyoung women,. Surg Gynaecol 
Obstet, 1949. 88: p. 332-336. 
125. Oockerty, M., B. Lovelady, and G. Foust, Carcinoma o/corpus uteri in young 
women. Am J Obstet Gynecoll, 1951. 61. 
126. jafari, K., G. javaheri, and G. Ruiz, Endometrial adenocarcinoma and the 
Stein-Leventhal syndrome. Obstet Gynecol. 1978.51: p.97-100. 
127. Simpson, E., et aI., Local estrogen biosynthesis in males and/emales. Endocr 
Relat Cancer, 1999.6(2): p. 131-7. 
128. Yen, S., Polycystic ovary syndrome (Hyperandrogenic chronic anovulation) .. 
Philadelphia, W.B. Saunders Company., 1999. 
129. Mahajan, O.K., Steroidogenesis in human polycystic ovary. Endocrinol 
Metab Clin North Am, 1988. 17(4): p. 751-69. 
130. Munir, I., et al., Resistin Stimulation 0/ 17(alpha}-Hydroxylase Activity in 
Ovarian Theca Cells in Vitro: Relevance to Polycystic Ovary Syndrome. J Clin 
Endocrinol Metab, 2005. 90(8): p. 4852-4857. 
131. Rodin, A, et aI., Hyperandrogenism in polycystic ovary syndrome. Evidence 
0/ dysregulation 0/ 11 beta-hydroxysteroid dehydrogenase. N Eng) J Ned. 
1994. 330(7): p. 460-5. 
132. Piltonen, T., et al., Ovarian and adrenal steroid production: regulatory role 
0/ LH/HCG. Hum Reprod, 2002. 17(3): p.620-4. 
133. Stewart, P.M., et al., 5 alpha-reductase activity in polycystic ovary syndrome. 
Lancet, 1990. 335(8687): p. 431-3. 
134. Barnes, R, et ai., Pituitary-ovarian responses to na/arelin testing in the 
polycystic ovary syndrome. N Engl J Med, 1989. 320: p. 559-65. 
135. Gilling-Smith, C., et aI., Evidence for a primary abnormality of thecal cell 
steroidogenesis in the polycystic ovary syndrome . . Clin Endocrinol, 1997. 
47(1): p. 93-99. 
136. Zhang, G. and J. Veldhuis, Insulin Drives Transcriptional Activity 0/ the 
CYP17 Gene in Primary Cultures of Swine Theca Cells. Biology of 
Reproduction, 2004. 70: p. 1600. 
137. Zhou, G., et ai., Role 0/ AMP-activated protein kinase in mechanism 0/ 
metformin action. J Clin Invest, 2001. 108(8): p. 1167-74. 
138. OeFronzo, R.A. and AM. Goodman, Efficacy 0/ metformin in patients with 
non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study 
Group. N Engl j Med, 1995. 333(9): p. 541-9. 
139. La Marca, A, et aI., Anti-Mullerian hormone plasma levels in spontaneous 
menstrual cycle and during treatment with FSH to induce ovulation. Hum 
Reprod, 2004. 19(12): p. 2738-41. 
140. Mansfield, R, et aI., Metformin has direct effects on human ovarian 
steroidogenesis. FertiJ Steril, 2003. 79(4): p. 956-62. 
141. Arlt, W., RJ. Auchus, and W.L. Miller, Thiazolidinedlones but not metformin 
directly inhibit the steroidogenic enzymes P450c17 and 3beta -
hydroxysteroid dehydrogenase. J Bioi Chem, 2001. 276(20): p. 16767-71. 
142. Spiegelman, B.M., PPAR-gamma: adipogenic regulator and 
thiazolidinedione receptor. Diabetes, 1998. 4 7( 4): p. 507-14. 
143. Mitwally, M.F., S.F. Witchel, and RF. Casper, Troglitazone: a possible 
modulator%varian steroidogenesis. J Soc Gynecollnvestig, 2002.9(3): p. 
163-7. 
218 
Chapter 10: Bibliography 
144. Balen, A, Hypersecretion of luteinizing hormone and the polycystic ovary 
syndrome. Hum Reprod (Suppl 2), 1993: p. 123-128. 
145. Poretsky, L. and B. Piper. Insulin Resistance, hypersecretion of LH, and a 
dual defect hypothesis for the pathogenesis of polycystic ovarian syndrome. 
Obstetrics & Gynecology, 1994. 84(4, Part 1): p. 613-621. 
146. Chang, R., et aI., Steroid secretion in polycystic ovarian disease after ovarian 
suppression bya long-acting gonadotropin-releasing hormone agonis. J Clin 
Endocrinol Metab, 1983. 56(5): p. 897-903. 
147. Ehrmann, D., R. Barnes, and R. Rosenfield, Polycystic ovary syndrome as a 
form of functional ovarian .hyperandrogenism due to dysregulation of 
androgen secretion. Endocr Rev, 1995. 16(3): p. 322-353. 
148. Rosenfield. R. Ovarian and adrenal function in polycystic ovary syndrome. 
Endocrinol Metab CUn N A. 1999. 28(2): p. 265-293. 
149. Konishi .• M. Koshiyama. and M. Mandai, Increased expression of LH/hCG 
receptors in endometrial hyperplasia and carcinoma in anovulatory women. 
Gynecol Oncol, 1997.65: p. 273-280. 
150. Pigny, P., et al., Elevated serum level of anti-mullerian hormone in patients 
with polycystic ovary syndrome: relationship to the ovarian follicle excess 
and to thefolliculara"est. J Clin Endocrinol Metab, 2003. 88(12): p. 5957-
62. 
151. Heineman. M .• et aI., Hormonal characteristics of women with clinical 
features of the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod BioI, 
1984. 17: p. 263-271. 
152. Legro, R., et al.. Elevated dehydroepiandrosterone suI/ate levels as the 
reproductive phenot:ype in the brothers of women with polycystic ovary 
syndrome. J Clin Endocrinol Metab, 20<12. 87: p. 2134-2138. 
153. Levrant, S., R. Barnes, and R. Rosenfield, A pilot study of the human 
chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod, 
1997.12(7): p. 1416-1420. 
154. Convery, M. and 1.R. Brawer, Thecal and interstitial cells in polycystic 
ovaries (peO) in the rat Anat Ree, 1991.231(3): p. 324-32. 
155. Dunaif. A, Insulin action in the polycystic ovary syndrome. Endocrinol 
Metab Clin North Am, 1999. 28(2): p. 341-59. 
156. Barbieri. R.L.. A Makris, and K.J. Ryan, Insulin stimulates androgen 
accumulation in incubations of human ovarian stroma and theca. Obstet 
Gynecol, 1984.64(3 Suppl): p. 73S-80S. 
157. Nestler, J., et aI., Insulin stimulates testosterone biosynthesis by human 
thecal cells from women with polycystic ovarian syndrome by activating its 
own receptor and using insitol glycan mediators as the signal transduction 
system. journal of clinical endicrinology and metabolism, 1998. 83. 
158. Dunaif, A, Insulin action in the polycystic ovary syndrome. Endocrinol 
Metab Clin N A, 1999. 28(2): p. 341-359. 
159. Dunaif, A, Insulin Resistance and the Polycystic Ovary Syndrome: 
Mechanism and Implications for Pathogenesis. Endocr Rev, 1997. 18(6): p. 
774-800. 
160. Brankin, Y., et ai., BMP-2 and -6 modulate porcine theca cell function alone 
and co-cultured with granulosa cells Domestic Animal Endocrinology, 
2005.29(4): p. 593. 
219 
Chapter 10: Bibliography 
161. Stewart, R.E., et al., Effects of insulin-like growth factor I and insulin on 
proliferation and on basal and luteinizing hormone-induced steroidogenesis 
of bovine thecal cells: involvement of glucose and receptors for insulin-like 
growth factor I and luteinizing hormone. J Anim Sci, 1995. 73(12): p. 3719-
31. 
162. Magoffin, DA and S.R. Weitsman, Effect of insulin-like growth factor-Ion 
cholesterol side-chain cleavage cytochrome P450 messenger ribonucleic 
acid expression in ovarian theca-interstitial cells stimulated to differentiate 
in vitro. Mol Cell Endoerinol, 1993.96(1-2): p. 45-51. 
163. Ehrmann, D., et al., Prevalence of imptJired glucose tolerance and diabetes 
in women with polycystic ovary syndrome. Diabetes care, 1999. 22(1): p. 
141-146. 
164. Wang, J. and R. Norman, Risk factors for the deterioration of glucose 
metabolism in polycystic ovarian syndrome. Repro Biomed Online. 2004. 
9(2): p. 201-204. 
165. Tsilehorozidou, T., C. Overton, and G. Conway, The pathophysiology of 
polycystic ovarian syndrome Clinical Endo. 2004. 60: p. 1-17. 
166. Bhatia, V., Insulin resistance in polycystic ovarian disease. South Med J. 
2005:98(9): p. 902-909. 
167. Henquin, J., et ai., Hierachy of the Beta-cell signal controlling insulin 
secretion. Europe J Clin invest, 2003. 33: p. 742-750. 
168. Diamanti-Kandarakis, E., et ai., Pancreatic beta-cells dysfunction in 
polycystic ovary syndrome. Panminerv3 Med, 2008. 50(4): p. 315-25. 
169. Dunaif, A. and D.T. Finegood, Beta-cell dysfunction independent of obesity 
and glucose intolerance in the polycystic ovary syndrome. ) Clin Endocrinol 
Metab, 1996. 81(3): p. 942-7. 
170. Col ilia, S., N.J. Cox, and D.A. Ehrmann, Heritability of insulin secretion and 
insulin action in women with polycystic ovary syndrome and their /lrst 
degree relatives. ) Clin Endoerinol Metab, 200t. 86(5): p. 2027-31. 
171. Dhindsa, G., et al., Insulin resistance, insulin sensitization and inflammation 
in polycystic ovarian syndrome. J Postgrad Med, 2004. 50: p. 140-144. 
172. Ciaraldi, T.P., et al., Cellular mechanisms of insulin resistance in polycystic 
ovarian syndrome. ) Clin Endoerinol Metab, 1992.75(2): p. 577-83. 
173. Pasquali, R. and F. Casimirri, The impact of obesity on hyperandrogenism 
and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 
(Oxt), 1993.39(1): p. 1-16. 
174. Pasquali, R., A. Gambineri, and U. Pagotto, The impact of obesit;y on 
reproduction in women with polycystic ovary syndrome. BJOG, 2006. 
113(10): p. 1148-59. 
175. Dabelea, D. and G. Klingensmith, Epidemiology of pediatric and adolescent 
diabetes. Informa Health Care, 2008: p. 356. 
176. Legro, R.S., Diabetes prevalence and risk factors in polycystic ovary 
syndrome. Obstet Gyneeol Clin North Am, 2001. 28(1): p. 99-109. 
177. Legro, R.S., et ai., Prevalence and predictors of risk for type 2 diabetes 
mellitus and impaired glucose tolerance in polycystic ovary syndrome: a 
prospective, controlled study in 254 affected women. J Clin Endoerinol 
Metab, 1999. 84(1): p. 165-9. 
220 
Chapter 10: Bibliography 
178. Ohlson, L.O., et aI., The influence of body fat distribution on the incidence of 
diabetes mellitus. 13.S years of follow-up of the participants in the study of 
men born in 1913. Diabetes, 1985. 34(10): p. 1055-8. 
179. Carmina, E., et aI., Abdominal fat quantity and distribution in women with 
polycystic ovary syndrome and extent of its relation to insulin resistance. J 
Clin Endocrinol Metab, 2007. 92(7): p. 2500-5. 
180. Evans, D.J., et ai., Relationship of body fat topography to insulin sensitivity 
and metabolic profiles in premenopausal women. Metabolism, 1984.33(1): 
p.68-75. 
181. Canoy, D., et al., Fat distribution, body mass index and blood pressure in 
22,090 men and women in the Norfolk cohort of the European Prospective 
Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens, 
2004.22(11): p. 2067-74. 
182. Rich-Edwards, J.W., et al., Physical activity, body mass index, and ovulatory 
disorder infertilit;y. Epidemiology, 2002. 13(2): p. 184-90. 
183. Diamanti-Kandarakis, E., Insulin resistance in PCOS. Endocrine, 2006. 
30(1): p. 13-7. 
184. Ek, I., et al., A unique defect in the regulation of visceral fat cell lipolysis in 
the polycystic ovary syndrome as an early link to insulin resistance. 
Diabetes, 2002. Sl(2): p. 484-92. 
185. Dunaif, A., et aI., Evidence for distinctive and intrinsic defects in insulin 
action in polycystic ovary syndrome. Diabetes, 1992.41(10): p.1257-66. 
186. Crosignani, P.G., et aI., Overweight and obese anovulatory patients with 
polycystic ovaries: parallel improvements in anthropometric indices, 
ovarian physiology and fertility rate induced by diet Hum Reprod, 2003. 
18(9): p. 1928-32. 
187. Crosignani, P.G., et al., Resumption of fertility with diet in overweight 
women. Reprod Biomed Online, 2002. 5(1): p. 60-4. 
188. Kiddy, D.S., et al., Differences in clinical and endocrine features between 
obese and non-obese subjects with polycystic ovary syndrome: an analysis of 
263 consecutive cases. Clin Endocrinol (Oxf), 1990.32(2): p. 213-20. 
189. Huber-Buchholz, M.M., D.G. Carey, and R.J. Norman, Restoration of 
reproductive potential by lifestyle modification in obese polycystic ovary 
syndrome: role of insulin sensitivit;y and luteinizing hormone. J Clin 
Endocrinol Metab, 1999. 84(4): p.1470-4. 
190. Tchernof, A. and J.P. Despres, Sex steroid hormones, sex hormone-binding 
globulin, and obesity in men and women. Horm Metab Res, 2000.32(11-
12): p. 526-36. 
191. Belanger, C., et al., Omental and subcutaneous adipose tissue steroid levels 
in obese men. Steroids, 2006. 71(8): p. 674-82. 
192. Zhang, B., et al., Potentiation of insulin stimulation of phosphatidylinositol 
3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese 
hamster ovary cells expressing human insulin receptors and L6 myotubes. J 
Bioi Chern, 1994. 269(41): p. 25735-41. 
193. Rohner-Jeanrenaud, F. and B. Jeanrenaud, The discovery of leptin and its 
impact in the understanding of obesit;y. Eur J Endocrinol, 1996. 135(6): p. 
649-50. 
221 
Chapter J 0: Bibliography 
194. Trayhurn, P. and 1.5. Wood, Adipolcines: inflammation and the pleiotropic 
role of white adipose tissue. Br I Nutr, 2004. 92(3): p. 347-55. 
195. Hauner, H., Secretory factors from human adipose tissue and their 
functional role. Proc Nutr Soc, 2005. 64(2): p. 163-9. 
196. Campos, D.B., et al., The 'beneficial' adipokines in reproduction and fertility. 
Int lObes (Lond), 2008. 32(2): p. 223-31. 
197. Mitchell, M., et al., Adipolcines: implications for female fertility and obesity. 
Reproduction, 2005. 130(5): p. 583-97. 
198. Moschos, 5., J.L. Chan, and C.S. Mantzoros, Leptin and reproduction: a 
review. Fertil Steril, 2002. 77(3): p. 433-44. 
199. Goumenou, AG., et aI., The role of leptin in fertility. Eur I Obstet Gynecol 
Reprod Bioi, 2003. 106(2): p. 118-24. 
200. Mantzoros, C.S., A Dunaif, and J.S. Flier, Leptin concentrations in the 
polycystic ovary syndrome. I Clin Endocrinol Metab, 1997. 82(6): p. 1687-
91. 
201. Mahde, A, M. Shaker, and Z. AI-Mashhadani, Study of Omen tin 1 and Other 
Adipokines and Hormones in PCOS Patients. Oman Med J, 2009. 24(2): p. 
108-18. 
202. Yang, R.Z., et al., Identification of omen tin as a novel depot-specific 
adipokine in human adipose tissue: possible role in modulating insulin 
action. Am J Physiol Endocrinol Metab, 2006. 290(6): p. EI253-61. 
203. Deslypere, I.P., L. Verdonck, and A Vermeulen, Fat tissue: a steroid 
reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985. 
61(3): p. 564-70. 
204. Weyer, C., et aI., Hypoadiponectinemia in obesity and type 2 diabetes: close 
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol 
Metab, 2001. 86(5): p. 1930-5. 
205. Toulis, K.A., et aI., Adiponectin levels in women with polycystic ovary 
syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 
2009.15(3): p. 297-307. 
206. Taponen, 5., et aI., Hormonal profile of women with se/freported symptoms 
of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 
study. I Clin Endocrino) Metab, 2003. 88(1): p. 141-7. 
207. Siiteri, P.K., Adipose tissue as a source of hormones. Am J Clin Nutr, 1987. 
45: p. 277-282. 
208. Belanger, C., et al., Adipose tissue intracrinology: potential importance 0/ 
local androgen/estrogen metabolism in the regulation of adiposity. Honn 
Metab Res, 2002. 34(11-12): p. 737-45. 
209. Blanchette,S., et aI., Expression and activity of 20alpha-hydroxysteroid 
dehydrogenase (AKRICl) in abdominal subcutaneous and omental adipose 
tissue in women. J Clin Endocrinol Metab, 2005. 90(1): p.264-70. 
210. Corbould, AM., 5.1. Judd, and R.J. Rodgers, Expression of types 1, 2, and 317 
beta-hydroxysteroid dehydrogenase in subcutaneous abdominal and intra-
abdominal adipose tissue of women. I Clin Endocrinol Metab, 1998.83(1): 
p.187-94. 
211. Azziz, R., Diagnostic criteria for polycystic ovary syndrome: a reappraisaL 
Fertil Steril, 2005. 83(5): p. 1343-6. 
222 
Chapter 10: Bibliography 
212. Rotterdam, E.A.-S.P.C.W.G., Revised 2003 consensus on diagnostic criteria 
and long-term health risks related to polycystic ovary syndrome. FertiJ 
Steril, 2004. 81(1): p. 19-25. 
213. Willenberg, H.S., et aI., Helpful diagnostic markers of steroidogenesis for 
defining hyperandrogenemia in hirsute women. Steroids, 2008. 73(1): p. 
41-6. 
214. Mcallister, J., M. Byrd, and E. Simpson, The effects of growth factors and 
phorbol esters on steroid biosynthesis in isolated human theca interna and 
granulosa lutien cells in long term culture. The Journal of Clinical 
Endocrinology and Metabolism, 1994. 79(106-112). 
215. Kiriakidou, M., et ai., Expression of steroidogenic acute regulatory protein 
(StAR) in the human ovary. lournal of Clinical Endocrinology & 
Metabolism, 1996. 81(4122). 
216. Yamamoto, N., et al., Growth Differentiation Factor-9 Inhibits 3'5'-
Adenosine Monophosphate-Stimulated Steroidogenesis in Human Granulosa 
and Theca Cells The lournal of Clinical Endocrinology & Metabolism, 2002. 
87. 
217. Mcallister J, M Byrd, and S. E., The effects of growth factors and phorbol 
esters on steroid biosynthesis in isolated human theca interna and 
granulosa lutien cells in long term culture. The Journal of Clinical 
Endocrinology and Metabolism, 1994. 79(106-112). 
218. Hassel, l.a.H., A.R. Fixation Strategies and Formulations used in [He staining. 
Histochem, Cytochem, 1974. 22: p. 229-239. 
219. Ferguson, R.E., et ai., Housekeeping proteins: a preliminary study 
illustrating some limitations as useful references in protein expression 
studies. Proteomics, 2005. 5(2): p. 566-71. 
220. Lequin, R.M., Enzyme immunoassay (EIA)/enzyme-linked immunosorbent 
assay (ELISA). Clin Chern, 2005. 51(12): p. 2415-8. 
221. Gilling-Smith, C., et al., Hypersecretion of androstenedione by isolated 
thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994. 79(4): p. 
1158-65. 
222. Nahum, R., K.J. Thong, and S.G. Hillier, Metabolic regulation of androgen 
production by human thecal cells in vitro. Hum Reprod, 1995. 10(1): p. 75-
81. 
223. Kazuo Kajita1, I.M., Takayuki Hanamotol, Wu Zhiliang2, Takahide Ikeda1, 
Kei Fujioka1, Masahiro Yamauchil, Hideyuki Okada1, Aki Minamil, 
Toshiko Kajital. Yoshihiro Unol, Hiroyuki Morital, Isao Nagan02, Masao 
Takemura3, Mitsuru Seishima3, Yuzo Takahashi2. Tatsuo Ishizuka1. 
Evidence of mature adipocyte proliferation regulated by prolifer;n. Nature 
Preceedings, 2010(4714): p. 1. 
224. Ahima, RS. and I.S. Flier, Adipose tissue as an endocrine organ. Trends 
Endocrinol Metab, 2000. 11(8): p. 327-32. 
225. Zhang, Y., et aI., Positional cloning of the mouse obese gene and its human 
homologue. Nature, 1994.372(6505): p.425-32. 
226. Kim, S. and N. Moustaid-Moussa, Secretory, endocrine and 
autocrine/paracrine function of the adipocyte. I Nutr, 2000. 130(12): p. 
3110S-3115S. 
223 
Chapter 10: Bibliography 
227. Dieudonne, M.N., et at., Androgen receptors in cultured rat adipose 
precursor cells during proliferation and differentiation: regional 
specificities and regulation by testosterone. Endocrine, 1995. 3(7): p. 537-
41. 
228. Dieudonne, M.N., et al., Androgen receptors in human preadipocytes and 
adipocytes: regional specificities and regulation by sex steroids. Am J 
Physiol, 1998. 274(6 Pt 1): p. C1645-52. 
229. Azziz, R, et al., The Androgen Excess and peDS Society criteria for the 
polycystic ovary syndrome: the complete task force report. Fertil Steril, 
2009.91(2): p. 456-88. 
230. Dunaif, A, et al., The insulin-sensitizing agent troglitazone improves 
metabolic and reproductive abnormalities in the polycystic ovary syndrome. 
J Clin Endocrinol Metab, 1996.81(9): p. 3299-306. 
231. Nestler, J.E., et al., Suppression of serum insulin by diazoxide reduces serum 
testosterone levels in obese women with polycystic ovary syndrome. J Clin 
Endocrinol Metab, 1989. 68(6): p. 1027-32. 
232. Manneras-Holm, L., et al., Adipose tissue has aberrant morphology and 
/unction in peDS: enlarged adipocytes and low serum adiponectin, but not 
circulating sex steroids, are strongly associated with insulin resistance. J 
Clin Endocrinol Metab. 96(2): p. E304-11. 
233. Rosenbaum, D., RS. Haber, and A Dunaif, Insulin resistance in polycystic 
ovary syndrome: decreased expression of GLUT-4 glucose transporters in 
adipocytes. Am J Physiol, 1993.264(2 Pt 1): p. EI97-202. 
234. Dunaif, A., et al., Profound peripheral insulin resistance, independent of 
obesity, in polycystic ovary syndrome. Diabetes, 1989.38(9): p. 1165-74. 
235. Faulds, G., et al., Mechanisms behind lipolytic catecholamine resistance of 
subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol 
Metab, 2003. 88(5): p. 2269-73. 
236. Dickerson, E.H., et ai., Insulin resistance and free androgen index correlate 
with the outcome of controlled ovarian hyperstimulation in non-peDS 
women undergoing IVF. Hum Reprod, 2010. 25(2): p. 504-9. 
237. Green, H. and O. Kehinde, An established preadipose cell line and its 
differentiation in culture. I/. Factors affecting the adipose conversion. Cell, 
1975.5(1): p. 19-27. 
238. Khan, AH. and J.E. Pessin, Insulin regulation of glucose uptake: a complex 
interplay of intracellular signalling pathways. Diabetologia, 2002. 45(11): 
p.1475-83. 
239. Monjo, M., E. Pujol, and P. Roca, alpha2- to beta3-Adrenoceptor switch in 
3T3-Ll preadipocytes and adipocytes: modulation by testosterone, 17beta-
estradiol, and progesterone. Am J Physiol Endocrinol Metab, 2005. 289(1): 
p. E145-50. 
240. Rodriguez-Cuenca, S., et ai., Depot differences in steroid receptor expression 
in adipose tissue: possible role of the local steroid milieu. Am J Physiol 
Endocrinol Metab, 2005. 288(1): p. E200-7. 
241. Zeigerer, A, et al., Insulin regulates leptin secretion from 3T3-Ll adipocytes 
by a Pl3 kinase independent mechanism. Exp Cell Res, 2008. 314(11-12): p. 
2249-56. 
224 
Chapter 10: Bibliography 
242. Armelin, HA, Pituitary extracts and steroid hormones in the control of 3T3 
cell growth. Proc Natl Acad Sci USA, 1973. 70(9): p. 2702-6. 
243. Collison, M.1. et at, Sex hormones induce insulin resistance in 3T3-Ll 
adipocytes by reducing cellular content of IRS proteins. Diabetologia, 2000. 
43(11): p. 1374-80. 
244. Limonta, P., et al., Antiprolijerative effects of luteinizing hormone-releasing 
hormone agonists on the human prostatic cancer cell line LNCaP. J Clin 
Endocrinol Metab, 1992.75(1): p. 207-12. 
245. Zhang, H.H., et al., Ceiling culture of mature human adipocytes: use in 
studies of adipocyte junctions. J Endocrinol, 2000. 164(2): p. 119-28. 
246. Flier, J.S., Leptin expression and action: new experimental paradigms. Proc 
Natl Acad Sci USA, 1997.94(9): p. 4242-5. 
247. QuinkIer, M., et aI., Androgen generation in adipose tissue in women with 
simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase 
type 5. J Endocrinol, 2004.183(2): p. 331-42. 
248. Wood, I.S., et at, The prO-inflammatory cytokine IL-18 is expressed in 
human adipose tissue and strongly upregulated by TNFalpha in human 
adipocytes. Biochem Biophys Res Commun, 2005. 337(2): p. 422-9. 
249. Gregoire, F.M., C.M. Smas, and H.S. Sui, Understanding adipocyte 
differentiation. Physiol Rev, 1998. 78(3): p. 783-809. 
250. Janke, J., et al., Mature adipocytes inhibit in vitro differentiation of human 
preadipocytes via angiotensin type 1 receptors. Diabetes, 2002. 51(6): p. 
1699-707. 
251. Bujalska, I.J., et ai., Differentiation of adipose stromal cells: the roles of 
glucocorticoids and 11 beta-hydroxysteroid dehydrogenase. Endocrinology, 
1999. 140(7): p. 3188-96. 
252. Barr, VA, et al., Insulin stimulates both leptin secretion and production by 
rat white adipose tissue. Endocrinology, 1997. 138(10): p. 4463-72. 
253. Chen, C.L., AE. Brodie, and C.Y. Hu, CCAAT/enhancer-binding protein beta 
is not affected by tetrachlorodibenzo-p-dioxin [TCDD) inhibition of 3T3-Ll 
preadipocytedifferentiation. Obes Res, 1997.5(2): p.146-52. 
254. Chawla, A, et al., Peroxisome prolijerator-activated receptor (PPAR) 
gamma: adipose-predominant expression and induction early in adipocyte 
differentiation. Endocrinology, 1994. 135(2): p. 798-800. 
255. Prins, J.B., et al., Tumor necrosis factor-alpha induces apoptosis of human 
adipose cells. Diabetes, 1997.46(12): p. 1939-44. 
256. Prins, J.B. and S. O'Rahilly, Regulation of adipose cell number in man. Clin 
Sci (Lond), 1997.92(1): p. 3-11. 
257. Sieminska, 1.., et al., Serum adiponectin in women with polycystic ovarian 
syndrome and its relation to clinical, metabolic and endocrine parameters. J 
Endocrinol Invest, 2004. 27(6): p. 528-34. 
258. Marsden, P.J., A Murdoch, and R Taylor, Severe impairment of insulin 
action in adipocytes from amenorrheic subjects with polycystic ovary 
syndrome. Metabolism, 1994.43(12): p. 1536-42. 
259. Danforth, E., Jr., Failure of adipocyte differentiation causes type II diabetes 
mellitus? Nat Genet, 2000. 26(1): p. 13. 
260. Yang, x., et at, Evidence of impaired adipogenesis in insulin resistance. 
Biochem Biophys Res Commun, 2004. 317(4): p.1045-51. 
225 
Chapler 10: Bibliography 
261. Gupta, V., et aI., Effects of dihydrotestosterone on differentiation and 
proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell 
Endocrinol, 2008. 296(1-2): p. 32-40. 
262. Aprath-Husmann, I., et aI., Effects of leptin on the differentiation and 
metabolism of human adipocytes. Int JObes Relat Metab Disord, 2001. 
25(10): p.1465-70. 
263. Chen, X. W., et aI., [Experimental study of human adipocyte dedifferentiation 
for adipose tissue engineering]. Nan Fang Vi Ke Da Xue Xue Bao. 2009. 
29(4): p. 606-10. 
264. Smas. e.M. and H.S. Sui, Control of adipocyte differentiation. Biochem J, 
1995.309 (Pt 3): p. 697-710. 
265. Moro, C., et aI., Aerobic exercise training improves atrial natriuretic peptide 
and catecholamine-mediated lipolysis in obese women with polycystic ovary 
syndrome. J elin Endocrinol Metab, 2009.94(7): p. 2579-86. 
266. Sokalska, A, et aI., Statins inhibit growth of human theca-interstitial cells in 
PCOS and non-PCOS tissues independently of cholesterol availability. J Clin 
Endocrinol Metab. 2010. 95(12): p. 5390-4. 
267. Hughes, lA, Management of congenital adrenal hyperplasia. Arch Dis Child, 
1988.63(11): p. 1399-404. 
268. Hiragun, A, Cell and tissue culture models of adipocyte development In New 
Perspective in Adipose Tissue: Structure, Function and Development 
Butterworth, London, 1985: p. 333-352. 
269. Glintborg, D., et aI., Plasma monocyte chemoattrQctant protein-1 (MCP-l) 
and macrophage inflammatory protein-l alpha are increased in patients 
with polycystic ovary syndrome (PCOS) and associated with adiposity, but 
unaffected by pioglitazone treatment elin Endocrinol (Oxt), 2009. 71(5): p. 
652-8. 
270. Hu, W.H., et aI., [Monocyte chemoattractant protein-l and its correlation 
with lipoprotein in polycystic ovary syndrome}. Beijing Da Xue Xue Bao. 
2006.38(5): p. 487-91. 
271. Gonzalez, F., et aI., Evidence of proatherogenlc inflammation in polycystic 
ovary syndrome. Metabolism, 2009. 58(7): p.954-62. 
272. Rebuffe-Scrive, M., Sex steroid hormones and adipose tissue metabolism in 
ovariectomized and adrenalectomized rats. Acta Physiol Scand, 1987. 
129(4): p.471-7. 
273. Sweeney, G., Leptin signalling. Cell Signal, 2002. 14(8): p. 655-63. 
274. Boulton, K.L., et al., Steroid hormone interconversions in human adipose 
tissue in vivo. Metabolism, 1992.41(5): p. 556-9. 
275. Basdevant, A., et al., [Metabolism of sex hormones and adipose tissue}. J 
Gynecol Obstet Bioi Reprod (Paris), 1986.15(2): p. 147-52. 
276. Dieudonne, M.N., et aI., Opposite effects of androgens and estrogens on 
adipogenesis in rat preadipocytes: evidence for sex and site-related 
specificities and possible involvement of insulin-like growth factor 1 
receptor and peroxisome proliferator-activated receptor gamma2. 
Endocrinology, 2000.141(2): p. 649-56. 
277. Thompson, D.L., N. Horton, and R.S. Rittmaster, Androsterone glucuronide 
is a marker of adrenal hyperandrogenism in hirsute women. elln 
Endocrinol (Oxt), 1990.32(3): p. 283-92. 
226 
Chapter J 0: Bibliography 
278. Acien, P., et aI., Insulin, androgens, and obesity in women with and without 
polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril, 
1999. 72(1): p. 32-40. 
279. Schwartz, I.R. and S.K. Roy, Developmental expression of cytochrome P450 
side-chain cleavage and cytochrome P450 17 alpha-hydroxylase messenger 
ribonucleic acid and protein in the neonatal hamster ovary. Bioi Reprod, 
2000.63(6): p. 1586-93. 
280. Wang, H., et al., Exogenous granulocyte-macrophage colony-stimulating 
factor promotes follicular development in the newborn rat in vivo. Hum 
Reprod, 2005. 20(10): p. 2749-56. 
281. Blouin, K., et ai., Pathways of adipose tissue androgen metabolism in 
women: depot differences and modulation by adipogenesis. Am I Physiol 
Endocrinol Metab, 2009. 296(2): p. E244-55. 
282. McTernan, P.G., et ai., Glucocorticoid regulation ofp450 aromatase activity 
in human adipose tissue: gender and site differences. J Clin Endocrinol 
Metab, 2002. 87(3): p. 1327-36. 
283. Ghosh, S., et al., IKKbeta mediates cell shape-induced aromatase expression 
and estrogen biosynthesis in adipose stromal cells. Mol Endocrinol, 2009. 
23(5): p.662-70. 
284. Blouin, K., et al., Androgen metabolism in adipose tissue: recent advances. 
Mol Cell Endocrinol, 2009. 301(1-2): p. 97-103. 
285. Anderson, L.A, et' al., The effects of androgens and estrogens on 
preadipocyte proliferation in human adipose tissue: influence of gender and 
site. I Clin Endocrinol Metab, 2001. 86(10): p. 5045-51. 
286. Garcia, E., et al., Modulation of rat preadipocyte adipose conversion by 
androgenic status: involvement of CIEBPs transcription factors. J 
Endocrinol, 1999. 161(1): p. 89-97. 
287. Lea-Currie, V.R., P. Wen, and M.K. McIntosh, Dehydroepiandrosterone 
reduces proliferation and differentiation of 3T3-Ll preadipocytes. Biochem 
Biophys Res Commun, 1998.248(3): p. 497-504. 
288. Lacasa, D., et al., Progesterone stimulates adipocyte determination and 
differentiation 11sterol regulatory element-binding protein lc gene 
expression. potential mechanism for the lipogenic effect of progesterone in 
adipose tissue. J Bioi Chern, 2001. 276(15): p. 11512-6. 
289. Tausk, M., Pharmacology of the endocrine system and related drugs. 
Progesterone, pro-gestational drugs, and antifertility agents. International 
Encyclopedia of Pharmacology and Therapeutics, 1971. 
290. Bjomtorp, P., The regulation of adipose tissue distribution in humans. Int J 
Obes Relat Metab Disord, 1996.20(4): p. 291-302. 
291. Pasquali, R. and V. Vicennati, Activity of the hypothalamic-pituitary-
adrenal axis in different obesity phenotypes. Int JObes Relat Metab Disord, 
2000.24 Suppl2: p. S47-9. 
292. Vettor, R., et al., Leptin and the hypothalamic-pituitary-adrenal axis activity 
in women with different obesity phenotypes. Int JObes Relat Metab Disord, 
1997.21(8): p. 708-11. 
293. Hautanen, A, Synthesis and regulation of sex hormone-binding globulin in 
obesity. Int JObes Relat Metab Disord, 2000. 24 Suppl 2: p. S64-70. 
227 
Chapter J 0: Bibliography 
294. Wildes, J.E., et aI., Self-reported binge eating in severe pediatric obesity: 
impact on weight change in a randomized controlled trial of family-based 
treatment Int JObes (Land), 2010. 34(7): p. 1143-8. 
295. Harlass, F.E., et aI., Weight loss is associated with correction of 
gonadotropin and sex steroid abnormalities in the obese anovulatory 
female. Fertil Steril, 1984. 42(4): p.649-52. 
296. Acien, P., M. Mauri, and M. Gutierrez, Clinical and hormonal effects of the 
combination gonadotrophin-releasing hormone agonist plus oral 
contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone 
acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-
related hyperandrogenisms. Hum Reprod, 1997. 12(3): p. 423-9. 
297. Glueck, C.J., et aI., Metformin-induced resumption of normal menses in 39 of 
43 (91%) previously amenorrheic women with the polycystic ovary 
syndrome. Metabolism, 1999.48(4): p. 511-9. 
298. Blouin, K., et aI., Effects of androgens on adipocyte differentiation and 
adipose tissue explant metabolism in men and women. Clin Endocrinol 
(Oxt), 2010. 72(2): p. 176-88. 
299. Campbell, B.K., D.T. Baird, and R. Webb, Effects of dose of LH on androgen 
production and luteinization of ovine theca cells cultured in a serum-free 
system. J Reprod Fertil, 1998.112(1): p. 69-77. 
300. Dos Santos, E., et aI., In vitro effects of chorionic gonadotropin hormone on 
human adipose development I Endocrinol, 2007.194(2): p. 313-25. 
301. Grulet, H., et aI., Roles of LH and insulin resistance in lean and obese 
polycystic ovary syndrome. Clin Endocrinol (Oxt), 1993.38(6): p. 621-6. 
302. Poretsky, L., I. Clemons, and K. Bogovich, Hyperinsulinemia and human 
chorionic gonadotropin synergistically promote the growth of ovarian 
follicular cysts in rats. Metabolism, 1992.41(8): p. 903-10. 
303. Cara, I.F.R., RL., Insulin-like growth factor I and insulin potentiate 
luteinizing hormone-induced androgen synthesis by rat ovarian thecal-
interstitial cells. Endocrinology, 1988. 123: p. 733-9. 
304. Anttila, L., et aI., Insulin hypersecretion together with high luteinizing 
hormone concentration augments androgen secretion in oral glucose 
tolerance test in women with polycystic ovarian disease. Hum Reprod, 1993. 
8(8): p. 1179-83. 
305. Schaffler, A, et aI., Hypothesis paper Brain talks with fat--evidence for a 
hypothalamic-pituitary-adipose axis? Neuropeptides, 2005. 39(4): p.363-
7. 
306. Tonacchera, M., et al., Effects of a thyroid-stimulating human monoclonal 
autoantibody (M22) on functional activity of LH and FSH receptors. Thyroid, 
2006.16(11): p. 1085-9. 
307. Mukhina, S., et al., Phenotypic conversion of human mammary carcinoma 
cells by autocrine human growth hormone. Proc Natl Acad Sci USA, 2004. 
101(42): p. 15166-71. 
308. Shahparaki, A, L. Grunder, and A Sorisky, Comparison of human 
abdominal subcutaneous versus omental preadipocyte differentiation in 
primary culture. Metabolism, 2002. 51(9): p. 1211-5. 
228 
Chapter 10: Bibliography 
309. Shillabeer, G., J.M. Forden, and D.C. Lau, Induction of preadipocyte 
differentiation by mature fat cells in the rat J Clin Invest, 1989. 84(2): p. 
381-7. 
310. F. S a r a ~ , , S.Y., F. SaygIll, G. Ozgen, C. YIlmaz, T. Kabalak, M. Tiiziin Ege 
University Endocrinology and Metabolism Department, Izmir, Turkey, 
Insulin alters the proliferation of subcutaneous and viceral adipose cells. 
Biotechnol. & Biotechnol. Eq., 2004. 
311. Ascoli, M., F. Fanelli, and D.L. Segaloff, The lutropin/choriogonadotropin 
receptor, a 2002 perspective. Endocr Rev, 2002. 23(2): p. 141-74. 
312. Zhang, M., et al., Expression and localization of luteinizing hormone 
receptor in the female mouse reproductive tract Bioi Reprod, 2001. 64(1): 
p.179-87. 
313. Rao, C.V., An overview 0/ the past, present, and future of nongonadal 
LH/hCG actions in reproductive biology and medicine. Semin Reprod Med, 
2001.19(1): p. 7-17. 
314. Menon, K.M., et al., Regulation of luteinizing hormone/human chorionic 
gonadotropin receptor expression: a perspective. Bioi Reprod, 2004. 70(4): 
p.861-6. 
315. Ziecik, A.I., et al., Nongonadal LH/hCG receptors in pig: functional 
importance and parallels to human. Semin Reprod Med, 2001. 19(1): p. 
19-30. 
316. Ziecik, A.I., et al., Nongonadal LH receptors, their involvement in female 
reproductive function and a new applicable approach. Vet J, 2005. 169(1): 
p.75-84. 
317. Shores, E., H. Picton, and M. Hunter, Differential regulation of pig theca cell 
steroidogenesis by LH, insulin-like growth factor I and granulosa cells in 
serum-free culture. Journal of Reproduction and Fertility, 2000. 118: p. 
211-219. 
318. Erickson, G.F. and K.J. Ryan, Stimulation of testosterone production in 
isolated rabbit thecal tissue by LH/FSH, dibut;yryl cyclic AMP, PGE2aipha, 
and PCE2. Endocrinology, 1976.99(2): p. 452-8. 
319. Schanbacher, B.D. and S.E. Echternkamp, Testicular steroid secretion in 
response to GnRH-mediated LH and FSH release in bulls. J Anim Sci, 1978. 
47(2): p. 514-20. 
320. Minegishi, T., C. Delgado, and M.L. Dufau, Phosphorylation and 
glycosylation of the luteinizing hormone receptor. Proc Natl Acad Sci USA, 
1989.86(5): p.1470-4. 
321. Bluher, S., J. Kratzsch, and W. Kiess, Insulin-like growth factor I, growth 
hormone and insulin in white adipose tissue. Best Pract Res Clin Endocrinol 
Metab, 2005.19(4): p. 577-87. 
322. Richardson, R.L., et al., Adipocyte development in primary rat cell cultures: 
a scanning electron microscopy study. Anat Rec, 1986.216(3): p. 416-22. 
323. Hansen, L.H., et al., Characterization of the inhibitory effect of growth 
hormone on primary preadipocyte differentiation. Mol Endocrinol, 1998. 
12(8): p.1140-9. 
324. Yamamura, N., et aI., Expression of messenger RNA for gonadotropin 
receptor in the granulosa layer during the ovulatory cycle of hens. Comp 
Biochem Physiol A Mollntegr Physiol, 2001. 129(2-3): p. 327-37. 
229 
Chapter 10: Bibliography 
325. Zhou, f., et al., Insulin-like growth factor binding protein 4 expression 
parallels luteinizing hormone receptor expression and follicular 
luteinization in the primate ovary. Bioi Reprod, 2003. 69(1): p. 22-9. 
326. Zhang, F.P., T. EI-Hefnawy, and I. Huhtaniemi, Regulation of luteinizing 
hormone receptor gene expression by insulin-like growth factor-I in an 
immortalized murine Leydig tumor cell line (BLT-l). BioI Reprod, 1998. 
59(5): p. 1116-23. 
327. Onagbesan, O.M., M.J. Peddie, and J. Williams, Regulation of cell 
proliferation and estrogen synthesis by ovine LH, IGF-I, and EGF in theca 
interstitial cells of the domestic hen cultured in defined media. Gen Comp 
Endocrinol, 1994. 94(2): p. 261-72. 
328. Sriraman, V., et ai., Effect of deprival of LH on Leydig cell proliferation: 
involvement of PCNA, cyclin D3 and IGF-l. Mol Cell Endocrinol, 2000. 
162(1-2): p. 113-20. 
329. Lobner, D., Comparison of the LDH and MIT assays for quantifying cell 
death: validity for neuronal apoptosis? J Neurosci Methods, 2000. 96(2): p. 
147-52. 
330. Huang, K. T., Y.H. Chen, and A.M. Walker, Inaccuracies in Mrs assays: major 
distorting effectso/medium, serum albumin, and/attyacids. Biotechniques, 
2004.37(3): p. 406,408,410-2. 
331. Chen, L., et al., LY294002 enhances cytotoxicity o/temozolomide in glioma 
by down-regulation of the PI3K/Akt pathway. Mol Med Report, 2012. 5(2): 
p.575-9. 
332. Monjo, M., et ai., Direct effects 0/ testosterone, 17 beta-estradiol, and 
progesterone on adrenergic regulation in cultured brown adipocytes: 
potential mechanism for gender-dependent thermogenesis. Endocrinology, 
2003. 144(11): p. 4923-30. 
333. Mendes, A.M., R.f. Madon, and D.J. Flint, Effects of cortisol and progesterone 
on insulin binding and lipogenesis in adipocytes from normal and diabetic 
rats. f Endocrinol, 1985. 106(2): p. 225-31. 
334. Hamosh, M. and P. Hamosh, The effect of estrogen on the lipoprotein lipase 
activity of rat adipose tissue. J Clin Invest, 1975.55(5): p. 1132-5. 
335. Zhang, Y., et al., Progesterone metabolism in adipose cells. Mol Cell 
Endocrinol, 2009. 298(1-2): p. 76-83. 
336. Morey, A.I<., et aI., Estrogen and progesterone inhibit vascular smooth 
muscle proliferation. Endocrinology, 1997. 138(8): p. 3330-9. 
337. Teede, H.J. and R. Norman, Polycystic ovarian syndrome: insights into the 
enigma that is PCDS today. Endocrine, 2006. 30(1): p. 1-2. 
338. Hart, R. and R. Norman, Polycystic ovarian syndrome--prognosis and 
outcomes. Best Pract Res Clin Obstet Gynaecol, 2006. 20(5): p. 751-78. 
339. Franks,S., Polycystic ovary syndrome. N Engl f Med, 1995. 333(13): p. 853-
61. 
340. Erickson, G.F., et ai., The ovarian androgen producing cells: a review of 
structure/function relationships. Endocr Rev, 1985.6(3): p. 371-99. 
341. Puurunen, J., et ai., Adrenal androgen production capacity remains high up 
to menopause in women with polycystic ovary syndrome. J Clin Endocrinol 
Metab, 2009. 94(6): p. 1973-8. 
230 
Chapter 10: Bibliography 
342. Adashi, E.Y., The climacteric ovary as a functional gonadotropin-driven 
androgen-producing gland. Fertil Steril, 1994.62(1): p. 20-7. 
343. Izhar, B., The Polycystic ovary syndrome: What does insulin resistance have 
to do with it? Reproductive BioMedicine Online, 2003. 6(1): p. 36 - 42. 
344. Jamnongjit, M. and S. Hammes, Ovarian Steriods: The Good, the Bad and the 
Signals that Raise Them. Cell Cycle, 2006. 5(11): p. 1178-1183. 
345. Stoklosowa, S., J. Bahr, and E. Gregoraszczuk, Some morphological and 
functional characteristics of cells of the porcine theca interna in tissue 
culture. Bioi Reprod, 1978.19(4): p. 712-9. 
346. Talbot, J.A., et aI., Molecular scanning of the insulin receptor gene in women 
with polycystic ovarian syndrome. J Clin Endocrinol Metab, 1996. 81(5): p. 
1979-83. 
347. Dunaif, A and C. Book, Selective Insulin Resistance in the Polycystic Ovary 
Syndrome. J Clin Endocrinol Metab,1999. 84(9): p. 3110. 
348. Wu, x.K., et al., Selective ovary resistance to insulin signaling in women with 
polycystic ovary syndrome. Fertil Steril, 2003. 80(4): p. 954-65. 
349. Nestler, J.E., et al., Insulin stimulates testosterone biosynthesis by human 
thecal cells from women with polycystic ovary syndrome by activating its 
own receptor and using inositolglycan mediators as the signal transduction 
system. J Clin Endocrinol Metab, 1998.83(6): p. 2001-5. 
350. Sam, K., B. Milton, and T. Hearn, Isolation of thecal cells: an assessment of 
purit;)' and sterOidogenic potential Journal of Biochemical and Biophysical 
Methods 2000(2): p. 169-181. 
351. Stoklsowa, S., Tissue culture association manual. Culture of Follicular Theca 
Interna Methods of cell SCience, 1975. 1(4): p. 205,208. 
352. Kataoka, N., et al., Preparation of highly purified porcine theca cells. J 
Reprod Fertil, 1994. 102(1): p. 73-9. 
353. Apter, D., et al., Accelerated 24-hour luteinizing hormone pulsatile activity 
in adolescent girls with ovarian hypera ndrogen ism: relevance to the 
developmental phase of polycystic ovarian syndrome. J Clin Endocrinol 
Metab,1994. 79(1): p.119-25. 
354. Stoklosowa, 5., E.L. Gregoraszczuk, and L. Zabaglo, LHRH - modulator of 
progesterone and estradiol secretion by theca and granulosa cells on 
porcine follicle in mono- and co-culture. Endocr Regul, 1996. 30(1): p. 45-
50. 
355. Hillier, S.G., et al., Effect of recombinant activin on androgen synthesis in 
cultured human thecal cells. J Clin Endocrinol Metab, 1991. 72(6): p. 1206-
11. 
356. Porter, T.E., et al., Differential steroid production between theca interna 
and theca externa (ells: a three-cell model for follicular steroidogenesis in 
avian species. Endocrinology, 1989. 125(1): p. 109-16. 
357. Franks,S., et al., Insulin action in the normal and polycystic ovary. 
Endocrinol Metab Clin North Am, 1999.28(2): p. 361-78. 
358. Manna, P.R., M.T. Dyson, and D.M. Stocco, Regulation of the steroidogenic 
acute regulatory protein gene expression: present and future perspectives. 
Mol Hum Reprod, 2009.15(6): p. 321-33. 
359. Magoffin, DA, Ovarian theca cell. Int J Biochem Cell BioI, 2005. 37(7): p. 
1344-9. 
231 
Chapler 10: Bibliography 
360. Gilling-Smith, C., et al., Evidence for a primary abnormality of thecal cell 
steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 
1997.47(1): p.93-9. 
361. Manneras, L., et al., A new rat model exhibiting both ovarian and metabolic 
characteristics of polycystic ovary syndrome. Endocrinology, 2007.148(8): 
p.3781-91. 
362. Kondo, H., et al., Differential regulation of intestinal lipid metabolism-
related genes in obesity-resistant AI] vs. obesity-prone CS7BLI6J mice. Am J 
Physiol Endocrinol Metab, 2006. 291(5): p. E1092-9. 
363. Hughesdon, P.E., Morphology and morphogenesis of the Stein-Leventhal 
ovary and of so-called "hyperthecosis". Obstet Gynecol Su[V, 1982.37(2): p. 
59-77. 
364. Givens, J.R, et aI., Features of Turner's syndrome in women with polycystic 
ovaries. Obstet Gynecol, 1975. 4S(6): p. 619-24. 
365. Kim, M.H., et al., Ovarian hyperandrogenism with normal and abnormal 
histologic findings of the ovaries. Am J Obstet Gynecol, 1979. 134(4): p. 
445-52. 
366. Ortega, I., et al., Simvastatin reduces steroidogenesis by inhibiting Cyp17al 
gene expression in rat ovarian theca-interstitial cells. Bioi Reprod, 2012. 
86(1): p. 1-9. 
367. la Marca, A., et aI., Met/ormin treatment reduces ovarian cytochrome p_ 
4S0c17alpha response to human chorionic gonadotrophin in women with 
insulin resistance-related polycystic ovary syndrome. Hum Reprod, 2000. 
15(1): p. 21-3. 
368. Book, C.B. and A Dunaif, Selective insulin resistance in the polycystic ovary 
syndrome. J Clin Endocrinol Metab, 1999.84(9): p. 3110-6. 
369. Dunaif, A, et aI., Excessive insulin receptor serine phosphorylation in 
cultured fibroblasts and in skeletal muscle. A potential mechanism for 
insulin resistance in the polycystic ovary syndrome. J Clin Invest, 1995. 
96(2): p. 801-10. 
370. Magoffin, DA and S.R Weitsman, Insulin-like growth factor-I regulation of 
luteiniZing hormone (LH) receptor messenger ribonucleic acid expression 
and LH-stimulated signal transduction in rat ovarian theca-interstitial cells. 
Bioi Reprod, 1994. 51(4): p. 766-75. 
371. Zhang, G., J.C. Garmey, and J.D. Veldhuis, Interactive stimulation by 
luteinizing hormone and insulin of the steroidogenic acute regulatory 
(StAR) protein and 17alpha-hydroxylasej17,20-lyase (CYP17) genes in 
porcine theca cells. Endocrinology, 2000.141(8): p. 2735-42. 
372. Nestler, J.E. and D.J. Jakubowicz, Decreases in ovarian cytochrome P4S0c17 
alpha activity and serum free testosterone after reduction of insulin 
secretion in polycystic ovary syndrome. N Eng) J Med, 1996. 335(9): p. 617-
23. 
373. Rosenfield, R.L., et aI., Dysregulation of cytochrome P4S0c 17 alpha as the 
cause of polycystic ovarian syndrome. Fertil Steril, 1990. S3(5): p. 785-91. 
374. Ehrmann, D., et al., Detection of functional ovarian hyperandrogenism in 
women with androgen excess. N Engl J Med, 1992.327: p. 157-62. 
375. Erickson, G.F., et aI., Granulosa cells of polycystic ovaries: are they normal 
or abnormal? Hum Reprod, 1992. 7(3): p. 293-9. 
232 
Chapter 10: Bibliography 
376. Yen, S., P. VeJa, and J. Rankin, Inappropriate secretion offollicle-stimulating 
hormone and luteinizing hormone in polycystic ovarian disease. 1 Clin 
Endornnol Metab, 1970. 30(4): p. 435-442. 
377. Chang, R.I., et aI., Insulin resistance in nonobese patients with polycystic 
ovarian disease. I Clin Endocrinol Metab, 1983. 57(2): p. 356-9. 
378. Corbould, A., Effects of androgens on insulin action in women: is androgen 
excess a component of female metabolic syndrome? Diabetes Metab Res 
Rev, 2008. 24(7): p. 520-32. 
379. DeUgarte, C.M., A.A. Bartolucci, and R. Azziz, Prevalence of insulin 
resistance in the polycystic ovary syndrome using the homeostasis model 
assessment. Fertil Steril, 2005. 83(5): p. 1454-60. 
380. Escobar-Morreale, H.F. and I.L. San Millan, Abdominal adiposity and the 
polycystic ovary syndrome. Trends Endocrinol Metab, 2007. 18(7): p. 266-
72. 
381. Norman, R., Hyperandrogenaemia and the ovary. Molecular and Cellular 
Endocrinology, 2002.191(1): p.113-119. 
382. Norman, R.I., et aI., Polycystic ovary syndrome. Lancet, 2007. 370(9588): p. 
685-97. 
383. Risch, HA, Hormonal etiology of epithelial ovarian cancer, with a 
hypothesis concerning the role of androgens and progesterone. I Natl 
Cancer Inst, 1998. 90(23): p. 1774-86. 
384. Bard, D.R., I. Lasnitzki, and T. Mizuno, Metabolism of testosterone by the 
epithelium and mesenchyme of the rat urogenital sinus. J Endocrinol, 1979. 
83(2): p. 211-8. 
385. Bard, D.R., I. Lasnitzki, and T. Mizuno, Testosterone metabolism in the 
urogenital epithelium and mesenchyme of the foetal rat [proceedings}. J 
Endocrinol, 1979.83(1): p. 35P. 
386. Sairam, M.R., et aI., Early obesity and age-related mimicry of metabolic 
syndrome in female mice with sex hormonal imbalances. Obesity (Silver 
Spring), 2006.14(7): p. 1142-54. 
387. Legro, R.S., The genetics of obesity. Lessons for polycystic ovary syndrome. 
Ann N Y Acad Sci, 2000. 900: p. 193-202. 
388. Balen, A.H., et al., Polycystic ovary syndrome: the spectrum of the disorder 
in 1741 patients. Hum Reprod, 1995.10(8): p. 2107-11. 
389. Kirschner, MA, et al., Androgen-estrogen metabolism in women with upper 
body versus lower body obesity. I Clin Endocrinol Metab, 1990. 70(2): p. 
473-9. 
390. Elbers, J.M., et aI., Long-term testosterone administration increases visceral 
fat in female to male transsexuals. I Clin Endocrinol Metab, 1997. 82(7): p. 
2044-7. 
391. Brandon, E.F., et al., An update on in vitro test methods in human hepatic 
drug biotransformation research: pros and cons. Toxicol Appl Pharmacol, 
2003. 189(3): p. 233-46. 
392. Noll, T., et al., A cell-culture reactor for the on-line evaluation of 
radiopharmaceuticals: evaluation of the lumped constant of FDG in human 
glioma cells. J Nucl Med, 2000.41(3): p. 556-64. 
393. Skelin, M., M. Rupnik, and A. Cencic, Pancreatic beta cell lines and their 
applications in diabetes mellitus research. ALTEX, 2010. 27(2): p. 105-13. 
233 
Chapter 10: Bibliography 
394. Liu, J., et aI., cAMP-dependent protein kinase activation inhibits 
proliferation and enhances apoptotic effect of tumor necrosis factor-alpha 
in NCI-H295R adrenocortical cells. J Mol Endocrinol. 2004. 33(2): p. 511-
22. 
395. Kurino. M.. et aI., Cyclic AMP inhibits activation of mitogen-activated 
protein kinase and cell proliferation in response to growth factors in 
cultured rat cortical astrocytes. f Neurochem. 1996. 67(6): p. 2246-55. 
396. Bornfeldt, K.E .• et al.. The mitogen-activated protein kinase pathway can 
mediate growth inhibition and proliferation in smooth muscle cells. 
Dependence on the availability of downstream mrgets. J Clin Invest, 1997. 
100(4): p. 875-85. 
397. Sharpless. f., Polycystic ovarian syndrome and the membolic syndrome. 
Clinical Diabetes, 2003. 21(4): p. 154-161. 
398. Barbieri, R.L., et aI., Insulin stimulates androgen accumulation in 
incubations of ovarian stroma obmined from women with 
hyperandrogenism. f Clin Endocrinol Metab.1986. 62(5): p.904-10. 
399. Gambineri, A., et aI., Obesity and the polycystic ovary syndrome. Int f Obes 
Relat Metab Disord, 2002. 26(7): p.883-96. 
400. Soule. S.G., Neuroendocrinology of the polycystic ovary syndrome. Baillieres 
Clin Endocrinol Metab, 1996. 10(2): p. 205-19. 
401. Preziosi, P., et aI., Interrelation between plasma sex hormone-binding 
globulin and plasma insulin in healthy adult women: the telecom study. J 
Clin Endocrinol Metab. 1993.76(2): p. 283-7. 
402. Nestler, f.E., Relation of adrenal androgen to insulin levels. Ann Intern Med, 
1993.118(10): p. 826. 
403. Magoffin. DA and S.R. Weitsman. Insulin-like growth factor-I stimulates 
the expression of 3 beta-hydroxysteroid dehydrogenase messenger 
ribonucleic acid in ovarian theca-interstitial cells. Bioi Reprod. 1993. 
48(5): p. 1166-73. 
404. Jakimiuk, A.J., et al .• Luteinizing hormone receptor, steroidogenesis acute 
regulatory protein, and steroidogenic enzyme messenger ribonucleic acids 
are overexpressed in thecal and granulosa cells from polycystic ovaries. J 
Clin Endocrinol Metab. 2001. 86(3): p. 1318-23. 
405. Attia, G.R., W.E. Rainey, and B.R. Carr, Metformin directly inhibits androgen 
production in human thecal cells. FertiJ Steril, 2001. 76(3): p. 517-24. 
406. Nestler, J.E., et al.. Effects of metformin on spontaneous and c1omiphene-
induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998. 
338(26): p. 1876-80. 
407. Ulloa-Aguirre. A., et aI., Effects of met form in on inappropriate LH release in 
women with polycystic ovarian syndrome and insulin resistDnce. Reprod 
Biomed Online. 2006. 12(6): p. 669-83. 
408. Richards, f.S .• Maturation of ovarian follicles: actions and interactions of 
pituitary and ovarian hormones on follicular cell differentiation. Physiol 
Rev, 1980.60(1): p. 51-89. 
409. Geffner, M., et al.. Persistence of insulin resistance in polycystic ovarian 
disease after inhibition of ovarian steroid secretion. Fernl Steril 1986. 45: p. 
327-33. 
234 
Chapter 10: Bibliography 
410. Rojas, I.M., 1.1. Oliva, and E. Santos, Mammalian son of sevenless Guanine 
nucleotide exchange factors: old concepts and new perspectives. Genes 
Cancer, 2011. 2(3): p. 298-305. 
411. Camps, M., A. Nichols, and S. Arkinstall, Dual specificity phosphatases: a 
gene family for control of MAP kinase function. FASEB I, 2000. 14(1): p. 6-
16. 
412. Keyse, S.M., Protein phosphatases and the regulation of mitogen-activated 
protein kinase signalling. Curr Opin Cell Bioi, 2000. 12(2): p. 186-92. 
413. Alberts, B., The Molecular Biology of the Cell. Garland Science, New York, 
2002. 
414. Nelson-Degrave, V.L, et aI., Alterations in mitogen-activated protein kinase 
kinase and extracellular regulated kinase signaling in theca cells contribute 
to excessive androgen production in polycystic ovary syndrome. Mol 
Endocrinol, 2005.19(2): p. 379-90. 
415. Fukuda, S., et aI., Luteinizing hormone-induced Akt phosphorylation and 
androgen production are modulated by MAP Kinase in bovine theca cells. J 
Ovarian Res, 2009. 2(1): p. 17. 
416. Marino, M., F. Acconcia, and A. Trentalance, Biphasic estradiol-induced AKT 
phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol 
Bioi Cell, 2003. 14(6): p. 2583-91. 
417. Downward, I., Ras signalling and apoptosis. Curr Opin Genet Dev, 1998. 
8(1): p. 49-54. 
418. Downward, I., Mechanisms and consequences of activation of protein kinase 
B/Akt Curr Opin Cell Bioi, 1998.10(2): p. 262-7. 
419. Seger, R., et al., The ERK signaling cascade inhibits gonadotropin-
stimulated steroidogenesis. I Bioi Chern, 2001. 276(17): p. 13957-64. 
420. Tajima, K., et al., Luteinizing hormone-induced extracellular-signal 
regulated kinase activation differently modulates progesterone and 
androstenedione production in bovine theca cells. Endocrinology, 2005. 
146(7): p. 2903-10. 
421. de Rooij, I., et al., Epac ;s a Rapl guanine-nucleotide-exchange factor 
directly activated by cyclic AMP. Nature, 1998.396(6710): p. 474-7. 
235 
Chapter 10: Bibliography 
1. Armstrong, D.T. and I.H. Dorrington, Estrogen biosynthesis in the ovaries 
and testes. Adv Sex Horm Res, 1977.3: p. 217-58. 
2. McMinn, R., Lasts Anatomy, Regional and Applied. 2003(9): p. 391. 
3. Cunningham, D., Cunninghams Text book of Anatomy. 1818.5. 
4. Jones, I.H., Menstruation: the curse of Eve. Nurs Times, 1980. 76(10): p. 
404-6. 
5. Rosenblatt, P., Menstrual Cycle. MERCK Medical Journal, Womens Health 
Issue, 2007. 
6. Erickson, G.F. and S. Shimasaki, The physiology of folliculogenesis: the role 
of novel growth factors. Fertility and Sterility, 2001. 76(5): p.943-949. 
7. Carla, R., et al., Novel Signal Transduction Pathway for Luteinizing 
Hormone and Its Interaction with Insulin: Activation of Janus Kinase/Signal 
Transducer and Activator of Transcription and Phosphoinositol 3-
Kinase/Akt Pathways. Endicrinology, 2003.144(2): p.638-647. 
8. Rosenfield, L., Ovarian and adrenal function in polycystic ovary syndrome. 
Endocrinol Metab Clin North Am, 1999.28. 
9. Evans, G., et al., Estrogen, Androgen, and Progesterone Biosynthesis by 
Theca and Granulosa of Preovulatory Follicles in the Pig. Biology of 
Reproduction, 1981. 25: p. 673-682. 
10. Crews, D., et al., The Relative Effectiveness of Estrone, Estradiol-17P, and 
Estriol in Sex Reversal in the Red-Eared Slider {Trachemys scripta), a Turtle 
with Temperature-Dependent Sex Determination General and Comparative 
Endocrinology, 1996.102(3): p. 317-326. 
11. Cheng, x., et al., Endocrine regulation of gender-divergent mouse organic 
anion-transporting polypeptide (Oatp) expression. Mol Pharmacol, 2006. 
70(4): p. 1291-7. 
12. Dochi, M., et al., Relationship between shift work and hypercholesterolemia 
injapan. Scand I Work Environ Health, 2008. 34(1): p. 33-9. 
13. Sauerwein, H. and H.H. Meyer, Androgen and estrogen receptors in bOVine 
skeletal muscle: relation to steroid-induced allometric muscle growth. J 
Anim Sci, 1989.67(1): p. 206-12. 
14. Bremer, A and W. Miller, The serine phosphorylation hypothesis Of 
polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia 
and insulin resistance. Fertility and Sterility, 2008. 89(5): p. 1039-1048. 
15. Check, J.H., et aI., The effect of follicle-maturing drugs on mid-cycle 
androgen levels in women with normal baseline levels. Gynecol Endocrinol. 
1992.6(2): p. 107-11. 
16. Michael, RP .• et al.. Artificial menstrual cycles, behaviour and the role of 
androgens in female rhesus monkeys. Nature, 1978.275(5679): p. 439-40. 
17. Buyalos, RP., et al., Androgen response to hypothalamic-pituitary-adrenal 
stimulation with naloxone in women with myotonic muscular dystrophy. J 
Clin Endocrinol Metab, 1998. 83(9): p. 3219-24. 
18. Sinha-Hikim, I., et al., Androgen receptor in human skeletal muscle and 
cultured muscle satellite cells: up-regulation by androgen treatment J Clin 
Endocrinol Metab, 2004. 89(10): p. 5245-55. 
19. Blouin, K., A. Boivin, and A Tchernof, Androgens and body fat distribUtion. 
J Steroid Biochem Mol Bioi, 2008. 108(3-5): p. 272-80. 
236 
Chapter J 0: Bibliography 
20. Burger, H., Androgen production in women Fertil Steril, 2002. 77(4): p. 3-
5. 
21. Heffner. L. Human Reproduction ata Glance. 2001. 
22. Davis, S., The clinical use of androgens in female sexual disorders Journal of 
Sex & Marital Therapy, 1998. 24(3): p. 158-168. 
23. Pitkin, J., et aI., Obstetrics and gynaecology. 2003. 
24. Blandau, R., E. Warrick, and R.E. Rumery, In vitro cultivation of fetal mouse 
ovaries. Fertil Steril, 1965.16(6): p. 705-15. 
25. Sanderson, J., The Steroid Hormone Biosynthesis Pathway as a Target for 
Endocrine-Disrupting Chemicals. Toxicol. Sci., 2006. 94(1): p. 3-21. 
26. Biting, M., et al, Women with polycystic ovary syndrome gain regular 
menstrual cycles when ageing. Hum Reprod 15, 2000. 1: p. 24-28. 
27. Hillier, S. and M. Tetsuka. Role of androgens in follicle maturation and 
atresia .. Baill Clin Obstet Gynaecol, 1997. 11(2): p. 249-260. 
28. Fortune, J., et aI., The primordial to primary follicle transition Molecular 
and Cellular Endocrinology, 2000.163(1-2): p. 53-60. 
29. Kolibianakis, E., et al., Estrogen and folliculogenesis: is one necessary for the 
other? Curr Opin Obstet Gynecol. , 2005. 17(3): p. 249-253. 
30. Baggish, M. and M. Karram, The Atlas of Pelvic Anatomy and Gynaecologic 
Surgery. 2006. 2. 
31. Wandji, SA, G. Pelletier, and M.A. Sirard, Ontogeny and cellular 
localization of 12SI-labeled basic fibroblast growth factor and 1251-labeled 
epidermal growth factor binding sites in ovaries from bovine fetuses and 
neonatal calves. Bioi Reprod, 1992.47(5): p. 807-13. 
32. Azziz, R., et al., Adrenal androgen excess in the polycystic ovary syndrome: 
sensitivity and responsivity of the hypothalamic-pitUitary-adrenal axis. J 
Clin Endocrinol Metab, 1998.83(7): p. 2317-23. 
33. Diamanti-Kandarakis, E., et aI., Defects in insulin signaling pathways in 
ovarian sterOidogenesis and other tissues in polycystic ovary syndrome 
(peDS). The Journal of Steroid Biochemistry and Molecular Biology, 2008. 
109(3-5): p. 242-246. 
34. Hunzicker-Dunn, M. and E.T. Maizels, FSH Signaling pathways in immature 
granulosa cells that regulate target gene expression: branching out from 
protein kinase A. Cell Signal, 2006.18(9): p. 1351-9. 
35. Polan, M., et al., Ovulation induction with human menopausal gonadotropin 
compared to human urinary follicle-stimulating hormone results in a 
significant shift in follicular flUid androgen levels without discernible 
differences in granulosa-luteal cell function . . 63, 1986.6: p. 1284-1291. 
36. Miller, W.L, StAR search--what we know about how the steroidogenic acute 
regulatory protein mediates mitochondrial cholesterol import Mol 
Endocrinol, 2007. 21(3): p. 589-601. 
37. Schroeder, F., et al., Intracellular Cholesterol Trafficking. 1998: p. 213-234. 
38. Petrescu, A., et al., Steroidogenic acute regulatory protein binds cholesterol 
and modulates mitochondrial membrane sterol domain dynamics. J Bioi 
Chern, 2001. 276(40): p. 36970-82. 
39. MilJer, W., Mechanism of StAR's regulation of mitochondrial cholesterol 
import Molecular and Cellular Endocrinology, 2007. 265-266,: p. 46-50 
237 
Chapter 10: Bibliography 
40. Arukwe, A., Steroidogenic acute regulatory (StAR) protein and cholesterol 
side-chain cleavage (P4S0 scc )-regulated steroidogenesis as an organ-
specific molecular and cel/ular target for endocrine disrupting chemicals in 
fish. Cell Biology and Toxicology, 2008. 24(6): p. 527-540. 
41. Diamanti-Kandarakis, E. and A Papavassiliou, Molecular mechanisms of 
insulin resistance in polycystic ovary syndrome. Trends in Molecular 
Medicine, 2006. 12(7): p. 324-332. 
42. Gongqiao, Z., et al., Interactive Stimulation by Luteinizing Hormone and 
Insulin of the Steroidogenic Acute Regulatory (StAR) Protein and 17-
Hydroxylasel17, 20-Lyase (CYP17) Genes in Porcine Theca Cells 
endicrinology, 2000. 141(8): p. 2735. 
43. Jakubowicz, D.). and ).E. Nestler, 17 alpha-Hydroxyprogesterone responses 
to leuprolide and serum androgens in obese women with and without 
polycystic ovary syndrome offer dietary weight loss. ) Clin Endocrinol 
Metab, 1997.82(2): p. 556-60. 
44. Nelson, V., et al., Augmented Androgen Production Is a Stable Steroidogenic 
Phenotype of Propagated Theca Cells from Polycystic Ovaries. Molecular 
Endocrinology, 1999. 13(6): p. 946-57. 
45. Munir, I., et al., Insulin Augmentation of 17{alpha}-Hydroxylase Activity Is 
Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-
Regulated Kinase-112 in Human Ovarian Theca Cells. Endocrinology, 2004. 
145(1): p.175-183. 
46. Hanukoglu, f., Steroidogenic enzymes: structure, function, and role in 
regulation of steroid hormone biosynthesis. Steroid Biochem. Mol. Biol., 
1992.43: p. 779-804. 
47. Pikuleva, I., Cytochrome P4S0s and cholesterol homeostasis. Pharmacology 
& Therapeutics, 2006. 112(3): p. 761-773. 
48. Shikita, M. and P. Hall, The Stoichiometry of the Conversion of Cholesterol 
and Hydroxycholesterols to Pregnenolone (3p-Hydroxypregn-S-en-20-one) 
Catalysed by Adrenal Cytochrome P-4S0. Proc Natl Acad Sci USA, 1974. 
4(71): p. 1441-1445 .. 
49. Felig, P. and L. Frohman, Endocrinology & Metabolism. 2001. 
50. Sander, V.A., et aL, Alterations of folliculogenesis in women with polycystic 
ovary syndrome.) Steroid Biochem Mol BioI, 2011.124(1-2): p. 58-64. 
51. Nelson, V.L., et al., The biochemical basis for increased testosterone 
production in theca cells propagated from patients with polycystic ovary 
syndrome. ) Clin Endocrinol Metab, 2001. 86(12): p. 5925-33. 
52. Comim, F.H., K. Franks, S., Increased intensity of P4S0c17 protein 
expression in theca cells from polycystic ovaries. Society of Endicrinology, 
2011(11): p. 25. 
53. Somma, M., T. Sandor, and A. Lanthier, Site of origin Of androgenic and 
estrogenic steroids in the normal human ovary. ) Clin Endocrinol Metab, 
1969.29(4): p. 457-66. 
54. Miller, W., Molecular biology of steroid hormone synthesis. Endocr. Rev., 
1988.9: p. 295-318. 
55. Stevens, V., T. Xu, and J. Lambeth, Cholesterol pools in rat adrenal 
mitochondria: use of cholesterol oxidase to infer a complex pool structure. 
Endocrinology, 1992.130: p. 1557-1563. 
238 
Chapter 10: Bibliography 
56. Bowen. R., Steroidogenesis. 2001. 
51. Chapman. J., et aI., Mitochondrial 3 beta-hydroxysteroid dehydrogenase 
(HSD) is essential for the synthesis of progesterone by corpora lutea: An 
hypothesis. Reproductive Biology and Endocrinology. 2005. 1: p. 1477-
7827. 
58. Ruckpaul, K. and H. Rein, Molecular Mechanisms of Adrenal Steroidogenesis 
and Aspects of Regulation and Application. Frontiers in Biotransformation. 
1990.3. 
59. Fukuda, S., et aL, Luteinizing Hormone Stimulates CYP17 A1 mRNA 
Expression and Androgen Production in Bovine Theca Cells via Activation of 
the PI3K/Akt Pathway. BIOLOGY OF REPRODUCTION, 2009. 81(525). 
60. McAllister, J .. et al., Regulation of cholesterol side-chain cleavage and 17 
alpha-hydroxylaseflyase activities in proliferating human theca interna 
cells in long term monolayer culture. . endicrinology, 1989. 125(4): p. 1959. 
61. Labrie, F., et aI., Structure, {unction and tissue-specific gene expression of 
3(J-hydroxysteroid dehydrogenase/S-ene-4-ene isomerase enzymes. J. 
Steroid Biochem. Molec BioI, 1992.43: p. 805-826. 
62. Inano, H •• et al, Purification and properties of enzymes related to steroid 
hormone synthesis.. Annals N.Y. Acad. Sci. ,1990. S9S: p. 17-25. 
63. Martel. c., et al.. Distribution of 17(J-hydroxysteroid dehydrogenase gene 
expression and activity in rat and human tissues. J. Steroid Biochem. Molec. 
Bioi. 1992. 41: p. S97-603. 
64. Steiner. D.F. and P.E. Oyer. The Biosynthesis of Insulin and a Probable 
Precursor of Insulin bya Human Islet Cell Adenoma. Proc Natl Acad Sci U S 
A. 1967. 57(2): p.473-480. 
65. Buggs, c.. et aL, Insulin augments GnRH-stimulated LHbeta gene expression 
by Egr-l. Mol Cell Endocrinol. 2006. 249(1-2): p. 99-106. 
66. LeRoith, D •• et aI .• Insulin-like growth factors. BioI Signals, 1992. 1: p. 173-
81. 
67. Marsters. P., N. Kendall. and B. Campbell, Temporal relationships between 
FSH receptor. type 1 insulin-like growth Jactor receptor, and aromatase 
expression during FSH-induced differentiation of bovine granulosa cells 
maintained in serum-free culture Molecular and Cellular Endocrinology, 
2003.203(111-127). 
68. Poretsky, L, et al.. Phosphatidyl-lnositol-3 Kinase-Independent Insulin 
Action Pathway(s) in the Human Ovary. J Clin Endocrinol Metab, 2001. 
86(7): p. 3115-3119. 
69. Clarke, I. and J.T. Cummins, GnRH pulse frequency determines LH pulse 
amplitude by altering the amount of releasable LH in the pituitary glands of 
ewes. 73, 1985: p.425-431 
70. Yen. H.W., et aL, Selective alterations in insulin receptor substrates-I, -2 and 
-4 In theca but notgranulosa cells from polycystic ovaries. Mol Hum Reprod, 
2004.10(7): p. 473-9. 
11. Virkamaki. A. U. Kohjiro. and C. Ronald Kahn, Protein-protein interaction 
in insulin signaling and the molecular mechanisms of insulin resistance. J. 
Clin. Invest. 1999. 103(7): p. 931·943. 
239 
Chapter 10: Bibliography 
72. Tee, M., D. Quing, and W. Miller, Pathways Leading to Phosphorylation 0/ 
P450c17 and to the Posttranslational Regulation of Androgen Biosynthesis. 
Endocrinology, 2008.149(5): p. 2667-2677. 
73. Hirshfield, A.N., Development 0/ follicles in the mammalian ovary. Int Rev 
Cytol, 1991.124: p. 43-101. 
74. Virkamaki, A., K. Ueki, and C. Kahn, Protein-protein interaction in insulin 
signaling and the molecular mechanisms o/insulin resistance. J Clin Invest, 
1999(103): p. 931-943. 
75. White, M., The insulin signalling system and the IRS proteins. . Diabetologia, 
1997.40. 
76. White, M. and L. Yenush, The IRS-signaling system: a network of docking 
proteins that mediate insulin and cytokine action. Curr Topics Microbiol 
Immunol, 1998. 1228: p. 179-208. 
77. Stadtmauer, L. and O. Rosen, Increasing the cAMP content of IM-9 cells 
alters the phosphorylation state and protein kinase activity of the insulin 
receptor .. J Bioi Chern, 1986. 261: p. 3402-3407. 
78. Takayama, S., et al., Phorhol ester-induced serine phosphorylation 0/ the 
insulin receptor decreases its tyrosine kinase activity . . J Bioi Chern, 1988. 
263: p. 3440-3447. 
79. Sigalit, B.-H. and Z. Yehiel, Phosphorylation of IRS proteins, insulin action, 
and insulin resistance. Am J Physiol Endocrinol Metab 2008. 296. 
80. Gell, J., et al., Adrenarche results from development of a 3{3-hydroxysteroid 
dehydrogenase-deficient adrenal reticularis. J elin Endocrtnol Metab 1998. 
83. 
81. Meng, K. T., D. Qing, and M. Walter L, Pathways Leading to Phosphorylation 
0/ P450c17 and to the Posttranslational Regulation 0/ Androgen 
Biosynthesis. endicrinology, 2008.145(9): p. 2667-2677. 
82. Craig, C., et al., Insulin Rapidly Inhibits Insulin-Like Growth Factor-Binding 
Protein-l Gene Expression in H4-II-E Rat Hepatoma Cells Mol. Endocrinol., 
1991.5: p. 1180-1187. 
83. Cantley, L., The Phosphoinositide 3-Kinase Pathway Science 2002. 
296(5573): p. 1655 - 1657. 
84. Shepherd, P., D. Witherspoon, and K. Siddle, Phosphoinosltide 3-kinase: the 
key switch mechanism in insulin signalling. Biochem, 1998. 333: p.471-
490. 
85. Stephens, L.R, T.R Jackson, and P.T. Hawkins, Agonist-stimulated synthesis 
0/ phosphatidylinositol(3,4,Sj-trisphosphate: a new intracellular Signalling 
system? Biochim. Biophys. Acta, 1993. 1179(27): p. 75. 
86. Fruman, D., R Meyers, and L. Cantley, Phosphoinositide kinases. Biochem., 
1998. 
87. Karpova, A., P. Sanna, and T. Behnisch, Involvement 0/ mUltiple 
phosphatidylinositol 3-kinase-dependent pathways in the persistence 0/ 
late-phase long term potentiation expression. Neuroscience, 2006. 137(3): 
p.844-841. 
88. Alessi, D. and C. Downes, The role of PI 3-kinase in insulin action. Biochim 
Biophys Acta, 1998. 1436: p. 151-164. 
89. Brown, R, et al., Insulin Activates the Is%rm of Class II Phosphoinositide 
3-Kinase*J Bioi Chern, 1999. 274(21): p.14529-14532. 
240 
Chapter 10: Bibliography 
90. Leevers, S.J., B. Vanhaesebroeck, and M.D. Waterfield, Signalling through 
phosphoinositide 3-kinases: the lipids take centre stage. Current Opinion in 
Cell Biology, 1999. 11(2): p. 219-225. 
91. Gilling-Smith, c., et aI., Hypersecretion of androstenedione by isolated 
thecal cells from polycystic ovaries. J Clin Endocrinol Metab, 1994. 79(4): p. 
1158-1165. 
92. McArthur, J., F. Ingersoll, and J. Worcester, The urinary excretion of 
interstitial-cell and follicle stiimulating hormone activity by women with 
diseases of the reproductive system. J. Clin, Endicrinol, Metab, , 1958. 18: p. 
1202-1215. 
93. Rebar, R., et al., Characterization of the inappropriate gonadotropin 
secretion in polycystic ovary syndrome. J Clin Invest, 1976. 57(5): p. 1320-
9. 
94. Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome (PCDS). Hum Reprod, 2004. 19(1): p. 
41-7. 
95. Lachelin, G., et al., Long term effects of nightly dexamethasone 
administration in patientswith polycystic ovarian disease. J Clin Endocrinol 
Metab, 1982. 55: p. 768-773. 
96. Rittmaster, R. and D. Thompson, Effect of leuprolide and dexamethasone 
on hair growth and hormone levels in hirsute women: the relative importance 
of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol 
Metab, 1990. 70: p. 1096-1102. 
97. National Womens Health Center, N. Prevalence and incidence statistics for 
polycystic ovary syndrome. Womens Health [Web Page] 2009; Available 
from: http://www.womenshealth.gov/. 
98. Khan, C., J. Flier, and R. Bar, The syndromes of insulin resistance and 
acanthsis niagricans: insulin receptor disorders in man. New England 
Journal of Medicine, 1976.294: p. 739-745. 
99. Baillargeon, J. and J. Nestler, Polycystic Ovary Syndrome: A Syndrome of 
Ovarian Hypersensitivity to Insulin? J Clin Endocrinol Metab, 2006. 91(1): 
p.22-24. 
100. Belosi, C., et ai., Is the peDS diagnosis solved by ESHRE/ASRM 2003 
consensus or could it include ultrasound examination of the ovarian 
stroma? Hum Reprod, 2006. 21(12): p. 3108-15. 
101. Stein, I. and M. Leventhal, Amenorrhea associated with bilateral polycystic 
ovaries. Am J Obstet Gynecol, 1935. 1(29): p. 181. 
102. Dewailly, D., et aI., Ovarian stromal hypertrophy in hyperandrogenic 
women. Clin Endocrinol (Oxt), 1994.41(5): p. 557-62. 
103. Andrews, M.C., Bilateral polycystic ovaries associated with sterility, 
amenorrhea and hirsutism. Va Med Mon (1918), 1952. 79(10): p. 544-8. 
104. Stein, I. and M. Cohen, Surgical treatment of bilateral polycystic ovaries -
Amenorrhea and sterility. American Journal of Obstetrics and Gynaecology, 
1939.38:p.465-478 
105. Tulandi, T. and S. Took, Surgical management of polycystic ovarian 
syndrome. Baillieres Clin. Obstet. Gynaecol, 1998.12: p. 541-553. 
241 
Chapter 10: Bibliography 
106. Carmina, E. and R Azziz, Diagnosis, phenot;ype, and prevalence of polycystic 
ovary syndrome Fertility and Sterility, 2006. 86: p. 7-8. 
107. Franks, S., Controversy in clinical endocrinology: diagnosis of polycystic 
ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol 
Metab, 2006. 91(3): p. 786-9. 
108. Azziz, R, Controversy in clinical endocrinology: diagnosis of polycystic 
ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol 
Metab, 2006. 91(3): p. 781-5. 
109. Geisthovel, F. and T. Rabe, The ESHRE/ASRM consensus on polycystic ovary 
syndrome (PCOS)--an extended critical analysis. Reprod Biomed Online, 
2007.14(4): p. 522-35. 
110. Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome. Fertil Steril, 2004. 81(1): p. 19-25. 
111. Franks, S., et al., Ovulatory disorders in women with polycystic ovary 
syndrome. Clin Obstet Gynaecol, 1985. 12(3): p. 605-32. 
112. Diamanti-Kandarakis, E., Role of obesit;y and adiposit;y in polycystic ovary 
syndrome. International Journal of Obesity, 2007(31): p.8-13. 
113. Corbould, A, Effects of androgens on insulin action in women: is androgen 
excess a component of female metabolic syndrome? Diabetes/Metabolism 
Research and Reviews, 2008. 24(7): p. 520-532. 
114. Poretsky, L., et ai., The Insulin-Related Ovarian Regulatory System in Health 
and Disease. Endoer Rev, 1999.20(4): p. 535-582. 
115. Barber, T.M., et al., Obesity and polycystic ovary syndrome. Clin Endocrinol 
(Oxt), 2006. 65(2): p. 137-45. 
116. Schmid, J., et al., Infertility caused by PCOS--health-related qualit;y of life 
among Austrian and Moslem immigrant women in Austria. Hum Reprod, 
2004.19(10): p. 2251-7. 
117. Goldzieher, J.W. and J.A Green, The polycystic ovary. I. Clinical and 
histologic features. J Clin Endocrinol Metab, 1962.22: p. 325-38. 
118. Pasquali, R, et al., Clinical and hormonal characteristics of obese 
amenorrheic hyperandrogenic women before and after weight loss. J Clin 
Endoerinol Metab, 1989. 68(1): p. 173-9. 
119. Abbott, D.H., D.A Dumesic, and S. Franks, Developmental origin Of 
polycystic ovary syndrome - a hypothesis. J Endocrinol, 2002. 174(1): p. 1-5. 
120. Franks, S., Adult polycystic ovary syndrome begins in childhood. Best Pract 
Res Clin Endocrinol Metab, 2002.16(2): p. 263-72. 
121. Norman, RJ., R Wu, and M.T. Stankiewicz, 4: Polycystic ovary syndrome. 
Med J Aust, 2004.180(3): p. 132-7. 
122. Watson, H., et ai., Hypersecretion 0/ luteinizing hormone and ovarian 
steroids in women with recurrent early miscarriage. Hum Reprod, 1993. 
8(6): p. 829-33. 
123. Solomon, C., The epidemiology of polycystic ovary syndrome. Prevalence 
and associated disease risks. Endoerinol. Metab. Clin., 1999. 28: p. 247-263. 
124. Speert, H., Carcinoma of the endometrium in young women,. Surg Gynaecol 
Obstet, 1949. 88: p. 332-336. 
125. Dockerty, M., B. Lovelady, and G. Foust, Carcinoma o/corpus uteri in young 
women. Am J Obstet Gynecoll, 1951. 61. 
242 
Chapter 10: Bibliography 
126. lafari, K., G. lavaheri, and G. Ruiz, Endometrial adenocarcinoma and the 
Stein-Leventhal syndrome. Obstet Gynecol, 1978. 51: p. 97-100. 
127. Simpson, E., et aI., Local estrogen biosynthesis in males andfemales. Endocr 
Relat Cancer, 1999. 6(2): p. 131-7. 
128. Yen, S., Polycystic ovary syndrome (Hyperandrogenic chronic anovulation) .. 
Philadelphia, W.B. Saunders Company., 1999. 
129. Mahajan, O.K., Steroidogenesis in human polycystic ovary. Endocrinol 
Metab Clin NorthAm, 1988.17(4): p. 751-69. 
130. Munir, I., et al., Resistin Stimulation of 17{alpha}-Hydroxylase Activity in 
Ovarian Theca Cells in Vitro: Relevance to Polycystic Ovary Syndrome. I Clin 
Endocrinol Metab, 2005. 90(8): p. 4852-4857. 
131. Rodin, A., et al., Hyperandrogenism in polycystic ovary syndrome. Evidence 
of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med, 
1994. 330(7): p. 460-5. 
132. Piltonen, T., et al., Ovarian and adrenal steroid production: regulatory role 
of LH/HCG. Hum Reprod, 2002. 17(3): p. 620-4. 
133. Stewart, P.M., et al., 5 alpha-reductase activity in polycystic ovary syndrome. 
Lancet, 1990.335(8687): p. 431-3. 
134. Barnes, R., et al., Pituitary-ovarian responses to nafarelin testing in the 
polycystic ovary syndrome. N Engl J Med, 1989. 320: p. 559-65. 
135. Gilling-Smith, C., et aJ., Evidence for a primary abnormality of thecal cell 
steroidogenesis in the polycystic ovary syndrome . . Clin Endocrinol, 1997. 
47(1): p. 93-99. 
136. Zhang, G. and J. Veldhuis, Insulin Drives Transcriptional Activity of the 
CYP17 Gene in Primary Cultures of Swine Theca Cells. Biology of 
Reproduction,2004.70:p.1600. 
137. Zhou, G., et al., Role of AMP-activated protein kinase in mechanism of 
metformin action. J Clin Invest, 2001.108(8): p.1167-74. 
138. OeFronzo, R.A. and A.M. Goodman, Efficacy of metformin in patients with 
non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study 
Group. N Engl J Med, 1995. 333(9): p. 541-9. 
139. La Marca, A., et al., Anti-Mullerian hormone plasma levels in spontaneous 
menstrual cycle and during treatment with FSH to induce ovulation. Hum 
Reprod, 2004.19(12): p. 2738-41. 
140. Mansfield, R., et al., Metformin has direct effects on human ovarian 
steroidogenesis. Fertil Steril, 2003. 79(4): p. 956-62. 
141. Arlt, W., R.J. Auchus, and W.L. Miller, Thiazolidinediones but not metformin 
directly inhibit the steroidogenic enzymes P450c17 and 3beta -
hydroxysteroid dehydrogenase. J BioI Chem, 2001. 276(20): p.16767-71. 
142. Spiegelman, B.M., PPAR-gamma: adipogenic regulator and 
thiazolidinedione receptor. Diabetes, 1998.47(4): p. 507-14. 
143. Mitwally, M.F., S.F. Witchel, and R.F. Casper, Troglitazone: a possible 
modulator of ovarian steroidogenesis. J Soc Gynecollnvestig, 2002. 9(3): p. 
163-7. 
144. Balen, A., Hypersecretion of luteinizing hormone and the polycystic ovary 
syndrome. Hum Reprod (SuppI2), 1993: p. 123-128. 
243 
Chapter 10: Bibliography 
145. Poretsky, L. and B. Piper, Insulin Resistance, hypersecretion of LH, and a 
dual defect hypothesis for the pathogenesis of polycystic ovarian syndrome. 
Obstetrics & Gynecology, 1994.84(4, Part 1): p. 613-621. 
146. Chang, R., et al., Steroid secretion in polycystic ovarian disease after ovarian 
suppression bya long-acting gonadotropin-releasing hormone agonis. J Clin 
Endocrinol Metab, 1983. 56(5): p. 897-903. 
147. Ehrmann, D., R. Barnes, and R. Rosenfield, Polycystic ovary syndrome as a 
form of functional ovarian hyperandrogenism due to dysregulation of 
androgen secretion. Endocr Rev, 1995. 16(3): p. 322-353. 
148. Rosenfield, R., Ovarian and adrenal function in polycystic ovary syndrome. 
Endocrinol Metab Clin N A, 1999. 28(2): p. 265-293. 
149. Konishi., M. Koshiyama, and M. Mandai, Increased expression of LH/hCG 
receptors in endometrial hyperplasia and carcinoma in anovulatory women. 
Gynecol Oncol, 1997.65: p. 273-280. 
150. Pigny, P., et al., Elevated serum level of anti-mullerian hormone in patients 
with polycystic ovary syndrome: relationship to the ovarian follicle excess 
and to the follicular arrest J Clin Endocrinol Metab, 2003. 88(12): p. 5957-
62. 
151. Heineman, M., et al.,· Hormonal characteristics of women with clinical 
features of the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Bioi, 
1984. 17: p. 263-271. 
152. Legro, R., et aI., Elevated dehydroepiandrosterone sulfate levels as the 
reproductive phenotype in the brothers of women with polycystic ovary 
syndrome. J Clin Endocrinol Metab, 2002. 87: p.2134-2138. 
153. Levrant, S., R. Barnes, and R. Rosenfield, A pilot study of the human 
chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod, 
1997.12(7): p. 1416-1420. 
154. Convery, M. and J.R. Brawer, Thecal and interstitial cells in polycystic 
ovaries (peO) in the rat Anat Rec, 1991. 231(3): p. 324-32. 
155. Dunaif, A, Insulin action in the polycystic ovary syndrome. Endocrinol 
Metab Clin North Am, 1999. 28(2): p. 341-59. 
156. Barbieri, R.L., A Makris, and K.J. Ryan, Insulin stimulates androgen 
accumulation in incubations of human ovarian stroma and theca. Obstet 
Gynecol, 1984.64(3 Suppl): p. 73S-80S. 
157. Nestler, J., et al., Insulin stimulates testosterone biosynthesis by human 
thecal cells from women with polycystic ovarian syndrome by activating its 
own receptor and using insitol glycan mediators as the signal transdUction 
system. journal of clinical endicrinology and metabolism, 1998. 83. 
158. Dunaif, A, Insulin action in the polycystic ovary syndrome. Endocrinol 
Metab Clin N A, 1999.28(2): p. 341-359. 
159. Dunaif, A, Insulin Resistance and the Polycystic Ovary Syndrome: 
Mechanism and Implications for Pathogenesis. Endocr Rev, 1997. 18(6): p. 
774-800. 
160. Brankin, V., et al., BMP-2 and -6 modulate porcine theca cell function alone 
and co-cultured with granulosa cells Domestic Animal Endocrinology, 
2005. 29(4): p. 593. 
161. Stewart, R.E., et aI., Effects of insulin-like growth factor I and insulin on 
proliferation and on basal and luteinizing hormone-induced steroidogenesis 
244 
Chapter 10: Bibliography 
of bovine thecal cells: involvement of glucose and receptors for insulin-like 
growth factor I and luteinizing hormone. J Anim Sci, 1995. 73(12): p. 3719-
31. 
162. Magoffin, D.A. and S.R. Weitsman, Effect of insulin-like growth factor-Ion 
cholesterol side-chain cleavage cytochrome P450 messenger ribonucleic 
acid expression in ovarian theca-interstitial cells stimulated to differentiate 
in vitro. Mol Cell Endocrinol, 1993. 96(1-2): p. 45-51. 
163. Ehrmann, D., et al., Prevalence of impaired glucose tolerance and diabetes 
in women with polycystic ovary syndrome. Diabetes care, 1999. 22(1): p. 
141-146. 
164. Wang, J. and R. Norman, Risk factors for the deterioration of glucose 
metabolism in polycystic ovarian syndrome. Repro Biomed Online, 2004. 
9(2):p.201-204. 
165. Tsilchorozidou, T., C. Overton, and G. Conway, The pathophysiology of 
polycystic ovarian syndrome Clinical Endo, 2004. 60: p. 1-17. 
166. Bhatia, V., Insulin resistance in polycystic ovarian disease. South Med J, 
2005.98(9): p. 902-909. 
167. Henquin, J., et al., Hierachy of the Beta-cell signal controlling insulin 
secretion. Europe J Clin invest, 2003. 33: p. 742-750. 
168. Diamanti-Kandarakis, E., et ai., Pancreatic beta-cells dysfunction in 
polycystic ovary syndrome. Panminerva Med, 2008.50(4): p. 315-25. 
169. Dunaif, A. and D.T. Finegood, Beta-cell dysfunction independent of obesity 
and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol 
Metab, 1996.81(3): p. 942-7. 
170. Colilla, S., N.J. Cox, and D.A. Ehrmann, Heritability of insulin secretion and 
insulin action in women with polycystic ovary syndrome and their first 
degree relatives. J Clin Endocrinol Metab, 2001. 86(5): p. 2027-31. 
171. Dhindsa, G., et aI., Insulin resistance, insulin sensitization and inflammation 
in polycystic ovarian syndrome. J Postgrad Med, 2004. SO: p. 140-144. 
172. Ciaraldi, T.P., et al., Cellular mechanisms of insulin resistance in polycystic 
ovarian syndrome. J Clin Endocrinol Metab, 1992. 75(2): p. 577-83. 
173. PasquaJi, R. and F. Casimirri, The impact of obesity on hyperandrogenism 
and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 
(Oxt), 1993. 39(1): p.1-16. 
174. Pasquali, R., A. Gambineri, and U. Pagotto, The impact of obesity on 
reproduction in women with polycystic ovary syndrome. BJOG, 2006. 
113(10): p. 1148-59. 
175. Dabelea, D. and G. Klingensmith, Epidemiology of pediatric and adolescent 
diabetes. Informa Health Care, 2008: p. 356. 
176. Legro, R.S., Diabetes prevalence and risk factors in polycystic ovary 
syndrome. Obstet Gynecol Clin North Am, 2001. 28(1): p. 99-109. 
177. Legro, R.S., et aI., Prevalence and predictors of risk for type 2 diabetes 
mellitus and impaired glucose tolerance in polycystic ovary syndrome: a 
prospective, controlled study in 254 affected women. J Clin Endocrinol 
Metab, 1999. 84(1): p. 165-9. 
178. Ohlson, L.O., et at., The influence of body fat distribution on the incidence of 
diabetes mellitus. 13.5 years of follow-up of the participants in the study of 
men born in 1 9 1 3 ~ ~ Diabetes, 1985.34(10): p. 1055-8. 
245 
Chapter 10: Bibliography 
179. Carmina, E., et al., Abdominal fat quantity and distribution in women with 
polycystic ovary syndrome and extent of its relation to insulin resistance. J 
Clin Endocrinol Metab, 2007. 92(7): p. 2500-5. 
180. Evans, D.J., et al., Relationship of body fat topography to insulin sensitivity 
and metabolic profiles in premenopausal women. Metabolism, 1984. 33(1): 
p.68-75. 
181. Canoy, D., et al., Fat distribution, body mass index and blood pressure in 
22,090 men and women in the Norfolk cohort of the European Prospective 
Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens, 
2004.22(11): p. 2067-74. 
182. Rich-Edwards, J.W., et al., Physical activity, body mass index, and ovulatory 
disorder infertility. Epidemiology, 2002.13(2): p. 184-90. 
183. Diamanti-Kandarakis, E., Insulin resistance in PCDS. Endocrine, 2006. 
30(1): p. 13-7. 
184. Ek, I., et al., A unique defect in the regulation of visceral fat cell lipolysis in 
the polycystic ovary syndrome as an early link to insulin resistance. 
Diabetes, 2002. 51(2): p. 484-92. 
185. Dunaif, A., et al., Evidence for distinctive and intrinsic defects in insulin 
action in polycystic ovary syndrome. Diabetes, 1992.41(10): p. 1257-66. 
186. Crosignani, P.G., et at, Overweight and obese anovulatory patients with 
polycystic ovaries: parallel improvements in anthropometric indices, 
ovarian physiology and fertility rate induced by diet Hum Reprod, 2003. 
18(9): p. 1928-32. 
187. Crosignani, P.G., et al., Resumption of fertility with diet in overweight 
women. Reprod Biomed Online, 2002. S(l): p. 60-4. 
188. Kiddy, D.S., et al., Differences in clinical and endocrine features between 
obese and non-obese subjects with polycystic ovary syndrome: an analysis of 
263 consecutive cases. Clin Endocrinol (Oxt), 1990. 32(2): p. 213-20. 
189. Huber-Buchholz, M.M., D.G. Carey, and R.J. Norman, Restoration of 
reproductive potential by lifestyle modification in obese polycystic ovary 
syndrome: role of insulin sensitivity and luteinizing hormone. J Clin 
Endocrinol Metab, 1999.84(4): p.1470-4. 
190. Tchernof, A. and J.P. Despres, Sex steroid hormones, sex hormone-binding 
globulin, and obesity in men and women. Horm Metab Res, 2000. 32(11-
12): p. 526-36. 
191. Belanger, c., et aI., Omental and subcutaneous adipose tissue steroid levels 
in obese men. Steroids, 2006. 71(8): p. 674-82. 
192. Rohner-Jeanrenaud, F. and B. Jeanrenaud, The discovery of leptin and its 
impact in the understanding of obesity. Eur J Endocrinol, 1996. 135(6): p. 
649-50. 
193. Trayhurn, P. and 1.5. Wood, Adipokines: inflammation and the pleiotropic 
role of white adipose tissue. Br J Nutr, 2004. 92(3): p. 347-55. 
194. Hauner, H., Secretory factors from human adipose tissue and their 
functional role. Proc Nutr Soc, 2005. 64(2): p. 163-9. 
195. Campos, D.B., et a!., The 'beneficial' adipokines in reprodUction and fertility. 
Int JObes (Lond), 2008. 32(2): p. 223-31. 
196. Mitchell, M., et al., Adipokines: implications for female fertility and obesity. 
Reproduction, 2005. 130(5): p. 583-97. 
246 
Chapter 10: Bibliography 
197. Moschos, S., J.1.. Chan, and C.S. Mantzoros, Leptin .and reproduction: a 
review. Fernl Steril, 2002. 77(3): p. 433-44. 
198. Goumenou, A.G., et al., The role of leptin in fertility. Eur J Obstet Gynecol 
Reprod Bioi, 2003. 106(2): p. 118-24. 
199. Mantzoros, C.S., A. Dunaif, and J.S. Flier, Leptin concentrations in the 
polycystic ovary syndrome. J Clin Endocrinol Metab, 1997. 82(6): p. 1687-
91. . 
200. Mahde, A., M. Shaker, and Z. Al-Mashhadani, Study of Omen tin 1 and Other 
Adipokines and Hormones in PCOS Patients. Oman Med J, 2009. 24(2): p. 
108-18. 
201. Yang, R.Z., et al., Identification of omen tin as a novel depot-specific 
adipokine in human adipose tissue: possible role in modulating insulin 
action. Am J Physiol Endocrinol Metab, 2006. 290(6): p. E1253-61. 
202. Deslypere, J.P., I.. Verdonck, and A. Vermeulen, Fat tissue: a steroid 
reservoir and site of steroid metabolism. J Clin Endocrinol Metab, 1985. 
61(3): p. 564-70. 
203. Weyer, C., et al., Hypoadiponectinemia in obesity and type 2 diabetes: close 
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol 
Metab, 2001. 86(5): p. 1930-5. 
204. Toulis, K.A., et al., Adiponectin levels in women with polycystic ovary 
syndrome: a systematic review and a meta-analysis. Hum Reprod Update, 
2009.1S(3): p. 297-307. 
205. Taponen, S., et at, Hormonal profile of women with self-reported symptoms 
of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 
study. J Clin Endocrinol Metab, 2003. 88(1): p. 141-7. 
206. Siiteri, P.K., Adipose tissue as a source of hormones. Am J Clin Nutr, 1987. 
4S: p. 277-282. 
207. Belanger, C., et al., Adipose tissue intracrinology: potential importance of 
local androgen/estrogen metabolism in the regulation of adiposity. Horm 
Metab Res, 2002. 34(11:-12): p. 737-45. 
208. Blanchette, S., et al., Expression and activity of 20alpha-hydroxysteroid 
dehydrogenase (AKRIC1) in abdominal subcutaneous and omental adipose 
tissue in women. J Clin Endocrinol Metab, 2005. 90(1): p. 264-70. 
209. Corbould, AM., S.J. Judd, and RJ. Rodgers, ExpreSSion of types 1,2, and 317 
beta-hydroxysteroid dehydrogenase in subcutaneous abdominal and intra-
abdominal adipose tissue of women. J Clin Endocrinol Metab, 1998. 83(1): 
p.187-94. 
210. Willenberg, H.S., et at, Helpful diagnostic markers of steroidogenesis for 
defining hyperandrogenemia in hirsute women. Steroids, 2008. 73(1): p. 
41-6. 
211. Mcallister, J., M. Byrd, and E. Simpson, The effects of growth factors and 
phorbol esters on steroid biosynthesis in isolated human theca interna and 
granulosa lutien cells in long term culture. The Journal of Clinical 
Endocrinology and Metabolism, 1994. 79(106-112). 
212. Kiriakidou, M., et al., Expression of ~ t e r o i d o g e n i c c acute regulatory protein 
(StAR) in the human ovary. Journal of Clinical Endocrinology & 
Metabolism, 1996. 81(4122). 
247 
Chapter 10: Bibliography 
213. Yamamoto, N., et ai., Growth Differentiation Factor-9 Inhibits 3'5'-
Adenosine Monophosphate-Stimulated Steroidogenesis in Human Granulosa 
and Theca Cells The Journal of Clinical Endocrinology & Metabolism, 2002. 
87. 
214. Mcallister J, M Byrd, and S. E., The effects of growth factors and phorbol 
esters on steroid biosynthesis in isolated human theca interna and 
granulosa lutien cells in long term culture. The Journal of Clinical 
Endocrinology and Metabolism, 1994. 79(106-112). 
215. Hassel, ).a.H., A.R, Fixation Strategies and Formulations used in IHC staining. 
Histochem, Cytochem, 1974. 22: p. 229-239. 
216. Ferguson, RE., et al., Housekeeping proteins: a preliminary study 
illustrating some limitations as useful references in protein expression 
studies. Proteomics, 2005. 5(2): p. 566-71. 
217. Lequin, RM., Enzyme immunoassay (EIA}/enzyme-Iinked immunosorbent 
assay (ELISA). Clin Chern, 2005.51(12): p. 2415-8. 
218. Gilling-Smith, C., et ai., Hypersecretion of androstenedione by isolated 
thecal cells from polycystic ovaries. J Clin Endocrinol Metab, 1994. 79(4): p. 
1158-65. 
219. Nahum, R, KJ. Thong, and S.G. Hillier, Metabolic regulation of androgen 
prodUction by human thecal cells in vitro. Hum Reprod, 1995. 10(1): p. 75-
81. 
220. Green, H. and O. Kehinde, An established preadipose cell line and its 
differentiation in culture. /I. Factors affecting the adipose conversion. Cell, 
1975. S(l): p. 19-27. 
221. Khan, A.H. and J.E. Pessin, Insulin regulation of glucose uptake: a complex 
interplay of intracellular signalling pathways. Diabetologia, 2002. 45(11): 
p.1475-83. 
222. Monjo, M., E. Pujol, and P. Roca, alpha2- to beta3-Adrenoceptor switch in 
3T3-Ll preadipocytes and adipocytes: modulation by testosterone, 17beta-
estradiol, and progesterone. Am J Physiol Endocrinol Metab, 2005. 289(1): 
p. E145-50. 
223. Rodriguez-Cuenca, S., et ai., Depot differences in steroid receptor expression 
in adipose tissue: possible role of the local steroid milieu. Am J Physiol 
Endocrinol Metab, 2005. 288(1): p. E200-7. 
224. Zeigerer, A., et ai., Insulin regulates leptin secretion from 3T3-Ll adipocytes 
bya PI3 kinase independent mechanism. Exp Cell Res, 2008. 314(11-12): p. 
2249-56. 
225. Armelin, H.A., Pituitary extracts and steroid hormones in the control of3T3 
cell growth. Proe Natl Acad Sci USA, 1973. 70(9): p. 2702-6. 
226. Limonta, P., et al., Antiproliferative effects of luteinizing hormone-releasing 
hormone agonists on the human prostatic cancer cell line LNCaP. J Clin 
Endocrinol Metab, 1992. 75(1): p. 207-12. 
227. Zhang, H.H., et ai., Ceiling culture of mature human adipocytes: use in 
studies of adipocyte functions. J Endocrinol, 2000. 164(2): p. 119-28. 
228. Flier, ).S., Leptin expression and action: new experimental paradigms. Proc 
Natl Acad Sci USA, 1997.94(9): p. 4242-5. 
229. Kazuo Kajital, I.M., Takayuki Hanamoto1, Wu Zhiliang2, Takahide Ikeda1, 
Kei Fujiokal, Masahiro Yamauchil, Hideyuki Okada1, Aki Minamil, 
248 
Chapter 10: Bibliography 
Toshiko Kajital, Yoshihiro Unol, Hiroyuld MOrital, Isao Nagano2, Masao 
Takemura3, Mitsuru Seishima3, Yuzo Takahashi2, Tatsuo Ishizukal, 
Evidence of mature adipocyte proliferation regulated by proliferin. Nature 
Preceedings, 2010(4714): p. 1. 
230. Ahlma, R.s. and J.S. Flier, Adipose tissue as an endocrine organ. Trends 
Endocrinol Metab, 2000. 11(8): p. 327-32. 
231. Zhang, Y., et al., Positional cloning of the mouse obese gene and its human 
homologue. Nature, 1994.372(6505): p. 425-32. 
232. Kim, S. and N. Moustaid-Moussa, Secretory, endocrine and 
autocrine/paracrine {unction of the adipocyte. J Nutr, 2000. 130(12): p. 
31105-3115S. 
233. Dieudonne, M.N., et aL, Androgen receptors in cultured rat adipose 
precursor cells during proliferation and differentiation: regional 
spedfldties and regulation by testosterone. Endocrine, 1995. 3(7): p. 537-
41. 
234. Dleudonne, M.N., et aL, Androgen receptors in human preadipocytes and 
adipocytes: regional specificities and regulation by sex steroids. Am J 
Physiol, 1998. 274(6 Pt 1): p. el645-52. 
235. Azzlz, R., et al., The Androgen Excess and PCDS Society criteria for the 
polycystic ovary syndrome: the complete task force report Fertil Steril, 
2009. 91(2): p. 456-88. 
236. Dunaif, A, et al., The insulin-sensitizing agent troglitazone improves 
metDbolic and reproductive abnormalities in the polycystic ovary syndrome. 
I Clln Endocrinol Metab, 1996.81(9): p. 3299-306. 
237. Nestler, J.E., et al., Suppression of serum insulin by diazoxide reduces serum 
testosterone levels in obese women with polycystic ovary syndrome. J Clin 
Endocrinol Metab, 1989.68(6): p. 1027-32. 
238. Manneras-Holm, L. et aI., Adipose tissue has aberrant morphology and 
function in PCDS: enlarged adipocytes and low serum adiponectin, but not 
drculatlng sex steroids, are strongly associated with insulin resistance. J 
Clm Endocrinol Metab. 96(2): p. E304-11. 
239. Rosenbaum, D., R.S. Haber, and A Dunaif, Insulin resistance in polycystic 
ovary syndrome: decreased expression of GLUT-4 glucose transporters in 
adipocytes. Am I Physiol, 1993. 264(2 Pt 1): p. E197-202. 
240. Dunaif, A, et al., Profound peripheral insulin resistance, independent of 
obesit;y. in polycystic ovary syndrome. Diabetes, 1989.38(9): p. 1165-74. 
241. Faulds, G., et al., Mechanisms behind lipolytic catecholamine resistance of 
subcutDneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol 
Metab, 2003. 88(5): p. 2269-73. 
242. Dickerson, E.H., et al., Insulin resistance and free androgen index correlate 
with the outcome of controlled ovarian hyperstimulation in non-PCDS 
women undergoing IVF. Hum Reprod, 2010. 25(2): p. 504-9. 
243. Gregoire, F.M., C.M. Smas, and H.S. Sui, Understanding adipocyte 
differentiation. Physiol Rev, 1998. 78(3): p. 783-809. 
244. lanke, I., et aL, Mature adipocytes inhibit in vitro differentiation of human 
preadlpocytes via angiotensin type 1 receptors. Diabetes, 2002. 51(6): p. 
1699-707. 
249 
Chapter 10: Bibliography 
245. Barr, V.A., et al., Insulin stimulates both leptin secretion and production by 
rat white adipose tissue. Endocrinology, 1997. 138(10): p. 4463-72. 
246. Prins, J.B., et al., Tumor necrosis factor-alpha induces apoptosis of human 
adipose cells. Diabetes, 1997.46(12): p. 1939-44. 
247. Prins, J.B. and S. O'Rahilly, Regulation of adipose cell number in man. Clin 
Sci (Lond), 1997. 92 (1): p. 3-11. 
248. Sieminska, L., et al., Serum adiponectin in women with polycystic ovarian 
syndrome and its relation to clinical, metabolic and endocrine parameters. J 
Endocrinol Invest, 2004. 27(6): p. 528-34. 
249. Marsden, P.J., A. Murdoch, and R Taylor, Severe impairment of insulin 
action in adipocytes from amenorrheic subjects with polycystic ovary 
syndrome. Metabolism, 1994.43(12): p. 1536-42. 
250. Danforth, E., Jr., Failure of adipocyte differentiation causes type II diabetes 
mellitus? Nat Genet, 2000. 26(1): p. 13. 
251. Yang, x., et al., Evidence of impaired adipogenesis in insulin resistance. 
Biochem Biophys Res Commun, 2004. 317(4): p. 1045-51. 
252. Gupta. V .• et al., Effects of dihydrotestosterone on differentiation and 
proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell 
Endocrinol, 2008. 296(1-2): p. 32-40. 
253. Aprath-Husmann, I.. et aI., Effects of leptin on the differentiation and 
metabolism of human adipocytes. Int JObes Relat Metab Disord. 2001. 
25(10): p. 1465-70. 
254. Chen. X.W .• et al.. [Experimental study of human adipocyte dedifferentiation 
for adipose tissue engineering}. Nan Fang Yi Ke Da Xue Xue Bao, 2009. 
29(4): p. 606-10. 
255. Smas. C.M. and H.S. Sui. Control of adipocyte differentiation. Biochem J, 
1995.309 (Pt3): p. 697-710. 
256. Moro. C., et al., Aerobic exercise training improves atrial natriuretic peptide 
and catecholamine-mediated lipolysis in obese women with polycystic ovary 
syndrome. J Clin Endocrinol Metab, 2009.94(7): p. 2579-86. 
257. Hiragun, A.. Cell and tissue culture models of adipocyte development In New 
Perspective in Adipose Tissue: Structure, Function and Development 
Butterworth, London, 1985: p. 333-352. 
258. Glintborg, D., et al., Plasma monocyte chemoattractant protein-l (MCP-l) 
and macrophage inflammatory protein-l alpha are increased in patients 
with polycystic ovary syndrome (PCOS) and associated with adiposity, but 
unaffected by pioglitazone treatment Clin Endocrinol (Oxt), 2009. 71(5): p. 
652-8. 
259. Hu. W.H., et aI., [Monocyte chemoattractant protein-1 and its correlation 
with lipoprotein in polycystic ovary syndrome}. Beijing Da Xue Xue Bao, 
2006.38(5): p. 487-91. 
260. Gonzalez, F., et al., Evidence of proatherogenic inflammation in polycystic 
ovary syndrome. Metabolism, 2009. 58(7): p. 954-62. 
261. Rebuffe-Scrive, M., Sex steroid hormones and adipose tissue metabolism in 
ovariectomized and adrenalectomized rats. Acta Physiol Scand, 1987. 
129(4): p. 471-7. 
262. Sweeney, G., Leptin signalling. Cell Signal, 2002. 14(8): p. 655-63. 
250 
Chapter 10: Bibliography 
263. Boulton, K.L, et aI., Steroid hormone interconversions in human adipose 
tissue in vivo. Metabolism, 1992.41(5): p. 556-9. 
264. Basdevant, A, et al., [Metabolism of sex hormones and adipose tissue]. J 
Gynecol Obstet Bioi Reprod (Paris), 1986. 15(2): p. 147-52. 
265. Dieudonne, M.N., et aI., Opposite effects of androgens and estrogens on 
adipogenesis in rat preadipocytes: evidence for sex and site-related 
specificities and possible involvement of insulin-like growth factor 1 
receptor and peroxisome proliferator-activated receptor gamma2. 
Endocrinology, 2000. 141(2): p. 649-56. 
266. Thompson, D.L, N. Horton, and R.S. Rittmaster, Androsterone glucuronide 
is a marker of adrenal hyperandrogenism in hirsute women. Clin 
Endocrinol (Oxf), 1990. 32(3): p. 283-92. 
267. Acien, P., et aI., Insulin. androgens. and obesity in women with and without 
polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril, 
1999. 72(1): p. 32-40. 
268. Schwartz, J.R. and S.K. Roy, Developmental expression of cytochrome P450 
side-chain cleavage and cytochrome P450 17 alpha-hydroxylase messenger 
ribonucleic acid and protein in the neonatal hamster ovary. Bioi Reprod, 
2000.63(6): p. 1586-93. 
269. Zhang, B., et al., Potentiation of insulin stimulation of phosphatidylinositol 
3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese 
hamster ovary cells expressing human insulin receptors and L6 myotubes. J 
Bioi Chern, 1994. 269(41): p. 25735-41. 
270. Wang, H., et al., Exogenous granulocyte-macrophage colony-stimulating 
factor promotes follicular development in the newborn rat in vivo. Hum 
Reprod, 2005. 20(10): p. 2749-56. 
271. Ghosh,S., et al., IKKbeta mediates cell shape-induced aromatase expression 
and estrogen biosynthesis in adipose stromal cells. Mol Endocrinol, 2009. 
23(5): p. 662-70. 
272. Blouin, K., et al., Androgen metabolism in adipose tissue: recent advances. 
Mol Cell Endocrinol, 2009. 301(1-2): p. 97-103. 
273. Anderson, LA, et ai., The effects of androgens and estrogens on 
preadipocyte proliferation in human adipose tissue: influence of gender and 
site. J Clin Endocrinol Metab, 2001. 86(10): p. 5045-51. 
274. Garcia, E., et a1., Modulation of rat preadipocyte adipose conversion by 
androgeniC status: involvement of C/EBPs transcription factors. J 
Endocrinol, 1999. 161(1): p. 89-97. 
275. Lea-Currie, V.R., P. Wen, and M.K. Mcintosh, Dehydroepiandrosterone 
reduces proliferation and differentiation of 3T3-Ll preadipocytes. Biochem 
Biophys Res Commun, 1998. 248(3): p. 497-504. 
276. Lacasa, D., et aI., Progesterone stimulates adipocyte determination and 
differentiation l/sterol regulatory element-binding protein lc gene 
expression. potential mechanism for the lipogenic effect of progesterone in 
adipose tissue. J Bioi Chern, 2001. 276(15): p. 11512-6. 
277. Tausk. M., Pharmacology of the endocrine system and related drugs. 
Progesterone, pro-gestational drugs. and antifertility agents. International 
Encyclopedia of Pharmacology and Therapeutics, 1971. 
251 
Chapter 10: Bibliography 
278. Blouin, K., et al., Pathways of adipose tissue androgen metabolism in 
women: depot differences and modulation by adipogenesis. Am , Physiol 
Endocrinol Metab, 2009. 296(2): p. E244-SS. 
279. Bjorntorp, P., The regulation of adipose tissue distribution in humans. Int J 
Obes Relat Metab Disord, 1996.20(4): p.291-302. 
280. Pasquali, R. and V. Vicennati, Activity of the hypothalamic-pituitary-
adrenal axis in different obesity phenotypes. Int JObes Relat Metab Disord, 
2000.24 Suppl2: p. S47-9. 
281. Vettor, R., et al., Leptin and the hypothalamic-pituitary-adrenal axis activity 
in women with different obesity phenotypes. Int J Obes Relat Metab Disord, 
1997.21(8): p. 708-11. 
282. Hautanen, A., Synthesis and regulation of sex hormone-binding globulin in 
obesity. Int JObes Relat Metab Disord, 2000. 24 Suppl2: p. S64-70. 
283. Wildes, J.E., et al., Self-reported binge eating in severe pediatric obesity: 
impact on weight change in a randomized controlled trial of family-based 
treatment Int JObes (Lond), 2010. 34(7): p. 1143-8. 
284. Harlass, F.E., et al., Weight loss is associated with correction 01 
gonadotropin and sex steroid abnormalities in the obese anovulatory 
lemale. Fertil Steril, 1984.42(4): p. 649-S2. 
285. Acien, P., M. Mauri, and M. Gutierrez, Clinical and hormonal effects 0/ the 
combination gonadotrophin-releasing hormone agonist plus oral 
contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone 
acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian dlsease-
related hyperandrogenisms. Hum Reprod, 1997. 12(3): p.423-9. 
286. Glueck, C.,., et aI., Met/ormin-induced resumption of normal menses in 390/ 
43 (91%) previously amenorrheic women with the polycystic ovary 
syndrome. Metabolism, 1999.48(4): p. S11-9. 
287. Blouin, K., et al.. Effects 01 androgens on adipocyte differentiation and 
adipose tissue explant metabolism in men and women. Clin Endocrinol 
(OxfJ. 2010. 72(2): p. 176-88. 
288. Campbell. B.K.. D.T. Baird, and R. Webb, Effects 01 dose of LH on androgen 
production and luteinization %vine theca cells cultured in a serum-free 
system. J Reprod Fertil, 1998.112(1): p. 69-77. 
289. Dos Santos, E .• et al.. In vitro effects 0/ chorionic gonadotropin hormone on 
human adipose development J Endocrinol, 2007.194(2): p. 313-2S. 
290. Grulet. H., et ai., Roles of LH and insulin resistance in lean and obese 
polycystic ovary syndrome. Clin Endocrinol (Oxt). 1993.38(6): p. 621-6. 
291. Poretsky, L .• J. Clemons, and K. Bogovich. Hyperinsulinemia and human 
chorionic gonadotropin synergistically promote the growth of ovarian 
follicular cysts in rats. Metabolism. 1992.41(8): p.903-10. 
292. Cara. }.F.R.. RL., Insulin-like growth factor I and insulin potentiate 
luteinizing hormone-induced androgen synthesis by rat ovarian thecal-
interstitial cells. Endocrinology, 1988. 123: p. 733-9. 
293. Anttila. L.. et al.. Insulin hypersecretion together with high luteinizing 
hormone concentration augments androgen secretion in oral glucose 
tolerance test in women with polycystic ovarian disease. Hum Reprod, 1993. 
8(8): p. 1179-83. 
252 
Chapter J 0: Bibliography 
294. Schaftler, A., et al., Hypothesis paper Brain talks with lat--evidence for a 
hypothalamic-pituitary-adipose axis? Neuropeptides, 2005. 39(4): p. 363-
7. 
295. McTernan, P.G., et al., Glucocorticoid regulation ofp4S0 aromatase activity 
in human adipose tissue: gender and site differences. J Clin Endocrinol 
Metab, 2002. 87(3): p. 1327-36. 
296. Tonacchera, M., et al., Effects of a thyroid-stimulating human monoclonal 
autoantibody (M22) on functional activity of LH and FSH receptors. Thyroid, 
2006.16(11): p. 1085-9. 
297. Mukhina, S., et al., Phenotypic conversion of human mammary carcinoma 
cells by autocrine human growth hormone. Proc Natl Acad Sci USA, 2004. 
101(42): p.15166-71. 
298. Shahparaki, A., L Grunder, and A. Sorisky, Comparison of human 
abdominal subcutaneous versus omental preadipocyte differentiation in 
primary culture. Metabolism, 2002. 51(9): p. 1211-5. 
299. Shillabeer, G., J.M. Forden, and D.C. Lau, Induction of preadipocyte 
differentiation by mature fat cells in the rat J Clin Invest, 1989. 84(2): p. 
381-7. 
300. F. S a r a ~ , , S.Y., F. SaYgIb, G. Ozgen, C. Yllmaz, T. Kabalak, M. Tiiziin Ege 
University Endocrinology and Metabolism Department, Izmir, Turkey, 
Insulin alters the proliferation of subcutaneous and viceral adipose cells. 
BiotechnoL & Biotechnol. Eq., 2004. 
301. Ascoli, M., F. Fanelli, and D.L. Segaloff, The lutropin/choriogonadotropin 
receptor, a 2002 perspective. Endocr Rev, 2002. 23(2): p. 141-74. 
302. Zhang, M., et aI., Expression and localization of luteinizing hormone 
receptor in the female mouse reproductive tract Bioi Reprod, 2001. 64(1): 
p.179-87. 
303. Rao, C.V., An overview of the past, present, and juture of nongonadal 
LH/hCG actions in reproductive biology and medicine. Semin Reprod Med, 
2001.19(1): p. 7-17. 
304. Menon, K.M., et al., Regulation of luteinizing hormone/human chorionic 
gonadotropin receptor expression: a perspective. Bioi Reprod, 2004. 70(4): 
p.861-6. 
305. Ziecik, A.I., et aJ., Nongonadal LH/hCG receptors in pig: junctional 
importance and parallels to human. Semin Reprod Med, 2001. 19(1): p. 
19-30. 
306. Ziecik. A.I., et al., Nongonadal LH receptors, their involvement in female 
reproductive junction and a new applicable approach. Vet I, 2005. 169(1): 
p.75-84. 
307. Shores, E., H. Picton, and M. Hunter, Differential regulation of pig theca cell 
steroidogenesis by LH, insulin-like growth factor I and granulosa cells in 
serum-free culture. Iournal of Reproduction and Fertility, 2000. 118: p. 
211-219. 
308. Erickson, G.F. and K.J. Ryan, Stimulation 0/ testosterone production in 
isolated rabbit thecal tissue by LH/FSH, dibutyryl cyclic AMP, PGE2alpha, 
and PGE2. Endocrinology, 1976.99(2): p.452-8. 
253 
Chapter J 0: Bibliography 
309. Schanbacher, B.D. and S.E. Echtemkamp, Testicular steroid secretion in 
response to GnRH-mediated LH and FSH release in bulls. J Anim Sci, 1978. 
47(2): p. 514-20. 
310. Minegishi, T., C. Delgado, and M.L. Dufau, Phosphorylation and 
glycosylation of the luteinizing hormone receptor. Proc Natl Acad Sci USA. 
1989.86(5): p. 1470-4. 
311. Bluher, S., J. Kraasch, and W. Kiess, Insulin-like growth factor I, growth 
hormone and insulin in white adipose tissue. Best Pract Res Clin Endocrinol 
Metab, 2005.19(4): p. 577-87. 
312. Richardson, R.L., et ai., Adipocyte development in primary rat cell cultures: 
a scanning electron microscopy study. Anat Rec, 1986. 216(3): p. 416-22. 
313. Hansen, L.H., et ai., Characterization of the inhibitory effect of growth 
hormone on primary preadipocyte differentiation. Mol Endocrinol, 1998. 
12(8): p. 1140-9. 
314. Yamamura, N., et al., Expression of messenger RNA for gonadotropin 
receptor in the granulosa layer during the ovulatory cycle of hens. Comp 
Biochem Physiol A Mollntegr Physiol, 2001.129(2-3): p. 327-37. 
315. Zhou, J., et ai., Insulin-like growth factor binding protein 4 expression 
parallels luteinizing hormone receptor expression and follicular 
luteinization in the primate ovary. Bioi Reprod, 2003. 69(1): p. 22-9. 
316. Zhang, F.P., T. EI-Hefnawy, and I. Huhtaniemi, Regulation 0/ luteinizing 
hormone receptor gene expression by insulin-like growth factor-I in an 
immortalized murine Leydig tumor cell line (BLT-l). Bioi ReprOO, 1998. 
59(5): p. 1116-23. 
317. Onagbesan, O.M., M.J. Peddie, and J. Williams, Regulation of cell 
proliferation and estrogen synthesis by ovine LH, IGF-I, and EGF in theca 
interstitial cells of the domestic hen cultured in defined media. Gen Comp 
EndocrinoI. 1994.94(2): p. 261-72. 
318. Sriraman, V., et al., Effect of deprival of LH on Leydig cell proliferation: 
involvement of PCNA, cyclin D3 and IGF-l. Mol Cell Endocrinol, 2000. 
162(1-2): p. 113-20. 
319. Lobner, D., Comparison of the LDH and MTT assays for quantifying cell 
death: validity for neuronal apoptosis? J Neurosci Methods, 2000. 96(2): p. 
147-52. 
320. Huang, K. T., Y.H. Chen, and AM. Walker, Inaccuracies in MTS assays: major 
distorting effects of medium, serum albumin, and/atty acids. Biotechniques, 
2004.37(3): p. 406, 408, 410-2. 
321. Chen, L., et al., LY294002 enhances cytotoxicity oftemozolomide in glioma 
by down-regulation of the PI3K/Akt pathway. Mol Med Report, 2012. S(2): 
p.575-9. 
322. Monjo, M., et aI., Direct effects of testosterone, 17 beta-estradiol, and 
progesterone on adrenergic regulation in cultured brown adipocytes: 
potential mechanism for gender-dependent thermogenesis. Endocrinology, 
2003.144(11): p. 4923-30. 
323. Mendes, A.M., R.J. Madon, and D.}. Flint, Effects of cortisol and progesterone 
on insulin binding and lipogenesis in adipocytes from normal and diabetic 
rats. J Endocrinol, 1985. 106(2): p. 225-31. 
254 
Chapter 10: Bibliography 
324. Hamosh, M. and P. Hamosh, The effect of estrogen on the lipoprotein lipase 
activity of rat adipose tissue. J Clin Invest, 1975. 55(5): p. 1132-5. 
325. Morey. AK.. et al.. Estrogen and progesterone inhibit vascular smooth 
muscle proliferation. Endocrinology. 1997. 138(8): p. 3330-9. 
326. Teede, H.J. and R. Norman. Polycystic ovarian syndrome: insights into the 
enigma that is PCOS today. Endocrine, 2006. 30(1): p. 1-2. 
327. Hart, R. and R. Norman, Polycystic ovarian· syndrome--prognosis and 
outcomes. Best Pract Res Clin Obstet Gynaecol, 2006. 20(5): p. 751-78. 
328. Franks, S., Polycystic ovary syndrome. N Engl J Med, 1995. 333(13): p. 853-
61. 
329. Erickson, G.F., et al., The ovarian androgen producing cells: a review of 
structure/function relationships. Endocr Rev. 1985.6(3): p. 371-99. 
330. Puurunen, J., et al .• Adrenal androgen production capacity remains high up 
to menopause in women with polycystic ovary syndrome. J Clin Endocrinol 
Metab, 2009. 94(6): p. 1973-8. 
331. Adashi, E.Y., The climacteric ovary as a functional gonadotropin-driven 
androgen-producing gland. Fertil Steril, 1994. 62(1): p. 20-7. 
332. Izhar, B., The Polycystic ovary syndrome: What does insulin resistance have 
to do with it? Reproductive BioMedicine Online, 2003. 6(1): p. 36 - 42. 
333. Jamnongjit, M. and S. Hammes, Ovarian Steriods: The Good, the Bad and the 
Signals that Raise Them. Cell Cycle, 2006. 5(11): p. 1178-1183. 
334. Stoklosowa, S., J. Bahr, and E. Gregoraszczuk, Some morphological and 
functional characteristics of cells of the porcine theca interna in tissue 
culture. BioI Reprod, 1978. 19(4): p. 712-9. 
335. Talbot, lA, et at., Molecular scanning of the insulin receptor gene in women 
with polycystic ovarian syndrome. J Clin Endocrinol Metab, 1996. 81(5): p. 
1979-83. 
336. Dunaif, A. and C. Book, Selective Insulin Resistance in the Polycystic Ovary 
Syndrome. J Clin Endocrinol Metab,1999. 84(9): p. 3110. 
337. Wu, x.K., et al., Selective ovary'resistance to insulin signaling in women with 
polycystic ovary syndrome. Fertil Steril, 2003. 80(4): p. 954-65. 
338. Sam. K., B. Milton, and T. Hearn, Isolation of thecal cells: an assessment of 
purity and steroidogenic potential Journal of Biochemical and Biophysical 
Methods 2000(2): p. 169-181. 
339. Stoklsowa, S., Tissue culture association manual. Culture of Follicular Theca 
Interna Methods of cell science, 1975.1(4): p. 205,208. 
340. Kataoka, N., et al., Preparation of highly purified porcine theca cells. J 
Reprod Fertil, 1994. 102(1): p. 73-9. 
341. Apter, D., et al., Accelerated 24-hour luteinizing hormone pulsatile activity 
in adolescent girls with ovarian hyperan drogen ism: relevance to the 
developmental phase of polycystic ovarian syndrome. J Clin Endocrinol 
Metab.1994. 79(1): p.119-25. 
342. Stoklosowa. S., E.L. Gregoraszczuk, and L. Zabaglo, LHRH - modulator of 
progesterone and estradiol secretion by theca and granulosa cells on 
porcine follicle in mono- and co-culture. Endocr Regul, 1996. 30(1): p. 45-
50. 
255 
Chapter 10: Bibliography 
343. Hillier, S.G., et al., Effect of recombinant activin on androgen synthesis in 
cultured human thecal cells. I Clin Endocrinol Metab, 1991. 72(6): p. 1206-
11. 
344. Porter, T.E., et al., Differential steroid production between theca interna 
and theca externa cells: a three-cell model for follicular steroidogenesis in 
avian species. Endocrinology, 1989.125(1): p.l09-16. 
345. Franks, S., et al., Insulin. action in the normal and polycystic ovary. 
Endocrinol Metab Clin North Am, 1999. 28(2): p. 361-78. 
346. Manna, P.R., M.T. Dyson, and D.M. Stocco, Regulation Of the steroidogenic 
acute regulatory protein gene expression: present and future perspectives. 
Mol Hum Reprod, 2009.15(6): p. 321-33. 
347. Magoffin, D.A, Ovarian theca cell. Int I Biochem Cell Bioi, 2005. 37(7): p. 
1344-9. 
348. Gilling-Smith, C., et al., Evidence for a primary abnormality of thecal cell 
steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxt), 
1997.47(1): p. 93-9. 
349. Manneras, L., et al., A new rat model exhibiting both ovarian and metabolic 
characteristics of polycystic ovary syndrome. Endocrinology, 2007. 148(8): 
p.3781-91. 
350. Kondo, H., et al., Differential regulation of intestinal lipid metabolism-
related genes in obesity-resistant AI] vs. obesity-prone C57BL16] mice. Am J 
Physiol Endocrinol Metab, 2006. 291(5): p. El092-9. 
351. Hughesdon, P.E., Morphology and morphogenesis of the Stein-Leventhal 
ovary and of so-called "hyperthecosis". Obstet Gynecol Surv, 1982. 37(2): p. 
59-77. 
352. Sokalska, A, et al., Statins inhibitgrowth of human theca-interstitial cells in 
PCOS and non-PCOS tissues independently of cholesterol availability. J Clin 
Endocrinol Metab, 2010. 95(12): p. 5390-4. 
353. Givens, I.R, et al., Features of Turner's syndrome in women with polycystic 
ovaries. Obstet Gynecol, 1975.45(6): p. 619-24. 
354. Kim, M.H., et al., Ovarian hyperandrogenism with normal and abnormal 
histologic findings of the ovaries. Am J Obstet Gynecol, 1979. 134(4): p. 
445-52. 
355. Ortega, I., et aI., Simvastatin reduces steroidogenesis by inhibiting Cyp17al 
gene expression in rat ovarian theca-interstitial cells. BioI Reprod, 2012. 
86(1): p. 1-9. 
356. la Marca, A, et al., Metformin treatment reduces ovarian cytochrome p_ 
4S0c17alpha response to human chorionic gonadotrophin in women with 
insulin resistance-related polycystic ovary syndrome. Hum Reprod, 2000. 
15(1): p. 21-3. 
357. Book, C.B. and A. Dunaif, Selective insulin resistance in the polycystic ovary 
syndrome. J Clin Endocrinol Metab, 1999. 84(9): p. 3110-6. 
358. Dunaif, A, et al., Excessive insulin receptor serine phosphorylation in 
cultured fibroblasts and in skeletal muscle. A potential mechanism for 
insulin resistance in the polycystic ovary syndrome. J Clin Invest, 1995. 
96(2): p. 801-10. 
359. Magoffin, D.A and S.R Weitsman, Insulin-like growth factor-I regulation of 
luteinizing hormone (LH) receptor messenger ribonucleic acid expression 
256 
Chapter 10: Bibliography 
and LH-stlmulated signal transduction in rat ovarian theca-interstitial cells. 
Bioi Reprod, 1994.51(4): p. 766-75. 
360. Nestler. J.E. and D.J. Jakubowicz. Decreases in ovarian cytochrome P4S0c17 
alpha activity and serum free testosterone after reduction of insulin 
secretion in polycystic ovary syndrome. N Engl J Med. 1996. 335(9): p. 617-
23. 
361. .Rosenfield. R.L., et al., Dysregulation of cytochrome P4S0c 17 alpha as the 
cause of polycystic ovarian syndrome. FertH Steril, 1990.53(5): p. 785-91. 
362. Ehrmann, D., et al., Detection of functional ovarian hyperandrogenlsm In 
women with androgen excess. N Engl J Med, 1992. 327: p. 157-62. 
363. Erickson, G.F., et al., Granulosa cells of polycystic ovaries: are they normal 
or abnormal? Hum Reprod, 1992. 7(3): p. 293-9. 
364. Yen, S., P. Vela, and J. Rankin, Inappropriate secretion offollicle-stimulating 
hormone and luteinizing hormone in polycystic ovarian disease. J Clin 
Endocrinol Metab, 1970. 30(4): p. 435-442. 
365. Chang, R.f., et al.,lnsulin resistance in nonobese patients with polycystic 
ovarian disease. J Clin Endocrinol Metab, 1983. 57(2): p. 356-9. 
366. Corbould, A., Effects of androgens on insulin action in women: is androgen 
excess a component of female metabolic syndrome? Diabetes Metab Res 
Rev, 2008. 24(7): p. 520-32. 
367. DeUgarte, C.M., A.A. Bartolucci, and R. Azziz, Prevalence of insulin 
resistance in the polycystic ovary syndrome using the homeostasis model 
assessment Fertil Steril, 2005. 83(5): p. 1454-60. 
368. Escobar-Morreale, H.F. and J.L. San Millan, Abdominal adiposity and the 
polycystic ovary syndrome. Trends Endocrinol Metab, 2007. 18(7): p. 266-
72. 
369. Norman, R., Hyperandrogenaemia and the ovary. Molecular and Cellular 
Endocrinology, 2002.191(1): p.113-119. 
370. Norman, R.J., et al., Polycystic ovary syndrome. Lancet, 2007. 370(9588): p. 
685-97. 
371. Risch, H.A., Hormonal etiology of epithelial ovarian cancer, with a 
hypothesis concerning the role of androgens and progesterone. J Natl 
Cancer Inst, 1998.90(23): p. 1774-86. 
372. Bard, D.R., I. Lasnitzki, and T. Mizuno, Metabolism of testosterone by the 
epithelium and mesenchyme of the rat urogenital sinus. J Endocrinol, 1979. 
83(2): p. 211-8. 
373. Bard, D.R., I. Lasnitzki, and T. Mizuno, Testosterone metabolism in the 
urogenital epithelium and mesenchyme of the foetal rat [proceedings). J 
Endocrinol, 1979. 83(1): p. 35P. 
374. Sairam, M.R., et al., Early obesity and age-related mimicry of metabolic 
syndrome in female mice with sex hormonal imbalances. Obesity (Silver 
Spring), 2006. 14(7): p. 1142-54. 
375. Legro, R.S., The genetics of obesity. Lessons for polycystiC ovary syndrome. 
Ann N Y Acad Sci, 2000. 900: p. 193-202. 
376. Balen, A.H., et al., Polycystic ovary syndrome: the spectrum of the disorder 
in 1741 patients. Hum Reprod, 1995.10(8): p. 2107-11. 
257 
Chapter 10: Bibliography 
377. Kirschner, M.A., et aI., Androgen-estrogen metabolism in women with upper 
body versus lower body obesity. J Clin Endocrinol Metab, 1990. 70(2): p. 
473-9. 
378. Elbers. J.M., et al., Long-term testosterone administration increases visceral 
fat in female to male transsexuals. J Clin Endocrinol Metab. 1997. 82(7): p. 
2044-7. 
379. Brandon, E.F .• et al., An update on in vitro test methods in human hepatic 
drug biotransformation research: pros and cons. Toxicol Appl Pharmacol, 
2003. 189(3): p. 233-46. 
380. Noll, T., et al., A cell-culture reactor for the on-line evaluation of 
radiopharmaceuticals: evaluation of the lumped constant of FDG in human 
glioma cells. J Nucl Med, 2000. 41(3): p. 556-64. 
381. Skelin, M., M. Rupnik, and A. Cencic, Pancreatic beta cell lines and their 
applications in diabetes mellitus research. ALTEX, 2010. 27(2): p.l05-13. 
382. Quinkler, M., et al., Androgen generation in adipose tissue in women with 
simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase 
type 5. J Endocrinol. 2004.183(2): p. 331-42. 
383. Chen, C.L., A.E. Brodie, and C.Y. Hu, CCAATjenhancer-binding protein beta 
is not affected by tetrachlorodibenzo-p-dioxin (TCDD) inhibition of 3T3-Ll 
preadipocyte differentiation. Obes Res, 1997. 5(2): p. 146-52. 
384. Liu, J., et aI., cAMP-dependent protein kinase activation inhibits 
proliferation and enhances apoptotic effect of tumor necrosis factor-alpha 
in NCI-H295R adrenocortical cells. J Mol Endocrinol, 2004. 33(2): p. 511-
22. 
385. Kurino, M., et al., Cyclic AMP inhibits activation of mitogen-activated 
protein kinase and cell proliferation in response to growth factors in 
cultured rat cortical astrocytes. J Neurochem, 1996. 67(6): p. 2246-55. 
386. Bornfeldt, K.E., et al., The mitogen-activated protein kinase pathway can 
mediate growth inhibition and proliferation in smooth muscle cells. 
Dependence on the availability of downstream targets. J Clin Invest, 1997. 
100(4): p. 875-85. 
387. Sharpless, J., Polycystic ovarian syndrome and the metabolic syndrome. 
Clinical Diabetes, 2003. 21(4): p. 154-161. 
388. Barbieri, R.L., et al., Insulin stimulates androgen accumulation in 
incubations of ovarian stroma obtained from women with 
hyperandrogenism. J Clin Endocrinol Metab, 1986.62(5): p. 904-10. 
389. Gambineri, A., et al., Obesity and the polycystic ovary syndrome. Int JObes 
Relat Metab Disord, 2002. 26(7): p. 883-96. 
390. Soule, S.G .• Neuroendocrinology of the polycystic ovary syndrome. Baillieres 
Clin Endocrinol Metab, 1996.10(2): p. 205-19. 
391. Preziosi, P., et al., Interrelation between plasma sex hormone-binding 
globulin and plasma insulin in healthy adult women: the telecom study. J 
Clin Endocrinol Metab. 1993.76(2): p. 283-7. 
392. Hughes, I.A., Management of congenital adrenal hyperplasia. Arch Dis Child, 
1988.63(11): p. 1399-404. 
393. Nestler, J.E., Relation of adrenal androgen to insulin levels. Ann Intern Med, 
1993.118(10): p. 826. 
258 
Chapter 10: Bibliography 
394. Magoffin, DA and S.R. Weitsman, Insulin-like growth factor-I stimulates 
the expression of 3 beta-hydroxysteroid dehydrogenase messenger 
ribonucleic acid in ovarian theca-interstitial cells. Bioi Reprod, 1993. 
48(5): p. 1166-73. 
395. Jakimiuk, A.J., et al., Luteinizing hormone receptor, steroidogenesis acute 
regulatory protein, and steroidogenic enzyme messenger ribonucleic acids 
are overexpressed in thecal and granulosa cells from polycystic ovaries. J 
Clin Endocrinol Metab, 2001. 86(3): p. 1318-23. 
396. Attia, G.R., W.E. Rainey, and B.R. Carr, Metformin directly inhibits androgen 
production in human thecal cells. Fertil Steril, 2001. 76(3): p. 517-24. 
397. Nestler, J.E., et al., Effects of metformin on spontaneous and clomiphene-
induced ovulation in the polycystic ovary syndrome. N Engl J Med, 1998. 
338(26): p. 1876-80. 
398. Ulloa-Aguirre, A., et al., Effects ofmetformin on inappropriate LH release in 
women with polycystic ovarian syndrome and insulin resistance. Reprod 
Biomed Online, 2006.12(6): p. 669-83. 
399. Richards, J.S., Maturation of ovarian follicles: actions and interactions of 
pituitary and ovarian hormones on follicular cell differentiation. Physiol 
Rev, 1980. 60(1): p. 51-89. 
400. Nelson-Degrave, V.L., et al., Alterations in mitogen-activated protein kinase 
kinase and extracellular regulated kinase signaling in theca cells contribute 
to excessive androgen production in polycystic ovary syndrome. Mol 
Endocrinol, 2005. 19(2): p. 379-90. 
401. Geffner, M., et al., Persistence of insulin resistance in polycystic ovarian 
disease after inhibition of ovarian steroid secretion. Fertil Steril 1986. 45: p. 
327-33. 
402. Rojas, I.M., J.L. Oliva, and E. Santos, Mammalian son of sevenless Guanine 
nucleotide exchange factors: old concepts and new perspectives. Genes 
Cancer, 2011. 2(3): p. 298-305. 
403. Camps, M., A. Nichols, and S. Arkinstall, Dual specificity phosphatases: a 
gene family for control of MAP kinase function. FASEB J, 2000. 14(1): p. 6-
16. 
404. Keyse, S.M., Protein phosphatases and the regulation of mitogen-activated 
protein kinase Signalling. Curr Opin Cell Bioi, 2000. 12(2): p. 186-92. 
405. Alberts, B., The Molecular Biology of the Cell. Garland Science, New York, 
2002. 
406. Fukuda, S., et al., Luteinizing hormone-induced Akt phosphorylation and 
androgen production are modulated by MAP Kinase in bovine theca cells. J 
Ovarian Res, 2009. 2(1): p. 17. 
407. Marino, M., F. Acconcia, and A. Trentalance, Biphasic estradiol-induced AKT 
phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol 
Bioi Cell, 2003. 14(6): p. 2583-91. 
408. Downward, I., Ras signalling and apoptosis. Curr Opin Genet Dev, 1998. 
8(1): p. 49-54. 
409. Downward, J., Mechanisms and consequences of activation of protein kinase 
B/Akt Curr Opin Cell Bioi, 1998.10(2): p. 262-7. 
410. Seger, R., et ai., The ERK Signaling cascade inhibits gonadotropin-
stimulated steroidogenesis. J Bioi Chern, 2001. 276(17): p. 13957-64. 
259 
Chapter 10: Bibliography 
411. Tajima, K., et al., Luteinizing hormone-induced extracellular-signal 
regulated kinase activation differently modulates progesterone and 
androstenedione production in bovine theca cells. Endocrinology, 2005. 
146(7): p. 2903-10. 
412. de Rooij, J., et aI., Epac is a Rapl guanine-nucleotide-exchange factor 
directly activated by cyclic AMP. Nature, 1998.396(6710): p. 474-7. 
260 
Chapter J J: Appendix 
11.0 ApPENDIX 
I. SoIUtiOD colDpositiODI: 
PBS workiDa dOUtiOD: 
200m1 PBS stock, 300m1 SM NaCI, 770ml H20 
PBS stock: 
Na2HPO ... NaH2P04, pH 7.2-7.4 with NaOH 
10.". AlDlDoDiulD penulpbate (AP): 
0.1 g Ammonium persulphate in I ml H20 
4% w/v Parafonnaldebyde: 
4g PFA dissolved in dH20 at 6()OC. pH 7.4 using 1M NaOH. Stored at -SO°C for 
3months. 
HOSS: 
Sml of HEPES & Sml penicillin/streptomycin in SOOmI HBSS 
HOlDogeDisatioD buffer (ovartan): 
300mM, tris base pH 7.4 2SmM (Invitrogen Life Technologies), monothyioglycerol 
10mM, EDTA ImM, protease inhibitor cocktail 0.5% (v/v), 2.5% (v/v) igepal 
HOlDogenisation buffer (adipoeyte): 
320mM Sucrose, 10mM Tris base pH 7.S, SOmM KCI, ImM 
ethylenediaminetetraacetic acid (EDTA), 0.5% Igepal, protease inhibitor cocktail 
(Sigma) (I :5(0) supplemented with fresh phosphatase inhibitor cocktail (Sigma) 
1:100. 
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Enzyme dissociation solution: 
collagenase I, 1 mglml, hyaluronidase 0.5mglml and DNase I 15lcunits 
Lamelli buffer/sample loading buffer: 
5 0 ~ I l l - m e r c a p t o e t h a n o l , , 950 J11 sample loading butTer (Biorad) 
PBS:Glycerol: 
Equal v/v of PBS:Glycerol 
PSS: 
119 NaCI, 4.7 KCI, 25 NaHC03, 2.5 MgS04, 1.6 CaCh, 1.2 KH2P04, 5.5 glucose, 
0.034 EDTA pH7.4 Stored at 4°C 
Resolving gel: 
12%: 4.1 ml dHzOz,3.3ml Acrylamide, 2.5ml resolving gel butTer (Tris base pH8.8), 
100111 10% SDS, 100111 ammonium persulfate (APS), 4J11 N,N,N'N'. 
Tetramethlyethlyenediamine (TEMED). 
Running buffer: 
15.1 g Tris, 94g Glycine, 50ml 10% SDS in I L HzO. 
Solubilisation buffer: 
20mM Tris base pH 7.5, IOmM EDTA, 120mM NaCI, 50mM KCI. 2.5% )gepal 
supplemented with fresh protease inhibitor cocktail (Sigma) (I :500) and phosphatatse 
inhibitor cocktail (sigma) I: 100). 
Stacking gel: 
4%: 3.4ml dHzOz, 0.S5ml Acrylamide, 0.625ml resolving gel butTer (Tris base pHS.S), 
5 0 ~ 1 1 10% SDS, 50111 APS, 5111 TEMED. 
TBS-Tween (TBST) O.I'Y.: 
IL TBS Iml Tween-20 
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Transfer buffer: 
24mM Tris Base, 80mM glycine, 20% methanol 
Tria buffered saline (TBS): 
12.11g Tris, 146.lg NaCl, in 5L H20 pH to 7.4 with 5M HCI. 
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II.' Working dilutions of antibodies 
Table I. Detailing the dilution factor for each antibody included in our studies according to 
which technique was used. 
Antibody Host Type Working Secondary antibody 
DUution & & Conjugate 
Technique 
Alpha actin Mouse Monoclonal 1:50 IF 1:50 FITC (Sigma) 
(DakoCytomation) 
I : 1000 FITC (Molecular 
Probes) 
Vectorstain Elite Kit 1:50IHC (Universal) (Vector 
laboratories) 
Beta actin Rabbit Polyclonal 1:8000WB 1:30000 AP (Sigma) 
(Abeam) 
1:2000 AP 
(DakoCytomation) 
CYPI7al Rabbit Polyclonal 1:500 WB 1:30000 AP (Sigma) 
(Santa Cruz) 1:2000 AP 
(DakoCytomation) 
I :50 IF 
1:50 FITC (Sigma) 
CYPI7 Rabbit Polyclonal 1:200 WB 1 :30000 AP (Sigma) 
(Abgent) 1:2000 AP 
1:50 IF 
(DakoCytomation) 
1:50 FITC (Sigma) 
CD45 Mouse Monoclonal I: 100 WB 1 :30000 AP (Sigma) 
(Sigma) 1:20 IF 1 :2000 AP 
(DakoCytomation) 
1:50 FITC (Sigma) 
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antiOB Goat Polyclonal 1:1000 WB 1 :30000 AP (Sigma) 
(R&D 1:2000- AP 
Systrems) 
1:50 IF 
(DakoCytomation) 
1 :50 FITC (Sigma) 
LHR(H-50) Rabbit Polyclonal 1:200WB 1 :30000 AP (Sigma) 
(Santa Cruz) 1:50 IF 1:2000 AP 
(DakoCytomation) 
1 :50 FITC (Sigma) 
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III. Suppliers 
Abcam 
Abnova 
BD Transduction Laboratories 
Biorad 
DakoCytomation 
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330 Cambridge Science Park 
Cambridge 
CB40FL 
UK 
Web http://www.abeam.com 
Abnova GmbH c/o EMBLEM 
Boxbergring 107 
69126 Heidelberg 
Gennany 
Web: http://www.abnova.com 
E-mail: sales@abnova.com 
BD Biosciences 
21588 Network Place 
Chicago, IL 60673-1215 
Tel: 44.1865.78.16.66 
Fax: 44.1865.78.16.27 
Web http://www.bdbiosciences.comlhome. jsp 
E-mail admetox@bd.com 
Bio-Rad Laboratories Ltd. 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire 
HP27DX 
Tel: +44 (0)208 3282000 
Fax: +44 (0) 208 328 2550 
Web: http://www3.bio-rad.coml 
E-mail: uk.lsg.marketing@bio-rad.com 
Dako UK Ltd 
Cambridge House 
St Thomas Place, Ely 
Cambridgeshire 
CB74EX 
Tel: +44 (0)1 3536699 11 
Fax: +44 (0)1 353667309 
Web: www.dako.co.uk 
E-mail: info.uk@dako.com 
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Fisher Scientific 
Molecular probes 
SantaCruz 
Sigma Aldrich 
Tocris 
Chapter 11.' Appendix 
Fisher Scientific UK Ltd, 
Bishop Meadow Road, 
Leicestershire 
LEll 5RG 
Tel: 01509231166 
Fax: 01509 231893 
Web: http://www.fisher.co.uk 
Invitrogen Ltd 
Inchinnan Business Park 
Paisley 
UK 
PA49RF 
Tel: 0141 8146100 
Fax: 01418146260 
Web: http://www.invitrogen.com 
E-mail: euroinfo@invitrogen.com 
Santa Cruz Biotechnology, Inc. 
Bergheimer Str. 89-2 
69115 Heidelberg 
Germany 
Tel: +49 6221 4503 0 
Fax: +49 6221 4503 45 
Web: http://www.scbt.com 
E-mail: europe@scbt.com 
Sigma-Aldrich Company Ltd. 
The Old Brickyard 
New Road 
Dorset 
SP84XT 
UK 
Tel: +44 1202712300 
Fax:+44 1202715460 
Web: http://www.sigmaaldrich.com/united-kingdom.html 
E-mail: ukcustsv@europe.sial.com 
Tocris Bioscience 
Tocris House, 10 Centre 
Moorend Farm Avenue 
Bristol, 
BSII OQL 
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Vector Laboratories 
VWR 
(formerly BDH) 
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United Kingdom 
Tel: + 44 (0)117916-3333 
Fax: + 44 (0) 117 916-3344 
Web: http://www.tocris.comlcontact.php 
E-mail: customerservice@tocris.co.uk 
3, Accent Park, Bakewell Road 
Orton Southgate 
Peterborough 
PE26XS 
Tel: (01733) 237999 
Fax: (01733) 237119 
Web http://www.vectorlabs.comluk 
E-mail: vector@vectorlabs.co.uk 
Hunter Boulevard 
Magna Park 
Leicestershire 
LEI74XN 
Tel: 0800 22 33 44 
Web: http://uk.vwr.com 
E-mail: uksales@uk.vwr.com 
268 
Chapter 11: Appendix 
IV. Patient information sheet & Consent forms 
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At which I said: "And after the great sentence - 0 master - will these torments grow. 
or else be less. or will they be just as intense?" And he to me: "Remember now your 
science. which says that when a thing has more perfection. so much the greater is its 
pain or pleasure. " 
(Dante,lnf. VI, 103-111) 
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